

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 December 2004 (02.12.2004)

PCT

(10) International Publication Number
WO 2004/104161 A2

(51) International Patent Classification⁷: **C12N**

First Avenue, Apt. 13a, New York, NY 10016 (US). ROT-
MAN, Galit [IL/IL]; 5 Yair Shtern Street, 46 412 Herzlia
(IL).

(21) International Application Number:
PCT/IL2004/000429

(74) Agent: G.E. EHRLICH (1995) LTD.; 11 Menachem Be-
gin Street, 52 521 Ramat Gan (IL).

(22) International Filing Date: 20 May 2004 (20.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/441,281 20 May 2003 (20.05.2003) US

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(71) Applicant (for all designated States except US): COMPU-
GEN LTD. [IL/IL]; 72 Pinchas Rosen Street, 69 512 Tel
Aviv (IL).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEVANON, Erez
[IL/IL]; 73 Menachem Begin Street, 49732 Petach Tikva
(IL). POLLOCK, Sarah [IL/IL]; 16 Hoshea Street, Apt.
2, 63 506 Tel Aviv (IL). NEMZER, Sergey [IL/IL]; 5
HaRenanim Street, 52 595 Ramat Gan (IL). SHOSHAN,
Avi [IL/IL]; 2/4 Rachavat Har Sinai Street, 82 000 Kiryat
Gat (IL). KHOSRAVI, Rami [IL/IL]; 36/1 Halevi Street,
46490 Herzlia (IL). WALACH, Shira [IL/IL]; 40 Bnei
Brit Street, 45 265 Hod HaSharon (IL). LEVINE, Zu-
rit [IL/IL]; 4 Reihan Street, 46 419 Herzlia (IL). BERN-
STEIN, Jeanne [IL/IL]; 23 Harimon Street, 40 300 Kfar
Yona (IL). DAHARY, Dvir [IL/IL]; 23 Pinkas Street, 62
662 Tel Aviv (IL). WASSERMAN, Alon [IL/US]; 564

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND SYSTEMS FOR IDENTIFYING NATURALLY OCCURRING ANTISENSE TRANSCRIPTS AND
METHODS, KITS AND ARRAYS UTILIZING SAME

(57) Abstract: A method of identifying putative naturally occurring antisense transcripts is provided. The method is effected by
(a) computationally aligning a first database including sense-oriented polynucleotide sequences with a second database including
expressed polynucleotide sequences; and (b) identifying expressed polynucleotide sequences from the second database being capa-
ble of forming a duplex with at least one sense-oriented polynucleotide sequence of the first database, thereby identifying putative
naturally occurring antisense transcripts.

WO 2004/104161 A2

METHODS AND SYSTEMS FOR IDENTIFYING NATURALLY
OCCURRING ANTISENSE TRANSCRIPTS AND METHODS, KITS AND
ARRAYS UTILIZING SAME

5 BACKGROUND OF THE INVENTION

The present invention relates to the field of naturally occurring antisense transcripts. More particularly, the present invention relates to methods of identifying naturally occurring antisense transcripts, databases storing polynucleotide sequences encoding identified naturally occurring antisense transcripts, oligonucleotides derived
10 therefrom and methods and kits utilizing same.

FIELD OF THE INVENTION

Naturally occurring antisense RNA transcripts are endogenous transcripts, which exhibit complementarity to sense transcripts of which are typically of a known
15 function. It has been established that these endogenous antisense transcripts play an important role in regulating prokaryotic gene expression and are increasingly implicated as involved in eukaryotic gene regulation.

Cis-encoded antisense transcripts are encoded by the same locus as the sense transcripts and are transcribed from strand of DNA opposite to that encoding the
20 sense transcript; as such, *cis* encoded antisense transcripts are typically completely complementary with a portion of the sense transcript. *Trans*-encoded antisense transcripts are, by contrast, transcripts, which are encoded on a different locus and as such, may display only partial complementarity with a sense transcript.

Natural antisense RNAs were first described in prokaryote studies, which
25 suggested that such transcripts play a role in gene expression regulation. Prokaryotic antisense transcripts are widely distributed and are involved in the control of numerous biological functions including transposition, plasmid replication, incompatibility and conjugation. In prokaryotes, antisense transcripts are typically involved in down-regulation of sense transcript expression, although involvement in
30 positive regulation was also suggested [reviewed in Wagner EG. and Simons RW. (1994) *Annu. Rev. Microbiol.* 48:713-742].

The first example of transcription from both strands of eukaryotic DNA was illustrated in human and mouse mitochondrial genes [Anderson S. et al. (1981) *Nature*

290:457-465 and Bibb MJ. et al. (1981) Cell 26:167-180]. Since then, examples of antisense transcripts have been documented in a variety of organisms including viruses, slime molds, insects, amphibians and birds as well as mammals. It is thought that these antisense RNAs are involved in extremely diverse biological functions, such as, hormonal response, control of proliferation, development, structure, viral replication and others. Some antisense RNAs are conserved between species suggesting that these antisense RNAs are not fortuitous but rather play an important role in gene expression regulation [Kidny MS. et al. (1987) Mol. Cell Biol. 7:2857-2862, Nepveu A. and Marcu KB. (1986) EMBO J. 5:2859-2865 and Bentley DL. et al. (1986) Nature 321:702-706].

Antisense transcripts can also encode proteins. Examples for protein encoding antisense transcripts include *rev-ErbA α* [Lazar MA. (1989) Mol. Cell. Biol. 9:1128-1136], *gfg* [Kimelman D. et al. (1989) Cell 59:687-696] and *n-cym* [Armstrong BC. et al. (1992) Cell Growth Differ. 3:385-390]. Such antisense transcripts typically include a distinct open reading frame (ORF) and polyadenylation signal for cytoplasm transportation.

However, it is believed that most antisense transcripts play a role in gene expression regulation. This assumption is mostly based on spatial and/or temporal distributions of sense and antisense transcripts. Indeed, tissue distribution studies suggest that high levels of sense and antisense transcripts rarely occur together, as was exemplified for the *dopa decarboxylase* transcripts in *Drosophila* [Spencer CA. et al. (1986) Nature 322:279-281]. Additional studies demonstrated that changes in sense gene expression correlate with presence of antisense RNA. Furthermore, an inverse relationship between levels of accumulation of sense and antisense transcripts such as has been reported for $\alpha 1(I)$ collagen transcripts in chondrocytes under chemotherapy has also been reported [Farrell CM. And Lukens LN. (1995) J. Biol. Chem. 270:3400-3408]. However, it will be appreciated that mutual expression of sense and their corresponding antisense transcripts is also reported and may involve a different mechanism of regulation.

Evidence for involvement of antisense-mediated gene regulation in the development of pathologies has also been presented. For example, endogenous antisense transcripts may be involved in regulation of the expression levels of the

tumor suppressor gene WT1 observed in Wilm's tumors [Eccles MR. et al. (1994) Oncogene 9:2059-2063].

Natural antisense regulation of gene expression can be effected via one of several mechanisms.

5 ***Nuclear regulation***

Nuclear regulation can be effected via several gene-processing pathways [reviewed in Vanhee-Brosollet C. and Vaquero C. (1998) Gene 211:1-9]

dsRNA-mediated DNA methylation - complementation between endogenous sense transcripts and antisense transcripts of sequences as short as 30 bp may initiate
10 DNA-methylation, a well-established phenomenon in a number of organisms [Sharp A. (2001) Genes Dev. 15:485-490]. Methylation can be directed to different portions of an encoding region of the gene or to the promoter region. DNA methylation results in complete suppression of transcription probably by recruitment of histone deacetylases.

15 ***Transcriptional regulation*** – in which case antisense transcription hampers sense transcription. Such interference may involve the collision of two transcription complexes. Alternatively, interference may result from competition on an essential rate limiting transcription factor resulting in premature termination or in reduced elongation of transcription, the transcripts with the highest rate of transcription being
20 predominant.

Post-transcriptional nuclear regulation – involves antisense intervention of either maturation and/or transport of the sense transcript to the cytoplasm. Alternatively, antisense transcripts displaying similar structural features to sense transcripts can bind proteins expected to interact with their sense counterparts,
25 thereby depriving sense messengers from proteins necessary for their function.

Cytoplasmic regulation

Messenger stability –double stranded RNA may affect messenger stability via “RNA interference”, which involves short segments of double stranded RNA (dsRNA) homologous in sequence to the silenced gene. These undersized segments,
30 which are generated by a ribonuclease III cleavage of longer dsRNAs, can guide a single stranded target mRNA, via base pairing, to a multisubunit complex which participates in the degradation of the target mRNA. Alternatively, messenger stability

may be affected by RNA degradation, which is mediated by double stranded RNA-directed Rnases.

Translation – masking the 3' untranslated region (UTR) and the polyA tail of the sense transcript is believed to modulate translation efficiency probably via direct or indirect interaction between 3'-proximal elements and upstream sequences or structures [reviewed in Jackson RJ. And Standart N. (1990) Cell 62:15-24].

Realizing the fundamental role antisense transcripts play in regulating sense transcription, stability and function, resulted in a number of attempts to systematically identify natural antisense transcripts. Accordingly, differential approaches were taken for exploring non-coding antisense RNA transcripts and antisense transcripts including an ORF. Although the latter carries ORF consensus parameters, uncovering antisense data from general sequence databases has proven to be a complicated task, as many of these sequences include an evolutionary conserved secondary structure rather than a conserved primary sequence, therefore primary sequence alignment methods are often not very effective. Indeed, only a few attempts have been tried to date with only limited success.

Maziel's group [Chen JH. et al. (1990) Comput. Applic. Biosci. 6:7-18 and Le SY. et al (1990) Human Genome Initiative and DNA Recombination Vol. 1:127-136] has experimented with methods that look for regions of a genome with predicted RNA structures that are significantly more stable thermodynamically than random sequence of the same base composition. Although this approach detected a few highly structured non-coding RNAs, as well as few *cis*-regulatory structures, it appears that it is of limited use for large-scale applications.

Another approach examined coding dense genomes, having suspicious-looking large regions with little or no coding potential termed "gray holes" [Olivas WM. et al. (1997) Nucleic acids Res. 25:4619-4625]. Fifty nine gray holes were tested in the yeast genome. Northern analysis detected distinct transcripts from 15 of the gray holes. Only one transcript appeared to be a non-coding antisense transcript illustrating the low efficiency of this method.

SUMMARY OF THE INVENTION

The background art does not teach or suggest methods of systematically and efficiently identifying novel naturally occurring antisense molecules and methods of generating and using same for detecting, quantifying and/or regulating sense transcripts, such as for example, mRNA transcripts associated with a pathological state.

According to one aspect of the present invention there is provided a method of identifying putative naturally occurring antisense transcripts, the method comprising: (a) computationally aligning a first database including sense-oriented polynucleotide sequences with a second database including expressed polynucleotide sequences; and (b) identifying expressed polynucleotide sequences from the second database being capable of forming a duplex with at least one sense-oriented polynucleotide sequence of the first database according to at least one sequence criterion, thereby identifying putative naturally occurring antisense transcripts, wherein the at least one sequence criterion includes one or more of sequence length, sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

According to another aspect of the present invention there is provided a kit for quantifying at least one mRNA transcript of interest, the kit comprising at least one oligonucleotide being designed and configured so as to be complementary to a sequence region of the mRNA transcript of interest, the sequence region not being complementary with a naturally occurring antisense transcript.

According to yet another aspect of the present invention there is provided a kit for quantifying at least one mRNA transcript of interest, the kit comprising at least one pair of oligonucleotides including a first oligonucleotide capable of binding the at least one mRNA transcript of interest and a second oligonucleotide being capable of binding a naturally occurring antisense transcript complementary to the mRNA of interest.

According to still another aspect of the present invention there is provided a method of designing artificial antisense transcripts, the method comprising: (a) providing a database of naturally occurring antisense transcripts; (b) extracting from the database criteria governing structure and/or function of the naturally occurring antisense transcripts, wherein the criteria governing structure and/or function of the

naturally occurring antisense transcripts include one or more of antisense length, complementarity length, complementarity position, intron molecules, alternative splicing sites, tissue specificity, pathological abundance, chromosomal mapping, open reading frames, promoters, hairpin structures, helix structures, stem and loops, pseudoknots and tertiary interactions, guanidine and/or cytosine content, guanidine tandems, adenosine content, thermodynamic criteria, RNA duplex melting point, RNA modifications, protein-binding motifs, palindromic sequence and predicted single stranded and double stranded regions.; and (c) designing the artificial antisense transcripts according to the criteria.

According to further features in preferred embodiments of the invention described below the criteria governing structure and/or function of the naturally occurring antisense transcripts are selected from the group consisting of antisense length, complementarity length, complementarity position, intron molecules, alternative splicing sites, tissue specificity, pathological abundance, chromosomal mapping, open reading frames, promoters, hairpin structures, helix structures, stem and loops, pseudoknots and tertiary interactions, guanidine and/or cytosine content, guanidine tandems, adenosine content, thermodynamic criteria, RNA duplex melting point, RNA modifications, protein-binding motifs, palindromic sequence and predicted single stranded and double stranded regions.

According to an additional aspect of the present invention there is provided a computer readable storage medium comprising a database including a plurality of sequences, wherein each sequence is of a naturally occurring antisense transcript.

According to still further features in the described preferred embodiments the database further includes information pertaining to each sequence of the naturally occurring antisense transcripts, the information is selected from the group consisting of related sense gene, antisense length, complementarity length, complementarity position, intron molecules, alternative splicing sites, tissue specificity, pathological abundance, chromosomal mapping, open reading frames, promoters, hairpin structures, helix structures, stem and loops, pseudoknots and tertiary interactions, guanidine and/or cytosine content, guanidine tandems, adenosine content, thermodynamic criteria, RNA duplex melting point, RNA modifications, protein-

binding motifs, palindromic sequence and predicted single stranded and double stranded regions.

According to still further features in the described preferred embodiments the database further includes information pertaining to generation of the database and
5 potential uses of the database.

According to yet an additional aspect of the present invention there is provided a method of generating a database of naturally occurring antisense transcripts, the method comprising: (a) computationally aligning a first database including sense-oriented polynucleotide sequences with a second database including
10 expressed polynucleotide sequences; (b) identifying expressed polynucleotide sequences from the second database being capable of forming a duplex with at least one sense-oriented polynucleotide sequence of the first database so as to identify putative naturally occurring antisense transcripts; and (c) storing sequence information of the identified naturally occurring antisense transcripts, thereby
15 generating the database of the naturally occurring antisense transcripts.

According to still an additional aspect of the present invention there is provided a system for generating a database of a plurality of putative naturally occurring antisense transcripts, the system comprising a processing unit, the processing unit executing a software application configured for: (a) computationally aligning a first database including sense-oriented polynucleotide sequences with a second database including expressed polynucleotide sequences; and (b) identifying expressed polynucleotide sequences from the second database being capable of forming a duplex with at least one sense-oriented polynucleotide sequence of the first database according to at least one sequence criterion, wherein the at least one sequence criterion includes at least one of sequence length, sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

According to a further aspect of the present invention there is provided a method of identifying putative naturally occurring antisense transcripts, the method comprising screening a database of expressed polynucleotides sequences according to at least one sequence criterion, the at least one sequence criterion being selected to
20 identify putative naturally occurring antisense transcripts.

According to yet a further aspect of the present invention there is provided a method of quantifying at least one mRNA of interest in a biological sample, the method comprising: (a) contacting the biological sample with at least one oligonucleotide capable of binding with the at least one mRNA of interest, wherein
5 the at least one oligonucleotide is designed and configured so as to be complementary to a sequence region of the mRNA transcript of interest, the sequence region not being complementary with a naturally occurring antisense transcript; and (b) detecting a level of binding between the at least one mRNA of interest and the at least one oligonucleotide to thereby quantify the at least one mRNA of interest in the biological
10 sample.

According to still a further aspect of the present invention there is provided a method of quantifying the expression potential of at least one mRNA of interest in a biological sample, the method comprising: (a) contacting the biological sample with at least one pair of oligonucleotides including a first oligonucleotide capable of
15 binding the at least one mRNA of interest and a second oligonucleotide being capable of binding a naturally occurring antisense transcript complementary to the mRNA of interest; and (b) detecting a level of binding between the at least one mRNA of interest and the first oligonucleotide and a level of binding between the naturally occurring antisense transcript complementary to the mRNA of interest and the second
20 oligonucleotide to thereby quantify the expression potential of the at least one mRNA of interest in the biological sample.

According to other aspect of the present invention there is provided a method of quantifying at least one naturally occurring antisense transcript of interest in a biological sample, the method comprising: (a) contacting the biological sample with
25 at least one oligonucleotide capable of binding with the at least one naturally occurring antisense transcript of interest, wherein the at least one oligonucleotide is designed and configured so as to be complementary to a sequence region of the naturally occurring antisense transcript of interest, the sequence region not being complementary with a naturally occurring mRNA transcript; and (b) detecting a level
30 of binding between the at least one naturally occurring antisense transcript of interest and the at least one oligonucleotide to thereby quantify the at least one naturally occurring antisense transcript of interest in the biological sample.

According to still further features in the described preferred embodiments the first database includes sequences of a type selected from the group consisting of genomic sequences, expressed sequence tags, contigs, intron sequences, complementary DNA (cDNA) sequences, pre-messenger RNA (mRNA) sequences and mRNA sequences.

According to still further features in the described preferred embodiments the second database includes sequences of a type selected from the group consisting of expressed sequence tags, contigs, complementary DNA (cDNA) sequences, pre-messenger RNA (mRNA) sequences and mRNA sequences.

According to still further features in the described preferred embodiments an average sequence length of the expressed polynucleotide sequences of the second database is selected from a range of 0.02 to 0.8 Kb.

According to still further features in the described preferred embodiments the second database is generated by: (i) providing a library of expressed polynucleotides; (ii) obtaining sequence information of the expressed polynucleotides; (iii) computationally selecting at least a portion of the expressed polynucleotides according to at least one sequence criterion; and (iv) storing the sequence information of the at least a portion of the expressed polynucleotides thereby generating the second database.

According to still further features in the described preferred embodiments the at least one sequence criterion for computationally selecting the at least a portion of the expressed polynucleotide is selected from the group consisting of sequence length, sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

According to still further features in the described preferred embodiments the step of testing the putative naturally occurring antisense transcripts for an ability to form the duplex with the at least one sense oriented polynucleotide sequence under physiological conditions.

According to still further features in the described preferred embodiments the method further comprising the step of computationally testing the putative naturally occurring antisense transcripts according to at least one criterion selected from the

group consisting of sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

According to still further features in the described preferred embodiments a
5 length of the at least one oligonucleotide is selected from a range of 15-200 nucleotides.

According to still further features in the described preferred embodiments the at least one oligonucleotide is a single stranded oligonucleotide.

According to still further features in the described preferred embodiments the
10 at least one oligonucleotide is a double stranded oligonucleotide.

According to still further features in the described preferred embodiments a guanine and cytosine content of the at least one oligonucleotide is at least 25 %.

According to still further features in the described preferred embodiments the at least one oligonucleotide is labeled.

15 According to still further features in the described preferred embodiments the at least one oligonucleotide is attached to a solid substrate.

According to still further features in the described preferred embodiments the solid substrate is configured as a microarray and whereas the at least one oligonucleotide includes a plurality of oligonucleotides each attached to the
20 microarray in a regio-specific manner.

According to still further features in the described preferred embodiments a length of each of the first and second oligonucleotides is selected from a range of 15-200 nucleotides.

According to still further features in the described preferred embodiments the
25 first and second oligonucleotides are single stranded oligonucleotides.

According to still further features in the described preferred embodiments the first and second oligonucleotides are double stranded oligonucleotide.

According to still further features in the described preferred embodiments a guanine and cytosine content of each of the first and second oligonucleotides is at
30 least 25 %.

According to still further features in the described preferred embodiments the first and second oligonucleotides are labeled.

According to still further features in the described preferred embodiments the first and second oligonucleotides are attached to a solid substrate.

According to still further features in the described preferred embodiments the solid substrate is configured as a microarray and whereas each of the first and second
5 oligonucleotides includes a plurality of oligonucleotides each attached to the microarray in a regio-specific manner.

According to yet other aspect of the present invention there is provided a method of identifying a novel drug target, the method comprising: (a) determining expression level of at least one naturally occurring antisense transcript of interest in
10 cells characterized by an abnormal phenotype; and (b) comparing the expression level of the at least one naturally occurring antisense transcript of interest in the cells characterized by an abnormal phenotype to an expression level of the at least one naturally occurring antisense transcript of interest in cells characterized by a normal phenotype, to thereby identify the novel drug target.

15 According to still further features in the described preferred embodiments the abnormal phenotype of the cells is selected from the group consisting of biochemical phenotype, morphological phenotype and nutritional phenotype.

According to still further features in the described preferred embodiments determining expression level of at least one naturally occurring antisense transcript of
20 interest is effected by at least one oligonucleotide designed and configured so as to be complementary to a sequence region of the at least one naturally occurring antisense transcript of interest, the sequence region not being complementary with a naturally occurring mRNA transcript.

According to still other aspect of the present invention there is provided a
25 method of treating or preventing a disease, condition or syndrome associated with an upregulation of a naturally occurring antisense transcript complementary to a naturally occurring mRNA transcript, the method comprising administering a therapeutically effective amount of an agent for regulating expression of the naturally occurring antisense transcript.

30 According to still further features in the described preferred embodiments the agent for regulating expression of the naturally occurring antisense transcript is at

least one oligonucleotide designed and configured so as to hybridize to a sequence region of the at least one naturally occurring antisense transcript.

According to still further features in the described preferred embodiments the at least one oligonucleotide is a ribozyme.

5 According to still further features in the described preferred embodiments the at least one oligonucleotide is a sense transcript.

According to a supplementary aspect of the present invention there is provided a method of diagnosing a disease, condition or syndrome associated with a substandard expression ratio of an mRNA of interest over a naturally occurring antisense transcript complementary to the mRNA of interest, the method comprising:
10 (a) quantifying expression level of the mRNA of interest and the naturally occurring antisense transcript complementary to the mRNA of interest; (b) calculating the expression ratio of the mRNA of interest over the naturally occurring antisense transcript complementary to the mRNA of interest, thereby diagnosing the disease,
15 condition or syndrome.

According to still a supplementary aspect of the present invention there is provided A computer readable storage medium comprising data stored in a retrievable manner, said data including sequence information of co-regulated human polynucleotide sequences as set forth in files seqs_125 and/or seqs_133 of enclosed
20 CD-1, polypeptide sequences encoded by the polynucleotide sequences as set forth in the file pep_seqs_133 of enclosed CD-ROM 3 and sequence annotations as set forth in the file annotations_133 of enclosed CD-ROM 3.

According to still a supplementary aspect of the present invention there is provided a method of modulating an activity or expression of a gene product, the
25 method comprising upregulating or down regulating expression or activity of a naturally occurring antisense transcript of the gene product, thereby modulating the activity or expression of the gene product.

According to still further features in the described preferred embodiments the method further comprising upregulating or down regulating expression or activity of
30 the gene product.

According to still a supplementary aspect of the present invention there is provided an isolated polynucleotide comprising any of the nucleic acid sequences set

forth in the file seqs_125 or seqs_133 of the enclosed CD-ROM1 of the enclosed CD-ROM 1.

According to a supplementary aspect of the present invention there is provided an isolated polypeptide comprising any of the amino acid sequences set forth in the
5 pep_seqs_133 of enclosed CD-ROM-3.

According to still a supplementary aspect of the present invention there is provided a method of enhancing a therapeutic efficacy of a therapeutic agent, the method comprising providing to a subject in need thereof a naturally occurring antisense transcript of a gene encoding an expression product targeted by the therapeutic agent prior to, concomitant with, or following provision of the therapeutic agent, thereby enhancing the therapeutic efficacy of the therapeutic agent.

According to still a supplementary aspect of the present invention there is provided a method of enhancing a therapeutic efficacy of a therapeutic agent, the method comprising providing to a subject in need thereof a naturally occurring antisense transcript of a gene encoding an expression product capable of inhibiting therapeutic activity of the therapeutic agent, prior to, concomitant with, or following provision of the therapeutic agent thereby enhancing the therapeutic efficacy of the therapeutic agent.

According to still a supplementary aspect of the present invention there is provided a method of enhancing a therapeutic efficacy of a therapeutic agent, the method comprising providing to a subject in need thereof a polynucleotide complementary to a naturally occurring antisense transcript of a gene encoding an expression product capable of upregulating activity or expression of the therapeutic agent prior to, concomitant with, or following provision of the therapeutic agent, thereby enhancing the therapeutic efficacy of the therapeutic agent.

The present invention successfully addresses the shortcomings of the presently known configurations by providing a novel approach for identifying naturally occurring antisense transcripts, methods of designing artificial antisense transcripts according to information derived therefrom, methods and kits using
10 naturally occurring and synthetic antisense transcripts, and by providing the naturally occurring and synthetic antisense transcripts thereof.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

In the drawings:

FIG. 1 illustrates EST alignment along genomic DNA, generated according to the teachings of the present invention. Alignment results identify two strand groups of transcripts i.e., sense transcripts and antisense transcripts with an indicated sequence overlap.

FIG. 2 is a black box diagram illustrating a system designed and configured for generating a database of naturally occurring antisense sequences generated according to the teachings of the present invention.

FIG. 3 is a black box diagram illustrating a remote configuration of the system described in Figure 2.

FIGs. 4a-k are sequence alignments of overlapping regions of selected naturally occurring antisense and sense sequence pairs identified according to the teachings of the present invention.

FIGs. 5a-g are sequence alignments of overlapping regions of selected naturally occurring antisense and sense sequence pairs identified according to the teachings of the present invention.

FIG. 6 schematically illustrates two transcription products of 53BP1 gene (red and green) and their corresponding partial complementary antisense transcripts of the 76p gene (blue). Numbers in parenthesis indicate length of sequence complementation. Schematic location of strand-specific RNA probes used for northern blotting of sense (53BP1, Riboprobe#1) and antisense (76p, Riboprobe#2) transcripts is shown.

FIG. 7 is an autoradiogram of a northern blot analysis depicting cellular distribution and expression levels of 53BP1 transcripts. Arrows on the right indicate the molecular weight of the identified 53BP1 transcripts relative to the migration of 28S and 18S ribosomal RNA subunits. [Numbers on the left denote the size of molecular weight markers in Kb.

FIG. 8 is an autoradiogram of a northern blot analysis depicting cellular distribution and expression levels of 76p transcripts. Arrows on the right indicate the molecular weight of the identified 76p transcripts relative to the migration of 28S and 18S ribosomal RNA subunits. [Numbers on the left denote the size of molecular weight markers in Kb.

FIG. 9 is an autoradiogram of a northern blot analysis depicting tissue distribution and expression levels of 76p transcripts. Arrows on the right indicate the molecular weight of the identified 76p transcripts. Numbers on the left denote the migration of molecular weight marker in Kb.

FIG. 10 illustrates the genomic organization of the 53BP1 gene and 76p gene, as elucidated from the RT-PCR analysis presented in the Examples section hereinbelow. Black arrows indicate the location of the primers used for RT-PCR analysis. Asterisks denote stop codons.

FIG. 11 schematically illustrates two transcription products of CIDE-B gene and their corresponding partial complementary antisense transcript of the BLTR2 gene. Schematic location of the strand-specific 430 nucleotide RNA probe used for northern analysis of sense (CIDE-B) and antisense (BLTR2) transcripts is shown. Dashed rectangles indicate the predicted coding sequence of the transcripts.

FIG. 12 is an autoradiogram of a northern blot analysis depicting cellular distribution and expression levels of BLTR2 transcripts. Arrows on the right indicate the molecular weight of the identified BLTR2 transcripts relative to the migration of 28S and 18S ribosomal RNA subunits. Numbers on the left denote the size of molecular weight markers in Kb.

FIG. 13 shows autoradiogram of a northern blot analysis depicting cellular distribution and expression levels of CIDE-B transcripts. Arrows on the right indicate the molecular weight of the identified CIDE-B transcripts relatively to the migration of 28S and 18S ribosomal RNA subunits. Numbers on the left denote the migration size of molecular weight markers in Kb.

FIG. 14 schematically illustrates a transcription product of APAF-1 gene and its corresponding partial complementary antisense transcripts of the EB-1 gene. Schematic location of the strand-specific 366 nucleotide RNA probe used for northern analysis of sense (APAF-1) and antisense (EB-1) transcripts is shown. Asterisks indicate the predicted coding sequence borders of the transcripts.

FIGs. 15a-b are autoradiograms of northern blot analyses depicting cellular distribution and expression levels of EB-1 (Figure 15a) and APAF-1 transcripts (Figure 15b). Numbers on the left denote the size of molecular weight marker in Kb.

FIG. 16 schematically illustrates a transcription product of the MINK-2 gene and its corresponding partial complementary antisense transcript of the AchR- ϵ gene. Schematic location of the strand-specific 280 nucleotide RNA probe used for northern analysis of sense (Mink-2) and antisense (AchR- ϵ) transcripts is shown.

FIGs. 17a-b are autoradiograms of northern blot analyses depicting cellular distribution and expression levels of AchR- ϵ antisense transcripts (Figure 17a) and the sense complementary transcript of Mink-2 (Figure 17b). Arrows on the right denote the migration of molecular weight markers in Kb.

FIG. 18 schematically illustrates a transcription product of Cyclin-E2 gene and its corresponding partial complementary antisense transcript. Schematic location of strand-specific RNA probes used for northern blotting of sense (Riboprobe#1) and antisense (Riboprobe#2) transcripts is shown.

FIGs. 19a-b are autoradiograms of northern blot analyses depicting cellular distribution and expression levels of Cyclin E2 antisense transcript (Figure 19a) and

the sense complementary transcript (Figure 19b). Arrows on the left denote the migration of molecular weight markers in Kb.

FIG. 20 illustrates results from RT-PCR analysis of the expression patterns of CIDE-B transcript and its complementary naturally occurring antisense transcript following concentration dependent induction of apoptosis. Lanes: (1) 50 μ M etoposide; (2) 100 μ M etoposide; (3) 250 μ M etoposide; (4) 500 μ M etoposide; (5) 10 nM staurosporine; (6) 100 nM staurosporine; (7) 250 nM staurosporine; (8) 1000 nM staurosporine; (9) untreated cells (UT).

FIGs. 21a-c are results of RT-PCR analyses depicting expression patterns of AchRe and its naturally occurring antisense transcript following time-dependent induction of differentiation. Figure 21a illustrates the position of riboprobes used for reverse transcription reaction. Figure 21b shows the reciprocal expression pattern of sense and antisense transcripts (indicated by arrows). Figure 21c shows the expression pattern of the antisense transcript alone.

FIGs. 22a-j illustrate results of northern blot analysis of sense/antisense clusters revealing positive signals for sense/antisense genes in the microarray analysis. Diagrams describing genomic organization of the relevant region for each of the sense/antisense clusters are included above the autoradiograms, and regions of overlap (including GenBank accession number) from which the strand-specific riboprobes were derived are included. Sense-antisense pair numbers are as they appear in the microarray (as depicted in Table_S2 on the attached CD-ROM2 and in conversion Table 6). Figure 22a reveals expression patterns of randomly selected sequence pair number 235, denoted as Rand_235 in Table 6. Similarly, Figure 22b corresponds to pair number 173, Figure 22c to pair number 248, Figure 22d to pair number 6, Figure 22e to pair number 216, Figure 22f to pair number 239, Figure 22g to pair number 202, Figure 22h to pair number 114, Figure 22i to pair number 188, and Figure 22j to pair number 223. Eight pairs (Figures 22a-h) evaluated revealed positive signals for both sense and antisense expression, while two (Figures 22i-j) revealed a positive signal for only one of the genes, with the counterpart being a known RefSeq mRNA.

FIG. 23 is a Table depicting expression patterns in various cell lines and tissues as probed with a subset of 264 pairs from the putative sense/antisense dataset

of the present invention. The pairs are denoted by the pair number and described in Table_S1 of CD-ROM2. "C" and "AC" denote the two counterpart probes. Expression was also verified for positive controls, including the ubiquitously expressed genes *gapdh*, *actin*, *hsp70* and *gnb2l1* in various concentrations, and 11 previously documented sense/antisense pairs. Expression thresholds were verified and indicated as "+", if the probe passed the threshold in at least one cell line or tissue or "-", if the probe did not pass the threshold in all experiments. In cases where both the sense and the antisense oligo passed the expression threshold, the antisense was declared "verified". In cases where only one of the probes passed the expression threshold, but the other probe was fully contained within a known mRNA deposited in GenBank, the antisense was declared "indirectly verified". Normalization for microarray signals was conducted as described in the methods section. *R/ji* ratios were obtained for each cell line/tissue assessed. Cases of flagged-out spots for which there was no information were marked "-1.00". Data represent values of the two reciprocal experiments.

FIG. 24a is a sequence alignment showing a 5'-5' overlap between Nicastrin (NCSTN, GenBank Accession No. NM_015331) and coatomer protein complex subunit α (COPA, GenBank Accession No. NM_004371).

FIG. 24b is a histogram showing expression of NCSTN and two isoforms of COPA in a number of samples, as determined by Affymetrix U133 microarray. The expression levels of the long variant of COPA are shown in purple, while the expression levels of NCSTN are in yellow. The expression levels in different samples 1-5 are from different microarray experiments.

FIG. 25a is a sequence alignment showing a 3'-3' overlap between IL-24 (GenBank Accession No. NM_006850) and TOSO (GenBank Accession No. NM_005449).

FIG. 25b shows automatic annotation for IL-24 and TOSO obtained using the annotation platform described in Example 10 of the Examples section, which follows.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of methods of identifying naturally occurring antisense transcripts, which can be used in kits and methods for quantifying gene

expression levels. Specifically, the antisense molecules and related oligonucleotides generated according to information derived therefrom of the present invention can be used to detect, quantify, or specifically regulate antisense and respective sense transcripts thereby enabling detection and treatment of a wide range of disorders.

5 The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following
10 description or illustrated in the drawings described in the Examples section. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

15 ***Terminology***

As used herein, the term "oligonucleotide" refers to a single stranded or double stranded oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring bases, sugars and covalent internucleoside linkages (e.g.,
20 backbone) as well as oligonucleotides having non-naturally-occurring portions, which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

25 The term "antisense" refers to a complementary strand of an mRNA transcript e.g., antisense RNA.

The phrase "naturally occurring antisense transcripts" refers to RNA transcripts encoded from an antisense strand of the DNA. These endogenous transcript exhibit at least partial complementarity to mRNA transcripts transcribed
30 from the sense strand of a DNA, also termed sense transcripts. *cis*-encoded naturally occurring antisense transcripts are transcribed from the same locus as the sense

transcripts. *trans*-encoded antisense transcripts are transcribed from a different locus than the respective sense transcripts.

The phrase "antisense strand" or "anticoding strand" refers to a strand of DNA, which serves as a template for mRNA transcription and as such is
5 complementary to the mRNA transcript formed.

The phrase "sense strand" or "coding strand" refers to the strand of DNA, which is identical to the mRNA transcript formed.

The phrase "complementary DNA" (cDNA) refers to the double stranded or single stranded DNA molecule, which is synthesized from a messenger RNA
10 template.

The phrase "sense oriented polynucleotides" refers to polynucleotide sequences of a complementary or genomic DNA. Such polynucleotide sequences can be from exon regions, in which case they can encode mRNAs or portions thereof, or from intron regions, in which case they typically do not encode mRNA or portions
15 thereof.

The term "contig" refers to a series of overlapping sequences with sufficient identity to create a longer contiguous sequence.

The term "cluster" refers to a plurality of contigs all derived, with a high degree of probability, from a single gene. Clusters are generally formed based upon a
20 specified degree of homology and overlap (e.g., a stringency). The different contigs in a cluster do not typically represent the entire sequence of the gene, rather the gene may comprise one or more unknown intervening sequences between the defined contigs.

The phrase "open reading frame" (ORF) refers to a nucleotide sequence,
25 which could potentially be translated into a polypeptide. Such a stretch of sequence is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons. For the purposes of this application, an ORF may be any part of a coding sequence, with or without start and/or stop codons. For an ORF to be considered as a
30 good candidate for coding for a bona fide cellular protein, a minimum size requirement is often set, for example, a stretch of DNA that would code for a protein of 50 amino acids or more. An ORF is not usually considered an equivalent to a gene

or locus until a phenotype is associated with a mutation in the ORF, an mRNA transcript for a gene product generated from the ORF's DNA has been detected, and/or the ORF's protein product has been identified.

The term "annotation" refers to a functional or structural description of a sequence, which may include identifying attributes such as locus name, poly(A)/poly(T) tail and/or signal, key words, Medline references and orientation cloning data.

Naturally occurring antisense molecules can play a role in sense transcription stability and function (e.g. translation). To date, most, if not all of the information relating to naturally occurring antisense transcripts was obtained by either low efficiency computational approaches (described hereinabove) or by approaches utilizing RNase protection assays, northern blot analysis, strand-specific RT PCR, subtractive hybridization, differential plaque hybridization, affinity chromatography, electrospray mass spectrometry and the like. These methods, though highly reliable, are extremely laborious, time consuming and are directed at individual target transcripts. As such, current approaches for uncovering antisense transcripts can be used to detect a negligible portion of the number of naturally occurring antisense molecules thought to exist.

As described hereinunder and in the Examples section, which follows, the present invention provides a novel approach for systematically identifying naturally occurring antisense molecules.

Aside from large scale applicability, the present method can be used to identify naturally occurring antisense molecules even in cases where the antisense transcriptional unit is localized to an intron of an expressed gene or to a different locus than the complementary sense encoding gene (e.g., trans-encoded antisense), or in cases where the antisense molecule lacks an open reading frame or appreciable complementarity to known sense molecules. Antisense transcripts uncovered according to the teachings of the present invention can be used for detecting and accurately quantifying respective sense counterparts as well as for sensibly designing artificial antisense molecules suitable for down-regulation of sense counterparts.

Thus, according to one aspect of the present invention there is provided a method of identifying putative naturally occurring antisense transcripts.

The method according to this aspect of the present invention is effected by the following steps.

First, sense-oriented polynucleotide sequences of a first database are computationally aligned with expressed polynucleotide sequences of a second
5 database.

Following computational alignment, expressed polynucleotide sequences are analyzed according to one or more criteria for their ability to hybridize or form a duplex or partial complementation with the sense-oriented polynucleotide sequences (further detailed hereinbelow and in the Examples section which follows).

10 Expressed polynucleotide sequences which are capable of forming a duplex with sense oriented sequences are considered as putative naturally occurring antisense molecules and as such can be stored in a database which can be generated by a suitable computing platform.

Final confirmation of computationally obtained putative naturally occurring
15 antisense molecules can be effected either computationally or preferably by using suitable laboratorial methodologies, based on nucleotide hybridization including RNase protection assay, subtractive hybridization, differential plaque hybridization, affinity chromatography, electrospray mass spectrometry, northern analysis, RT-PCR and the like (for further details see the Examples section).

20 Information derived from the sequence, sense position and other structure characteristics of the naturally occurring antisense transcripts identified according to the teachings of the present invention can be used to quantify respective sense transcripts of interest or to generate corresponding artificial antisense polynucleotides, which can be packed in diagnostic or therapeutic kits and implemented in various
25 therapeutic and diagnostic methods.

Expressed polynucleotide sequences used as a potential source for identifying naturally occurring antisense transcripts according to this aspect of the present invention are preferably libraries of expressed messenger RNA [i.e., expressed sequence tags (EST), cDNA clones, contigs, pre-mRNA, etc.] obtained from tissue or
30 cell-line preparations which can include genomic and/or cDNA sequence.

Expressed polynucleotide sequences, according to this aspect of the present invention can be retrieved from pre-existing publicly available databases (i.e.,

GenBank database maintained by the National Center for Biotechnology Information (NCBI), part of the National Library of Medicine, and the TIGR database maintained by The Institute for Genomic Research) or private databases (i.e., the LifeSeq.TM and PathoSeq.TM databases available from Incyte Pharmaceuticals, Inc. of Palo Alto, CA).

5 Alternatively, the sequence database of the expressed polynucleotide sequences utilized by the present invention can be generated from sequence libraries (e.g., cDNA libraries, EST libraries, mRNA libraries and others). cDNA libraries are suitable sources for expressed sequence information.

 Generating a sequence database in such a case is typically effected by tissue or
10 cell sample preparation, RNA isolation, cDNA library construction and sequencing.

 It will be appreciated that such cDNA libraries can be constructed from RNA isolated from whole organisms, tissues, tissue sections, or cell populations. Libraries can also be constructed from tissue reflecting a particular pathological or physiological state. Of particular interest are libraries constructed from sources
15 associated with certain disease states, including malignant, neoplastic, hyperplastic tissues and the like.

 Once raw sequence data is obtained, sequences are selected and preferably annotated before stored in a database. Selection proceeds according to one or more sequence criterion, which will be further detailed hereinunder. The editing,
20 annotation and selection process is divided into two stages of processing. One stage comprises removal of repetitive, redundant or non-informative and contaminant sequences. The second stage involves selection of suitable candidates of putative naturally occurring antisense sequences.

 The following section describes the different selection criteria which can be
25 used for sequence filtering.

Vector contamination - "chops" vector elements and linker motifs used for the process of cloning from desired expressed nucleotide sequences. This selection can be effected by screening manually updated databases of sequences included in commonly used expression or cloning vectors.

30 *Contaminating sequences* - includes sequences which are derived from an undesired source. Such sequences can be recognized by their nucleotide distribution and/or by homology searches such as alignment searches using any sequence

alignment algorithm such as BLAST (Basic Local Alignment Search Tool, available through www.ncbi.nlm.nih.gov/BLAST) or the Smith-Waterman algorithm. Other contaminating sequences may include sequences exhibiting high occurrence of di-nucleotide distribution mostly related to sequencing artifacts and ribosomal RNA sequences.

Repetitive elements and low complexity sequences - eliminates or masks expressed sequences comprising known repetitive elements (ALU, L1 etc.) and low complexity sequences (i.e., a di- or tri-nucleotide repeat). Such elimination is preferably effected by comparison with database of known repetitive elements. It will be appreciated that this type of selection is mostly species specific. Masking of low complexity sequences can be effected by substituting an N (i.e., an inert character) for the actual nucleotide (i.e., G, A, T, or C). Masking of low complexity sequences facilitates further computational analysis and maintains the spacing of the molecule.

Sequence length - preferred expressed sequences are of a length between 20-2000, preferably 20-1000, more preferably 20-500, most preferably 20-300 base pairs.

Sequence annotation - expressed sequences retrieved from external databases, i.e., GenBank, oftentimes include an annotation which indicates direction of the sequencing of the insert clone (i.e., 5' or 3' direction). Sequence annotation, though "noisy" by nature due to multiple entries from various sources; artifacts taking place during directional cloning and incidence of palindromic eight-cutter restriction sites located at the end of the sequence, can serve as an important tool for deducing strand identity using dedicated computer software which are further discussed hereinunder

Intron splice site consensus sequence intron splice site sharing- intron sequences nearly always begin with a di-nucleotide sequence of GT ("splice donor") and end with an AG ("splice acceptor") preceded by a pyrimidine-rich tract. This consensus sequence is part of the signal for splicing. Intron splice site consensus sequence on the complementary strand (e.g., antisense strand) begins with CT and ends with AC. Thus, combined with genomic data, expressed sequences having a GT...AG can be considered as sense-oriented sequences, while a CT...AC pattern is considered as an antisense oriented sequence. This selection criterion is very stringent since only negligible portions of introns have a CT...AC pattern. Sequences

that share a similar splicing pattern, as deduced by alignment to genomic data, may be considered as having the same sense orientation, also termed herein as "intron sharing". It will be appreciated by one skilled in the art that using these selection criteria requires a careful and accurate alignment of expressed sequences to genomic
5 sequence.

Poly(A) tails and Poly(T) heads – most eukaryotic mRNA molecules contain a poly-adenylation [poly(A)] tail at their 3' end. This poly(A) tail is not encoded by DNA. Therefore an expressed sequence which has a poly(A) tail can be considered as sense oriented. Similarly, poly(T) heads, which are not encoded from a genomic
10 sequence indicate that a sequence is of the opposite direction, namely antisense oriented. Notably, genomically encoded Poly(A) tails and poly(T) heads provide no information as to the sequence orientation.

Poly(A) signal – some mature mRNA transcripts contain internal AAUAAA sequence. This internal sequence is part of an endonuclease cleavage signal.
15 Following cleavage by the endonuclease, a poly(A) polymerase adds about 250 A residues to the 3' end of the transcript. Hence, expressed sequences containing a poly(A) signal can be considered as sense oriented.

Rare restriction site used for cloning– for example, eight cutter endonucleases which cleave 8-mer palindromic sequences and are characterized by a
20 low frequency of cutting often used in genome mapping and EST library preparations (e.g., NotI. Commercially available from Promega: www.promega.com). Therefore, when a cluster of overlapping expressed sequences is characterized by a portion of sequences starting with a digestion site and another portion ending with the same, these sequences may be considered as encoded from the same strand. However, any
25 endonuclease capable of digesting a palindromic sequence (i.e., XhoI, Sall, PacI etc.) may also affect distorted sequence clustering, therefore strand orientation is preferably effected using other parameters as well.

Sequence overlap - sequences that completely overlap are considered to have the same strand orientation.

30 The above-described parameters are used individually or in combination to analyze the expressed polynucleotide sequences so as to select anti-sense oriented sequences.

Selection can be effected on the basis of a single criterion or several criteria considered individually or in combination.

In cases where several criteria are examined, a scoring system e.g., a scoring matrix, is preferably used.

5 Since in some cases identifying an intron splicing consensus site may be more important than both sequence annotation and NotI alignment, while in others, detection of poly(A) tails and poly(T) heads might be the most significant criterion, the use of a scoring matrix in which each criterion is weighted enables one to select qualified antisense transcripts.

10 Such a scoring matrix can list the various expressed polynucleotide sequences across the X-axis of the matrix while each criterion can be listed on the Y-axis of the matrix. Criteria include both a predetermined range of values from which a single value is selected from each sequence, and a weight. Each sequence is scored at each criterion according to its value and the weight of the criterion.

15 When using such a scoring matrix the scores of each criterion of a specific sequence are summed and the results are analyzed.

 Expressed sequences which exhibit a total score greater than a particular stringency threshold are grouped as members of either a sense-oriented sequence set or antisense-oriented sequence set; the higher the score the more stringent the criteria
20 of grouping.

 It will be appreciated that the above-described analysis can take place prior to computational alignment to sense oriented sequences, i.e., during the process of editing the expressed sequence database, which is, described hereinabove. Alternatively, selection can take place following computational alignment, thus
25 further facilitating identification of proper duplex formation between the sense oriented polynucleotide sequences and expressed polynucleotide sequences.

 Genomic DNA or a portion thereof is preferably used as sense-oriented sequence data according to this aspect of the present invention. It is conceivable that the present invention can determine sense orientation and antisense orientation of a
30 database of expressed sequences simply by computationally aligning the sequences of the expressed database onto the genome, and finding whether two complementary expressed sequences hybridize to the genome (e.g., virtually generate a double

stranded portion thereof). Such two overlapping sequences constitute sense and naturally occurring antisense transcripts.

Utilizing genomic DNA as a sense oriented template is preferred for the following reasons: (i) identifying trans-encoded antisense transcripts; (ii) analyzing
5 intron splice consensus site and intron sharing; (iii) omitting genomically encoded poly(A) and poly(T) sequences; and (iv) analyzing sequences encompassing eight-cutter restriction sites.

Computational alignment of expressed polynucleotide sequences to the sense-oriented polynucleotide sequences (e.g., genomic sense sequences) can be effected
10 using any commercially available alignment software, including sequence alignment tools utilizing algorithm such as BLAST (Basic Local Alignment Search Tool, available through www.ncbi.nlm.nih.gov/BLAST) or Smith-Waterman.

Assembly software is preferably used according to this aspect of the present invention. Such software is of high value when complete genomic information is
15 unavailable or when handling large amounts of expressed sequence data. A number of commonly used computer software fragment read assemblers capable of forming clusters of expressed sequences are now available. These packages include but are not limited to, The TIGR Assembler [Sutton G. et al. (1995) *Genome Science and Technology* 1:9-19], GAP [Bonfield JK. et al. (1995) *Nucleic Acids Res.* 23:4992-
20 4999], CAP2 [Huang X. et al. (1996) *Genomics* 33:21-31], The Genome Construction Manager [Laurence CB. Et al. (1994) *Genomics* 23:192-201], Bio Image Sequence Assembly Manager, SeqMan [Swindell SR. and Plasterer JN. (1997) *Methods Mol. Biol.* 70:75-89], LEADS and GenCarta (Compugen Ltd. Israel).

Computer assembly and alignment programs can be modified to incorporate
25 sequence criteria for determining sense or antisense orientation of expressed nucleotide sequences, as described hereinabove. Thereby, avoiding deliberate inversion of sequences during the assembly process, while ignoring the natural orientation of the sequences (i.e., sense or antisense orientation). Figure 1 illustrates results of expressed sequence assembly against genomic data and final distinction
30 between sense oriented transcripts and antisense oriented transcripts of a single gene.

Following a proper alignment of expressed sequences to sense oriented polynucleotide sequences, duplexes are identified. The term "duplex" is used herein

to indicate that a sequence identified according to this aspect of the present invention is complementary to a sense-oriented polynucleotide sequence. Complementation may be to a portion of the sense sequence, i.e., a region thereof, or alternatively, to two or more non-contiguous regions, which may be separated by one or more nucleotides on the sense strand.

The formation of sense-antisense duplexes does not require 100 % complementation nor does it require participation of the entire sense/antisense transcript sequence. The sense or antisense transcripts can have a secondary structure (e.g., stem and loop) generated by intra-sequence hybridization which can prevent specific sequence regions in the sense or antisense transcripts from participating in duplex formation. Thus, the antisense of the sequence identified, according to this aspect of the present invention can be complementary to its sense counterparts in several regions, which are not necessarily close to each other when the sense transcript is in linear form.

Although any length of sequence overlap can generate a duplex, overlaps of at least about 5, preferably about 20, more preferably about 30, even more preferably about 40 bp are considered more indicative of true sense-antisense duplex formation.

The method of uncovering putative antisense transcripts of the present invention is preferably carried out using a dedicated computational system.

Thus, according to another aspect of the present invention and as illustrated in Figure 2, there is provided a system for generating a database of putative naturally occurring antisense sequences which system is referred to hereinunder as system 10.

System 10 includes at least one central processing unit (CPU) 12, which executes a software application designed and configured for aligning sense oriented polynucleotide sequences with expressed polynucleotide sequences and identifying expressed polynucleotide sequences which are capable of forming a duplex with the sense oriented polynucleotide sequences, thereby recognizing putative naturally occurring antisense transcripts. System 10 may also include a user input interface 14 [e.g., a keyboard and/or a cursor control device (e.g., a joy stick)] for inputting database or database related information, and a user output interface 16 (e.g., a monitor) for providing database information to a user.

System 10 may also include random access memory 24, ROM memory 26, a modem 28 and a graphic processing unit (GPU) 30.

System 10 preferably stores sequence information of the putative antisense transcripts identified thereby on an internal and/or external storage device 20 such as a magnetic, optico-magnetic or optical disk as a database of putative antisense transcript sequences. Such a database further includes information pertaining to database generation (e.g., source library), parameters used for selecting polynucleotide sequences, putative uses of the stored sequences, and various other annotations (as described below) and references which relate to the stored sequences or respective sense transcripts.

The hardware elements of system 10 may be tied together by a common bus or several interlinked buses for transporting data between the various elements. Examples of system 10 include but are not limited to, a personal computer, a work station, a mainframe and the like.

System 10 of the present invention may be used by a user to query the stored database of sequences, to retrieve nucleotide sequences stored therein or to generate polynucleotide sequences from user inputted sequences.

The methods of the present invention can be effected by any software application executable by system 10. The software application can be stored in random access memory 24, or internal and/or external data storage device 20 of system 10.

The database generated and stored by system 10 can be accessed by an on-site user of system 10, or by a remote user communicating with system 10, through for example, a terminal or thin client.

The latter configuration is best exemplified by the client-server system 50 which is shown in Figure 3. System 50 is configured to perform similar functions to those performed by system 10. In system 50, communication between a remote client 18 (e.g., computer, PDA, cell phone etc) and processing unit 12 of a local server or computer is typically effected via a communication network 32. Communication network 32 can be any private or public communication network including, but not limited to, a standard or cellular telephony network, a computer

network such as the Internet or intranet, a satellite network or any combination thereof.

As illustrated in Figure 3, communication network 32 can include one or more communication servers 22 (one shown in Figure 3) which serve for communicating data pertaining to the sequence of interest between remote client 18 and processing unit 12. Thus, a request for data or processed data is communicated from remote client 18 to processing unit 12 through communication network 32 and processing unit 12 sends back a reply which includes data or processed data to remote client 18. Such a system configuration is advantageous since it enables users of system 50 to store and share gathered information and to collectively analyze gathered information.

Such remote configuration can be implemented over a local area network (LAN) or a wide area network (WAN) using standard communication protocols.

It will be appreciated that existing computer networks such as the Internet can provide the infrastructure and technology necessary for supporting data communication between any number of users 18 and processors 12.

Novel polynucleotide sequences uncovered using the above-described methodology can be used in various clinical applications (e.g., therapeutic and diagnostic) as is further described hereinbelow.

A polynucleotide sequence of the present invention refers to a single or double stranded nucleic acid sequence which is isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a genomic polynucleotide sequence and/or a composite polynucleotide sequence (e.g., a combination of the above).

As used herein the phrase "complementary polynucleotide sequence" refers to a sequence, which results from reverse transcription of messenger RNA using a reverse transcriptase or any other RNA dependent DNA polymerase. Such a sequence can be subsequently amplified *in vivo* or *in vitro* using a DNA dependent DNA polymerase.

As used herein the phrase "genomic polynucleotide sequence" refers to a sequence derived (isolated) from a chromosome and thus it represents a contiguous portion of a chromosome.

As used herein the phrase "composite polynucleotide sequence" refers to a sequence, which is composed of genomic and cDNA sequences. A composite sequence can include some exonal sequences required to encode the polypeptide of the present invention, as well as some intronic sequences interposing therebetween. The intronic sequences can be of any source, including of other genes, and typically will include conserved splicing signal sequences. Such intronic sequences may further include cis acting expression regulatory elements.

Thus, the present invention encompasses nucleic acid sequences described hereinabove; fragments thereof, sequences hybridizable therewith, sequences homologous thereto (e.g., at least about 50 %, at least about 55 %, at least about 60%, at least about 65 %, at least about 70 %, at least about 75 %, at least about 80 %, at least about 85 %, at least about 95 % or more say 100 % homologous to the nucleic acid sequences set forth in the file seqs_125 or seqs_133 of the enclosed CD-ROM1), sequences encoding similar polypeptides with different codon usage, altered sequences characterized by mutations, such as deletion, insertion or substitution of one or more nucleotides, either naturally occurring or man induced, either randomly or in a targeted fashion.

In cases where the polynucleotide sequences of the present invention encode previously unidentified polypeptides, the present invention also encompasses novel polypeptides or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the polynucleotide sequences of the present invention. The present invention also encompasses homologues of these polypeptides, which can optionally be at least about 50 %, at least about 55 %, at least about 60%, at least about 65 %, at least about 70 %, at least about 75 %, at least about 80 %, at least about 85 %, at least about 95 % or more say 100 % homologous to the amino acid sequences set forth in the file pep_seqs_133 of the enclosed CD-ROM3. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

Thus, data extracted from the database of naturally occurring antisense transcripts of the present invention is of high value for designing oligonucleotides suitable for transcript detection and quantification and for sensibly designing artificial antisense oligonucleotides for down-regulation and elimination of a transcript of interest or changing the balance between sense and complementary antisense transcripts. The possibility of up-regulating a transcript of interest using naturally occurring antisense based-oligonucleotides generated according to the teachings of the present invention is also realized. In addition, data extracted from the database of naturally occurring antisense transcripts may also be used for assessing endogenous double stranded-RNA also termed interfering RNA, which may distort gene-expression due to either RNA-degradation, DNA-methylation, polycomb mediated suppression etc. (for details see the Background section hereinabove).

Antisense technology is based upon the pairing of an artificially designed antisense oligonucleotide, with a target nucleic acid. The use of antisense technology requires a complementarity of the antisense nucleotide sequence to a target zone of an mRNA target sequence that will effect inhibition of gene expression [reviewed in Stein CA. and Cohen JS. (1988) Cancer Res. 48:2659-68]. Based on empiric experience it was shown that the success of antisense technology relies on: (i) cellular uptake; (ii) stability of artificial antisense molecules under physiological conditions (i.e., cellular pH, endonucleases etc.); (iii) complementation between the oligonucleotide and a single stranded target sequence (i.e., tertiary structure of target RNA will not form a good target); (iv) binding specificity of antisense oligonucleotide so as not to compete with other RNA binders (e.g. proteins) to thereby maintain an effective antisense concentration.

Various attempts to employ antisense technology while considering the above discussed limitations included using large amounts of oligonucleotides to overcome cellular uptake and environmental barriers and chemically modified antisense nucleotide compositions, for obtaining higher level of cellular stability. However, even in case where uptake difficulties are traversed, the step of target identification (i.e., RNA-target sequence region) continues to be the major bottleneck for successful implementation of antisense technology.

U.S. Pat. No: 6,183,966 discloses a method and an apparatus for ranking nucleic acid sequences based on stability of nucleic acid oligomer sequence binding interactions to select sequence zones for antisense targeting. This method however systematic, relies on thermodynamic analyses combined with numerous predictions
5 which cannot be considered empirically accurate and reliable.

Thus according to another aspect of the present invention there is provided a method of designing artificial antisense transcripts.

The method according to this aspect of the present invention is effected by the following steps.

10 First, structural and/or functional parameters pertaining to naturally occurring antisense transcripts are extracted/deduced from a database such as the one described hereinabove. These parameters may be generally deduced from all sequences stored in the database, or extracted from specific antisense sequences or preferably groups of antisense sequences.

15 Second, artificial antisense molecules of interest are designed according to the extracted parameters.

Such parameters may be divided into three groups, topographical parameters, functional parameters and structural parameters.

Topographical parameters - (i) position of sequence overlap on the sense
20 transcript (i.e., coding region, 5'UTR, 3'UTR); (ii) position of the sequence overlap on the antisense transcript (end overlap, middle overlap, full overlap). (iii) length of overall sequence overlap; (iv) continuity or discontinuity of sequence overlap.

Structural parameters - pertains to both sense and antisense transcripts (i) tertiary structure (i.e., hairpin, helix, stem and loop, pseudoknot, and the like); (ii)
25 single stranded versus double stranded regions; (iii) GC content; (iv) tandem Gs; (v) adenosine/inosine content; (vi) thermodynamic stability of tertiary structures; (vii) duplex melting point; (viii) methylations and other RNA modifications; (ix) RNA-protein interactions ; and (x) transcript length.

Functional parameters - (i) alternative splicing; (ii) tissue expression; (iii)
30 pathology specific expression; (iv) antisense promoters; (v) intron content; (vi) open reading frame in antisense transcript.

These parameters can be used individually or in combination, in which case, each parameter is preferably weighted according to its importance. Due to the multi-factorial design of artificial antisense transcripts according to this aspect of the present invention, employing a scoring system (described hereinabove) is preferably
5 used to simplify and increase the accuracy of the process.

Synthetic antisense oligonucleotides designed according to the teachings of the present invention can be generated according to any oligonucleotide synthesis method known in the art such as enzymatic synthesis or solid phase synthesis. Equipment and reagents for executing solid-phase synthesis are commercially
10 available from, for example, Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the capabilities of one skilled in the art.

Oligonucleotides used according to this aspect of the present invention are those having a length selected from a range of from about 10 to about 200 bases, preferably from about 15 to about 150 bases, more preferably from about 20 to about
15 100 bases, most preferably from about 20 to about 50 bases.

The oligonucleotides of the present invention may comprise heterocyclic nucleosides consisting of purines and the pyrimidines bases, bonded in a 3' to 5' phosphodiester linkage.

20 Preferably used oligonucleotides are those modified in either backbone, internucleoside linkages or bases, as is broadly described hereinunder. Such modifications can oftentimes facilitate oligonucleotide uptake and resistance to intracellular conditions.

Specific examples of preferred oligonucleotides useful according to this aspect
25 of the present invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone, as disclosed in U.S. Pat. NOs: ,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496;
30 5,455,233; 5,466, 677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms can also be used.

Alternatively, modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts, as disclosed in U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623, 070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439.

Other oligonucleotides which can be used according to the present invention, are those modified in both sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for complementation with the appropriate polynucleotide target. An example for such an oligonucleotide mimetic, includes peptide nucleic acid (PNA). A PNA oligonucleotide refers to an oligonucleotide where the sugar-backbone is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The

bases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Other backbone
5 modifications, which can be used in the present invention are disclosed in U.S. Pat. No:6,303,374.

Oligonucleotides of the present invention may also include base modifications or substitutions. As used herein, "unmodified" or "natural" bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine
10 (C) and uracil (U). Modified bases include but are not limited to other synthetic and natural bases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl
15 uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further bases include those disclosed in U.S. Pat.
20 No: 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and
25 Applications, pages 289-302, Crooke, S. T. and Lebleu, B. , ed., CRC Press, 1993. Such bases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine
30 substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2 °C. [Sanghvi YS et al. (1993) Antisense Research and Applications, CRC Press, Boca

Raton 276-278] and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates, which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety, as disclosed in U.S. Pat. No: 6,303,374.

It is not necessary for all positions in a given oligonucleotide molecule to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide.

The present invention also includes antisense molecules, which are chimeric molecules. "Chimeric" antisense molecules", are oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target polynucleotide. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. An example for such include RNase H, which is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense molecules of the present invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, as described above. Representative U.S. patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein fully incorporated by reference.

Finally, chimeric oligonucleotides of the present invention can comprise a ribozyme sequence. Ribozymes are being increasingly used for the sequence-specific inhibition of gene expression by the cleavage of mRNAs. Several ribozyme sequences can be fused to the oligonucleotides of the present invention. These sequences include but are not limited ANGIOZYME specifically inhibiting formation of the VEGF-R (Vascular Endothelial Growth Factor receptor), a key component in the angiogenesis pathway, and HEPTAZYME, a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, (Ribozyme Pharmaceuticals, Incorporated - WEB home page).

Naturally occurring antisense sequences uncovered using the teachings of the present invention can be annotated using information available from a number of publicly available sources of gene annotations well known to those of skill in the art. Examples include, but are not limited to Locus Link and RefSeq: GO annotations, Gencarta (described in Example 10 of the Examples section), GeneCards, GeneLynx, TIGR and the like.

Annotative information obtained using the Gencarta (Compugen, Tel-Aviv, Israel) database is set forth in the file "annotations_133" of the enclosed CD-ROM3. The relation between the co-regulated nucleotide sequences of the present invention and corresponding polypeptide sequences is described in Trans2Pep file in the enclosed CD-ROM3.

Elucidating protein function, pattern of expression, therapeutic and diagnostic roles, allows for the design of highly specific and effective clinical tools, for a wide range of diseases as described in the Examples section which follows.

For example, gene products (nucleic acid and/or protein products), which exhibit tumor specific expression (i.e., tumor associated antigens, TAAs) can be

utilized for in-vitro generation of antibodies and/or for in-vivo immunization/cancer vaccination, essentially eliciting an immune response against such gene products and cells expressing same (see e.g., U.S. Pat. No. 4,235,877, Vaccine preparation is generally described in, for example, M. F. Powell and M. J. Newman, eds., "Vaccine Design (the subunit and adjuvant approach)," Plenum Press (NY, 1995); Other references describing adjuvants, delivery vehicles and immunization in general include Rolland, Crit. Rev. Therap. Drug Carrier Systems 15:143-198, 1998; Fisher-Hoch et al., Proc. Natl. Acad. Sci. USA 86:317-321, 1989; Flexner et al., Ann. N.Y. Acad. Sci. 569:86-103, 1989; Flexner et al., Vaccine 8:17-21, 1990; U.S. Pat. Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Pat. No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, Biotechniques 6:616-627, 1988; Rosenfeld et al., Science 252:431-434, 1991; Kolls et al., Proc. Natl. Acad. Sci. USA 91:215-219, 1994; Kass-Eisler et al., Proc. Natl. Acad. Sci. USA 90:11498-11502, 1993; Guzman et al., Circulation 88:2838-2848, 1993; and Guzman et al., Cir. Res. 73:1202-1207, 1993; Ulmer et al., Science 259:1745-1749, 1993; Cohen, Science 259:1691-1692, 1993; U.S. Pat. Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094; U.S. Pat. Nos. 6,008,200 and 5,856,462; Zitvogel et al., Nature Med. 4:594-600, 19980.

Tumor-specific gene products of the present invention, in particular membrane bound, can be utilized as targeting molecules for binding therapeutic toxins, antibodies and small molecules, to thereby specifically target the tumor cell. Alternatively, neoplastic properties of tumor specific gene products (nucleic acid and/or protein products) of the present invention, may be beneficially used in the promotion of wound healing and neovascularization in ischemic conditions and diabetes.

Secreted variants of known autoantigens associated with a specific autoimmune syndrome, such as for example, those listed in Table 11, below, can be used to treat such syndromes. Typically, autoimmune disorders are characterized by a number of different autoimmune manifestations (e.g., multiple endocrine syndromes). For these reasons secreted variants may be used to treat any combination of autoimmune phenomena of a disease as detailed in Table 11 below. The therapeutic effect of these variants may be a result of (i) competing with autoantigens for binding with autoantibodies; (ii) antigen-specific immunotherapy, essentially suggesting that

systemic administration of a protein antigen can inhibit the subsequent generation of the immune response to the same antigen (proven in mice models for Myasthenia Gravis and type I Diabetes).

Biomolecular sequences, which are over-expressed in a pathology can be used as diagnostic markers, such as for cancer. Variants of autoantigens may also be used for diagnosis. The diagnosis of many autoimmune disorders is based on identification of autoantibodies specific to autoantigens known to be associated with an autoimmune condition. Most of the diagnostic techniques are based on having a recombinant form of the autoantigen and using it to look for serum autoantibodies. It is possible that currently considered autoantigens are not "true" autoantigens but rather variants thereof. For example, TPO is a known autoantigen for thyroid autoimmunity. It has been shown that its variant TPOzanelli also takes part in the autoimmune process and can bind the same antibodies as TPO [Biochemistry. 2001 Feb 27;40(8):2572-9.]. Antibodies formed against the true autoantigen may bind to other variants of the same gene due to sequence overlap but with reduced affinity. Novel splice variant of the genes in Table 11 may be revealed as true autoantigens, therefore their use for detection of autoantibodies is expected to result in a more sensitive and specific test.

Additionally, variants of known drug targets can be used in cases where the known drug has major side effects, the therapeutic efficacy of the known drug is moderate, the drug failed clinical trials due to one of the above. A drug which is specific to a new protein variant of the target or to the target only (without affecting the novel variant) is likely to have less side effects as compared with the original drug, higher efficacy and may treat different indications than the original drug.

For example, COX3, which is a variant of COX1, is known to bind COX inhibitors with a different affinity than COX1. This molecule is also associated with different physiological processes than COX1. Therefore, a compound specific to COX1 or compounds specific to COX3 would have lower side effects (by not affecting the other variant), treat different indications and treat successfully bigger populations.

Polynucleotide sequence data (i.e., mRNAs and/or naturally occurring antisense transcripts thereof) obtained according to the teachings of the present invention may also be used for modulating the expression of a gene of interest.

For example, when a product of a gene of interest is an oncogene, it may be desirable to upregulate an expression of a naturally occurring antisense transcript thereof, which is in turn capable of downregulating expression of the gene product (i.e., the oncogene), to thereby inhibit the onset or progression of a malignant disease. See also Example 11 of the Examples section which follows.

Alternatively, when a gene product of interest is a tumor suppressor gene it may be desirable to downregulate expression of a naturally occurring antisense molecule thereof to thereby elevate expression of the tumor suppressor gene and inhibit the onset or progression of a malignant disease.

Upregulation or downregulation of the naturally occurring antisense transcript of the gene product of interest, as described above, may be accompanied by upregulation or down regulation of the gene product itself as necessary (e.g., upregulation of a tumor suppressor gene and down regulation of an oncogene).

Agents for upregulating and down regulating gene products (i.e., mRNA or proteins) are summarized infra.

Upregulating expression of a naturally occurring antisense transcript of interest may be effected via the administration of at least one of the exogenous polynucleotide sequences of the present invention, ligated into a nucleic acid expression construct designed for expression of coding sequences in eukaryotic cells (e.g., mammalian cells). Accordingly, the exogenous polynucleotide sequence may be a DNA or RNA sequence encoding the naturally occurring antisense transcript of interest.

For therapeutic applications, the nucleic acid construct can be administered to an individual in need therefore by employing any suitable mode of administration described hereinbelow (i.e., in-vivo gene therapy). Alternatively, the nucleic acid construct can be introduced into an isolated cells, of for example, a cell culture, using an appropriate gene delivery vehicle/method (transfection, transduction, homologous recombination, etc.). The genetically modified cells thus generated can then be expanded in culture and returned to the individual (i.e., ex-vivo gene therapy).

To enable cellular expression of the polynucleotides of the present invention, the nucleic acid construct of the present invention further includes at least one cis acting regulatory element. As used herein, the phrase "cis acting regulatory element" refers to a polynucleotide sequence, preferably a promoter, which binds a trans acting
5 regulator and regulates the transcription of a coding sequence located downstream thereto.

Any suitable promoter sequence can be used by the nucleic acid construct of the present invention.

Preferably, the promoter utilized by the nucleic acid construct of the present
10 invention is active in the specific cell population transformed. Examples of cell type-specific and/or tissue-specific promoters include promoters such as albumin that is liver specific [Pinkert et al., (1987) Genes Dev. 1:268-277], lymphoid specific promoters [Calame et al., (1988) Adv. Immunol. 43:235-275]; in particular promoters of T-cell receptors [Winoto et al., (1989) EMBO J. 8:729-733] and immunoglobulins;
15 [Banerji et al. (1983) Cell 33:729-740], neuron-specific promoters such as the neurofilament promoter [Byrne et al. (1989) Proc. Natl. Acad. Sci. USA 86:5473-5477], pancreas-specific promoters [Edlun et al. (1985) Science 230:912-916] or mammary gland-specific promoters such as the milk whey promoter (U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). The nucleic acid
20 construct of the present invention can further include an enhancer, which can be adjacent or distant to the promoter sequence and can function in up regulating the transcription therefrom.

The nucleic acid construct of the present invention preferably also includes an appropriate selectable marker and/or an origin of replication. Preferably, the nucleic
25 acid construct utilized is a shuttle vector, which can propagate both in *E. coli* (wherein the construct comprises an appropriate selectable marker and origin of replication) and be compatible for propagation in cells, or integration in a gene and a tissue of choice. The construct according to the present invention can be, for example, a plasmid, a bacmid, a phagemid, a cosmid, a phage, a virus or an artificial
30 chromosome.

Examples of suitable constructs include, but are not limited to, pcDNA3, pcDNA3.1 (+/-), pGL3, PzeoSV2 (+/-), pDisplay, pEF/myc/cyto, pCMV/myc/cyto

each of which is commercially available from Invitrogen Co. (www.invitrogen.com). Examples of retroviral vector and packaging systems are those sold by Clontech, San Diego, Calif., including Retro-X vectors pLNCX and pLXSN, which permit cloning into multiple cloning sites and the transgene is transcribed from CMV promoter.

- 5 Vectors derived from Mo-MuLV are also included such as pBabe, where the transgene will be transcribed from the 5'LTR promoter.

Currently preferred in vivo nucleic acid transfer techniques include transfection with viral or non-viral constructs, such as adenovirus, lentivirus, Herpes simplex I virus, or adeno-associated virus (AAV) and lipid-based systems. Useful
10 lipids for lipid-mediated transfer of the gene are, for example, DOTMA, DOPE, and DC-Chol [Tonkinson et al., Cancer Investigation, 14(1): 54-65 (1996)]. The most preferred constructs for use in gene therapy are viruses, most preferably adenoviruses, AAV, lentiviruses, or retroviruses. A viral construct such as a retroviral construct includes at least one transcriptional promoter/enhancer or locus-defining element(s),
15 or other elements that control gene expression by other means such as alternate splicing, nuclear RNA export, or post-translational modification of messenger. Such vector constructs also include a packaging signal, long terminal repeats (LTRs) or portions thereof, and positive and negative strand primer binding sites appropriate to the virus used, unless it is already present in the viral construct. In addition, such a
20 construct typically includes a signal sequence for secretion of the peptide from a host cell in which it is placed. Preferably the signal sequence for this purpose is a mammalian signal sequence or the signal sequence of the polypeptide variants of the present invention. Optionally, the construct may also include a signal that directs polyadenylation, as well as one or more restriction sites and a translation termination
25 sequence. By way of example, such constructs will typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3' LTR or a portion thereof. Other vectors can be used that are non-viral, such as cationic lipids, polylysine, and dendrimers.

When the naturally occurring antisense transcript and/or gene product of
30 interest are splice isoforms it is possible to promote expression of a specific splice variant by using antisense oligonucleotides, which are directed at splice sites of interest, thereby altering the splicing pattern of the gene. This approach has been

successfully used for shifting the balance of expression of the two isoforms of Bcl-x [Taylor (1999) *Nat. Biotechnol.* 17:1097-1100; and Mercatante (2001) *J. Biol. Chem.* 276:16411-16417]; IL-5R [Karras (2000) *Mol. Pharmacol.* 58:380-387]; and c-myc [Giles (1999) *Antisense Acid Drug Dev.* 9:213-220].

5 For example, interleukin 5 and its receptor play a critical role as regulators of hematopoiesis and as mediators in some inflammatory diseases such as allergy and asthma. Two alternatively spliced isoforms are generated from the IL-5R gene, which include (i.e., long form) or exclude (i.e., short form) exon 9. The long form encodes an intact membrane-bound receptor, while the shorter form encodes a secreted soluble
10 non-functional receptor. Using 2'-O-MOE-oligonucleotides specific to regions of exon 9, Karras and co-workers (supra) were able to significantly decrease the expression of the wild type receptor and increase the expression of the shorter isoforms. Approaches which can be used to design and synthesize oligonucleotides according to the teachings of the present invention are described hereinbelow and by
15 Sazani and Kole (2003) *Progress in Molecular and Subcellular Biology* 31:217-239.

Upregulation at the protein level may be effected by providing the polypeptide gene product (i.e., either of the gene of interest or of the naturally occurring antisense transcript). It will be appreciated that since the bioavailability of large polypeptides is relatively small due to high degradation rate and low penetration rate, administration
20 of polypeptides is preferably confined to small peptide fragments (e.g., about 100 amino acids).

Oligonucleotides for downregulating gene expression are described hereinabove.

Antibodies can also be used to down regulate activity of a gene product (i.e.,
25 protein) of interest. Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art. See for example, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference. Other methods for the generation of antibody fragments include for example, U.S. Pat. Nos. 4,036,945 and 4,331,647, and
30 references contained therein; Porter, R. R. *Biochem. J.* 73: 119-126 (1959); *Proc. Nat'l Acad. Sci. USA* 69:2659-62 (1972); Whitlow and Filpula, *Methods* 2: 97-105 (1991); Bird et al., *Science* 242:423-426 (1988); Pack et al., *Bio/Technology* 11:1271-

77 (1993); and U.S. Pat. No. 4,946,778. References for methods of humanizing non-human antibodies include Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature* 332:323-327 (1988); Verhoeyen et al., *Science*, 239:1534-1536 (1988); U.S. Pat. No. 4,816,567; Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks et al., *J. Mol. Biol.*, 222:581 (1991). The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies [Cole et al., *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, p. 77 (1985) and Boerner et al., *J. Immunol.*, 147(1):86-95 (1991)].

The present invention also envisages enhancing a therapeutic efficacy of a therapeutic agent.

As used herein a "therapeutic agent" refers to a polynucleotide, a polypeptide or a small molecule, which targets a gene product of interest to induce a therapeutic effect in a subject.

Therapeutic agents (drugs), which are used to treat diseases or disorders function through one of several mechanisms. Typically, therapeutic agents target one or more endogenous molecules to exert a negative or positive effect thereupon. The following section describes several therapeutic modalities in which use of naturally occurring antisense transcripts in combination with the therapeutic agent is advantageous.

In cases where the gene product targeted is suppressed or eliminated by the therapeutic agent [e.g., a soluble receptor (i.e., therapeutic agent) which is capable of downregulating an activity of an oncogenic receptor (i.e., target)], the effect of the therapeutic agent can be enhanced by providing to a subject in need thereof a naturally occurring antisense transcript of the gene encoding the expression product targeted by the therapeutic agent prior to, concomitant with, or following provision of the therapeutic agent. Such combination therapy can be utilized to suppress the gene target at both the translational and functional level thus substantially enhancing therapeutic efficacy. Methods of administration are further described hereinbelow.

Alternatively, the subject may be provided with a naturally occurring antisense transcript of a gene which encodes an expression product capable of inhibiting activity or expression of the therapeutic agent prior to, concomitant with, or following provision of the therapeutic agent. For example, any of the sequences shown in Table

9 below, which are of proteins that are involved in drug-drug interactions, may be suitable for selection in this regard. A non-limiting example of such a sequence has the name (gene symbol) "ABCB9". If such a protein was shown to be involved in an interaction which would reduce the efficacy of a therapeutic agent, then the naturally occurring antisense transcript of the corresponding gene could optionally be provided as an adjunct therapy, by being provided to the subject prior to, concomitant with, or following provision of the therapeutic agent.

Still alternatively, the subject may be provided with an inhibitor [e.g., oligonucleotide, small molecule, antibody) of a naturally occurring antisense transcript of a gene which encodes an expression product capable of upregulating activity or expression of the therapeutic agent prior to, concomitant with, or following provision of the therapeutic agent. For example, see Example 12 of the Examples section which follows. In this case the naturally occurring antisense transcript performs a dual function, by both downregulating activity of the therapeutic agent at the transcript level and inhibiting activity at the protein level.

Still alternatively, in cases where a therapeutic agent functions by activating an endogenous molecule such as a cell receptor (e.g., VEGF-R); it may be beneficial to upregulate expression or activity of a naturally occurring antisense transcript of an endogenous non-functional form of this receptor (e.g., soluble VEGF-R). Since the non-functional form of the receptor may be capable of competing for the therapeutic agent and thus masking or eliminating its effect on the cell bound (wt) form of the receptor, provision of a naturally occurring antisense transcript of the non-functional form of the target gene can either increase the beneficial effect of the therapeutic agent and/or reduce the amount of therapeutic agent used in treatment.

The oligonucleotides and polynucleotides of the present invention can be used for therapeutic purposes. For example, oligonucleotides of the present invention can be used to treat a variety of diseases or pathological conditions associated with an abnormal expression (i.e., up-regulation or down-regulation) of at least one mRNA molecule of interest, including but not limited to diabetes, autoimmune diseases, Parkinson, Alzheimer' disease, HIV, malaria, cholera, influenza, rabies, diphtheria, breast cancer, colon cancer, cervical cancer, melanoma, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, lymphomas, leukemias and the like and any other

diseases (see Example 8 of the Examples section) which are associated with aberrant expression of multiple mRNAs (i.e., sense and/or antisense) or with unregulated formation of endogenous double stranded RNA complexes.

Furthermore, accumulated knowledge strongly correlates human diseases with mutations, over-expression and function of the protein building blocks (i.e., protein kinases, phosphatases) and their effectors and regulators, which constitute numerous intracellular signaling pathways. For instance, inactivation of both copies of ZAP-70 or Jak-3 causes severe combined immunodeficiency and mutation of the X-linked BTK gene results in agammaglobulinemia. Many genetic disorders are also associated with mutations for example, in protein-serine kinases (PSKs) and phosphatases. The Coffin-Lowry syndrome results from inactivation of the X-linked Rsk2 gene, and myotonic dystrophy is due to decreased levels of expression of the myotonic dystrophy PSK. In addition, over-expression of ErbB2 receptor tyrosine kinase is implicated in breast and ovarian carcinoma [reviewed by Hunter T. (2000) Cell 100:113-127].

Given the importance of activated kinases in a variety of disorders such as cancer, it would be anticipated that phosphatases regulation would be found as tumor suppressor genes and as promising drug targets. So far this has not proved to be the case. Furthermore, a number of diseases are associated with insufficient expression of signaling molecules, including non-insulin-dependent diabetes and peripheral neuropathies.

Thus, it is conceivable that identification of naturally occurring antisense transcripts of signaling molecules participating in specified signaling pathways may serve as promising tools for both identification and particularly treatment of a variety of disorders at any gene expression level (i.e., RNA, DNA or protein).

The term "treating" refers to alleviating or diminishing a symptom associated with the disease or the condition and/or eliminating the cause of the disease or condition. Preferably, treating cures, e.g., substantially eliminates, and/or substantially decreases, the symptoms and/or cause of the disease or condition.

The treatment method according to the teachings of the present invention includes administering to an individual a therapeutically effective amount of the oligonucleotides, polynucleotides or other agents of the present invention. Preferred

individual subjects according to the present invention are mammals such as canines, felines, ovines, porcines, equines, bovines, humans and the like.

A therapeutically effective amount implies an amount of agent effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the individual being treated

The agent of the method of the present invention can be administered to an individual *per se*, or as part of a pharmaceutical composition where it is mixed with a pharmaceutically acceptable carrier.

As used herein a "pharmaceutical composition" refers to a composition of one or more of the agents described hereinabove, or physiologically acceptable salts or prodrugs thereof, with other chemical components. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

5 Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

10 The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid
15 carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

 The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present
20 invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

 In one embodiment of the present invention the pharmaceutical compositions
25 may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and
30 formulation arts and may be applied to the formulation of the compositions of the present invention.

The pharmaceutical compositions of the present invention may employ various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants [Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems (1991) 92] as disclosed in U.S. Pat. No: 6,300,132, 6,271,030, 6,277,633, 6,284,538, 6,287,860, 6,294,382, 6,277,640 and 6,258,601 each of which is herein fully incorporated by reference.

Other substances that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical compositions of the present invention. For example, cationic lipids, such as lipofectin [U.S. Pat. No. 5,705,188], cationic glycerol derivatives, and polycationic molecules, such as polylysine [PCT Application WO 97/30731], are also known to enhance the cellular uptake of oligonucleotides.

Other reagents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Certain pharmaceutical compositions of the present invention may also incorporate carrier compounds. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The co-administration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4' isothiocyano-stilbene-2,2'-disulfonic acid [Miyao et al., Antisense Res.

Dev., (1995) 5:115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.* (1996) 6:177-183].

In contrast to a carrier compound, an "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical excipients include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration, which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose,

magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation. Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC50 found to be effective in in vitro and in vivo animal models. Persons of ordinary skill in the art can easily estimate dosing and repetition rates based on measured residence times and concentrations of the oligonucleotide in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient

undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses.

As mentioned hereinabove, biomolecular sequences of the present invention can also be used in diagnostic applications. Present-day mRNA-based diagnostic assays utilize oligonucleotide probes which are complementary to one or more regions of the mRNA to be qualified or quantified. Such probes are designed while considering interspecies sequence variation, sequence length, GC content etc. However design of such prior art probes (i.e., riboprobes or deoxyriboprobes) does not take into consideration the presence of antisense transcripts which can effect probe binding efficiency. Discounting antisense presence can lead to inaccurate qualification/quantification and thus diagnosis, and thus lead to erroneous treatment protocols.

The present invention provides an mRNA-detection/quantification assay, which is devoid of this limitation.

Thus, according to an additional aspect of the present invention there is provided a method of quantifying at least one mRNA of interest in a biological sample.

As used herein, the phrase "biological sample" refers to any sample derived from biological tissues or fluids, including blood (serum or plasma), sputum, pleural effusions, urine, biopsy specimens, isolated cells and/or cell membrane preparation. Methods of obtaining tissue biopsies and body fluids from mammals are well known in the art.

The method of this aspect of the present invention is effected by contacting mRNA from a cell type or within a cell with one or more oligonucleotides that hybridizes efficiently with a sequence region of an mRNA transcript which is not complementary with a naturally occurring antisense transcript.

In addition to the limitation described above, prior art diagnostic/detection assays also fail to consider the effect of antisense transcription on the protein expression levels of a gene of interest. It stands to reason that presence of antisense transcripts in a biological sample can substantially reduce the resultant protein levels translated from a complementary sense transcript. Consistently, diseases which are associated with endogenous dsRNA complexes, are also very difficult to detect and

moreover to treat, due to insufficient sequence data pertaining to duplex forming transcripts.

Thus, for accurate quantification of gene expression, both the sense and antisense levels must be quantified and/or their respective expression ratio must be determined.

By contacting a biological sample with one or more pairs of oligonucleotides, where one oligonucleotide is capable of hybridizing with the mRNA of interest and the second oligonucleotide is capable of hybridizing with a naturally occurring antisense transcript which is complementary with the mRNA of interest such accurate quantification can be effected.

Contacting the oligonucleotides of the present invention with the biological sample is effected by stringent, moderate or mild hybridization (as used in any polynucleotide hybridization assay such as northern blot, dot blot, RNase protection assay, RT-PCR and the like). Wherein stringent hybridization is effected by a hybridization solution of 6 x SSC and 1 % SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS, 100 mg/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature of 1 - 1.5 °C below the T_m, final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS at 1 - 1.5 °C below the T_m; moderate hybridization is effected by a hybridization solution of 6 x SSC and 0.1 % SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS, 100 mg/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature of 2 - 2.5 °C below the T_m, final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS at 1 - 1.5 °C below the T_m, final wash solution of 6 x SSC, and final wash at 22 °C; whereas mild hybridization is effected by a hybridization solution of 6 x SSC and 1 % SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS, 100 mg/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature of 37 °C, final wash solution of 6 x SSC and final wash at 22 °C.

The oligonucleotides of the present invention can be attached to a solid substrate, which may consist of a particulate solid phase such as nylon filters, glass slides or silicon chips [Schena et al. (1995) Science 270:467-470].

In a particular embodiment, oligonucleotides of the present invention can be attached to a solid substrate, which is designed as a microarray. Microarrays are known in the art and consist of a surface to which probes that correspond in sequence to gene products (e.g., cDNAs, mRNAs, cRNAs, polypeptides, and fragments thereof), can be specifically hybridized or bound at a known position (regiospecificity).

Several methods for attaching the oligonucleotides to a microarray are known in the art including but not limited to glass-printing, described generally by Schena et al., 1995, Science 270:467-47, photolithographic techniques [Fodor et al. (1991) Science 251:767-773], inkjet printing, masking and the like.

In general, quantifying hybridization complexes is well known in the art and may be achieved by any one of several approaches. These approaches are generally based on the detection of a label or marker, such as any radioactive, fluorescent, biological or enzymatic tags or labels of standard use in the art. A label can be applied on either the oligonucleotide probes or nucleic acids derived from the biological sample.

The following illustrates a number of labeling methods suitable for use in the present invention. For example, oligonucleotides of the present invention can be labeled subsequent to synthesis, by incorporating biotinylated dNTPs or rNTP, or some similar means (e.g., photo-cross-linking a psoralen derivative of biotin to RNAs), followed by addition of labeled streptavidin (e.g., phycoerythrin-conjugated streptavidin) or the equivalent. Alternatively, when fluorescently-labeled oligonucleotide probes are used, fluorescein, lissamine, phycoerythrin, rhodamine (Perkin Elmer Cetus), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, FluorX (Amersham) and others [e.g., Kricka et al. (1992), Academic Press San Diego, Calif] can be attached to the oligonucleotides. It will be appreciated that pairs of fluorophores are chosen when distinction between two emission spectra of two oligonucleotides is desired or optionally, a label other than a fluorescent label is used. For example, a radioactive label, or a pair of radioactive labels with distinct emission spectra, can be used [Zhao et al. (1995) Gene 156:207]. However, because of scattering of radioactive particles, and the consequent requirement for widely spaced binding sites, the use of fluorophores rather than radioisotopes is more preferred.

The intensity of signal produced in any of the detection methods described hereinabove may be analyzed manually or using a software application and hardware suited for such purposes.

In general, mRNA quantification is preferably effected alongside a calibration
5 curve so as to enable accurate mRNA determination. Furthermore, quantifying transcript(s) originating from a biological sample is preferably effected by comparison to a normal sample, which sample is characterized by normal expression pattern of the examined transcript(s).

It will be appreciated that the detection method described above can also be
10 used for quantifying at least one naturally occurring antisense transcript in a biological sample. In such a case, the oligonucleotide used for quantification is designed to hybridize with a sequence region of naturally occurring antisense transcript of interest, which is not complementary with a naturally occurring mRNA transcript.

15 The diagnostic assays described hereinabove can be used to accurately distinguish between absence, presence and excess expression of any transcripts of interest (e.g., sense, antisense), and to monitor their level during therapeutic intervention. These methods are also capable of diagnosing diseases associated with an improper balance or ratio between sense and antisense expression and diseases
20 associated with endogenous dsRNA.

Further description of oligonucleotide-pair arrays is provided in Example 9 of the Examples section which follows.

As discussed hereinabove oligonucleotides of the present invention can be also used for therapeutic purposes, such as treating diseases or conditions associated
25 with aberrant expression levels of one or more sense and/or antisense transcripts and conditions, which are associated with endogenous dsRNA such as unregulated formation of double-strand RNA (i.e., up/down-regulation).

The oligonucleotides generated according to the teachings of the present invention can be included in a diagnostic or therapeutic kit. For example,
30 oligonucleotides sets pertaining to specific disease related transcripts can be packaged in a one or more containers with appropriate buffers and preservatives along with

suitable instructions for use and used for diagnosis or for directing therapeutic treatment.

Preferably, the containers include a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic.

In addition, other additives such as stabilizers, buffers, blockers and the like may also be added.

Apart from clinical applications, the biomolecular sequences of the present invention can find other commercial uses such as in the food, agricultural, electro-mechanical, optical and cosmetic industries [www.physics.unc.edu/~rsuper/XYZweb/XYZchipbiomotors.rs1.doc; www.bio.org/er/industrial.asp]. For example, newly uncovered gene products, which can disintegrate connective tissues, can be used as potent anti scarring agents for cosmetic purposes. Non-limiting examples of such gene products include the matrix metalloproteinase family of proteins (MMP), which are a group of proteases having varying specificities for ECM components as substrates, non-limiting examples of which have the gene symbols "CLG" and "CGL4B" in the attached files. These proteins are involved in ECM break-down as part of the wound healing process, for example for cell migration. The activity of these proteins is also modulated by specific tissue inhibitors of MMPs (TIMP) and other factors in the microenvironment in and around the wound area. Therefore, one possible optionally application for the present invention would be the selection of appropriate antisense oligonucleotides for either one or more MMPs and /or for factors related to TIMPs, in order to modulate wound healing activities (and/or as previously noted, for treatment of arthritis).

As another optional treatment, production of collagen may be optionally modulated through the use of appropriate antisense oligonucleotides. Collagen is an important connective tissue element, but is also involved in pathological conditions such as fibrosis and the formation of adhesions between tissues of different organs, a condition which may occur for example after surgery. Therefore, modulation of collagen production, for example to reduce collagen production, may optionally be performed according to the present invention.

Other applications include, but are not limited to, the making of gels, emulsions, foams and various specific products, including photographic films, tissue replacers and adhesives, food and animal feed, detergents, textiles, paper and pulp, and chemicals manufacturing (commodity and fine, e.g., bioplastics).

5 Research applications include, for example, differential cloning, detection of rearrangements in DNA sequences as disclosed in U.S. Pat. No: 5,994,320, drug discovery and the like.

As used herein the term "about" refers to $\pm 10\%$.

10

Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

EXAMPLES

Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.

Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III

Cellis, J. E., ed. (1994); "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available
 5 immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds.
 10 (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al.,
 15 "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated
 20 herein by reference.

In-vitro expression substantiation of computationally retrieved naturally occurring antisense transcripts

In-vitro expression assays were conducted in order to validate the existence of
 25 naturally occurring antisense sequences identified according to the teachings of the present invention.

Table 1 below lists polynucleotide sequence pairs that were selected for the *in-vitro* expression validation assays described in examples 1-7.

Table 1

Name of sense antisense pair	Sense transcript	Sense Length (nt)	Antisense transcript	Anti- sense Length (nt)	Overlap length (nt)	Start of overlap sense transcript	Start of overlap anti- sense

53BP1_76P	53BP1	10394	76P	6837	3046	5463	2018
	(SEQ ID NO: 15)		(SEQ ID NO: 16)				
CIDEB_BLTR2 (1)	CIDEB1	2289	BLTR2	6530	2254	17	1
	(SEQ ID NO: 19)		(SEQ ID NO: 21)				
CIDEB_BLTR2 (2)	CIDEB2	1511	BLTR2	6530	1410	1	1
	(SEQ ID NO: 20)						
APAF1_EB1	aAPAF1	7042	EB1a	1752	141	6889	1612
	(SEQ ID NO: 24)		(SEQ ID NO: 25)				
AChR_MINK2	AChR	2457	MINK2	4863	236	2175	4853
	(SEQ ID NO: 29)		(SEQ ID NO: 30)				
M-AChR_Anti-AChR	M-AChR	1590	M-Anti-AChR	2227	672	934	506
	(SEQ ID NO: 35)		(SEQ ID NO: 36)				
CyclinE2_Anti-CyclinE2	CyclinE2	2714	Anti-CyclinE2	5773	1855	565	2006
	(SEQ ID NO: 33)		(SEQ ID NO: 34)				

Sequence alignments of overlapping regions of each sense-antisense pair were performed using the BLAST sequence alignment algorithm (Basic Local Alignment Search Tool, available through www.ncbi.nlm.nih.gov/BLAST using the default parameters) and are exhibited in Figure 5a-g.

A microarray-based analysis was conducted, as well, in order to validate the existence of naturally occurring, antisense sequences identified according to the teachings of the present invention. The results are described in Example 9.

Materials and Experimental Methods

RNA probes generation and northern analysis

RNA probes for northern analysis were generated by PCR amplification of a desired DNA fragment and cloning into Zero Blunt TOPO (Invitrogen Corp.) or pSPT18/19 vectors (Roche Ltd.). Alternatively PCR products were ligated into T7 RNA polymerase promoter-containing adaptors using the Lignscribe kit (Ambion Europe Ltd.). Corresponding RNA transcripts were synthesized using T7 RNA polymerase (Roche Ltd.) and labeled with 32P-UTP according to manufacturer's instructions. RNA probes were purified on Mini Quick Spin RNA columns.

Commercial membranes containing Poly(A)-RNA from various human tissues (2 µg RNA per lane) were obtained from Origene (OriGene Technologies Inc.) and Ambion (Ambion Inc.).

Alternatively, 2 µg of poly(A)-RNA prepared from various human cell-lines were electrophoretically separated on 1 % agarose gel, and electrotransferred to Nytran SuperCharge membrane (Schleicher & Schuell) and subjected to fixing by UV radiation. Membranes were stained with methylene blue to ensure quantitative RNA transfer. Membranes were then prehybridized in a hybridization solution (UltraHyb solution Ambion Europe Ltd.) for 30 minutes at 68 °C in a rotating hybridization tube.

Hybridization solution was then supplemented with 106 cpm of labeled RNA probe per each ml of hybridization solution. Blots were hybridized for 16 hours at 68 °C in a rotating hybridization tube. Membranes were then washed twice with 2 x SSC, 0.1 % sodium dodecyl sulfate (SDS) and twice with 0.1 % SDS at 68 °C. RNA transcripts signals were detected using a phosphoimager (Molecular Dynamics, Sunnyvale CA).

Microarray

Oligonucleotide design - oligonucleotide design tools (1) were applied to each pair of sense/antisense genes in order to select two complementary 60-mer oligonucleotides from the region where the two genes overlap. The design criteria included the following: low cross-homology (up to 75%) to other expressed sequences in the human transcriptome; a continuous hit of no more than 17 bp to the sequence of another gene; balanced GC content (30-70%) without significant windows of local imbalance; no more than 2 palindromes with a length of 6 bp; a hit of no more than 15 bp to a repeat, vector or low-complexity region; and no long stretches of identical nucleotides.

Microarray preparation - 60-mer oligonucleotides were synthesized by Sigma-Genosys (The Woodlands, TX), resuspended at 40 µM in 3X SSC, and spotted in quadruplicates on poly-L-lysine coated glass slides as detailed in the online protocol of the National Human Genome Research Institute (<http://www.nhgri.nih.gov/DIR/Microarray/Protocols.pdf>). To avoid local differences in the hybridization conditions, the probes selected from the overlapping regions of each sense/antisense pair were spotted in the same block, next to each other.

Human cell lines - The following cell lines utilized were purchased from ATCC (Manassas, VA): MCF7 (breast adenocarcinoma, Cat. No. HTB-22,), HeLa

(cervical adenocarcinoma, Cat. No. CCL-2) HEK-293 (embryonal kidney cells, Cat. No. CRL-1573), Jurkat (acute T-cell leukemia, Cat. No. TIB-152), K-562 (chronic myelogenous leukemia, Cat. No. CCL-243), HepG2 (liver carcinoma, Cat. No. HB-8065), T24 (urinary bladder carcinoma, Cat. No. HTB-4), SK-N-DZ (neuroblastoma, Cat. No. CRL-2149), NK-92 (non-Hodgkin's lymphoma, Cat. No. CRL-2407), MG-63 (osteosarcoma, Cat. No. CRL-1427), DU 145 (prostatic carcinoma, Cat. No. HTB-81), G-361 (melanoma, Cat. No. CRL-1424), PANC-1 (pancreatic carcinoma, Cat. No. CRL-1469), ES-2 (ovary clear cell carcinoma, Cat. No. CRL-1978), Y79 (retinoblastoma, Cat. No. HTB-18), HT-29 (colorectal adenocarcinoma, Cat. No. HTB-38), H1299 (large cell lung carcinoma, Cat. No. CRL-5803), SNU1 (gastric carcinoma, Cat. No. CRL-5971), NL564 (EBV-transformed human lymphoblasts) and MCF10 (benign tumor breast cells).

RNA purification - Total RNA was extracted from the above mentioned human cell lines using TriReagent (Molecular Research Center, Cincinnati, OH). Poly(A)+ mRNA was purified using two cycles of the Dynabeads mRNA Purification Kit (DynaL Biotech ASA, Oslo, Norway), as per manufacturer instructions. The removal of traces of ribosomal RNA was confirmed by agarose gel electrophoresis. Poly(A)+ mRNAs from human testis, placenta, lung and brain tissue were purchased from BioChain Institute, Inc. (Hayward, CA). mRNAs of all cell lines described above were combined in equal quantities to obtain the reference 'mRNA pool'.

Preparation of labeled cDNA - For each hybridization, labeled cDNA was synthesized by reverse transcription of 0.5 µg of mRNA, in the presence of 100 pmol of random 9-mers, 1 µg of oligo(dT)20, 1X RT buffer, 10 mM DTT, 3 nmol of Cy5- or Cy3-conjugated dUTP, 0.5 mM of dATP, dGTP and dCTP, and 0.2 mM dTTP, in a final volume of 40 µl (Amersham). The reaction mixture was incubated for 5 minutes at 65 °C and cooled to 42 °C. 600 Units of reverse transcriptase (Superscript II, Invitrogen, Carlsbad, CA) and 40 U of Rnase inhibitor (RNasin Promega, Madison, WI) were added and the reaction was incubated for 30 minutes at 42 °C. An additional 200 U of Superscript II were added and the reaction was incubated for another 15 minutes. Remaining RNA was degraded by the addition of 200 mM NaOH and 50 mM EDTA, at 65 °C for 10 minutes. The mixture was neutralized by adding half a volume of 1M Tris-HCl pH 7.5. Hybridizations were performed in

duplicate using fluorescent reversal of Cy3- and Cy5-labeled cDNA from test cell mRNAs and pooled mRNAs. Pairs of Cy5/Cy3-labeled cDNA samples were combined, and subsequently purified and concentrated to a final volume of 5-7 μ l using a Microcon-30 (Millipore) concentrator.

5 **Hybridization and washing conditions** - Microarray slides were prehybridized with 40 μ l of 5X SSC, 0.1 % SDS and 1 % BSA for 30 min at 42 °C, washed for 2 minutes with double distilled water, then rinsed with isopropanol, and spun dried at 500 g for 3 minutes. Prior to hybridization, the labeled probe was combined with 10 μ g of Cot-1 DNA, 10 μ g poly(dA)80, and 4 μ g yeast tRNA, in a final volume of 15
10 μ l. The mixture was denatured at 100 °C for 3 minutes and placed on ice. Formamide (final concentration 16 %), SSC (to 5X concentration) and 0.1 % SDS were added to a final volume of 30 μ l. The mixture was placed on the array under a glass cover slip in a tightly sealed hybridization chamber, and immersed in a water bath at 42 °C, for 16 hours. Microarray slides were then washed for 4 minutes with 2X SSC, 0.1 % SDS; 4
15 minutes with 1X SSC, 0.01 % SDS; 4 minutes with 0.2X SSC and 15 seconds with 0.05X SSC and spun dry by centrifugation for 3 minutes at 500g.

Image processing - Following hybridization, arrays were scanned using a GenePix 4000B scanner (Axon Instruments, Union City, CA). Scanned array images were manually inspected and areas with visible artifacts or deformities were marked.
20 Images were processed using GenePix Pro 3.0 (www.axon.com) software.

Normalization - The intensity for each spot was calculated as its mean intensity minus the median background around the spot. The signal for each oligo was calculated as the average of intensity values of the four redundant spots of each oligo. Normalization of the oligo signals was performed at several levels as is further
25 described below.

 Normalization of blocks was carried out in order to normalize the gradient of intensities within each slide. For each block i , an A_i parameter was calculated as the average of intensities of 56 positive control spots (oligonucleotide probes for the ubiquitously expressed housekeeping genes *gapdh*, *actin*, *hsp70* and *gnb2l1*, in
30 various probe concentrations). An average A of all A_i averages was calculated. Based on this, a block normalization factor B_i was calculated for each block, as $B_i = A/A_i$, and applied to each spot in the block.

Normalization between slides was performed to bring all experiments to the same scale. For each experiment, the average of intensities of the 192 negative control spots on the array was set to be the 0 (zero) of the new scale. For a subset of highly signaling oligos, with intensities between the 70th and the 95th percentiles of the oligo signal distribution of the experiment, the average was arbitrarily set to be 500 in the new scale. The intensity of each oligo signal was accordingly converted to this new scale, to obtain the normalized signal. A ratio between the normalized cell-line signal and the normalized pool signal was calculated for each oligo in each experiment. To avoid misleading ratios coming from signals that were too low, the ratio R_{ji} for oligo j in experiment i was calculated as: $R_{ji} = \max [100, \text{cell-line-signal}_{ji}] / \max [100, \text{pool-signal}_{ji}]$.

To normalize between red/green intensities in reciprocal experiments, the ratio R_{jk} for oligo j in cell-line k was calculated as the average of calculated ratios R_{ji} between the two reciprocal experiments of the cell-line k . In cases where only one of the two reciprocal experiments showed an elevated or decreased ratio, while in the other the ratio was 1.0, the average R_{jk} was converted to 1.0.

The actual pool signal for each oligo was calculated to be the average of the normalized oligo signals in the pool channel of all experiments. A virtual pool signal was calculated as the average of the normalized oligo signals in the cell-line channel of all experiments. The virtual pool signals were found to be very close to the actual pool signals, indicating consistency in the analysis.

Threshold determination - To determine an expression threshold above, in which a normalized signal would be considered a 'positive' signal indicating expression, the distribution of all 16,512 normalized negative control signals and the standard deviation (neg-std-dev) were calculated. The neg-std-dev obtained was 38. An oligo j was considered 'present' in a cell-line k if $R_{jk} \times \text{actual-pool-signal}_j \geq 4 \times \text{neg-std-dev}$.

EXAMPLE 1

Identification of 53BP1 and 76P RNA transcripts in a variety of human tissues and cell-lines

Background:

The tumor suppressor p53 binding protein 1 (SEQ ID NO: 15) is one of the various p53 target proteins. It binds to the DNA-binding domain of p53 and enhances p53-mediated transcriptional activation. 53BP1 is characterized by several structural motifs shared by several proteins involved in DNA repair and/or DNA damage-signaling pathways. 53BP1 becomes hyperphosphorylated and forms discrete nuclear foci in response to DNA damage induced by radiation and chemotherapy. Recent reports suggest that 53BP1 is an ataxia telangiectasia mutated (ATM) substrate that is involved early in the DNA damage-signaling pathways in mammalian cells, attributing a role to 53BP1 in the development of various mammalian pathologies.

Results:

Two 53BP1 RNA sense transcripts with dissimilar 3' UTRs were previously described [Iwabuchi K. et al. (1994) Proc. Natl. Acad. Sci. USA] and are illustrated in Figure 6 (red and green). Leads assembly program modified to uncover novel antisense transcripts was used to uncover three such transcripts for the 53BP1 gene, which transcripts have different 3' UTRs (SEQ ID NO: 16, 37 and 38) and encode the 76p gene product (Genbank accession number NM014444)(illustrated in blue).

To confirm expression of computationally retrieved antisense transcripts, two RNA-probes were generated. Schematic location of the probes used for sense and antisense validation (Riboprobe#1 and Riboprobe#2, respectively SEQ ID NO: 17 and 18, respectively) is illustrated in Figure 6. These RNA probes were used to identify the corresponding full-length transcripts.

As shown in Figure 7, Riboprobe#1 detected two transcripts of approximately 6.3 Kb and 10.5 Kb, corresponding to the sense mRNA. The absolute levels of the short messenger were rather homogeneous in all cell-lines examined. The 10.5 Kb variant exhibited a more heterogenic pattern of cellular distribution, and was mostly expressed in K562, MG-63, 293 HEK and Hela cells. In general, the longer sense transcript which is an alternatively polyadenylated variant was markedly lower expressed in the various cell lines examined.

The same membrane was used to perform northern analysis with Riboprobe#2 in order to validate expression of antisense transcripts of 53BP1. Results are shown in Figure 8. Three variants corresponding to the 76p gene were detected in most of the cell lines: 6.8 Kb, 4.2 Kb and 2.5 Kb. Minor fluctuations of expression were

observed and the largest transcript was expressed at significantly higher levels than the smaller transcripts.

A sense strand probe was used to detect expression of the antisense transcripts in a variety of human tissues (Figure 9). The three alternatively polyadenylated variants with different 3' UTRs were expressed in most of the tissues. Total levels of these transcripts varied in the different tissues assayed. For example, highest level of expression for all three transcripts was observed in the brain and testis, while no expression of the 6.8 Kb and 4.2 Kb variants was detected in the spleen. Expression levels of each transcript were summarized in Table 2 below.

10

Table 2

Tissue	Transcript Mol. Weight (Kb)		
	6.8	4.2	2.5
brain	+++	++++	++++
colon	+	++	+
heart	-	+	++
kidney	++	++	+
Liver	-	-	+
lung	++++	+++	+
muscle	++	+	+
placenta	+	++	++
Small intestine.	++	++	-
spleen	-	-	+
stomach	-	-	+
testis	++	++	++++

Reverse transcription amplification (RT-PCR) analysis was performed in order to substantiate the northern blot results. Primers were synthesized according to the scheme shown in Figure 10 (indicated by arrows). The expected amplification products corresponded completely to the observed amplification reaction products, supporting the existence of the various 53BP1 and 76p transcription variants.

EXAMPLE 2

20 Identification of mRNA and complementary transcripts of the Cell death inducing DFF45-like effector (CIDE)-B

Background:

Cell death inducing DFF45-like effector (CIDE-B) (GenBank Accession numbers AF190901 and AF218586) is a member of a novel family of apoptosis-inducing factors that share homology with the N-terminal region of DFF, the DNA fragmentation factor. Although the molecular mechanism of CIDE-B induced apoptosis is unclear, mitochondrial localization and dimerization, both were shown to be required [Chen Z. et al. (2000) J. Biol. Chem. 275:22619-22622]. Notably, over-expression of CIDE-B in mammalian cells shows strong cell death-inducing activity, suggesting that aberrant expression of this protein may be associated with a number of mammalian pathologies [Inohara N. et al. (1998) EMBO J. 17:2526-2533].

Results:

Two sense transcripts of the CIDE-B gene were previously described with different 5' UTRs [Inohara N. et al. (1998) EMBO J. 17:2526-2533 and Lugovskoy AA. et al. (1999) Cell 99:745-755] (SEQ ID NOs: 19 and 20). Computational analysis recovered a potential elongated BLTR2 transcript (SEQ ID NO: 21), showing full complementarity to the CIDE-B mRNA transcripts (Figure 11).

Northern blot analysis was done in order to determine the distribution of the CIDE-B sense and antisense transcripts in various cell-lines. A 430 base pairs DNA fragment was selected to generate RNA probes for identification of both sense and antisense transcripts (SEQ ID NOs: 22 and 23, respectively).

Expression of antisense mRNA transcripts was detected in various cell-lines and especially in the mammary gland adenocarcinoma cell line-MCF-7 as a predominant 6.5 Kb transcript, although higher forms were also visualized (Figure 12). Low hybridization with a CIDE-B probe was detected (Figure 13).

Conclusion:

BLTR2 was recently identified as a putative seven-transmembrane receptor with a high homology to the Leukotriene B (4) receptor [Tryselius Y. et al. (2000) Biochem. Biophys. Res. Commun. 274:377-82]. Although the mechanism of action of BLTR2 is poorly understood, it is conceivable that BLTR2 mRNA plays a role in the regulation of CIDE-B apoptotic effector and vice versa.

EXAMPLE 3

Identification of mRNA and complementary transcripts of the apoptosis inducing factor APAF-1

Background:

A conserved series of events including cellular shrinkage, nuclear
5 condensation, externalization of plasma membrane phosphatidyl serine, and
oligonucleosomal DNA fragmentation characterizes apoptotic cell death. Regardless
of the circumstance, induction and execution of apoptotic events require activation of
caspases, a family of aspartate-specific cysteine proteinases. Caspase activation may
be regulated by the mitochondrion and specifically by the apoptosome consisting of
10 an oligomeric complex of apoptotic protease-activating factor-1 (APAF-1),
cytochrome C and dATP. The apoptosome recruits and activates caspase-9, which in
turn activates the executioner caspases, caspase-3 and -7. The active executioners kill
the cell by proteolysis of key cellular substrates [Zou H. et al. (1999) J. Biol. Chem.
274:11549-11556]. Evasion or inactivation of the mitochondrial apoptosis pathway
15 may contribute to oncogenesis by allowing cell proliferation. In this instance,
unregulated cell proliferation may occur by inactivation of APAF-1, which has been
suggested to occur via genetic loss or inhibition by HSP-70 and HSP-90. Although
aberrant expression of APAF-1 was found in a variety of malignancies (including
ovarian epithelial cancer), no link was found to accelerated protein degradation.

20 ***Results:***

One RNA transcript has been previously described for APAF-1 [Zou H. et al.
(1999) J. Biol. Chem. 274:11549-11556] (SEQ ID NO: 10) (SEQ ID NO: 24).
Computational search for natural antisense transcripts has revealed two
complementary transcripts for APAF-1 messenger RNA (SEQ ID NOs: 25 and 26).
25 These antisense transcripts include an open reading frame encoding the EB-1 gene
(GenBank accession numbers AF145204; AF164792). The overlap between the
APAF-1 messenger RNA and the longer antisense transcript is of at least 300
nucleotides.

To validate expression of computationally retrieved antisense transcripts for
30 APAF-1, as well as expression of APAF-1 mRNA in the assayed human cell lines,
RNA-probes of 366 ribonucleotides were generated (sense and antisense strands,
respectively). Schematic location of the probes used for sense and antisense

validation (Riboprobe#1 and Riboprobe#2, SEQ ID NOs: 27 and 28, respectively) is illustrated in Figure 14.

As shown in Figure 15a, the sense RNA probe directed at visualizing the antisense transcripts, identified a clear band of 3 Kb corresponding to the long computationally retrieved antisense transcript as well as other transcripts sizing from 1 Kb to 8 Kb (Figure 15a). Transcripts were essentially found in all cell lines but especially in 293 HEK and LN-Cap lines.

Hybridization with an RNA probe directed at visualizing the mRNA transcript of APAF-1 resulted only in a blurred patterns (Figure 15b). However, a 7 Kb mRNA transcript consistent with APAF-1mRNA was seen in Ln Cap and 293 HEK cell lines.

Conclusion:

A reciprocal pattern of expression was observed for both APAF-1 and EB-1 transcripts, exhibiting an interesting expressional relationship between the sense and antisense transcripts suggesting antisense-mediated expression regulation.

15

EXAMPLE 4

mRNA expression of muscle nicotinic Acetyl-Choline Receptor ϵ subunit and its complementary MINK transcript

Background:

The muscle nicotinic Acetylcholine Receptor ϵ subunit (AChR ϵ) encodes for one of five subunits of a ligand gated ion channel receptor located at the neuromuscular synapse. AChR ϵ is up-regulated in the postnatal period when it replaces α subunit of the receptor [Witzemann, V. et al., (1987) FEBS Lett. 223, 104-112]. It is also up-regulated in synapse development, specifically by the trophic factor neuregulin [Martinou J. C. (1991) Proc. Natl. Acad. Sci. USA 88, 7669-7673]. In an attempt to decipher AChR ϵ function and mechanism of regulation, computational screen for AChR ϵ K complementary transcript was carried out.

Results:

One mRNA transcript of AChR ϵ gene was previously described [Beeson D. Eur. J. Biochem (1993) 215, 229-238] (SEQ ID NO: 29). Computational analysis recovered a complementary transcript belonging to Mink, a new member of the germinal center kinase (GCK) family (SEQ ID NO: 30) [Dan I. FEBS Lett. (2000)

469, 19-23] showing an overlap of at least 280 nucleotides to the AchRe mRNA, as schematically illustrated in Figure 16.

To validate the overlap of the two genes and to learn about their tissue distribution, northern analysis of a variety of human tissues was performed. Poly(A)-
5 RNA containing membrane was hybridized with a 280 nucleotides RNA probes, corresponding to the overlap region in either antisense or sense orientation (SEQ ID NOs: 31 and 32, respectively).

As is evident from Figure 17a an AChRe transcript was expressed as a predominant 4 Kb band and had the highest expression in the heart, kidney and brain
10 while surprisingly only a limited expression was observed in the skeletal muscle.

Hybridization with a MINK specific RNA probe revealed a major transcript of about 5 Kb, in accordance with previous results [Dan I. FEBS Lett. (2000) 469, 19-23] (Figure 17b). The mRNA transcript was ubiquitously expressed with strongest expression found in brain, liver, thymus, spleen and pancreas, again in agreement with
15 Dan I. et al.

Conclusion:

The finding that AChRe and Mink genes are antisense each to one another with a significant overlap, and the fact that the two genes are co-expressed in some tissues (eg., brain) suggest the possibility that one of them may regulate the other
20 under certain conditions.

EXAMPLE 5

Expression of Cyclin E2 mRNA and complementary transcripts in a variety of human cell-lines

Background:

The human cyclin E2 gene encodes a 404-amino-acid protein that is most closely related to cyclin E. Cyclin E2 associates with Cdk2 in a functional kinase complex that is inhibited by both p27(Kip1) and p21(Cip1). The catalytic activity associated with cyclin E2 complexes is cell cycle regulated and peaks at the G1/S
30 transition. Overexpression of cyclin E2 in mammalian cells accelerates cell-cycle progression. Unlike cyclin E1, cyclin E2 levels are low to undetectable in

nontransformed cells and increase significantly in tumor-derived cells suggesting specific mechanism of regulation.

Results:

One RNA transcript was found for cyclin E2 (SEQ ID NO: 33. Computational
5 search for natural antisense transcripts has revealed one complementary transcript for cyclin E2 messenger RNA (SEQ ID NO: 34). The overlap between the cyclin E2 sense RNA and the antisense transcript is of at least 72 nucleotides.

To confirm expression of the computationally retrieved antisense transcript for cyclin E2 as well as of cyclin E2 mRNA in human cell lines, two RNA-probes of 800
10 ribonucleotides were generated. Schematic location of the probes used for sense and antisense validation (SEQ ID NO: 44, Riboprobe#1 is illustrated in Figure 18).

As shown in Figure 19a, Riboprobe#1 detected two transcripts of approximately 3 Kb and 4.3 Kb. The absolute levels of the transcripts were quite heterogenic in all cell-lines examined. Both transcripts were completely absent from
15 the Ln Cap cell line, while significantly high expression was observed in MCF-7 and DLD-1 lines, especially of the short transcript.

The same membrane was used to perform northern analysis with Riboprobe#2 in order to validate expression of antisense transcripts of cyclin E2. As is evident from Figure 19b, an antisense transcript 3.8 Kb long was observed in most cells
20 assayed. Significantly high pattern of expression was observed in K562, MCF-7 and DLD-1 cell lines, while only a very moderate level of expression was detected in Ln Cap and HepG2 cell lines.

EXAMPLE 6***Co-regulated expression of CIDE-B and its complementary transcript upon induction of apoptosis***

The discovery of a novel naturally occurring antisense transcript to the apoptosis inducing factor, CIDE-B (see Example 2 hereinabove), suggested that the latter may be regulated by its complementary transcript, thereby establishing a novel mechanism of regulation. To address this, differential expression analysis of CIDE-B expression and its endogenous antisense transcript expression was performed following induction of apoptosis.

Materials and methods***Induction of apoptosis and reverse transcription analysis -***

Monolayers of 293 cells were either left untreated (UT) or incubated with increasing concentrations of etoposide or staurosporine (Sigma IL). Twenty-four hours following addition of the drug, total RNA was extracted as described hereinabove. Purified RNA was further treated with DNaseI. A reverse transcription reaction were carried out with equivalent amounts of RNA in a final volume of 20 µl containing 100 pmol of the oligo(dT) primer, 250 ng of total RNA, 0.5 mM each of four deoxynucleoside triphosphates and 5 units of reverse transcriptase. The reaction mixture was incubated at 65 °C for 5 min, 42 °C for 50 min and 70 °C for 15 min. PCR was carried out in a final volume of 25 µl containing 12.5 pmol each of the oligonucleotide primers derived of exons 3 and 7 of CIDE-B (SEQ ID NOs: 39 and 40), 1 µl of RT solution and 1.75 units of *Taq* polymerase. Amplification was carried out by an initial denaturation step at 94 °C for 5 min followed by 35 cycles of [94 °C for 30 s, 68 °C for 30 s, and 68 °C for 130 min]. At the end of the PCR amplification, products were analyzed on agarose gels stained with ethidium bromide and visualized with UV light.

Results

Amplification reaction yielded two major PCR products of 740 bp and 2285 bp (Figure 20). The small (740 bp) PCR product derived from the sense (CIDE-B) strand, whereas the larger (2285 bp) product represented an intronless antisense transcript. Evidently, an increase of sense transcript, concomitant with a decrease of antisense transcript, was observed following treatment with etoposide (lanes 1-4) as

compared to untreated cells (lane 9), while no change was detected following staurosporine treatment (lanes 5-8).

These results suggest that following induction of apoptosis, antisense regulation of CIDE-B is abolished thereby allowing CIDE-B mediated apoptosis to proceed.

EXAMPLE 7

Reciprocal variation in sense and antisense expression of mouse nicotinic acetylcholine receptor, epsilon subunit during differentiation

The mouse nicotinic acetylcholine receptor, epsilon (mAChR ϵ) subunit (SEQ ID NO: 35) has a critical function in a variety of differentiation processes. To address a novel concept of antisense regulation of AchR ϵ -mediated differentiation, expression patterns of AchR ϵ and its naturally occurring antisense transcript (SEQ ID NO: 36) were examined following induction of differentiation.

Materials and methods

Induction of apoptosis and reverse transcription analysis - C2 mouse myoblast cells were incubated with a differentiation medium (Dulbecco's modified Eagle's medium (DMEM) including 10 μ g/ml insulin and 10 μ g/ml transferrin) or control medium (untreated) for 48 and 72 hours. Total RNA was extracted from treated and control cells and reverse-transcribed. PCR was done using F4 and R3 primers, derived from exon numbers 10 and 12 (last exon, SEQ ID NOs: 41 and 42, respectively) of the mouse nicotinic acetylcholine receptor, epsilon subunit (mAChR ϵ) and directed at detecting sense and antisense transcripts (see Figure 21a).

Results

Amplification reaction showed a gradual increase in AchR ϵ transcript expression, concomitant with the differentiation state of the cells. A second amplification product, which corresponded to an unspliced transcript was seen in untreated cells and disappeared following induction of differentiation. This fragment corresponds to a putative antisense transcript of the AchR ϵ , and may represent an alternative 3' UTR of the Mink gene, of which the known transcript terminates 400 bp downstream to AchR ϵ (see Example 4). To overcome possible competition between the two transcripts, another PCR reaction was carried out using antisense

specific riboprobes F4 and R4 (SEQ ID NO: 43). Reverse transcription products of this amplification reaction showed a single band which corresponded to a naturally occurring antisense transcript of the AchR ϵ . As expected this transcript disappeared following induction of differentiation.

5 These results imply inverse regulation of the AchR ϵ and its naturally occurring antisense transcript, during muscle cells differentiation from myoblasts to myotubes. Regulation may proceed, possibly through complementation of the sense and antisense transcripts to form dsRNA which can serve as a substrate for double strand RNA processing enzymes such as RNase H.

10

EXAMPLE 8

A polynucleotide database of sequences corresponding to the naturally occurring antisense transcripts identified by the present invention and their complementary sense sequences

15 Naturally occurring antisense sequences identified according to the teachings of the present invention and their corresponding sense sequences are provided in CD-ROM1-3 enclosed herewith (CD content is further described hereinbelow). File content is described in file AS_patent_data_description.doc on CD-ROM1. Generally a "seq" text file contains the actual polynucleotide sequences; a "table" file contains
20 summarized data pertaining to each sense-antisense sequence pair; an "alignments" file contains sequence alignments of sense and antisense overlapping regions.

 The respective polypeptides, encoded by the naturally occurring antisense polynucleotides of the present invention, are described in the file "pep_seqs_133" in the attached CD-ROM-3. It should be noted that not all nucleotide sequences have a
25 corresponding polypeptide sequence.

 The correlation between the nucleic acid sequence and the respective polypeptide is described in the file "Trans2Pep" in the attached CD-ROM-3. Each line in the "Trans2Pep" file represents a transcript name followed by a respective polypeptide name (eg: T92147_5 T92147_P6)

30 Annotation of the polypeptides encoded by the naturally occurring antisense sequences of the present invention appear in the "annotations_133" file in the attached CD-ROM-3, and are further described in Example 10 below.

Version 133

6 files : *table_133*, *seqs_133*, *alignments_133*, *annotations_133*, *pep_seqs_133*, *Trans2Pep*.

- 5 *table* is a list of 175,644 pairs of transcripts representing 6230 pairs of contigs.

Numbering : *m_n*

m – contigs' pair number.

n – number of transcripts' pair that belongs to a pair of contigs.

(each pair of contigs is represented by one or more pairs of transcripts)

- 10 *seqs* contains 99,414 sequences of all the transcripts, ordered by pairs and numbered according to the list in *table*.

alignments contains the alignment of each pair of overlapping transcripts – 175,644 alignments.

Trans2Pep – table of 28,775 transcripts from *seqs_133* that correspond to 14,658

- 15 peptides.

pep_seqs_133 - 14,658 peptide sequences in Fasta format.

annotations_133 – 14,658 annotations of 14,658 peptides.

Version 125

3 files : *table_125*, *seqs_125*, *alignments_125*.

- 20 *table* is a list of 223,181 pairs of transcripts representing 4018 pairs of contigs.

Numbering : *m_n*

m – contigs' pair number.

n – number of transcripts' pair that belongs to a pair of contigs.

(each pair of contigs is represented by one or more pairs of transcripts)

- 25 *seqs* contains 79,884 sequences of all the transcripts, ordered by pairs and numbered according to the list in *table*.

alignments contains the alignment of each pair of overlapping transcripts – 223,181 alignments.

- 30 “Table S1” and “Table S2” are further described in Example 9.

Table 3 below exemplifies the format of the Tables provided in CD-ROMs 2 and 3. Each row represents a pair of transcripts. The columns of Table 3 represent

(from the left): the serial number of the pair, the name of the first transcript, its length in nucleotides, the name of the second transcript, its length in nucleotides, the number of base pairs that overlap between the two transcripts, offsets of overlap beginning at the first transcript, offsets of overlap beginning at the second transcript.

5

Table 3

Serial	First	First	Second	Second	Overlap	Start of overlap
No.	transcript	transcript	transcript	transcript	length	in first /
		length (nt)		length (nt)	(nt)	in second
						transcript
570_0	AV705532_0	190	Z44352_15	783	OL: 52	OF1: 1 OF2: 1
	(SEQ ID NO: 1)		(SEQ ID NO: 2)			
570_1	AV705532_0	190	Z44352_14	1649	OL: 52	OF1: 1 OF2: 1
			(SEQ ID NO: 3)			
570_2	AV705532_0	190	Z44352_13	1861	OL: 52	OF1: 1 OF2: 1
			(SEQ ID NO: 4)			
571_0	AW070860_0	214	T81142_7	1934	OL: 54	OF1: 1 OF2: 1162
	(SEQ ID NO: 5)		(SEQ ID NO: 6)			
571_1	AW070860_0	214	T81142_6	2353	OL: 54	OF1: 1 OF2: 1162
			(SEQ ID NO: 7)			
571_2	AW070860_0	214	T81142_4	2500	OL: 54	OF1: 1 OF2: 1264
			(SEQ ID NO: 8)			
571_3	AW070860_0	214	T81142_3	947	OL: 54	OF1: 1 OF2: 171
			(SEQ ID NO: 9)			
571_4	AW070860_0	214	T81142_2	1366	OL: 54	OF1: 1 OF2: 171
			(SEQ ID NO: 10)			
572_0	BE046369_0	422	W26553_3	1532	OL: 52	OF1: 1 OF2: 1532
	(SEQ ID NO: 11)		(SEQ ID NO: 12)			
572_1	BE046369_0	422	W26553_2	1753	OL: 52	OF1: 1 OF2: 1753
			(SEQ ID NO: 13)			
572_2	BE046369_0	422	W26553_1	1832	OL: 52	OF1: 1 OF2: 1832
			(SEQ ID NO: 14)			

Pairs of transcripts are numbered, (within a contig pair, right to the underscore) that belong to a pair of contigs (numbered left to the underscore). Transcript names are arbitrary designations.

Sequence alignment of the overlapping region in each sense and antisense pair of Table 1 is demonstrated in Figure 4a-k. Alignments were performed using the BLAST sequence alignment algorithm (Basic Local Alignment Search Tool, available through www.ncbi.nlm.nih.gov/BLAST). Interestingly, alignment profile shows high

10

level of variability with regard to overlap lengths. It is conceivable that short overlaps are due to technical reasons associated with insufficient sequence data.

The putative naturally occurring antisense transcripts identified by the present invention and disclosed in the enclosed CD-ROMs can be used to detect and/or treat a variety of diseases, disorders or conditions, examples of which are listed hereinunder. For example, antisense transcripts or sequence information derived therefrom can be used to construct microarray kits (described in details in the preferred embodiments section) dedicated to diagnosing specific diseases, disorders or conditions.

The following sections list examples of proteins (subsection i), based on their molecular function, which participate in variety of diseases (listed in subsection ii), which diseases can be diagnosed/treated using information derived from naturally occurring antisense transcripts such as those uncovered by the present invention.

The present invention is of biomolecular sequences, which can be classified to functional groups based on known activity of homologous sequences. This functional group classification, allows the identification of diseases and conditions, which may be diagnosed and treated based on the novel sequence information and annotations of the present invention.

This functional group classification includes the following groups:

Proteins involved in Drug-Drug interactions:

The phrase "proteins involved in drug-drug interactions" refers to proteins involved in a biological process which mediates the interaction between at least two consumed drugs.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to modulate drug-drug interactions. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such drug-drug interactions.

Examples of these conditions include, but are not limited to the cytochrom P450 protein family, which is involved in the metabolism of many drugs. Examples of proteins, which are involved in drug-drug interactions are presented in Table 9.

Proteins involved in the metabolism of a pro-drug to a drug:

The phrase "proteins involved in the metabolism of a pro-drug to a drug" refers to proteins that activate an inactive pro-drug by chemically chaining it into a biologically active compound. Preferably, the metabolizing enzyme is expressed in the target tissue thus reducing systemic side effects.

5 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to modulate the metabolism of a pro-drug into drug. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used
10 for diagnosis of such conditions.

Examples of these proteins include, but are not limited to esterases hydrolyzing the cholesterol lowering drug simvastatin into its hydroxy acid active form.

MDR proteins:

15 The phrase "MDR proteins" refers to Multi Drug Resistance proteins that are responsible for the resistance of a cell to a range of drugs, usually by exporting these drugs outside the cell. Preferably, the MDR proteins are ABC binding cassette proteins. Preferably, drug resistance is associated with resistance to chemotherapy.

Pharmaceutical compositions including such proteins or protein encoding
20 sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the transport of molecules and macromolecules such as neurotransmitters, hormones, sugar etc. is abnormal leading to various pathologies. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or
25 protein encoding sequences may be used for diagnosis of such diseases.

Examples of these proteins include, but are not limited to the multi-drug resistant transporter MDR1/P-glycoprotein, the gene product of MDR1, which belongs to the ATP-binding cassette (ABC) superfamily of membrane transporters and increases the resistance of malignant cells to therapy by exporting the therapeutic
30 agent out of the cell.

Hydrolases acting on amino acids:

The phrase "hydrolases acting on amino acids" refers to hydrolases acting on a pair of amino acids.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the transfer of a glycosyl chemical group from one molecule to another is abnormal thus, a beneficial effect may be achieved by modulation of such reaction. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to reperfusion of clotted blood vessels by TPA (Tissue Plasminogen Activator) which converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single ARG-VAL bond in plasminogen.

Transaminases:

The term "transaminases" refers to enzymes transferring an amine group from one compound to another.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the transfer of an amine group from one molecule to another is abnormal thus, a beneficial effect may be achieved by modulation of such reaction. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such transaminases include, but are not limited to two liver enzymes, frequently used as markers for liver function - SGOT (Serum Glutamic-Oxalocetic Transaminase - AST) and SGPT (Serum Glutamic-Pyruvic Transaminase - ALT).

Immunoglobulins:

The term "immunoglobulins" refers to proteins that are involved in the immune and complement systems such as antigens and autoantigens, immunoglobulins, MHC and HLA proteins and their associated proteins.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases involving the immune system such as inflammation, autoimmune diseases, infectious diseases, and cancerous processes. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases and molecules that may be target for diagnostics include, but are not limited to members of the complement family such as C3 and C4 that their blood level is used for evaluation of autoimmune diseases and allergy state and C1 inhibitor that its absence is associated with angioedema. Thus, new variants of these genes are expected to be markers for similar events. Mutation in variants of the complement family may be associated with other immunological syndromes, such as increased bacterial infection that is associated with mutation in C3. C1 inhibitor was shown to provide safe and effective inhibition of complement activation after reperfused acute myocardial infarction and may reduce myocardial injury [Eur. Heart J. 2002, 23(21):1670-7], thus, its variant may have the same or improved effect.

Transcription factor binding:

The phrase "transcription factor binding" refers to proteins involved in transcription process by binding to nucleic acids, such as transcription factors, RNA and DNA binding proteins, zinc fingers, helicase, isomerase, histones, and nucleases.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins may be used to treat diseases involving transcription factors binding proteins. Such treatment may be based on transcription factor that can be used to for modulation of gene expression associated with the disease. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to breast cancer associated with ErbB-2 expression that was shown to be successfully modulated by a transcription factor [Proc. Natl. Acad. Sci. U S A. 2000, 97(4):1495-500]. Examples of

novel transcription factors used for therapeutic protein production include, but are not limited to those described for Erythropoietin production [J. Biol. Chem. 2000, 275(43):33850-60; J. Biol. Chem. 2000, 275(43):33850-60] and zinc fingers protein transcription factors (ZFP-TF) variants [J. Biol. Chem. 2000, 275(43):33850-60].

5 ***Small GTPase regulatory/interacting proteins:***

The phrase "Small GTPase regulatory/interacting proteins" refers to proteins capable of regulating or interacting with GTPase such as RAB escort protein, guanyl-nucleotide exchange factor, guanyl-nucleotide exchange factor adaptor, GDP-dissociation inhibitor, GTPase inhibitor, GTPase activator, guanyl-nucleotide releasing factor, GDP-dissociation stimulator, regulator of G-protein signaling, RAS interactor, RHO interactor, RAB interactor, and RAL interactor.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which G-proteases mediated signal-transduction is abnormal, either as a cause, or as a result of the disease. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to diseases related to prenylation. Modulation of prenylation was shown to affect therapy of diseases such as osteoporosis, ischemic heart disease, and inflammatory processes. Small GTPases regulatory/interacting proteins are major component in the prenylation post translation modification, and are required to the normal activity of prenylated proteins. Thus, their variants may be used for therapy of prenylation associated diseases.

25 ***Calcium binding proteins:***

The phrase "calcium binding proteins" refers to proteins involve in calcium binding, preferably, calcium binding proteins, ligand binding or carriers, such as diacylglycerol kinase, Calpain, calcium-dependent protein serine/threonine phosphatase, calcium sensing proteins, calcium storage proteins.

30 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat calcium involved diseases.

Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

5 Examples of such diseases include, but are not limited to diseases related to hypercalcemia, hypertension, cardiovascular disease, muscle diseases, gastro-intestinal diseases, uterus relaxing, and uterus. An example for therapy use of calcium binding proteins variant may be treatment of emergency cases of hypercalcemia, with secreted variants of calcium storage proteins.

10 ***Oxidoreductase:***

The term "oxidoreductase" refers to enzymes that catalyze the removal of hydrogen atoms and electrons from the compounds on which they act. Preferably, oxidoreductases acting on the following groups of donors: CH-OH, CH-CH, CH-NH₂, CH-NH; oxidoreductases acting on NADH or NADPH, nitrogenous compounds, 15 sulfur group of donors, heme group, hydrogen group, diphenols and related substances as donors; oxidoreductases acting on peroxide as acceptor, superoxide radicals as acceptor, oxidizing metal ions, CH₂ groups; oxidoreductases acting on reduced ferredoxin as donor; oxidoreductases acting on reduced flavodoxin as donor; and oxidoreductases acting on the aldehyde or oxo group of donors.

20 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases caused by abnormal activity of oxidoreductases. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences 25 may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to malignant and autoimmune diseases in which the enzyme DHFR (DiHydroFolateReductase) that participates in folate metabolism and essential for *de novo* glycine and purine synthesis is the target for the widely used drug Methotrexate (MTX).

30 ***Receptors:***

The term "receptors" refers to protein-binding sites on a cell's surface or interior, that recognize and binds to specific messenger molecule leading to a biological response,

such as signal transducers, complement receptors, ligand-dependent nuclear receptors, transmembrane receptors, GPI-anchored membrane-bound receptors, various coreceptors, internalization receptors, receptors to neurotransmitters, hormones and various other effectors and ligands.

5 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases caused by abnormal activity of receptors, preferably, receptors to neurotransmitters, hormones and various other effectors and ligands. Antibodies and polynucleotides such as PCR primers and
10 molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

 Examples of such diseases include, but are not limited to, chronic myelomonocytic leukemia caused by growth factor β receptor deficiency [Rao D. S., et al., (2001) *Mol. Cell Biol.*, 21(22):7796-806], thrombosis associated with protease-
15 activated receptor deficiency [Sambrano G. R., et al., (2001) *Nature*, 413(6851):26-7], hypercholesterolemia associated with low density lipoprotein receptor deficiency [Koivisto U. M., et al., (2001) *Cell*, 105(5):575-85], familial Hibernian fever associated with tumor necrosis factor receptor deficiency [Simon A., et al., (2001) *Ned Tijdschr Geneeskde*, 145(2):77-8], colitis associated with immunoglobulin E receptor expression
20 [Dombrowicz D., et al., (2001) *J. Exp. Med.*, 193(1):25-34], and alagille syndrome associated with Jagged1 [Stankiewicz P. et al., (2001) *Am. J. Med. Genet.*, 103(2):166-71], breast cancer associated with mutated BRCA2 and androgen. Therapeutic applications of nuclear receptors variants may be based on secreted version of receptors such as the thyroid nuclear receptor that by binding plasma free thyroid hormone to
25 reduce its levels may have a therapeutic effect in cases of thyrotoxicosis. A secreted version of glucocorticoid nuclear receptor, by binding plasma free cortisol, thus, reducing, may have a therapeutic effect in cases of Cushing's disease (a disease associated with high cortisol levels in the plasma).

 Another example of a secreted variant of a receptor is a secreted form of the TNF
30 receptor, which is used to treat conditions in which reduction of TNF levels is of benefit including Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis.

Protein serine/threonine kinases:

The phrase "protein serine/threonine kinases" refers to proteins which phosphorylate serine/threonine residues, mainly involved in signal transduction, such as transmembrane receptor protein serine/threonine kinase, 3-phosphoinositide-dependent
5 protein kinase, DNA-dependent protein kinase, G-protein-coupled receptor phosphorylating protein kinase, SNF1A/AMP-activated protein kinase, casein kinase, calmodulin regulated protein kinase, cyclic-nucleotide dependent protein kinase, cyclin-dependent protein kinase, eukaryotic translation initiation factor 2 α kinase, galactosyltransferase-associated kinase, glycogen synthase kinase 3, protein kinase C,
10 receptor signaling protein serine/threonine kinase, ribosomal protein S6 kinase, and I κ B kinase.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases ameliorated by a
15 modulating kinase activity. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to schizophrenia. 5-HT(2A) serotonin receptor is the principal molecular target for LSD-like hallucinogens
20 and atypical antipsychotic drugs. It has been shown that a major mechanism for the attenuation of this receptor signaling following agonist activation typically involves the phosphorylation of serine and/or threonine residues by various kinases. Therefore, serine/threonine kinases specific for the 5-HT(2A) serotonin receptor may serve as drug targets for a disease such as schizophrenia. Other diseases that may be treated through
25 serine/threonine kinases modulation are Peutz-Jeghers syndrome (PJS, a rare autosomal-dominant disorder characterized by hamartomatous polyposis of the gastrointestinal tract and melanin pigmentation of the skin and mucous membranes [Hum. Mutat. 2000, 16(1):23-30], breast cancer [Oncogene. 1999, 18(35):4968-73], Type 2 diabetes insulin resistance [Am. J. Cardiol. 2002, 90(5A):11G-18G], and fanconi anemia [Blood. 2001,
30 98(13):3650-7].

Channel/pore class transporters:

The phrase "Channel/pore class transporters" refers to proteins that mediate the transport of molecules and macromolecules across membranes, such as α -type channels, porins, and pore-forming toxins.

5 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the transport of molecules and macromolecules are abnormal, therefore leading to various pathologies. Antibodies and polynucleotides such as PCR primers and molecular
10 probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

 Examples of such diseases include, but are not limited to diseases of the nerves system such as Parkinson, diseases of the hormonal system, diabetes and infectious diseases such as bacterial and fungal infections. For example, α -hemolysin, is a
15 protein product of *S. aureus* which creates ion conductive pores in the cell membrane, thereby diminishing its integrity.

Hydrolases, acting on acid anhydrides:

 The phrase "hydrolases, acting on acid anhydrides" refers to hydrolytic enzymes that are acting on acid anhydrides, such as hydrolases acting on acid
20 anhydrides in phosphorus-containing anhydrides or in sulfonyl-containing anhydrides, hydrolases catalyzing transmembrane movement of substances, and involved in cellular and subcellular movement.

 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of
25 altering expression of such proteins may be used to treat diseases in which the hydrolase-related activities are abnormal. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

 Examples of such diseases include, but are not limited to glaucoma treated with
30 carbonic anhydrase inhibitors (e.g. Dorzolamide), peptic ulcer disease treated with $H^{(+)}K^{(+)}ATPase$ inhibitors that were shown to affect disease by blocking gastric carbonic anhydrase (e.g. Omeprazole).

Transferases, transferring phosphorus-containing groups:

The phrase "transferases, transferring phosphorus-containing groups " refers to enzymes that catalyze the transfer of phosphate from one molecule to another, such as phosphotransferases using the following groups as acceptors: alcohol group, carboxyl group, nitrogenous group, phosphate; phosphotransferases with regeneration of donors catalyzing intramolecular transfers; diphosphotransferases; nucleotidyltransferase; and phosphotransferases for other substituted phosphate groups.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins may be used to treat diseases in which the transfer of a phosphorous containing functional group to a modulated moiety is abnormal. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to acute MI [Ann. Emerg. Med. 2003, 42(3):343-50], Cancer [Oral. Dis. 2003, 9(3):119-28; J. Surg. Res. 2003, 113(1):102-8] and Alzheimer's disease [Am. J. Pathol. 2003, 163(3):845-58]. Examples for possible utilities of such transferases for drug improvement include, but are not limited to aminoglycosides treatment (antibiotics) to which resistance is mediated by aminoglycoside phosphotransferases [Front. Biosci. 1999, 1;4:D9-21]. Using aminoglycoside phosphotransferases variants or inhibiting these enzymes may reduce aminoglycosides resistance. Since aminoglycosides can be toxic to some patients, proving the expression of aminoglycoside phosphotransferases in a patient can deter from treating him with aminoglycosides and risking the patient in vain.

Phosphoric monoester hydrolases:

The phrase "phosphoric monoester hydrolases" refers to hydrolytic enzymes that are acting on ester bonds, such as nuclease, sulfuric ester hydrolase, carboxylic ester hydrolase, thiolester hydrolase, phosphoric monoester hydrolase, phosphoric diester hydrolase, triphosphoric monoester hydrolase, diphosphoric monoester hydrolase, and phosphoric triester hydrolase.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of

altering expression of such proteins, may be used to treat diseases in which the hydrolytic cleavage of a covalent bond with accompanying addition of water (-H being added to one product of the cleavage and -OH to the other), is abnormal. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify
5 such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to diabetes and CNS diseases such as Parkinson and cancer.

Enzyme inhibitors:

10 The term "enzyme inhibitors" refers to inhibitors and suppressors of other proteins and enzymes, such as inhibitors of: kinases, phosphatases, chaperones, guanylate cyclase, DNA gyrase, ribonuclease, proteasome inhibitors, diazepam-binding inhibitor, ornithine decarboxylase inhibitor, GTPase inhibitors, dUTP pyrophosphatase inhibitor, phospholipase inhibitor, proteinase inhibitor, protein
15 biosynthesis inhibitors, and α -amylase inhibitors.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which beneficial effect may be achieved by modulating the activity of inhibitors and suppressors of
20 proteins and enzymes. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to α -1 antitrypsin (a natural serine proteases, which protects the lung and liver from proteolysis) deficiency
25 associated with emphysema, COPD and liver chirosis. α -1 antitrypsin is also used for diagnostics in cases of unexplained liver and lung disease. A variant of this enzyme may act as protease inhibitor or a diagnostic target for related diseases.

Electron transporters:

The term "Electron transporters" refers to ligand binding or carrier proteins
30 involved in electron transport such as flavin-containing electron transporter, cytochromes, electron donors, electron acceptors, electron carriers, and cytochrome-c oxidases.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which beneficial effect may be achieved by modulating the activity of electron transporters. Antibodies
5 and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to cyanide toxicity, resulting from cyanide binding to ubiquitous metalloenzymes rendering them inactive,
10 and interfering with the electron transport. Novel electron transporters to which cyanide can bind may serve as drug targets for new cyanide antidotes.

Transferases, transferring glycosyl groups:

The phrase "transferases, transferring glycosyl groups" refers to enzymes that catalyze the transfer of a glycosyl chemical group from one molecule to another such
15 as murein lytic endotransglycosylase E, and sialyltransferase.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the transfer of a glycosyl chemical group is abnormal. Antibodies and polynucleotides such as
20 PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Ligases, forming carbon-oxygen bonds:

The phrase "ligases, forming carbon-oxygen bonds" refers to enzymes that catalyze the linkage between carbon and oxygen such as ligase forming aminoacyl-
25 tRNA and related compounds.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the linkage between carbon and oxygen in an energy dependent process is abnormal. Antibodies
30 and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Ligases:

The term "ligases" refers to enzymes that catalyze the linkage of two molecules, generally utilizing ATP as the energy donor, also called synthetase. Examples for ligases are enzymes such as β -alanyl-dopamine hydrolase, carbon-oxygen bonds forming ligase, carbon-sulfur bonds forming ligase, carbon-nitrogen bonds forming ligase, carbon-carbon bonds forming ligase, and phosphoric ester bonds forming ligase.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the joining together of two molecules in an energy dependent process is abnormal. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to neurological disorders such as Parkinson's disease [Science. 2003, 302(5646):819-22; J. Neurol. 2003, 250 Suppl. 3:III25-III29] or epilepsy [Nat. Genet. 2003, 35(2):125-7], cancerous diseases [Cancer Res. 2003, 63(17):5428-37; Lab. Invest. 2003, 83(9):1255-65], renal diseases [Am. J. Pathol. 2003, 163(4):1645-52], infectious diseases [Arch. Virol. 2003, 148(9):1851-62] and fanconi anemia [Nat. Genet. 2003, 35(2):165-70].

Hydrolases, acting on glycosyl bonds:

The phrase "hydrolases, acting on glycosyl bonds" refers to hydrolytic enzymes that are acting on glycosyl bonds such as hydrolases hydrolyzing N-glycosyl compounds, S-glycosyl compounds, and O-glycosyl compounds.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the hydrolase-related activities are abnormal. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include cancerous diseases [J. Natl. Cancer Inst. 2003, 95(17):1263-5; Carcinogenesis. 2003, 24(7):1281-2; author reply 1283] vascular diseases [J. Thorac. Cardiovasc. Surg. 2003, 126(2):344-57], gastrointestinal diseases

such as colitis [J. Immunol. 2003, 171(3):1556-63] or liver fibrosis [World J. Gastroenterol. 2002, 8(5):901-7].

Kinases:

The term "kinases" refers to enzymes which phosphorylate serine/threonine or tyrosine residues, mainly involved in signal transduction. Examples for kinases include enzymes such as 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase, NAD⁽⁺⁾ kinase, acetylglutamate kinase, adenosine kinase, adenylate kinase, adenylosulfate kinase, arginine kinase, aspartate kinase, choline kinase, creatine kinase, cytidylate kinase, deoxyadenosine kinase, deoxycytidine kinase, deoxyguanosine kinase, dephospho-CoA kinase, diacylglycerol kinase, dolichol kinase, ethanolamine kinase, galactokinase, glucokinase, glutamate 5-kinase, glycerol kinase, glycerone kinase, guanylate kinase, hexokinase, homoserine kinase, hydroxyethylthiazole kinase, inositol/phosphatidylinositol kinase, ketohexokinase, mevalonate kinase, nucleoside-diphosphate kinase, pantothenate kinase, phosphoenolpyruvate carboxykinase, phosphoglycerate kinase, phosphomevalonate kinase, protein kinase, pyruvate dehydrogenase (lipoamide) kinase, pyruvate kinase, ribokinase, ribose-phosphate pyrophosphokinase, selenide, water dikinase, shikimate kinase, thiamine pyrophosphokinase, thymidine kinase, thymidylate kinase, uridine kinase, xylulokinase, 1D-myo-inositol-trisphosphate 3-kinase, phosphofructokinase, pyridoxal kinase, sphinganine kinase, riboflavin kinase, 2-dehydro-3-deoxygalactonokinase, 2-dehydro-3-deoxygluconokinase, 4-diphosphocytidyl-2C-methyl-D-erythritol kinase, GTP pyrophosphokinase, L-fuculokinase, L-ribulokinase, L-xylulokinase, isocitrate dehydrogenase (NADP⁺) kinase, acetate kinase, allose kinase, carbamate kinase, cobinamide kinase, diphosphate-purine nucleoside kinase, fructokinase, glycerate kinase, hydroxymethylpyrimidine kinase, hygromycin-B kinase, inosine kinase, kanamycin kinase, phosphomethylpyrimidine kinase, phosphoribulokinase, polyphosphate kinase, propionate kinase, pyruvate, water dikinase, rhamnulokinase, tagatose-6-phosphate kinase, tetraacyldisaccharide 4'-kinase, thiamine-phosphate kinase, undecaprenol kinase, uridylate kinase, N-acylmannosamine kinase, D-erythro-sphingosine kinase.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of

altering expression of such proteins, may be used to treat diseases which may be ameliorated by a modulating kinase activity. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

- 5 Examples of such diseases include, but are not limited to, acute lymphoblastic leukemia associated with spleen tyrosine kinase deficiency [Goodman P.A., et al., (2001) *Oncogene*, 20(30):3969-78], ataxia telangiectasia associated with ATM kinase deficiency [Boulton J., (2001) *J. Clin. Pathol.*, 54(7):512-6], congenital haemolytic anaemia associated with erythrocyte pyruvate kinase deficiency [Zanella A., et al., 10 (2001) *Br. J. Haematol.*, 113(1):43-8], mevalonic aciduria caused by mevalonate kinase deficiency [Houten S. M., et al., (2001) *Eur. J. Hum. Genet.*, 9(4):253-9], and acute myelogenous leukemia associated with over-expressed death-associated protein kinase [Guzman M. L., et al., (2001) *Blood*, 97(7):2177-9].

Nucleotide binding:

- 15 The term "nucleotide binding" refers to ligand binding or carrier proteins, involved in physical interaction with a nucleotide, preferably, any compound consisting of a nucleoside that is esterified with [ortho]phosphate or an oligophosphate at any hydroxyl group on the glycoside moiety, such as purine nucleotide binding proteins.

- 20 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases that are associated with abnormal nucleotide binding. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding 25 sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to Gout (a syndrome characterized by high urate level in the blood). Since urate is a breakdown metabolite of purines, reducing purines serum levels could have a therapeutic effect in Gout disease.

- 30 ***Tubulin binding:***

The term "tubulin binding" refers to binding proteins that bind tubulin such as microtubule binding proteins.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases which are associated with abnormal tubulin activity or structure. Binding the products of the genes of this family, or antibodies reactive therewith, can modulate a plurality of tubulin activities as well as change microtubulin structure. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, Alzheimer's disease associated with t-complex polypeptide 1 deficiency [Schuller E., et al., (2001) Life Sci., 69(3):263-70], neurodegeneration associated with *apoE* deficiency [Masliah E., et al., (1995) Exp. Neurol., 136(2):107-22], progressive axonopathy associated with dysfunctional neurofilaments [Griffiths I. R., et al., (1989) Neuropathol. Appl. Neurobiol., 15(1):63-74], familial frontotemporal dementia associated with tau deficiency [astor P., et al., (2001) Ann. Neurol., 49(2):263-7], and colon cancer suppressed by APC [White R. L., (1997) Pathol. Biol. (Paris), 45(3):240-4]. En example for a drug whose target is tubulin is the anticancer drug - Taxol. Drugs having similar mechanism of action (interfering with tubulin polymerization) may be developed based on tubulin binding proteins.

Receptor signaling proteins:

The phrase "receptor signaling proteins" refers to receptor proteins involved in signal transduction such as receptor signaling protein serine/threonine kinase, receptor signaling protein tyrosine kinase, receptor signaling protein tyrosine phosphatase, aryl hydrocarbon receptor nuclear translocator, hematopoietin/interferon-class (D200-domain) cytokine receptor signal transducer, transmembrane receptor protein tyrosine kinase signaling protein, transmembrane receptor protein serine/threonine kinase signaling protein, receptor signaling protein serine/threonine kinase signaling protein, receptor signaling protein serine/threonine phosphatase signaling protein, small GTPase regulatory/interacting protein, receptor signaling protein tyrosine kinase signaling protein, and receptor signaling protein serine/threonine phosphatase.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the signal-

transduction is abnormal, either as a cause, or as a result of the disease. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, complete
5 hypogonadotropic hypogonadism associated with GnRH receptor deficiency [Kottler M. L., et al., (2000) J. Clin. Endocrinol. Metab., 85(9):3002-8], severe combined immunodeficiency disease associated with IL-7 receptor deficiency [Puel A. and Leonard W. J., (2000) Curr. Opin. Immunol., 12(4):468-7], schizophrenia associated N-methyl-D-aspartate receptor deficiency [Mohn A.R., et al., (1999) Cell, 98(4):427-36], Yesinia-
10 associated arthritis associated with tumor necrosis factor receptor p55 deficiency [Zhao Y. X., et al., (1999) Arthritis Rheum., 42(8):1662-72], and Dwarfism of Sindh caused by growth hormone-releasing hormone receptor deficiency [aheshwari H. G., et al., (1998) J. Clin. Endocrinol. Metab., 83(11):4065-74].

Molecular function unknown:

15 The phrase "molecular function unknown" refers to various proteins with unknown molecular function, such as cell surface antigens.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which regulation
20 of the recognition, or participation or bind of cell surface antigens to other moieties may have therapeutic effect. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, autoimmune diseases,
25 various infectious diseases, cancer diseases which involve non cell surface antigens recognition and activity.

Enzyme activators:

The term "enzyme activators" refers to enzyme regulators such as activators of:
kinases, phosphatases, sphingolipids, chaperones, guanylate cyclase, tryptophan
30 hydroxylase, proteases, phospholipases, caspases, proprotein convertase 2 activator, cyclin-dependent protein kinase 5 activator, superoxide-generating NADPH oxidase

activator, sphingomyelin phosphodiesterase activator, monophenol monooxygenase activator, proteasome activator, and GTPase activator.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of
5 altering expression of such proteins, may be used to treat diseases in which beneficial effect may be achieved by modulating the activity of activators of proteins and enzymes. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

10 Examples of such diseases include, but are not limited to all complement related diseases, as most complement proteins activate by cleavage other complement proteins.

Transferases, transferring one-carbon groups:

The phrase "transferases, transferring one-carbon groups" refers enzymes that catalyze the transfer of a one-carbon chemical group from one molecule to another
15 such as methyltransferase, amidinotransferase, hydroxymethyl-, formyl- and related transferase, carboxyl- and carbamoyltransferase.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the transfer
20 of a one-carbon chemical group from one molecule to another is abnormal so that a beneficial effect may be achieved by modulation of such reaction. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Transferases:

25 The term "transferases" refers to enzymes that catalyze the transfer of a chemical group, preferably, a phosphate or amine from one molecule to another. It includes enzymes such as transferases, transferring one-carbon groups, aldehyde or ketonic groups, acyl groups, glycosyl groups, alkyl or aryl (other than methyl) groups, nitrogenous, phosphorus-containing groups, sulfur-containing groups,
30 lipoyltransferase, deoxycytidyl transferases.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of

altering expression of such proteins, may be used to treat diseases in which the transfer of a chemical group from one molecule to another is abnormal. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

5 Examples of such diseases include, but are not limited to cancerous diseases such as prostate cancer [Urology. 2003, 62(5 Suppl 1):55-62] or lung cancer [Invest. New Drugs. 2003, 21(4):435-43; JAMA. 2003, 22;290(16):2149-58], psychiatric disorders [Am. J. Med. Genet. 2003, 15;123B(1):64-9], colorectal disease such as Crohn's disease [Dis. Colon Rectum. 2003, 46(11):1498-507] or celiac diseases [N
10 Engl. J. Med. 2003, 349(17):1673-4; author reply 1673-4], neurological diseases such as Parkinson's disease [J. Chem Neuroanat. 2003, 26(2):143-51], Alzheimer disease [Hum. Mol. Genet. 2003 21] or Charcot-Marie-Tooth Disease [Mol. Biol. Evol. 2003 31].

Chaperones:

15 The term "chaperones" refers to functional classes of unrelated families of proteins that assist the correct non-covalent assembly of other polypeptide-containing structures *in vivo*, but are not components of these assembled structures when they are performing their normal biological function. The group of chaperones include proteins such as ribosomal chaperone, peptidylprolyl isomerase, lectin-binding chaperone,
20 nucleosome assembly chaperone, chaperonin ATPase, cochaperone, heat shock protein, HSP70/HSP90 organizing protein, fimbrial chaperone, metallochaperone, tubulin folding, and HSC70-interacting protein.

 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering
25 expression of such proteins, may be used to treat diseases which are associated with abnormal protein activity, structure, degradation or accumulation of proteins. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

 Examples of such diseases include, but are not limited to neurological syndromes
30 [J. Neuropathol. Exp. Neurol. 2003, 62(7):751-64; Antioxid Redox Signal. 2003, 5(3):337-48; J. Neurochem. 2003, 86(2):394-404], neurological diseases such as Parkinson's disease [Hum. Genet. 2003, 6; Neurol Sci. 2003, 24(3):159-60; J. Neurol.

2003, 250 Suppl. 3:III25-III29] ataxia [J. Hum. Genet. 2003;48(8):415-9] or Alzheimer diseases [J. Mol. Neurosci. 2003, 20(3):283-6; J. Alzheimers Dis. 2003, 5(3):171-7], cancerous diseases [Semin. Oncol. 2003, 30(5):709-16], prostate cancer [Semin. Oncol. 2003, 30(5):709-16] metabolic diseases [J Neurochem. 2003, 87(1):248-56], infectious
5 diseases, such as prion infection [EMBO J. 2003, 22(20):5435-5445]. Chaperones may be also used for manipulating therapeutic proteins binding to their receptors therefore, improving their therapeutic effect.

Cell adhesion molecule:

The phrase "cell adhesion molecule" refers to proteins that serve as adhesion
10 molecules between adjoining cells such as membrane-associated protein with guanylate kinase activity, cell adhesion receptor, neuroligin, calcium-dependent cell adhesion molecule, selectin, calcium-independent cell adhesion molecule, and extracellular matrix protein.

Pharmaceutical compositions including such proteins or protein encoding
15 sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which adhesion between adjoining cells is involved, typically conditions in which the adhesion is abnormal. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such
20 diseases.

Examples of such diseases include, but are not limited to cancer in which abnormal adhesion may cause and enhance the process of metastasis and abnormal growth and development of various tissues in which modulation adhesion among adjoining cells can improve the condition. Leucocyte-endothelial interactions characterized
25 by adhesion molecules involved in interactions between cells lead to a tissue injury and ischemia reperfusion disorders in which activated signals generated during ischemia may trigger an exuberant inflammatory response during reperfusion, provoking greater tissue damage than initial ischemic insult [Crit. Care Med. 2002, 30(5 Suppl):S214-9]. The blockade of leucocyte-endothelial adhesive interactions has the potential to reduce
30 vascular and tissue injury. This blockade may be achieved using a soluble variant of the adhesion molecule.

States of septic shock and ARDS involve large recruitment of neutrophil cells to the damaged tissues. Neutrophil cells bind to the endothelial cells in the target tissues through adhesion molecules. Neutrophils possess multiple effector mechanisms that can produce endothelial and lung tissue injury, and interfere with pulmonary gas transfer by disruption of surfactant activity [Eur. J. Surg. 2002, 168(4):204-14]. In such cases, the use of soluble variant of the adhesion molecule may decrease the adhesion of neutrophils to the damaged tissues.

Examples of such diseases include, but are not limited to, Wiskott-Aldrich syndrome associated with WAS deficiency [Westerberg L., et al., (2001) Blood, 98(4):1086-94], asthma associated with intercellular adhesion molecule-1 deficiency [Tang M. L. and Fiscus L. C., (2001) Pulm. Pharmacol. Ther., 14(3):203-10], intra-atrial thrombogenesis associated with increased von Willebrand factor activity [Fukuchi M., et al., (2001) J. Am. Coll. Cardiol., 37(5):1436-42], junctional epidermolysis bullosa associated with laminin 5- β -3 deficiency [Robbins P. B., et al., (2001) Proc. Natl. Acad. Sci., 98(9):5193-8], and hydrocephalus caused by neural adhesion molecule L1 deficiency [Rolf B., et al., (2001) Brain Res., 891(1-2):247-52].

Motor proteins:

The term "motor proteins" refers to proteins that generate force or energy by the hydrolysis of ATP and that function in the production of intracellular movement or transportation. Examples of such proteins include microfilament motor, axonemal motor, microtubule motor, and kinetochore motor (dynein, kinesin, or myosin).

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which force or energy generation is impaired. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, malignant diseases where microtubules are drug targets for a family of anticancer drugs such as myodystrophies and myopathies [Trends Cell Biol. 2002, 12(12):585-91], neurological disorders [Neuron. 2003, 25;40(1):25-40; Trends Biochem. Sci. 2003, 28(10):558-65;

Med. Genet. 2003, 40(9):671-5], and hearing impairment [Trends Biochem. Sci. 2003, 28(10):558-65].

Defense/immunity proteins:

5 The term "defense/immunity proteins" refers to proteins that are involved in the immune and complement systems such as acute-phase response proteins, antimicrobial peptides, antiviral response proteins, blood coagulation factors, complement components, immunoglobulins, major histocompatibility complex antigens and opsonins.

10 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases involving the immunological system including inflammation, autoimmune diseases, infectious diseases, as well as cancerous processes or diseases which are manifested by abnormal coagulation processes, which may include abnormal bleeding or excessive coagulation. Antibodies and
15 polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, late (C5-9) complement component deficiency associated with opsonin receptor allotypes [Fijen C. A., et al., (2000) Clin. Exp. Immunol., 120(2):338-45], combined
20 immunodeficiency associated with defective expression of MHC class II genes [Griscelli C., et al., (1989) Immunodef. Rev. 1(2):135-53], loss of antiviral activity of CD4 T cells caused by neutralization of endogenous TNF α [Pavic I., et al., (1993) J. Gen. Virol., 74 (Pt 10):2215-23], autoimmune diseases associated with natural resistance-associated macrophage protein deficiency [Evans C. A., et al., (2001) Neurogenetics, 3(2):69-78], Epstein-Barr virus-associated lymphoproliferative disease
25 inhibited by combined GM-CSF and IL-2 therapy [Baiocchi R. A., et al., (2001) J. Clin. Invest., 108(6):887-94], and sepsis in which activated protein C is a therapeutic protein itself.

Intracellular transporters:

30 The term "intracellular transporters" refers to proteins that mediate the transport of molecules and macromolecules inside the cell, such as intracellular

nucleoside transporter, vacuolar assembly proteins, vesicle transporters, vesicle fusion proteins, type II protein secretors.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the transport of molecules and macromolecules is abnormal leading to various pathologies. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Transporters:

The term "transporters" refers to proteins that mediate the transport of molecules and macromolecules, such as channels, exchangers, and pumps. Transporters include proteins such as: amine/polyamine transporter, lipid transporter, neurotransmitter transporter, organic acid transporter, oxygen transporter, water transporter, carriers, intracellular transports, protein transporters, ion transporters, carbohydrate transporter, polyol transporter, amino acid transporters, vitamin/cofactor transporters, siderophore transporter, drug transporter, channel/pore class transporter, group translocator, auxiliary transport proteins, permeases, murein transporter, organic alcohol transporter, nucleobase, nucleoside, and nucleotide and nucleic acid transporters.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the transport of molecules and macromolecules such as neurotransmitters, hormones, sugar etc. is impaired leading to various pathologies. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, glycogen storage disease caused by glucose-6-phosphate transporter deficiency [Hiraiwa H., and Chou J. Y. (2001) DNA Cell Biol., 20(8):447-53], tangier disease associated with ATP-binding cassette transporter-1 deficiency [McNeish J., et al., (2000) Proc. Natl. Acad. Sci., 97(8):4245-50], systemic primary carnitine deficiency associated with organic cation transporter deficiency [Tang N. L., et al., (1999) Hum. Mol. Genet., 8(4):655-60], Wilson

disease associated with copper-transporting ATPases deficiency [Payne A. S., et al., (1998) *Proc. Natl. Acad. Sci.* 95(18):10854-9], and atelosteogenesis associated with diastrophic dysplasia sulphate transporter deficiency [Newbury-Ecob R., (1998) *J. Med. Genet.*, 35(1):49-53], Central Nervous system diseases treated by inhibiting
5 neurotransmitter transporter (e.g. Depression, treated with serotonin transporters inhibitors – Prozac), and Cystic fibrosis mediated by the chloride channel CFTR. Other transporter related diseases are cancer [*Oncogene*. 2003, 22(38):6005-12] and especially cancer resistant to treatment [*Oncologist*. 2003, 8(5):411-24; *J. Med. Invest.* 2003, 50(3-4):126-35], infectious diseases, especially fungal infections [*Annu. Rev. Phytopathol.*
10 2003, 41:641-67], neurological diseases, such as Parkinson [*FASEB J.* 2003, Sep 4 [Epub ahead of print]], and cardiovascular diseases, including hypercholesterolemia [*Am. J. Cardiol.* 2003, 92(4B):10K-16K].

There are about 30 membrane transporter genes linked to a known genetic clinical syndrome. Secreted versions of splice variants of transporters may be therapeutic as the
15 case with soluble receptors. These transporters may have the capability to bind the compound in the serum they would normally bind on the membrane. For example, a secreted form ATP7B, a transporter involved in Wilson's disease, is expected to bind plasma Copper, therefore have a desired therapeutic effect in Wilson's disease.

Lyases:

20 The term "lyases" refers to enzymes that catalyze the formation of double bonds by removing chemical groups from a substrate without hydrolysis or catalyze the addition of chemical groups to double bonds. It includes enzymes such as carbon-carbon lyase, carbon-oxygen lyase, carbon-nitrogen lyase, carbon-sulfur lyase, carbon-halide lyase, and phosphorus-oxygen lyase.

25 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the double bonds formation catalyzed by these enzymes is impaired. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein
30 encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, autoimmune diseases [*JAMA*. 2003, 290(13):1721-8; *JAMA*. 2003, 290(13):1713-20], diabetes [*Diabetes*.

2003, 52(9):2274-8], neurological disorders such as epilepsy [J. Neurosci. 2003, 23(24):8471-9], Parkinson [J. Neurosci. 2003, 23(23):8302-9; Lancet. 2003, 362(9385):712] or Creutzfeldt-Jakob disease [Clin. Neurophysiol. 2003, 114(9):1724-8], and cancerous diseases [J. Pathol. 2003, 201(1):37-45; J. Pathol. 2003, 201(1):37-45; Cancer Res. 2003, 63(16):4952-9; Eur. J. Cancer. 2003, 39(13):1899-903].

Actin binding proteins:

The phrase "actin binding proteins" refers to proteins binding actin as actin cross-linking, actin bundling, F-actin capping, actin monomer binding, actin lateral binding, actin depolymerizing, actin monomer sequestering, actin filament severing, actin modulating, membrane associated actin binding, actin thin filament length regulation, and actin polymerizing proteins.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which actin binding is impaired. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, neuromuscular diseases such as muscular dystrophy [Neurology. 2003, 61(3):404-6], Cancerous diseases [Urology. 2003, 61(4):845-50; J. Cutan. Pathol. 2002, 29(7):430; Cancer. 2002, 94(6):1777-86; Clin. Cancer Res. 2001, 7(8):2415-24; Breast Cancer Res. Treat. 2001, 65(1):11-21], renal diseases such as glomerulonephritis [J. Am. Soc. Nephrol. 2002, 13(2):322-31; Eur. J. Immunol. 2001, 31(4):1221-7], and gastrointestinal diseases such as Crohn's disease [J. Cell Physiol. 2000, 182(2):303-9].

Protein binding proteins:

The phrase "protein binding proteins" refers to proteins involved in diverse biological functions through binding other proteins. Examples of such biological function include intermediate filament binding, LIM-domain binding, LLR-domain binding, clathrin binding, ARF binding, vinculin binding, KU70 binding, troponin C binding PDZ-domain binding, SH3-domain binding, fibroblast growth factor binding, membrane-associated protein with guanylate kinase activity interacting, Wnt-protein binding, DEAD/H-box RNA helicase binding, β -amyloid binding, myosin binding,

TATA-binding protein binding DNA topoisomerase I binding, polypeptide hormone binding, RHO binding, FH1-domain binding, syntaxin-1 binding, HSC70-interacting, transcription factor binding, metarhodopsin binding, tubulin binding, JUN kinase binding, RAN protein binding, protein signal sequence binding, importin α export
5 receptor, poly-glutamine tract binding, protein carrier, β -catenin binding, protein C-terminus binding, lipoprotein binding, cytoskeletal protein binding protein, nuclear localization sequence binding, protein phosphatase 1 binding, adenylate cyclase binding, eukaryotic initiation factor 4E binding, calmodulin binding, collagen binding, insulin-like growth factor binding, lamin binding, profilin binding, tropomyosin
10 binding, actin binding, peroxisome targeting sequence binding, SNARE binding, and cyclin binding.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases which are associated with
15 impaired protein binding. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, neurological and psychiatric diseases [J. Neurosci. 2003, 23(25):8788-99; Neurobiol. Dis. 2003, 14(1):146-
20 56; J. Neurosci. 2003, 23(17):6956-64; Am. J. Pathol. 2003, 163(2):609-19], and cancerous diseases [Cancer Res. 2003, 63(15):4299-304; Semin. Thromb. Hemost. 2003, 29(3):247-58; Proc. Natl. Acad. Sci. U S A. 2003, 100(16):9506-11].

Ligand binding or carrier proteins:

The phrase "ligand binding or carrier proteins" refers to proteins involved in
25 diverse biological functions such as: pyridoxal phosphate binding, carbohydrate binding, magnesium binding, amino acid binding, cyclosporin A binding, nickel binding, chlorophyll binding, biotin binding, penicillin binding, selenium binding, tocopherol binding, lipid binding, drug binding, oxygen transporter, electron transporter, steroid binding, juvenile hormone binding, retinoid binding, heavy metal
30 binding, calcium binding, protein binding, glycosaminoglycan binding, folate binding, odorant binding, lipopolysaccharide binding and nucleotide binding.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases which are associated with impaired function of these proteins. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, neurological disorders [J. Med. Genet. 2003, 40(10):733-40; J. Neuropathol. Exp. Neurol. 2003, 62(9):968-75; J. Neurochem. 2003, 87(2):427-36], autoimmune diseases (N. Engl. J. Med. 2003, 349(16):1526-33; JAMA. 2003, 290(13):1721-8]; gastroesophageal reflux disease [Dig. Dis. Sci. 2003, 48(9):1832-8], cardiovascular diseases [J. Vasc. Surg. 2003, 38(4):827-32], cancerous diseases [Oncogene. 2003, 22(43):6699-703; Br. J. Haematol. 2003, 123(2):288-96], respiratory diseases [Circulation. 2003, 108(15):1839-44], and ophtalmic diseases [Ophthalmology. 2003, 110(10):2040-4; Am. J. Ophthalmol. 2003, 136(4):729-32].

ATPases:

The term "ATPases" refers to enzymes that catalyze the hydrolysis of ATP to ADP, releasing energy that is used in the cell. This group include enzymes such as plasma membrane cation-transporting ATPase, ATP-binding cassette (ABC) transporter, magnesium-ATPase, hydrogen-/sodium-translocating ATPase or ATPase translocating any other elements, arsenite-transporting ATPase, protein-transporting ATPase, DNA translocase, P-type ATPase, and hydrolase, acting on acid anhydrides involved in cellular and subcellular movement.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases which are associated with impaired conversion of the hydrolysis of ATP to ADP or resulting energy use. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, infectious diseases such as *helicobacter pylori* ulcers [BMC Gastroenterol. 2003, Nov 6], Neurological, muscular and psychiatric diseases [Int. J. Neurosci. 2003, 13(12):1705-1717; Int. J.

Neurosci. 2003, 113(11):1579-1591; Ann. Neurol. 2003, 54(4):494-500], Amyotrophic Lateral Sclerosis [Other Motor Neuron Disord. 2003 4(2):96-9], cardiovascular diseases [J. Nippon. Med. Sch. 2003, 70(5):384-92; Endocrinology. 2003, 144(10):4478-83], metabolic diseases [Mol. Pathol. 2003, 56(5):302-4; Neurosci. Lett. 5 2003, 350(2):105-8], and peptic ulcer disease treated with inhibitors of the gastric H^+ - K^+ ATPase (e.g. Omeprazole) responsible for acid secretion in the gastric mucosa.

Carboxylic ester hydrolases:

The phrase "carboxylic ester hydrolases" refers to hydrolytic enzymes acting on carboxylic ester bonds such as N-acetylglucosaminylphosphatidylinositol deacetylase, 10 2-acetyl-1-alkylglycerophosphocholine esterase, aminoacyl-tRNA hydrolase, arylesterase, carboxylesterase, cholinesterase, gluconolactonase, sterol esterase, acylesterase, carboxymethylenebutenolidase, protein-glutamate methylesterase, lipase, and 6-phosphogluconolactonase.

Pharmaceutical compositions including such proteins or protein encoding 15 sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the hydrolytic cleavage of a covalent bond with accompanying addition of water ($-H$ being added to one product of the cleavage and $-OH$ to the other) is abnormal so that a beneficial effect may be achieved by modulation of such reaction. Antibodies and polynucleotides such as PCR 20 primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, autoimmune neuromuscular disease Myasthenia Gravis, treated with cholinesterase inhibitors.

Hydrolase, acting on ester bonds:

25 The phrase "hydrolase, acting on ester bonds" refers to hydrolytic enzymes acting on ester bonds such as nucleases, sulfuric ester hydrolase, carboxylic ester hydrolases, thiolester hydrolase, phosphoric monoester hydrolase, phosphoric diester hydrolase, triphosphoric monoester hydrolase, diphosphoric monoester hydrolase, and phosphoric triester hydrolase.

30 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the hydrolytic

cleavage of a covalent bond with accompanying addition of water (-H being added to one product of the cleavage and -OH to the other), is abnormal. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

5 ***Hydrolases:***

The term "hydrolases" refers to hydrolytic enzymes such as GPI-anchor transamidase, peptidases, hydrolases, acting on ester bonds, glycosyl bonds, ether bonds, carbon-nitrogen (but not peptide) bonds, acid anhydrides, acid carbon-carbon bonds, acid halide bonds, acid phosphorus-nitrogen bonds, acid sulfur-nitrogen bonds, 10 acid carbon-phosphorus bonds, acid sulfur-sulfur bonds.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the hydrolytic cleavage of a covalent bond with accompanying addition of water (-H being added to one 15 product of the cleavage and -OH to the other) is abnormal. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, cancerous diseases [Cancer. 2003, 98(9):1842-8; Cancer. 2003, 98(9):1822-9], neurological diseases such as 20 Parkinson diseases [J. Neurol. 2003, 250 Suppl 3:III15-III24; J. Neurol. 2003, 250 Suppl 3:III2-III10], endocrinological diseases such as pancreatitis [Pancreas. 2003, 27(4):291-6] or childhood genetic diseases [Eur. J. Pediatr. 1997, 156(12):935-8], coagulation diseases [BMJ. 2003, 327(7421):974-7], cardiovascular diseases [Ann. Intern. Med. 2003, Oct 139(8):670-82], autoimmunity diseases [J. Med. Genet. 2003, 40(10):761-6], and 25 metabolic diseases [Am. J. Hum. Genet. 2001, 69(5):1002-12].

Enzymes:

The term "enzymes" refers to naturally occurring or synthetic macromolecular substance composed mostly of protein, that catalyzes, to various degree of specificity, at least one (bio)chemical reactions at relatively low temperatures. The action of RNA 30 that has catalytic activity (ribozyme) is often also regarded as enzymatic. Nevertheless, enzymes are mainly proteinaceous and are often easily inactivated by

heating or by protein-denaturing agents. The substances upon which they act are known as substrates, for which the enzyme possesses a specific binding or active site.

The group of enzymes include various proteins possessing enzymatic activities such as mannosylphosphate transferase, para-hydroxybenzoate:polyprenyltransferase, rieske iron-sulfur protein, imidazoleglycerol-phosphate synthase, sphingosine hydroxylase, tRNA 2'-phosphotransferase, sterol C-24(28) reductase, C-8 sterol isomerase, C-22 sterol desaturase, C-14 sterol reductase, C-3 sterol dehydrogenase (C-4 sterol decarboxylase), 3-keto sterol reductase, C-4 methyl sterol oxidase, dihydronicotinamide riboside quinone reductase, glutamate phosphate reductase, DNA repair enzyme, telomerase, α -ketoacid dehydrogenase, β -alanyl-dopamine synthase, RNA editase, aldo-keto reductase, alkylbase DNA glycosidase, glycogen debranching enzyme, dihydropterin deaminase, dihydropterin oxidase, dimethylnitrosamine demethylase, ecdysteroid UDP-glucosyl/UDP glucuronosyl transferase, glycine cleavage system, helicase, histone deacetylase, mevaldate reductase, monooxygenase, poly(ADP-ribose) glycohydrolase, pyruvate dehydrogenase, serine esterase, sterol carrier protein X-related thiolase, transposase, tyramine- β hydroxylase, para-aminobenzoic acid (PABA) synthase, glu-tRNA(gln) amidotransferase, molybdopterin cofactor sulfurase, lanosterol 14- α -demethylase, aromatase, 4-hydroxybenzoate octaprenyltransferase, 7,8-dihydro-8-oxoguanine-triphosphatase, CDP-alcohol phosphotransferase, 2,5-diamino-6-(ribosylamino)-4(3H)-pyrimidonone 5'-phosphate deaminase, diphosphoinositol polyphosphate phosphohydrolase, γ -glutamyl carboxylase, small protein conjugating enzyme, small protein activating enzyme, 1-deoxyxylulose-5-phosphate synthase, 2'-phosphotransferase, 2-octoprenyl-3-methyl-6-methoxy-1,4-benzoquinone hydroxylase, 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase, 3,4 dihydroxy-2-butanone-4-phosphate synthase, 4-amino-4-deoxychorismate lyase, 4-diphosphocytidyl-2C-methyl-D-erythritol synthase, ADP-L-glycero-D-manno-heptose synthase, D-erythro-7,8-dihydroneopterin triphosphate 2'-epimerase, N-ethylmaleimide reductase, O-antigen ligase, O-antigen polymerase, UDP-2,3-diacetylglucosamine hydrolase, arsenate reductase, carnitine racemase, cobalamin [5'-phosphate] synthase, cobinamide phosphate guanylyltransferase, enterobactin synthetase, enterochelin esterase, enterochelin synthetase, glycolate oxidase, integrase, lauroyl transferase, peptidoglycan synthetase,

phosphopantetheinyltransferase, phosphoglucosamine mutase, phosphoheptose isomerase, quinolinate synthase, siroheme synthase, N-acylmannosamine-6-phosphate 2-epimerase, N-acetyl-anhydromuramoyl-L-alanine amidase, carbon-phosphorous lyase, heme-copper terminal oxidase, disulfide oxidoreductase, phthalate dioxygenase reductase, sphingosine-1-phosphate lyase, molybdopterin oxidoreductase, dehydrogenase, NADPH oxidase, naringenin-chalcone synthase, N-ethylmethylamine chlorohydrolase, polyketide synthase, aldolase, kinase, phosphatase, CoA-ligase, oxidoreductase, transferase, hydrolase, lyase, isomerase, ligase, ATPase, sulfhydryl oxidase, lipoate-protein ligase, δ -1-pyrroline-5-carboxylate synthetase, lipoic acid synthase, and tRNA dihydrouridine synthase.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases which can be ameliorated by modulating the activity of various enzymes which are involved both in enzymatic processes inside cells as well as in cell signaling. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Cytoskeletal proteins:

The term "cytoskeletal proteins" refers to proteins involved in the structure formation of the cytoskeleton.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases which are caused or due to abnormalities in cytoskeleton, including cancerous cells, and diseased cells such as cells that do not propagate, grow or function normally. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, liver diseases such as cholestatic diseases [Lancet. 2003, 362(9390):1112-9], vascular diseases [J. Cell Biol. 2003, 162(6):1111-22], endocrinological diseases [Cancer Res. 2003, 63(16):4836-41], neuromuscular disorders such as muscular dystrophy [Neuromuscul. Disord. 2003, 13(7-8):579-88], or myopathy [Neuromuscul. Disord. 2003, 13(6):456-67] neurological

disorders such as Alzheimer's disease [J. Alzheimers Dis. 2003, 5(3):209-28], cardiac disorders [J. Am. Coll. Cardiol. 2003, 42(2):319-27], skin disorders [J. Am. Coll. Cardiol. 2003, 42(2):319-27], and cancer [Proteomics. 2003, 3(6):979-90].

Structural proteins:

5 The term "structural proteins" refers to proteins involved in the structure formation of the cell, such as structural proteins of ribosome, cell wall structural proteins, structural proteins of cytoskeleton, extracellular matrix structural proteins, extracellular matrix glycoproteins, amyloid proteins, plasma proteins, structural proteins of eye lens, structural protein of chorion (sensu Insecta), structural protein of
10 cuticle (sensu Insecta), puparial glue protein (sensu Diptera), structural proteins of bone, yolk proteins, structural proteins of muscle, structural protein of vitelline membrane (sensu Insecta), structural proteins of peritrophic membrane (sensu Insecta), and structural proteins of nuclear pores.

Pharmaceutical compositions including such proteins or protein encoding
15 sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases which are caused by abnormalities in cytoskeleton, including cancerous cells, and diseased cells such as cells that do not propagate, grow or function normally. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding
20 sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, blood vessels diseases such as aneurysms [Cardiovasc. Res. 2003, 60(1):205-13], joint diseases [Rheum. Dis. Clin. North Am. 2003, 29(3):631-45], muscular diseases such as muscular dystrophies [Curr. Opin. Clin. Nutr. Metab. Care. 2003, 6(4):435-9], neuronal diseases such as
25 encephalitis [Neurovirol. 2003, 9(2):274-83], retinitis pigmentosa [Dev. Ophthalmol. 2003, 37:109-25], and infectious diseases [J. Virol. Methods. 2003, 109(1):75-83; FEMS Immunol. Med. Microbiol. 2003, 35(2):125-30; J. Exp. Med. 2003, 197(5):633-42].

Ligands:

The term "ligands" refers to proteins that bind to another chemical entity to
30 form a larger complex, involved in various biological processes, such as signal transduction, metabolism, growth and differentiation, etc. This group of proteins includes opioid peptides, baboon receptor ligand, branchless receptor ligand,

breathless receptor ligand, ephrin, frizzled receptor ligand, frizzled-2 receptor ligand, heartless receptor ligand, Notch receptor ligand, patched receptor ligand, punt receptor ligand, Ror receptor ligand, saxophone receptor ligand, SE20 receptor ligand, sevenless receptor ligand, smooth receptor ligand, thickveins receptor ligand, Toll
5 receptor ligand, Torso receptor ligand, death receptor ligand, scavenger receptor ligand, neuroligin, integrin ligand, hormones, pheromones, growth factors, and sulfonylurea receptor ligand.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering
10 expression of such proteins, may be used to treat diseases involved in impaired hormone function or diseases which involve abnormal secretion of proteins which may be due to abnormal presence, absence or impaired normal response to normal levels of secreted proteins. Those secreted proteins include hormones, neurotransmitters, and various other proteins secreted by cells to the extracellular environment. Antibodies and
15 polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, analgesia inhibited by orphanin FQ/nociceptin [Shane R., et al., (2001) Brain Res., 907(1-2):109-16], stroke protected by estrogen [Alkayed N. J., et al., (2001) J. Neurosci., 21(19):7543-50],
20 atherosclerosis associated with growth hormone deficiency [Elhadd T. A., et al., (2001) J. Clin. Endocrinol. Metab., 86(9):4223-32], diabetes inhibited by α -galactosylceramide [Hong S., et al., (2001) Nat. Med., 7(9):1052-6], and Huntington's disease associated with huntingtin deficiency [Rao D. S., et al., (2001) Mol. Cell Biol., 21(22):7796-806].

Signal transducer:

25 The term "signal transducers" refers to proteins such as activin inhibitors, receptor-associated proteins, α -2 macroglobulin receptors, morphogens, quorum sensing signal generators, quorum sensing response regulators, receptor signaling proteins, ligands, receptors, two-component sensor molecules, and two-component response regulators.

30 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases in which the signal-transduction

is impaired, either as a cause, or as a result of the disease. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, altered sexual
5 dimorphism associated with signal transducer and activator of transcription 5b [Udy G. B., et al., (1997) Proc. Natl. Acad. Sci. U S A, 94(14):7239-44], multiple sclerosis associated with sgp130 deficiency [Padberg F., et al., (1999) J. Neuroimmunol., 99(2):218-23], intestinal inflammation associated with elevated signal transducer and activator of transcription 3 activity [Suzuki A., et al., (2001) J Exp Med, 193(4):471-81],
10 carcinoid tumor inhibited by increased signal transducer and activators of transcription 1 and 2 [Zhou Y., et al., (2001) Oncology, 60(4):330-8], and esophageal cancer associated with loss of EGF-STAT1 pathway [Watanabe G., et al., (2001) Cancer J., 7(2):132-9].

RNA polymerase II transcription factors:

The phrase "RNA polymerase II transcription factors" refers to proteins such as
15 specific and non-specific RNA polymerase II transcription factors, enhancer binding, ligand-regulated transcription factor, and general RNA polymerase II transcription factors.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering
20 expression of such proteins, may be used to treat diseases involving impaired function of RNA polymerase II transcription factors. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, cardiac diseases [Cell
25 Cycle. 2003, 2(2):99-104], xeroderma pigmentosum [Bioessays. 2001, 23(8):671-3; Biochim. Biophys. Acta. 1997, 1354(3):241-51], muscular atrophy [J. Cell Biol. 2001, 152(1):75-85], neurological diseases such as Alzheimer's disease [Front Biosci. 2000, 5:D244-57], cancerous diseases such as breast cancer [Biol. Chem. 1999, 380(2):117-28], and autoimmune disorders [Clin. Exp. Immunol. 1997, 109(3):488-94].

30 ***RNA binding proteins:***

The phrase "RNA binding proteins" refers to RNA binding proteins involved in splicing and translation regulation such as tRNA binding proteins, RNA helicases,

double-stranded RNA and single-stranded RNA binding proteins, mRNA binding proteins, snRNA cap binding proteins, 5S RNA and 7S RNA binding proteins, polypyrimidine tract binding proteins, snRNA binding proteins, and AU-specific RNA binding proteins.

5 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases involving transcription and translation factors such as helicases, isomerases, histones and nucleases, diseases where there is impaired transcription, splicing, post-transcriptional processing, translation or
10 stability of the RNA. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

 Examples of such diseases include, but are not limited to, cancerous diseases such as lymphomas [Tumori. 2003, 89(3):278-84], prostate cancer [Prostate. 2003, 57(1):80-
15 92] or lung cancer [J. Pathol. 2003, 200(5):640-6], blood diseases, such as fanconi anemia [Curr. Hematol. Rep. 2003, 2(4):335-40], cardiovascular diseases such as atherosclerosis [J. Thromb. Haemost. 2003, 1(7):1381-90] muscle diseases [Trends Cardiovasc. Med. 2003, 13(5):188-95] and brain and neuronal diseases [Trends Cardiovasc. Med. 2003, 13(5):188-95; Neurosci. Lett. 2003, 342(1-2):41-4].

20 ***Nucleic acid binding proteins:***

 The phrase "nucleic acid binding proteins" refers to proteins involved in RNA and DNA synthesis and expression regulation such as transcription factors, RNA and DNA binding proteins, zinc fingers, helicase, isomerase, histones, nucleases, ribonucleoproteins, and transcription and translation factors.

25 Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases involving DNA or RNA binding proteins such as: helicases, isomerases, histones and nucleases, for example diseases where there is abnormal replication or transcription of DNA and RNA
30 respectively. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such diseases include, but are not limited to, neurological diseases such as renitis pigmentosa [Am. J. Ophthalmol. 2003, 136(4):678-87] parkinsonism [Proc. Natl. Acad. Sci. U S A. 2003, 100(18):10347-52], Alzheimer [J. Neurosci. 2003, 23(17):6914-27] and canavan diseases [Brain Res Bull. 2003, 61(4):427-35], cancerous diseases such as leukemia [Anticancer Res. 2003, 23(4):3419-26] or lung cancer [J. Pathol. 2003, 200(5):640-6], miopathy [Neuromuscul Disord. 2003, 13(7-8):559-67] and liver diseases [J. Pathol. 2003, 200(5):553-60].

Proteins involved in Metabolism:

The phrase "proteins involved in metabolism" refers to proteins involved in the totality of the chemical reactions and physical changes that occur in living organisms, comprising anabolism and catabolism; may be qualified to mean the chemical reactions and physical processes undergone by a particular substance, or class of substances, in a living organism. This group includes proteins involved in the reactions of cell growth and maintenance such as: metabolism resulting in cell growth, carbohydrate metabolism, energy pathways, electron transport, nucleobase, nucleoside, nucleotide and nucleic acid metabolism, protein metabolism and modification, amino acid and derivative metabolism, protein targeting, lipid metabolism, aromatic compound metabolism, one-carbon compound metabolism, coenzymes and prosthetic group metabolism, sulfur metabolism, phosphorus metabolism, phosphate metabolism, oxygen and radical metabolism, xenobiotic metabolism, nitrogen metabolism, fat body metabolism (sensu Insecta), protein localization, catabolism, biosynthesis, toxin metabolism, methylglyoxal metabolism, cyanate metabolism, glycolate metabolism, carbon utilization and antibiotic metabolism.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat diseases involving cell metabolism. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases.

Examples of such metabolism-related diseases include, but are not limited to, multisystem mitochondrial disorder caused by mitochondrial DNA cytochrome C

oxidase II deficiency [Campos Y., et al., (2001) Ann. Neurol. 50(3):409-13], conduction defects and ventricular dysfunction in the heart associated with heterogeneous connexin43 expression [Gutstein D. E., et al., (2001) Circulation, 104(10):1194-9], atherosclerosis associated with growth suppressor p27 deficiency [Diez-Juan A., and Andres V. (2001) FASEB J., 15(11):1989-95], colitis associated with glutathione peroxidase deficiency [Esworthy R. S., et al., (2001) Am. J. Physiol. Gastrointest. Liver Physiol., 281(3):G848-55], systemic lupus erythematosus associated with deoxyribonuclease I deficiency [Yasutomo K., et al., (2001) Nat. Genet., 28(4):313-4], alcoholic pancreatitis [Pancreas. 2003, 27(4):281-5], amyloidosis and diseases that are related to amyloid metabolism, such as FMF, atherosclerosis, diabetes, and especially diabetes long term consequences, neurological diseases such as Creutzfeldt-Jakob disease, and Parkinson or Rasmussen's encephalitis.

Cell growth and/or maintenance proteins:

The phrase "Cell growth and/or maintenance proteins" refers to proteins involved in any biological process required for cell survival, growth and maintenance, including proteins involved in biological processes such as cell organization and biogenesis, cell growth, cell proliferation, metabolism, cell cycle, budding, cell shape and cell size control, sporulation (sensu Saccharomyces), transport, ion homeostasis, autophagy, cell motility, chemi-mechanical coupling, membrane fusion, cell-cell fusion, and stress response.

Pharmaceutical compositions including such proteins or protein encoding sequences, antibodies directed against such proteins or polynucleotides capable of altering expression of such proteins, may be used to treat or prevent diseases such as cancer, degenerative diseases, for example neurodegenerative diseases or conditions associated with aging, or alternatively, diseases wherein apoptosis which should have taken place, does not take place. Antibodies and polynucleotides such as PCR primers and molecular probes designed to identify such proteins or protein encoding sequences may be used for diagnosis of such diseases, detection of pre-disposition to a disease, and determination of the stage of a disease.

Examples of such diseases include, but are not limited to, ataxia-telangiectasia associated with ataxia-telangiectasia mutated deficiency [Hande et al., (2001) Hum.

Mol. Genet., 10(5):519-28], osteoporosis associated with osteonectin deficiency [Delany et al., (2000) J. Clin. Invest., 105(7):915-23], arthritis caused by membrane-bound matrix metalloproteinase deficiency [Holmbeck et al., (1999) Cell, 99(1):81-92], defective stratum corneum and early neonatal death associated with
5 transglutaminase 1 deficiency [Matsuki et al., (1998) Proc. Natl. Acad. Sci. U S A, 95(3):1044-9], and Alzheimer's disease associated with estrogen [Simpkins et al., (1997) Am. J. Med., 103(3A):19S-25S].

Chaperones

Information derived from proteins such as ribosomal chaperone, peptidylprolyl
10 isomerase, lectin-binding chaperone, nucleosome assembly chaperone, chaperonin ATPase, cochaperone, heat shock protein, HSP70/HSP90 organizing protein, fimbrial chaperone, metallochaperone, tubulin folding, HSC70-interacting protein can be used to diagnose/treat diseases involving pathological conditions, which are associated with non-normal protein activity or structure. Binding of the products of the proteins of this
15 family, or antibodies reactive therewith, can modulate a plurality of protein activities as well as change protein structure. Alternatively, diseases in which there is abnormal degradation of other proteins, which may cause non-normal accumulation of various proteinaceous products in cells, caused non-normal (prolonged or shortened) activity of proteins, etc.

20 Example of diseases that involve chaperones are cancerous diseases, such as prostate cancer (Semin Oncol. 2003 Oct;30(5):709-16.); infectious diseases, such as prion infection (EMBO J. 2003 Oct 15;22(20):5435-5445.); neurological syndromes (J Neuropathol Exp Neurol. 2003 Jul;62(7):751-64.; Antioxid Redox Signal. 2003 Jun;5(3):337-48.; J Neurochem. 2003 Jul;86(2):394-404.)

Variants of proteins which accumulate an element/compound

Variant proteins which their wild type version naturally binds a certain compound or element inside the cell for storage of accumulation may have terapoetic effect as secreted variants. Ferritin, accumulates iron inside the cells. A secreted variant of this protein is expected to bind plasma iron, reduce its levels and therefore
30 have a desired therapeutic effect in the syndrome of Hemosiderosis characterized by high levels of iron in the blood.

Diseases that may be treated/diagnosed using the biomolecular sequences of the present invention

Inflammatory diseases

Examples of inflammatory diseases include, but are not limited to, chronic
5 inflammatory diseases and acute inflammatory diseases.

Inflammatory diseases associated with hypersensitivity

Examples of hypersensitivity include, but are not limited to, Types I-IV
hypersensitivity, immediate hypersensitivity, antibody mediated hypersensitivity,
immune complex mediated hypersensitivity, T lymphocyte mediated hypersensitivity
10 and DTH. An example of type I or immediate hypersensitivity is asthma. Examples
of type II hypersensitivity include, but are not limited to, rheumatoid diseases,
rheumatoid autoimmune diseases, rheumatoid arthritis [Krenn V. *et al.*, *Histol*
Histopathol 2000 Jul;15 (3):791], spondylitis, ankylosing spondylitis [Jan Voswinkel
et al., *Arthritis Res* 2001; 3 (3): 189], systemic diseases, systemic autoimmune
15 diseases, systemic lupus erythematosus [Erikson J. *et al.*, *Immunol Res* 1998;17 (1-
2):49], sclerosis, systemic sclerosis [Renaudineau Y. *et al.*, *Clin Diagn Lab Immunol.*
1999 Mar;6 (2):156; Chan OT. *et al.*, *Immunol Rev* 1999 Jun;169:107], glandular
diseases, glandular autoimmune diseases, pancreatic autoimmune diseases, diabetes,
Type I diabetes [Zimmet P. *Diabetes Res Clin Pract* 1996 Oct;34 Suppl:S125], thyroid
20 diseases, autoimmune thyroid diseases, Graves' disease [Orgiazzi J. *Endocrinol*
Metab Clin North Am 2000 Jun;29 (2):339], thyroiditis, spontaneous autoimmune
thyroiditis [Braley-Mullen H. and Yu S, *J Immunol* 2000 Dec 15;165 (12):7262],
Hashimoto's thyroiditis [Toyoda N. *et al.*, *Nippon Rinsho* 1999 Aug;57 (8):1810],
myxedema, idiopathic myxedema [Mitsuma T. *Nippon Rinsho*. 1999 Aug;57
25 (8):1759], autoimmune reproductive diseases, ovarian diseases, ovarian autoimmunity
[Garza KM. *et al.*, *J Reprod Immunol* 1998 Feb;37 (2):87], autoimmune anti-sperm
infertility [Diekman AB. *et al.*, *Am J Reprod Immunol*. 2000 Mar;43 (3):134],
repeated fetal loss [Tincani A. *et al.*, *Lupus* 1998;7 Suppl 2:S107-9],
neurodegenerative diseases, neurological diseases, neurological autoimmune diseases,
30 multiple sclerosis [Cross AH. *et al.*, *J Neuroimmunol* 2001 Jan 1;112 (1-2):1],
Alzheimer's disease [Oron L. *et al.*, *J Neural Transm Suppl.* 1997;49:77], myasthenia
gravis [Infante AJ. And Kraig E, *Int Rev Immunol* 1999;18 (1-2):83], motor

neuropathies [Kornberg AJ. J Clin Neurosci. 2000 May;7 (3):191], Guillain-Barre syndrome, neuropathies and autoimmune neuropathies [Kusunoki S. Am J Med Sci. 2000 Apr;319 (4):234], myasthenic diseases, Lambert-Eaton myasthenic syndrome [Takamori M. Am J Med Sci. 2000 Apr;319 (4):204], paraneoplastic neurological diseases, cerebellar atrophy, paraneoplastic cerebellar atrophy, non-paraneoplastic stiff man syndrome, cerebellar atrophies, progressive cerebellar atrophies, encephalitis, Rasmussen's encephalitis, amyotrophic lateral sclerosis, Sydeham chorea, Gilles de la Tourette syndrome, polyendocrinopathies, autoimmune polyendocrinopathies [Antoine JC. and Honnorat J. Rev Neurol (Paris) 2000 Jan;156 (1):23], neuropathies, dysimmune neuropathies [Nobile-Orazio E. *et al.*, Electroencephalogr Clin Neurophysiol Suppl 1999;50:419], neuromyotonia, acquired neuromyotonia, arthrogryposis multiplex congenita [Vincent A. *et al.*, Ann N Y Acad Sci. 1998 May 13;841:482], cardiovascular diseases, cardiovascular autoimmune diseases, atherosclerosis [Matsuura E. *et al.*, Lupus. 1998;7 Suppl 2:S135], myocardial infarction [Vaarala O. Lupus. 1998;7 Suppl 2:S132], thrombosis [Tincani A. *et al.*, Lupus 1998;7 Suppl 2:S107-9], granulomatosis, Wegener's granulomatosis, arteritis, Takayasu's arteritis and Kawasaki syndrome [Praprotnik S. *et al.*, Wien Klin Wochenschr 2000 Aug 25;112 (15-16):660], anti-factor VIII autoimmune disease [Lacroix-Desmazes S. *et al.*, Semin Thromb Hemost.2000;26 (2):157], vasculitises, necrotizing small vessel vasculitises, microscopic polyangiitis, Churg and Strauss syndrome, glomerulonephritis, pauci-immune focal necrotizing glomerulonephritis, crescentic glomerulonephritis [Noel LH. Ann Med Interne (Paris). 2000 May;151 (3):178], antiphospholipid syndrome [Flamholz R. *et al.*, J Clin Apheresis 1999;14 (4):171], heart failure, agonist-like β -adrenoceptor antibodies in heart failure [Wallukat G. *et al.*, Am J Cardiol. 1999 Jun 17;83 (12A):75H], thrombocytopenic purpura [Moccia F. Ann Ital Med Int. 1999 Apr-Jun;14 (2):114], hemolytic anemia, autoimmune hemolytic anemia [Efremov DG. *et al.*, Leuk Lymphoma 1998 Jan;28 (3-4):285], gastrointestinal diseases, autoimmune diseases of the gastrointestinal tract, intestinal diseases, chronic inflammatory intestinal disease [Garcia Herola A. *et al.*, Gastroenterol Hepatol. 2000 Jan;23 (1):16], celiac disease [Landau YE. and Shoenfeld Y. Harefuah 2000 Jan 16;138 (2):122], autoimmune diseases of the musculature, myositis, autoimmune myositis, Sjogren's syndrome [Feist E. *et al.*, Int

Arch Allergy Immunol 2000 Sep;123 (1):92], smooth muscle autoimmune disease [Zauli D. *et al.*, Biomed Pharmacother 1999 Jun;53 (5-6):234], hepatic diseases, hepatic autoimmune diseases, autoimmune hepatitis [Manns MP. J Hepatol 2000 Aug;33 (2):326] and primary biliary cirrhosis [Strassburg CP. *et al.*, Eur J Gastroenterol Hepatol. 1999 Jun;11 (6):595].

Examples of type IV or T cell mediated hypersensitivity, include, but are not limited to, rheumatoid diseases, rheumatoid arthritis [Tisch R, McDevitt HO. Proc Natl Acad Sci U S A 1994 Jan 18;91 (2):437], systemic diseases, systemic autoimmune diseases, systemic lupus erythematosus [Datta SK., Lupus 1998;7 (9):591], glandular diseases, glandular autoimmune diseases, pancreatic diseases, pancreatic autoimmune diseases, Type 1 diabetes [Castano L. and Eisenbarth GS. Ann. Rev. Immunol. 8:647], thyroid diseases, autoimmune thyroid diseases, Graves' disease [Sakata S. *et al.*, Mol Cell Endocrinol 1993 Mar;92 (1):77], ovarian diseases [Garza KM. *et al.*, J Reprod Immunol 1998 Feb;37 (2):87], prostatitis, autoimmune prostatitis [Alexander RB. *et al.*, Urology 1997 Dec;50 (6):893], polyglandular syndrome, autoimmune polyglandular syndrome, Type I autoimmune polyglandular syndrome [Hara T. *et al.*, Blood. 1991 Mar 1;77 (5):1127], neurological diseases, autoimmune neurological diseases, multiple sclerosis, neuritis, optic neuritis [Soderstrom M. *et al.*, J Neurol Neurosurg Psychiatry 1994 May;57 (5):544], myasthenia gravis [Oshima M. *et al.*, Eur J Immunol 1990 Dec;20 (12):2563], stiff-man syndrome [Hiemstra HS. *et al.*, Proc Natl Acad Sci U S A 2001 Mar 27;98 (7):3988], cardiovascular diseases, cardiac autoimmunity in Chagas' disease [Cunha-Neto E. *et al.*, J Clin Invest 1996 Oct 15;98 (8):1709], autoimmune thrombocytopenic purpura [Semple JW. *et al.*, Blood 1996 May 15;87 (10):4245], anti-helper T lymphocyte autoimmunity [Caporossi AP. *et al.*, Viral Immunol 1998;11 (1):9], hemolytic anemia [Sallah S. *et al.*, Ann Hematol 1997 Mar;74 (3):139], hepatic diseases, hepatic autoimmune diseases, hepatitis, chronic active hepatitis [Franco A. *et al.*, Clin Immunol Immunopathol 1990 Mar;54 (3):382], biliary cirrhosis, primary biliary cirrhosis [Jones DE. Clin Sci (Colch) 1996 Nov;91 (5):551], nephric diseases, nephric autoimmune diseases, nephritis, interstitial nephritis [Kelly CJ. J Am Soc Nephrol 1990 Aug;1 (2):140], connective tissue diseases, ear diseases, autoimmune connective tissue diseases, autoimmune ear disease [Yoo TJ. *et al.*, Cell Immunol

1994 Aug;157 (1):249], disease of the inner ear [Gloddek B. *et al.*, Ann N Y Acad Sci 1997 Dec 29;830:266], skin diseases, cutaneous diseases, dermal diseases, bullous skin diseases, pemphigus vulgaris, bullous pemphigoid and pemphigus foliaceus.

Examples of delayed type hypersensitivity include, but are not limited to,
5 contact dermatitis and drug eruption.

Autoimmune diseases

Examples of autoimmune diseases include, but are not limited to, cardiovascular diseases, rheumatoid diseases, glandular diseases, gastrointestinal diseases, cutaneous diseases, hepatic diseases, neurological diseases, muscular
10 diseases, nephric diseases, diseases related to reproduction, connective tissue diseases and systemic diseases.

Examples of autoimmune cardiovascular and blood diseases include, but are not limited to atherosclerosis [Matsuura E. *et al.*, Lupus. 1998;7 Suppl 2:S135], myocardial infarction [Vaarala O. Lupus. 1998;7 Suppl 2:S132], thrombosis [Tincani
15 A. *et al.*, Lupus 1998;7 Suppl 2:S107-9], Wegener's granulomatosis, Takayasu's arteritis, Kawasaki syndrome [Praprotnik S. *et al.*, Wien Klin Wochenschr 2000 Aug 25;112 (15-16):660], anti-factor VIII autoimmune disease [Lacroix-Desmazes S. *et al.*, Semin Thromb Hemost.2000;26 (2):157], necrotizing small vessel vasculitis, microscopic polyangiitis, Churg and Strauss syndrome, pauci-immune focal
20 necrotizing and crescentic glomerulonephritis [Noel LH. Ann Med Interne (Paris). 2000 May;151 (3):178], antiphospholipid syndrome [Flamholz R. *et al.*, J Clin Apheresis 1999;14 (4):171], antibody-induced heart failure [Wallukat G. *et al.*, Am J Cardiol. 1999 Jun 17;83 (12A):75H], thrombocytopenic purpura [Moccia F. Ann Ital Med Int. 1999 Apr-Jun;14 (2):114; Semple JW. *et al.*, Blood 1996 May 15;87
25 (10):4245], autoimmune hemolytic anemia [Efremov DG. *et al.*, Leuk Lymphoma 1998 Jan;28 (3-4):285; Sallah S. *et al.*, Ann Hematol 1997 Mar;74 (3):139], cardiac autoimmunity in Chagas' disease [Cunha-Neto E. *et al.*, J Clin Invest 1996 Oct 15;98 (8):1709] and anti-helper T lymphocyte autoimmunity [Caporossi AP. *et al.*, Viral Immunol 1998;11 (1):9].

30 Examples of autoimmune rheumatoid diseases include, but are not limited to rheumatoid arthritis [Krenn V. *et al.*, Histol Histopathol 2000 Jul;15 (3):791; Tisch R,

McDevitt HO. Proc Natl Acad Sci units S A 1994 Jan 18;91 (2):437) and ankylosing spondylitis [Jan Voswinkel *et al.*, Arthritis Res 2001; 3 (3): 189].

Examples of autoimmune glandular diseases include, but are not limited to, pancreatic disease, Type I diabetes, Type II diabetes, thyroid disease, Graves' disease, thyroiditis, spontaneous autoimmune thyroiditis, Hashimoto's thyroiditis, idiopathic myxedema, ovarian autoimmunity, autoimmune anti-sperm infertility, autoimmune prostatitis and Type I autoimmune polyglandular syndrome. diseases include, but are not limited to autoimmune diseases of the pancreas, Type 1 diabetes [Castano L. and Eisenbarth GS. Ann. Rev. Immunol. 8:647; Zimmet P. Diabetes Res Clin Pract 1996 Oct;34 Suppl:S125], autoimmune thyroid diseases, Graves' disease [Orgiazzi J. Endocrinol Metab Clin North Am 2000 Jun;29 (2):339; Sakata S. *et al.*, Mol Cell Endocrinol 1993 Mar;92 (1):77], spontaneous autoimmune thyroiditis [Braley-Mullen H. and Yu S, J Immunol 2000 Dec 15;165 (12):7262], Hashimoto's thyroiditis [Toyoda N. *et al.*, Nippon Rinsho 1999 Aug;57 (8):1810], idiopathic myxedema [Mitsuma T. Nippon Rinsho. 1999 Aug;57 (8):1759], ovarian autoimmunity [Garza KM. *et al.*, J Reprod Immunol 1998 Feb;37 (2):87], autoimmune anti-sperm infertility [Diekman AB. *et al.*, Am J Reprod Immunol. 2000 Mar;43 (3):134], autoimmune prostatitis [Alexander RB. *et al.*, Urology 1997 Dec;50 (6):893] and Type I autoimmune polyglandular syndrome [Hara T. *et al.*, Blood. 1991 Mar 1;77 (5):1127].

Examples of autoimmune gastrointestinal diseases include, but are not limited to, chronic inflammatory intestinal diseases [Garcia Herola A. *et al.*, Gastroenterol Hepatol. 2000 Jan;23 (1):16], celiac disease [Landau YE. and Shoenfeld Y. Harefuah 2000 Jan 16;138 (2):122], colitis, ileitis and Crohn's disease and ulcerative colitis.

Examples of autoimmune cutaneous diseases include, but are not limited to, autoimmune bullous skin diseases, such as, but are not limited to, pemphigus vulgaris, bullous pemphigoid and pemphigus foliaceus.

Examples of autoimmune hepatic diseases include, but are not limited to, hepatitis, autoimmune chronic active hepatitis [Franco A. *et al.*, Clin Immunol Immunopathol 1990 Mar;54 (3):382], primary biliary cirrhosis [Jones DE. Clin Sci (Colch) 1996 Nov;91 (5):551; Strassburg CP. *et al.*, Eur J Gastroenterol Hepatol. 1999 Jun;11 (6):595) and autoimmune hepatitis [Manns MP. J Hepatol 2000 Aug;33 (2):326].

Examples of autoimmune neurological diseases include, but are not limited to, multiple sclerosis [Cross AH. *et al.*, J Neuroimmunol 2001 Jan 1;112 (1-2):1], Alzheimer's disease [Oron L. *et al.*, J Neural Transm Suppl. 1997;49:77], myasthenia gravis [Infante AJ. And Kraig E, Int Rev Immunol 1999;18 (1-2):83; Oshima M. *et al.*, Eur J Immunol 1990 Dec;20 (12):2563], neuropathies, motor neuropathies [Kornberg AJ. J Clin Neurosci. 2000 May;7 (3):191], Guillain-Barre syndrome and autoimmune neuropathies [Kusunoki S. Am J Med Sci. 2000 Apr;319 (4):234], myasthenia, Lambert-Eaton myasthenic syndrome [Takamori M. Am J Med Sci. 2000 Apr;319 (4):204], paraneoplastic neurological diseases, cerebellar atrophy, paraneoplastic cerebellar atrophy and stiff-man syndrome [Hiemstra HS. *et al.*, Proc Natl Acad Sci units S A 2001 Mar 27;98 (7):3988], non-paraneoplastic stiff man syndrome, progressive cerebellar atrophies, encephalitis, Rasmussen's encephalitis, amyotrophic lateral sclerosis, Sydeham chorea, Gilles de la Tourette syndrome and autoimmune polyendocrinopathies [Antoine JC. and Honnorat J. Rev Neurol (Paris) 2000 Jan;156 (1):23], dysimmune neuropathies [Nobile-Orazio E. *et al.*, Electroencephalogr Clin Neurophysiol Suppl 1999;50:419], acquired neuromyotonia, arthrogryposis multiplex congenita [Vincent A. *et al.*, Ann N Y Acad Sci. 1998 May 13;841:482], neuritis, optic neuritis [Soderstrom M. *et al.*, J Neurol Neurosurg Psychiatry 1994 May;57 (5):544] multiple sclerosis and neurodegenerative diseases.

Examples of autoimmune muscular diseases include, but are not limited to, myositis, autoimmune myositis and primary Sjogren's syndrome [Feist E. *et al.*, Int Arch Allergy Immunol 2000 Sep;123 (1):92] and smooth muscle autoimmune disease [Zauli D. *et al.*, Biomed Pharmacother 1999 Jun;53 (5-6):234].

Examples of autoimmune nephric diseases include, but are not limited to, nephritis and autoimmune interstitial nephritis [Kelly CJ. J Am Soc Nephrol 1990 Aug;1 (2):140], glomerular nephritis.

Examples of autoimmune diseases related to reproduction include, but are not limited to, repeated fetal loss [Tincani A. *et al.*, Lupus 1998;7 Suppl 2:S107-9].

Examples of autoimmune connective tissue diseases include, but are not limited to, ear diseases, autoimmune ear diseases [Yoo TJ. *et al.*, Cell Immunol 1994 Aug;157 (1):249] and autoimmune diseases of the inner ear [Gloddek B. *et al.*, Ann N Y Acad Sci 1997 Dec 29;830:266].

Examples of autoimmune systemic diseases include, but are not limited to, systemic lupus erythematosus [Erikson J. *et al.*, Immunol Res 1998;17 (1-2):49] and systemic sclerosis [Renaudineau Y. *et al.*, Clin Diagn Lab Immunol. 1999 Mar;6 (2):156; Chan OT. *et al.*, Immunol Rev 1999 Jun;169:107].

5 ***Infectious diseases***

Examples of infectious diseases include, but are not limited to, chronic infectious diseases, subacute infectious diseases, acute infectious diseases, viral diseases, bacterial diseases, protozoan diseases, parasitic diseases, fungal diseases, mycoplasma diseases, and prion diseases.

10

Graft rejection diseases

Examples of diseases associated with transplantation of a graft include, but are not limited to, graft rejection, chronic graft rejection, subacute graft rejection, hyperacute graft rejection, acute graft rejection, and graft versus host disease.

15 ***Allergic diseases***

Examples of allergic diseases include, but are not limited to, asthma, hives, urticaria, pollen allergy, dust mite allergy, venom allergy, cosmetics allergy, latex allergy, chemical allergy, drug allergy, insect bite allergy, animal dander allergy, stinging plant allergy, poison ivy allergy and food allergy.

20 ***Cancerous diseases***

Examples of cancer include but are not limited to carcinoma, lymphoma, blastoma, sarcoma, and leukemia. Particular examples of cancerous diseases but are not limited to: Myeloid leukemia such as Chronic myelogenous leukemia. Acute myelogenous leukemia with maturation. Acute promyelocytic leukemia, Acute nonlymphocytic leukemia with increased basophils, Acute monocytic leukemia. Acute myelomonocytic leukemia with eosinophilia; malignant lymphoma, such as Birkitt's Non-Hodgkin's; Lymphocytic leukemia, such as acute lymphoblastic leukemia. Chronic lymphocytic leukemia; Myeloproliferative diseases, such as Solid tumors Benign Meningioma, Mixed tumors of salivary gland, Colonic adenomas; Adenocarcinomas, such as Small cell lung cancer, Kidney, Uterus, Prostate, Bladder, Ovary, Colon, Sarcomas, Liposarcoma, myxoid, Synovial sarcoma, Rhabdomyosarcoma (alveolar), Extraskelitel myxoid chondrosarcoma, Ewing's

25

30

tumor; other include Testicular and ovarian dysgerminoma, Retinoblastoma, Wilms' tumor, Neuroblastoma, Malignant melanoma, Mesothelioma, breast, skin, prostate, and ovarian.

5

EXAMPLE 9

Microarray analysis based validation of the antisense dataset

A microarray-based analysis using oligonucleotide probes that hybridize to the target in a strand-specific manner, was conducted in order to experimentally validate the predicted antisense/sense pairs of the database. Two complementary 60-mer oligonucleotide probes derived from the predicted overlap region of the sense/antisense pairs, were designed. Single 60-mer oligonucleotides were previously shown to offer reliability and sensitivity for detecting specific transcripts (T. R. Hughes, *et al.*, *Nature Biotech.* **19**, 342 (2001).) Initially only pairs of clusters with an overlap greater than 60 bases (2,464 pairs agree with this restriction) were selected for array construction. The overlap region of each antisense pair was then verified for the presence of 60-mer oligonucleotides that matched a set of standards, such as minimal sequence similarity elsewhere in the human genome, uniform GC-content and T_m, and absence of palindromic sequences, in order to maximize the hybridization specificity. Oligonucleotide probes meeting the criteria set forth were identified for 1,211 sense/antisense pairs and a random sample of 264 pairs, which constitutes roughly one-tenth of the original dataset of 2667 sense/antisense cluster pairs, was selected for analysis by Microarrays (Table_S1 on CD-ROM2, an excerpt of which is shown in Table 5 below). In this sample, the proportion of each of the nine subgroups depicted in Table 4 is similar to that of the original dataset, indicating a good representation of the various subgroups.

Table 4

mRNA/	No cluster	1 cluster	2 clusters	Total
Splicing	w introns	w intron(s)	w intron(s)	
No cluster w mRNA	48	132	197	377 (14%)
1 cluster w mRNA	17	490	1039	1546 (58%)
2 clusters w mRNA	1	85	658	744 (28%)
Total	66 (2.5%)	707 (26%)	1894 (71%)	2667 (100%)

123

Table represents the proportion of sense/antisense clusters in the dataset of 2667 that contain: 1) a known mRNA and 2) expressed sequences spanning at least one intron, in one of the two clusters, in both clusters or in none of the clusters.

5 Table 5 below is an excerpt of Table_S1 provided on CD-ROM2; Table 5 exemplifies five of the putative sense/antisense pairs that were selected for microarray analysis. The first column provides the pair number. The next two columns provide the accession numbers of representative expressed sequences from the overlapping region of the sense and the antisense genes, respectively. The two columns identified
10 by the "RNA" header provide the accession numbers of known mRNAs in the sense and antisense clusters (if available), and the last two columns provide the GenBank descriptions of these mRNAs.

Table 5

<i>Pair no.</i>	<i>sense seq. from overlapping region</i>	<i>antisense seq. from overlapping region</i>	<i>RNA in sense cluster</i>	<i>RNA in a-sense cluster</i>	<i>description of RNA in sense cluster</i>	<i>description of RNA in antisense cluster</i>
235	NM_6227	NM_308	NM_6227	NM_308	Homo sapiens phospholipid transfer protein (PLTP), mRNA #DV L26232.1	Homo sapiens protective protein for beta-galactosidase (galactosialidosis) (PPGB), mRNA
237	NM_4703	NM_2532	NM_4703	NM_2532	Homo sapiens rabaptin-5 (RAB5EP), mRNA #DV X91141.1	Homo sapiens nucleoporin 88kD (NUP88) mRNA #DV Y08612.2
217	NM_14885	AV 723808	NM_14885	NM_2940	Homo sapiens anaphase-promoting complex 10 (APC10) mRNA. #DV AL080090.1	Homo sapiens ATP-binding cassette, sub-family E (OABP), member 1 (ABCE1), mRNA.
209	BC 8865	BG 717574	NM_32231	NM_3099	Homo sapiens hypothetical protein FLJ22875 (FLJ22875), mRNA	Homo sapiens sorting nexin 1 (SNX1),mRNA. #DV U53225.1
196	BE 885605	AL 527611	NM_17832	NM_3640	Homo sapiens hypothetical protein FLJ20457 (FLJ20457), mRNA	Homo sapiens inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein (IKBKAP),mRNA

Table 5 Cont.

Microarrays were constructed by spotting each of the 264 pairs of oligonucleotide probes onto treated glass slides in quadruplicates. The two counterpart oligonucleotide probes of each pair were spotted next to each other to ensure similar hybridization conditions.

As positive controls, each of the blocks contained oligonucleotides spotted at various concentrations for four ubiquitously expressed housekeeping genes: guanine nucleotide binding protein beta polypeptide 2-like 1 (gnb2l1, HUMMHBA123, NM_006098), heat shock 70kD protein 10 (hsp70, HSHSC70CDS0, NM_006597), beta actin (actin, ACTB, NM_001101), and glyceraldehyde-3-phosphate dehydrogenase (gapdh, NM_002046).

Two random oligonucleotides were used as negative controls. These computer-generated arbitrary sequences displayed no alignment to human genome sequences but had the same physical characteristics as the other oligonucleotide probes. In addition, 22 probes for 11 previously documented sense/antisense pairs were also analyzed in the Microarrays (entries Pair no. "known 1"- "known 11" on Table_S1 of CD-ROM2).

The Microarrays were hybridized with poly(A)+ RNAs obtained from 19 human cell lines representing a variety of tissues and four normal human tissues (see *General Materials and Methods* section above). Each poly(A)+ RNA was reverse transcribed by priming with oligo(dT) and random nonamers, and engineered to incorporate a fluorescent marker. A pool containing an equal mix of the RNAs from all cell lines was also transcribed and used as a reference target. The resulting fluorescently-labeled cDNAs were combined and hybridized to the oligonucleotide Microarrays.

The experiments were performed in duplicate and utilized a fluorescent reversal of the Cy3- and Cy5-labelled cDNA. Stringent hybridization conditions were utilized in order to minimize the appearance of false positive signals, despite the possibility of compromised detection of low abundance transcripts.

The raw data was normalized at several levels; within each slide, between reciprocal slides, and globally between slides (see *General Materials and Methods* section above). Non-specific levels of hybridization were estimated from the negative

controls. The threshold for significant positive signals resulting from authentic hybridization was set at 4 standard deviations of the mean normalized signals for the negative controls. Processed data was presented as normalized signal intensity and as normalized signal ratios (Table_S2 on CD-ROM2).

5 To further substantiate array results, several pairs of oligonucleotides were also utilized in Northern blot analysis. Figures 22a-j illustrate results of such northern blot analysis. Figure 22a reveals expression patterns of randomly selected sequence pair number 235, denoted as Rand_235 in Table 6, below. Similarly, Figure 22b corresponds to pair number 173, Figure 22c to pair number 248, Figure 22d to pair
10 number 6, Figure 22e to pair number 216, Figure 22f to pair number 239, Figure 22g to pair number 202, Figure 22h to pair number 114, Figure 22i to pair number 188, and Figure 22j to pair number 223. Eight pairs (Figures 22a-h) evaluated revealed positive signals for both sense and antisense expression, while two (Figures 22i-j) revealed a positive signal for only one of the genes, with the counterpart being a
15 known RefSeq mRNA.

Figure 23 represents an excerpt of Table_S2 (provided in CD-ROM2) which summarizes the results obtained utilizing the array generated according to the teachings of the present invention. Expression thresholds were verified and indicated and normalization for microarray signals was conducted as described above. *Rji*
20 ratios were obtained for each cell line/tissue assessed.

Taken cumulatively, the data presented herein revealed positive signals for both sense and antisense transcripts in 65 cluster pairs. In another 47 cases, significant hybridization signals were detected for antisense sequences with known counterpart sense transcripts, i.e. RefSeq mRNAs, which did not give clear hybridization signals
25 on the Microarrays. Thus, 42.5 % (112 cases) of the 264 represented on the Microarrays, yielded detectable antisense transcription.

The conversion table, assigning the respective serial number as it appears in the "table_125" file of CD-ROM2 and "table_133" file of CD-ROM 3 enclosed herewith, is shown in Table 6 below.

30

Table 6

Rand_#	Serial No	Rand_#	Serial No	Rand_#	Serial No
Rand_1	2326	Rand_179	3266	Rand_258	3807

126

Rand_10	3647	Rand_18	3073	Rand_259	2621
Rand_100	2758	Rand_180	1794	Rand_26	4009
Rand_101	1595	Rand_181	1585	Rand_27	3393
Rand_102	3686	Rand_182	3554	Rand_28	3589
Rand_103	2331	Rand_183	3377	Rand_29	1837
Rand_104	3496	Rand_184	3466	Rand_3	3046
Rand_105	3134	Rand_185	3159	Rand_30	3297
Rand_106	1339	Rand_186	1413	Rand_31	3692
Rand_107	908	Rand_187	3645	Rand_32	707 2376
Rand_108	2929	Rand_188	3880	Rand_33	2052
Rand_109	2537	Rand_189	3009	Rand_34	1904
Rand_11	2806	Rand_19	3641	Rand_35	3718
Rand_110	3594	Rand_190	2549	Rand_36	3898
Rand_111	2819	Rand_191	2874	Rand_37	1821
Rand_112	3019	Rand_192	2515	Rand_38	3092
Rand_113	3815	Rand_193	3914	Rand_39	3262
Rand_114	2606	Rand_194	2751	Rand_4	3558
Rand_115	1662	Rand_195	2091	Rand_40	2474
Rand_116	2171	Rand_196	1966	Rand_41	3568
Rand_117	2539	Rand_197	3778	Rand_42	864
Rand_118	2802	Rand_198	3877	Rand_43	1864
Rand_119	2761	Rand_199	2248	Rand_44	3045
Rand_12	1947	Rand_2	3172	Rand_45	2854
Rand_120	3228	Rand_20	2360	Rand_46	3852
Rand_121	2076	Rand_200	2064	Rand_47	3096
Rand_122	1835	Rand_201	3597	Rand_48	1987
Rand_123	3029	Rand_202	2826	Rand_49	2893
Rand_124	2898	Rand_203	2388	Rand_5	2060
Rand_125	1568	Rand_204	3889	Rand_50	1058
Rand_126	2456	Rand_205	2211	Rand_51	3560
Rand_127	2019	Rand_206	3512	Rand_52	2604
Rand_128	2346	Rand_207	3452	Rand_53	3397
Rand_129	2460	Rand_208	3886	Rand_54	2040
Rand_13	2429	Rand_209	1600	Rand_55	3784
Rand_130	3374	Rand_21	2952	Rand_56	3659
Rand_131	3292	Rand_210	2432	Rand_57	2005 2688
Rand_132	3259	Rand_211	1651 3968	Rand_58	3187

127

Rand_133	3591	Rand_212	3074	Rand_59	1350
Rand_134	3340	Rand_213	2341	Rand_6	2202
Rand_135	1958	Rand_214	1984	Rand_60	3183
Rand_136	2274	Rand_215	2803	Rand_61	2275
Rand_137	3527	Rand_216	3806	Rand_62	3882
Rand_138	1533	Rand_217	2186	Rand_63	1044 3899
Rand_139	2622	Rand_218	857	Rand_64	2811
Rand_14	2058	Rand_219	1744	Rand_65	3232
Rand_140	2578	Rand_22	2285	Rand_66	3242
Rand_141	3492	Rand_220	2977	Rand_67	34 112 2727
Rand_142	3928	Rand_221	3863	Rand_68	3909
Rand_143	2282 3790	Rand_222	2846	Rand_69	4016
Rand_144	2820	Rand_223	3986	Rand_7	2337
Rand_145	1329	Rand_224	579 3688	Rand_70	2101 3707
Rand_146	1783	Rand_225	3984	Rand_71	3703
Rand_147	1527	Rand_226	2889	Rand_72	3477
Rand_148	2662	Rand_227	3869	Rand_73	2437
Rand_149	2031	Rand_228	3994	Rand_74	3808
Rand_15	2677	Rand_229	3818	Rand_75	3905
Rand_150	1303 1659	Rand_23	3890	Rand_76	1138 2194
Rand_151	1767	Rand_230	3152	Rand_77	819
Rand_152	3378	Rand_231	3445	Rand_78	3704
Rand_153	984	Rand_232	3663	Rand_79	2309
Rand_154	3759	Rand_233	3410	Rand_8	3441
Rand_155	2046	Rand_234	1112	Rand_80	1219
Rand_156	2528	Rand_235	3918	Rand_81	1416
Rand_157	283 1798 2048	Rand_236	2316	Rand_82	1543
Rand_158	3710	Rand_237	3673	Rand_83	3269
Rand_159	3178	Rand_238	3990	Rand_84	532 732
Rand_16	3336	Rand_239	4012	Rand_85	2607
Rand_160	1645	Rand_24	3250	Rand_86	1867
Rand_161	2074 3464	Rand_240	2932	Rand_87	627 3006
Rand_162	3436	Rand_241	3836	Rand_88	2068
Rand_163	2738	Rand_242	3424	Rand_89	2296
Rand_164	2749	Rand_243	3982	Rand_9	3741
Rand_165	2206	Rand_244	3472	Rand_90	1076
Rand_166	1349	Rand_245	2071	Rand_91	3385

128

Rand_167	2773	Rand_246	3904	Rand_92	2334
Rand_168	3305	Rand_247	2056	Rand_93	2833
Rand_169	1954	Rand_248	3855	Rand_94	2626
Rand_17	3940	Rand_249	2980	Rand_95	3671
Rand_170	2813	Rand_25	3453	Rand_96	1923
Rand_171	3868	Rand_250	3565	Rand_97	1863
Rand_172	762 1424 3942	Rand_251	2459	Rand_98	3437
Rand_173	3872	Rand_252	71 3147	Rand_99	3469
Rand_174	3801	Rand_253	3967	Rand_260	1975 3171
Rand_175	2547	Rand_254	702 2867 3088	Rand_261	4013
Rand_176	1251	Rand_255	3156	Rand_262	2418
Rand_177	1603	Rand_256	2324 2998	Rand_263	2451
Rand_178	2769	Rand_257	2284	Rand_264	3832

Table 6 Cont

Rand # = the name of the pair on the chip as it appears in Table_S2 on CD-ROM2, column "Probe"; Serial No = no of the pair in the Table files on CD-ROMs 2 and 3 (could be more than one in case the antisense event was separated to more than two contigs).

5

The sensitivity of the experimental approach utilized, i.e. the ability to detect a given transcript, stems from a combination of the stringency used in the microarray analysis and the level of expression and tissue specificity of the RNA. This can be estimated from the positive signals obtained for 65% of the oligos representing known RefSeq mRNAs on the Microarrays. This level of detection is comparable to that obtained in other studies, such as the 58% of known exons verified using microarray analysis (D. D. Shoemaker, et al., Nature 409, 922; 2001).

Thus, the present methodology provides a level of detection for a pair of genes that is $0.65 \times 0.65 = 0.42$, a value supported by the detection of positive signals for both sense and antisense expression in 5 out of 11 (0.45) clusters of previously described sense/antisense pairs (Table_S2 on CD-ROM2).

Of the 264 cluster pairs analyzed in the Microarrays of the present invention, 65 clusters (0.25) showed significant signals for both sense and antisense transcripts, which is 60% of the proposed level of detection for a pair of genes (0.25/0.42). Extrapolating this figure to the predicted antisense dataset of 2667 clusters, predicts at least 1600 sense/antisense transcriptional units in the human genome.

EXAMPLE 10***Annotation of newly uncovered naturally occurring antisense transcripts***

Newly uncovered naturally occurring transcripts were annotated using the Gencarta (Compugen, Tel-Aviv, Israel) platform. The Gencarta platform includes a
5 rich pool of annotations, sequence information (particularly of spliced sequences),
chromosomal information, alignments, and additional information such as SNPs, gene
ontology terms, expression profiles, functional analyses, detailed domain structures,
known and predicted proteins and detailed homology reports.

Brief description of the methodology used to obtain annotative sequence
10 information is summarized infra (for detailed description see U.S. Pat. Appl.
10/426,002).

The ontological annotation approach - An ontology refers to the body of
knowledge in a specific knowledge domain or discipline such as molecular biology,
microbiology, immunology, virology, plant sciences, pharmaceutical chemistry,
15 medicine, neurology, endocrinology, genetics, ecology, genomics, proteomics,
cheminformatics, pharmacogenomics, bioinformatics, computer sciences, statistics,
mathematics, chemistry, physics and artificial intelligence.

An ontology includes domain-specific concepts – referred to, herein, as sub-
ontologies. A sub-ontology may be classified into smaller and narrower categories.
20 The ontological annotation approach is effected as follows.

First, biomolecular (i.e., polynucleotide or polypeptide) sequences are
computationally clustered according to a progressive homology range, thereby
generating a plurality of clusters each being of a predetermined homology of the
homology range.

25 Progressive homology is used to identify meaningful homologies among
biomolecular sequences and to thereby assign new ontological annotations to
sequences, which share requisite levels of homologies. Essentially, a biomolecular
sequence is assigned to a specific cluster if displays a predetermined homology to at
least one member of the cluster (i.e., single linkage). A “progressive homology
30 range” refers to a range of homology thresholds, which progress via predetermined
increments from a low homology level (e.g. 35 %) to a high homology level (e.g. 99
%).

Following generation of clusters, one or more ontologies are assigned to each cluster. Ontologies are derived from an annotation preassociated with at least one biomolecular sequence of each cluster; and/or generated by analyzing (e.g., text-mining) at least one biomolecular sequence of each cluster thereby annotating
5 biomolecular sequences.

The hierarchical annotation approach - "Hierarchical annotation" refers to any ontology and subontology, which can be hierarchically ordered, such as, a tissue expression hierarchy, a developmental expression hierarchy, a pathological expression hierarchy, a cellular expression hierarchy, an intracellular expression hierarchy, a
10 taxonomical hierarchy, a functional hierarchy and so forth.

The hierarchical annotation approach is effected as follows.

First, a dendrogram representing the hierarchy of interest is computationally constructed. A "dendrogram" refers to a branching diagram containing multiple nodes and representing a hierarchy of categories based on degree of similarity or number of
15 shared characteristics.

Each of the multiple nodes of the dendrogram is annotated by at least one keyword describing the node, and enabling literature and database text mining, such as by using publicly available text mining software. A list of keywords can be obtained from the GO Consortium (www.geneontology.org). However, measures are taken to
20 include as many keywords, and to include keywords which might be out of date. For example, for tissue annotation, a hierarchy is built using all available tissue/libraries sources available in the GenBank, while considering the following parameters: ignoring GenBank synonyms, building anatomical hierarchies, enabling flexible distinction between tissue types (normal versus pathology) and tissue classification
25 levels (organs, systems, cell types, etc.).

In a second step, each of the biomolecular sequences is assigned to at least one specific node of the dendrogram.

The biomolecular sequences can be annotated biomolecular sequences, unannotated biomolecular sequences or partially annotated biomolecular sequences.

30 Annotated biomolecular sequences can be retrieved from pre-existing annotated databases as described hereinabove.

For example, in GenBank, relevant annotational information is provided in the definition and keyword fields. In this case, classification of the annotated biomolecular sequences to the dendrogram nodes is directly effected. A search for suitable annotated biomolecular sequences is performed using a set of keywords which are designed to classify the biomolecular sequences to the hierarchy (i.e., same keywords that populate the dendrogram)

In cases where the biomolecular sequences are unannotated or partially annotated, extraction of additional annotational information is effected prior to classification to dendrogram nodes. This can be effected by sequence alignment, as described hereinabove. Alternatively, annotational information can be predicted from structural studies. Where needed, nucleic acid sequences can be transformed to amino acid sequences to thereby enable more accurate annotational prediction.

Finally, each of the assigned biomolecular sequences is recursively classified to nodes hierarchically higher than the specific nodes, such that the root node of the dendrogram encompasses the full biomolecular sequence set, which can be classified according to a certain hierarchy, while the offspring of any node represent a partitioning of the parent set.

For example, a biomolecular sequence found to be specifically expressed in "rhabdomyosarcoma", will be classified also to a higher hierarchy level, which is "sarcoma", and then to "Mesenchymal cell tumors" and finally to a highest hierarchy level "Tumor". In another example, a sequence found to be differentially expressed in endometrium cells, will be classified also to a higher hierarchy level, which is "uterus", and then to "women genital system" and to "genital system" and finally to a highest hierarchy level "genitourinary system". The retrieval can be performed according to each one of the requested levels.

Annotating gene expression according to relative abundance - Spatial and temporal gene annotations are also assigned by comparing relative abundance in libraries of different origins. This approach can be used to find gene which are differentially expressed in tissues, pathologies and different developmental stages. In principal, the presentation of a contig in at least two tissues of interest is determined and significant over or under representation of the contig in one of the at least two

tissues is assessed to identify differential expression. Significant over or under representation is analyzed by statistical pairing.

Annotating spatial and temporal expression can also be effected on splice variants. This is effected as follows. First, a contig which includes exonal sequence presentation of the at least two splice variants of the gene of interest is obtained. This
5 contig is assembled from a plurality of expressed sequences;

Then, at least one contig sequence region unique to a portion (i.e., at least one and not all) of the at least two splice variants of the gene of interest is identified. Identification of such unique sequence region is effected using computer alignment
10 software.

Finally, the number of the plurality of expressed sequences in the tissue having the at least one contig sequence region is compared with the number of the plurality of expressed sequences not-having the at least one contig sequence region, to thereby compare the expression level of the at least two splice variants of the gene
15 of interest in the tissue.

Sequence annotations obtained using the above-described methodologies and other approaches are disclosed in a data table in the pep_seqs_133 of the enclosed CD-ROM3.

The data table shows a collection of annotations for biomolecular sequences, which were identified according to the teachings of the present invention using transcript data based on GenBank versions 136.
20

Each feature in the data table is identified by “#”.

#INDICATION – This field designates the indications (i.e., diseases, disorders, pathological conditions) and therapies that the polypeptide of the present invention can be utilized for. Specifically, an indication lists the disorders or diseases
25 in which the polypeptide of the present invention can be clinically used. A therapy describes a postulated mode of action of the polypeptide for the above-mentioned indication. For example, an indication can be “Cancer, general” while the therapy will be “Anticancer”.

Each protein was assigned a SWISSPROT and/or TrEMBL human protein accession as described in section “Assignment of Swissprot/TrEMBL accessions to Gencarta contigs” hereinbelow. The information contained in this field is the
30

indication concatenated to the therapies that were accumulated for the SWISSPROT and/or TremBl human protein from drug databases, such as PharmaProject (PJB Publications Ltd 2003 www.pjbpubs.com/cms.asp?pageid=340) and public databases, such as LocusLink (www.genelink.org/cgi-bin/resource?res=locuslink) and Swissprot
5 (<http://www.ebi.ac.uk/swissprot/index.html>). The field may comprise more than one term wherein a “;” separates each adjacent terms.

Example- #INDICATION Alopecia, general; Antianginal; Anticancer, immunological; Anticancer, other; Atherosclerosis; Buerger's syndrome; Cancer, general; Cancer, head and neck; Cancer, renal; Cardiovascular; Cirrhosis, hepatic;
10 Cognition enhancer; Dermatological; Fibrosis, pulmonary; Gene therapy; Hepatic dysfunction, general; Hepatoprotective; Hypolipaeic/Antiatherosclerosis; Infarction, cerebral; Neuroprotective; Ophthalmological; Peripheral vascular disease; Radio/chemoprotective; Recombinant growth factor; Respiratory; Retinopathy, diabetic; Symptomatic antidiabetic; Urological;

15 Assignment of Swissprot/TremBl accessions to Gencarta contigs - Gencarta contigs were assigned a Swissprot/TremBl human accession as follows. Swissprot/TremBl data were parsed and for each Swissprot/TremBl accession (excluding Swissprot/TremBl that are annotated as partial or fragment proteins) cross-references to EMBL and Genbank were parsed. The alignment quality of the
20 Swissprot/TremBl protein to their assigned mRNA sequences was checked by frame+2n alignment analysis. A good alignment was considered as having the following properties:

- For partial mRNAs (those that in the mRNA description have the phrase “partial cds” or annotated as “3’” or “5’”)- an overall identity of 97% and
25 coverage of 80 % of the Swissprot/TremBl protein.
- All the rest were considered as full coding mRNAs and for them an overall identity of 97% identity and coverage of the Swissprot/TremBl protein of over 95 %.

The mRNAs were searched in the LEADS database for their corresponding
30 contigs, and the contigs that included these mRNA sequences were assigned the Swissprot/TremBl accession.

#PHARM- This field indicates possible pharmacological activities of the polypeptide. Each polypeptide was assigned with a SWISSPROT and/or TrEMBL human protein accession, as described above. The information contained in this field is the indication concatenated to the therapies that were accumulated for the SWISSPROT and/or TrEMBL human protein from drug databases such as PharmaProject (PJB Publications Ltd 2003 www.pjbpubs.com/cms.asp?pageid=340) and public databases, such as LocusLink and Swissprot. Note that in some cases this field can include opposite terms in cases where the protein can have contradicting activities – such as:

- (i) Stimulant – inhibitor;
- (ii) Agonist – antagonist;
- (iii) Activator- inhibitor;
- (iv) Immunosuppressant – Immunostimulant;

In these cases the pharmacology was indicated as “modulator”. For example, if the predicted polypeptide has potential agonistics/antagonistic effects (e.g. Fibroblast growth factor agonist and Fibroblast growth factor antagonist) then the annotation for this code will be “Fibroblast growth factor modulator”

A documented example for such contradicting activities has been described for the soluble tumor necrosis factor receptors [Mohler et al., J. Immunology 151, 1548-1561]. Essentially, Mohler and co-workers showed that soluble receptor can act both as a carrier of TNF (i.e., agonistic effect) and as an antagonist of TNF activity.

#THERAPEUTIC_PROTEIN – This field predicts a therapeutic role for a protein represented by the contig. A contig was assigned this field if there was information in the drug database or the public databases (e.g., described hereinabove) that this protein, or part thereof, is used or can be used as a drug. This field is accompanied by the swissprot accession of the therapeutic protein which this contig most likely represents. Example: # THERAPEUTIC_PROTEIN UROK_HUMAN

GO annotations were predicted as described in “The ontological annotation approach” section hereinabove. Functional annotations of transcripts based on Gene Ontology (GO) are indicated by the following format.

*, ** “#GO_P”, annotations related to Biological Process,

*, ** "#GO_F", annotations related to Molecular Function, and

*, ** "#GO_C", annotations related to Cellular Component.

ProLoc was used for protein subcellular localization prediction that assigns GO cellular component annotation to the protein. The localization terms were assigned with
5 GO entries.

Cellular localization – ProLoc software, commercially available from Compugen LTD, was used to predict the cellular localization of the proteins. Two main approaches were used: (i) the presence of known extracellular domain/s in a protein; (ii) calculating putative transmembrane segments, if any, in the protein and
10 calculating 2 p-values for the existence of a signal peptide. The latter is done by a searching for a signal peptide at the N-terminal sequence of the protein generating a score. Running the program on real signal peptides and on N-terminal protein sequences that lack a signal peptide resulted in 2 score distributions: the first is the score distribution of the real signal peptides and the second is the score distribution of
15 the N-terminal protein sequences that lack the signal peptide. Given a novel protein product, ProLoc calculates the above-score score and provides the percentage of the scores that are higher than the current score, in the first distribution, as a first p-value (lower p-values mean more reliable signal peptide prediction) and the percentage of the scores that are lower than the current score, in the second distribution, as a second
20 p-value (lower p-values mean more reliable non signal peptide prediction).

Thus, using this algorithm secreted proteins and membrane proteins can be identified, for example. However, proteins which lack signal peptide while are still secreted (such as after lysis of viral infected cells) can be identified such as by
homology search to extracellular proteins which were identified as such by ProLoc.

25

Table 7

IPR000874	Bombesin-like peptide
IPR001693	Calcitonin-like
IPR001651	Gastrin/cholecystokinin peptide hormone
IPR000532	Glucagon/GIP/secretin/VIP
IPR001545	Gonadotropin, beta chain
IPR004825	Insulin/IGF/relaxin
IPR000663	Natriuretic peptide
IPR001955	Pancreatic hormone
IPR001400	Somatotropin hormone
IPR002040	Tachykinin/Neurokinin

IPR006081	Alpha defensin
IPR001928	Endothelin-like toxin
IPR001415	Parathyroid hormone
IPR001400	Somatotropin hormone
IPR001990	Chromogranin/secretogranin
IPR001819	Chromogranin A/B
IPR002012	Gonadotropin-releasing hormone
IPR001152	Thymosin beta-4
IPR000187	Corticotropin-releasing factor, CRF
IPR001545	Gonadotropin, beta chain
IPR000476	Glycoprotein hormones alpha chain
IPR000476	Glycoprotein hormones alpha chain
IPR001323	Erythropoietin/thrombopoietin
IPR001894	Cathelicidin
IPR001894	Cathelicidin
IPR001483	Urotensin II
IPR006024	Opioid neuropeptide precursor
IPR000020	Anaphylatoxin/fibulin
IPR000074	Apolipoprotein A1/A4/E
IPR001073	Complement C1q protein
IPR000117	Kappa casein
IPR001588	Casein, alpha/beta
IPR001855	Beta defensin
IPR001651	Gastrin/cholecystokinin peptide hormone
IPR000867	Insulin-like growth factor-binding protein, IGFBP
IPR001811	Small chemokine, interleukin-8 like
IPR004825	Insulin/IGF/relaxin
IPR002350	Serine protease inhibitor, Kazal type
IPR000001	Kringle
IPR002072	Nerve growth factor
IPR001839	Transforming growth factor beta (TGFB)
IPR001111	Transforming growth factor beta (TGFB), N-terminal
IPR001820	Tissue inhibitor of metalloproteinase
IPR000264	Serum albumin family
IPR005817	Wnt superfamily

For each category the following features are optionally addressed:

“#GO_Acc” represents the accession number of the assigned GO entry, corresponding to the following “#GO_Desc” field.

5 “#GO_Desc” represents the description of the assigned GO entry, corresponding to the mentioned “#GO_Acc” field.

“#CL” represents the confidence level of the GO assignment, when #CL1 is the highest and #CL5 is the lowest possible confidence level. This field appears only when the GO assignment is based on a Swissprot/TremBl protein accession or

Interpro accession and (not on Proloc predictions or viral proteins predictions). Preliminary confidence levels were calculated for all public proteins as follows:

PCL 1: a public protein that has a curated GO annotation,

PCL 2: a public protein that has over 85 % identity to a public protein with a
5 curated GO annotation,

PCL 3: a public protein that exhibits 50 - 85 % identity to a public protein with a curated GO annotation,

PCL 4: a public protein that has under 50 % identity to a public protein with a curated GO annotation.

10 For each protein a homology search against all public proteins was done. If the protein has over 95 % identity to a public protein with PCL X then the protein gets the same confidence level as the public protein. This confidence level is marked as “#CL X”. If the protein has over 85 % identity but not over 95 % to a public protein with PCL X then the protein gets a confidence level lower by 1 than the confidence level of
15 the public protein. If the protein has over 70 % identity but not over 85 % to a public protein with PCL X then the protein gets a confidence level lower by 2 than the confidence level of the public protein. If the protein has over 50 % identity but not over 70 % to a public protein with PCL X then the protein gets a confidence level lower by 3 than the confidence level of the public protein. If the protein has over 30
20 % identity but not over 50 % to a public protein with PCL X then the protein gets a confidence level lower by 4 than the confidence level of the public protein.

A protein may get confidence level of 2 also if it has a true interpro domain that is linked to a GO annotation www.geneontology.org/external2go/interpro2go/.

When the confidence level is above "1", GO annotations of higher levels of
25 the GO hierarchy are assigned (e.g. for “#CL 3” the GO annotations provided, is as appears plus the 2 GO annotations above it in the hierarchy).

“#DB” marks the database on which the GO assignment relies on. The “sp”, relates to SwissProt/TremBl Protein knowledgebase, available from www.expasy.ch/sprot/. “InterPro”, refers to the InterPro combined database,
30 available from www.ebi.ac.uk/interpro/, which contains information regarding protein families, collected from the following databases: SwissProt (<http://www.ebi.ac.uk/swissprot/>), Prosite (<http://www.expasy.ch/prosite/>), Pfam

(www.sanger.ac.uk/Software/Pfam/), Prints
 (www.bioinf.man.ac.uk/dbbrowser/PRINTS/), Prodom
 (prodes.toulouse.inra.fr/prodom/), Smart (<http://smart.embl-heidelberg.de/>) and
 Tigrfams (<http://www.tigr.org/TIGRFAMS/>). "Proloc statistical database"- meaning
 5 the statistics Proloc uses for predicting the subcellular localization of a protein.

"#EN" represents the accession of the entity in the database (#DB),
 corresponding to the accession of the protein/domain why the GO was predicted. If
 the GO assignment is based on a protein from the SwissProt/TremBl Protein database
 this field will have the locus name of the protein. Examples, "#DB *sp* #EN
 10 *NRG2_HUMAN*" means that the GO assignment in this case was based on a protein
 from the SwissProt/Trembl database, while the closest homologue (that has a GO
 assignment) to the assigned protein is depicted in SwissProt entry "*NRG2_HUMAN*
 "#DB *interpro* #EN *IPR001609*" means that GO assignment in this case was based on
 InterPro database, and the protein had an Interpro domain, *IPR001609*, that the
 15 assigned GO was based on. In Proloc predictions this field will have a Proloc
 annotation "#EN Proloc". In predictions based on viral proteins this field will have
 the gi. viral protein accession, "#EN 1491997".

#GENE_SYMBOL – for each Gencarta contig a HUGO gene symbol was
 assigned in two ways:

20 (i) After assigning a Swissprot/TremBl protein to each contig (see
Assignment of Swissprot/TremBl accessions to Gencarta contigs) all the gene symbols
 that appear for the Swissprot entry were parsed and added as a Gene symbol
 annotation to the gene.

(ii) LocusLink information- LocusLink was downloaded from NCBI
 25 <ftp.ncbi.nih.gov/refseq/LocusLink/> (files loc2acc, loc2ref, and LL.out_hs). The data
 was integrated producing a file containing the gene symbol for every sequence.
 Gencarta contigs were assigned a gene symbol if they contain a sequence from this
 file that has a gene symbol

Example: #GENE_SYMBOL MMP15

30 #DIAGNOSTICS- secreted/membranal proteins get an annotation of "can be
 used as diagnostic markers for" for the list of indications as appearing in the #
 INDICATION field, described hereinabove. All proteins that were identified as

secreted or membranal proteins (as described in the GO field section) will be assigned with this field.

In addition, known Gencarta contigs representing known diagnostic markers (such as listed in Table 8, below) and all transcripts and proteins deriving from this
5 contig will be assigned to this field and will get the above mentioned annotation followed by "as indicated in the Diagnostic markers table".

Table 8

<i>Enzymes</i>		
<i>Test</i>	<i>Gencarta Contig</i>	<i>Comments</i>
GPT	R35137 (GPT glutamic-pyruvate transaminase (alanine aminotransferase)) Z24841 (GPT2 glutamic pyruvate transaminase (alanine aminotransferase) 2)	Also called ALT – alanine aminotransferase. Standard liver function test
GOT	M78228 (GOT1 glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1)) M86145 (GOT2 glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2))	Also called AST – aspartate aminotransferase. Standard liver function test
GGT	<u>HUMGGTX</u> (GGT1: gamma-glutamyltransferase 1)	Liver disease
CPK	T05088 (CKB creatine kinase, brain) HUMCKMA (CKM creatine kinase, muscle) H20196 (CKMT1 creatine kinase, mitochondrial 1 (ubiquitous)) HUMSMCK (CKMT2 creatine kinase, mitochondrial 2 (sarcomeric))	Also called CK. Mostly used for muscle pathologies. The MB variant is heart specific and used in the diagnosis of myocardial infarction
CPK-MB	T05088 (CKB creatine kinase, brain) HUMCKMA (CKM creatine kinase, muscle)	Cardiac problems – hetro-dimer of CKB and CKM
Alkaline Phosphatase	HSAPHOL- ALPL: alkaline phosphatase, liver/bone/kidney HUMALPHB - ALPI: alkaline phosphatase, intestinal HUMALPP- ALPP: alkaline phosphatase, placental (Regan isozyme)	Bone related syndromes and liver diseases, mostly with biliary involvement
Amylase	AA367524- (AMY1A: amylase, alpha 1A; salivary) T10898- (AMY2B: amylase, alpha 2B; pancreatic and 2A)	Blood/Urine. Pancreas related diseases
LDH	HSLDHAR (LDHA lactate dehydrogenase A) M77886 (LDHB lactate dehydrogenase B) HSU13680 (LDHC lactate dehydrogenase C) AA398148 (LDHL lactate dehydrogenase A -like)	Lactate Dehydrogenase. Used for myocardial infarction diagnosis and neoplastic syndromes assessment.

	R09053 (LDHD lactate dehydrogenase D)	
G6PD	S58359 (G6PD glucose-6-phosphate dehydrogenase)	Glucose 6-phosphate dehydrogenase. Levels measured when deficiency is suspected (leading to susceptibility to hemolysis)
Alpha1 antiTrypsin	HUMA1ACM (SERPINA3 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3) T10891 (AGT angiotensinogen (serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 8)) R83168 (SERPINA6 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6) HUMCINHP (SERPINA5 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5) HSA1ATCA (SERPINA1 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1) HUMKALLS (SERPINA4 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4) HUMTBG (SERPINA7 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7) T60354 (SERPINA10 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 10)	Chronic lung diseases
Renin	HSRENK (REN renin)	Some hypertension syndromes
Acid Phosphatase	HUMAAPA (ACP1: acid phosphatase 1, soluble) T48863 (ACP2: acid phosphatase 2, lysosomal) HSMRACP5 (ACP5: acid phosphatase 5, tartrate resistant) T85211 (ACP6: lysophosphatidic acid phosphatase) HSPROSAP (ACPP: acid phosphatase, prostate) AA005037 (ACPT: acid phosphatase, testicular)	Used to differentiate multiple myeloma with other monoclonal gammopathies of uncertain significance
Beta glucuronidase	T11069 (GUSB glucuronidase, beta)	Used to differentiate multiple myeloma with other monoclonal gammopathies of uncertain significance
Aldolase	HSALDAR (ALDOA aldolase A, fructose-bisphosphate)	Glycogen storage diseases

	HSALDOBR (ALDOB aldolase B, fructose-bisphosphate) M62176 (ALDOC aldolase C, fructose-bisphosphate)	
Choline esterase	HUMCHEF (BCHE butyrylcholinesterase) F00931 (ACHE acetylcholinesterase (YT blood group))	Probably used for organophosphates/"nerve gases" intoxications
Pepsinogen	HUMPGCA PGC: progastricsin (pepsinogen C)	(in the stomach), high in gastritis, low in pernicious anemia
ACE	HSACE (ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1) AA397955 (ACE2: angiotensin I converting enzyme (peptidyl-dipeptidase A) 2)	Angiotensin-converting enzyme. Sarcoidosis
Miscellaneous		
Test	Gencarta Contig	Comments
Prion Protein	HUMPRP0A (PRNP prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia)) W73057 (PRND prion protein 2 (duplet))	BSE diagnosis
Myelin basic protein	M78010 (MBP myelin basic protein) R13982 (MOBP myelin-associated oligodendrocyte basic protein)	In CSF. In Multiple sclerosis
Albumin	HSALB1 (ALB albumin)	Mostly liver function and failure of intestine absorption
Prealbumin	HSALB1 (ALB albumin)	early diagnosis of malabsorption
Ferritin	HUMFERLS (FTL ferritin, light polypeptide) HUMFERHA (FTH1 ferritin, heavy polypeptide 1)	Iron deficiency anemia
Transferrin	S95936 (TF transferrin)	Iron deficiency anemia
Haptoglobin	HUMHPA1B (HP haptoglobin)	Used in anemia states and neoplastic syndromes
CRP	HSCREACT (CRP C-reactive protein, pentraxin-related)	C reactive protein. Associated with active inflammation
AFP	D11581 (AFP alpha-fetoprotein)	Alpha Feto Protein. Used in pregnancy for abnormalities screening and as a cancer marker.
C3	T40158 (C3 complement component 3)	Various auto-immune and allergy syndromes
C4	HSCOC4 (C4A complement component 4A; C4B complement component 4B)	Various auto-immune and allergy syndromes
Ceruloplasmin	HSCP2 (CP ceruloplasmin (ferroxidase))	Wilson's disease (liver disease)
Myoglobin	T11628 (MB myoglobin)	Rhabdomyolysis, Myocardial infarction
FABP	S67314 (FABP3: fatty acid binding protein 3, muscle and heart)	myoglobin and Fatty Acid Binding

	D11754 (FABP1 liver- L-FABP- fatty acid binding protein 1) AW605378 (FABP2: fatty acid binding protein 2, intestinal) HUMALBP (FABP4: fatty acid binding protein 4, adipocyte) T06152 (FABP5: fatty acid binding protein 5 (psoriasis-associated)) HSI15PGN1 (FABP6: fatty acid binding protein 6, ileal (gastrotropin)) R60348 (FABP7: fatty acid binding protein 7, brain)	
Troponin I	HUMTROPNIN (TNNT2 troponin I, skeletal, fast) Z25083 (TNNT1 troponin I, skeletal, slow) HUMTROPIA (TNNT3 troponin I, cardiac)	Acute myocardial infarction
Beta-2-microglobulin	HSB2MMU (B2M beta-2-microglobulin)	
Macroglobin	M62177 (A2M: alpha-2-macroglobulin)	Elevated in inflammation
Alpha-1 glycoprotein	T72188 (A1BG: alpha-1-B glycoprotein)	Elevated in inflammation and tumors.
Apo A-I	HUMAPOAIP (APOA1: apolipoprotein A-I)	Risk for coronary artery disease
Apo B-100	HSAPOBR2 (APOB: apolipoprotein B (including Ag(x) antigen))	Atherosclerotic heart disease
Apo E	T61627 (APOE: apolipoprotein E)	diagnosis of Type III hyperlipoproteinemia, evaluate a possible genetic component to atherosclerosis, or to help confirm a diagnosis of late onset AD
CF gene	HUMCFTRM (CFTR: cystic fibrosis transmembrane conductance regulator, ATP-binding cassette (sub-family C, member 7))	Cystic fibrosis disease (a DNA test – blood sample)
PSEN1 gene	T89701 (PSEN1: presenilin 1 (Alzheimer disease 3))	Early onset of familial AD (a DNA test – blood sample)
Hormones		
Test	Gencarta Contig	Comments
Erythropoietin	HSERPR (EPO erythropoietin)	Hardly used for diagnosis. Used as treatment
GH	HSGROW1 (GH1 growth hormone 1) HUMCS2 (GH2 growth hormone 2)	Growth Hormone. Endocrine syndromes
TSH	AV745295 (TSHB thyroid stimulating hormone, beta)	Part of thyroid functions tests
BetaHCG	R27266 (CGB5 chorionic gonadotropin, beta polypeptide 5)	Pregnancy, malignant syndromes in men and women
LH	HUMCGBB50 (LHB luteinizing hormone beta polypeptide)	Part of standard hormonal profile for fertility, gynecological syndromes and endocrine syndromes
FSH	AV754057 (FSHB follicle stimulating hormone, beta)	Part of standard hormonal profile for fertility, gynecological syndromes and

	polypeptide)	endocrine syndromes
TBG	S40807 (TG thyroglobulin)	Thyroxin binding globulin. Thyroid syndromes
Prolactin	HSLACT (PRL prolactin)	Various endocrine syndromes
Thyroglobulin	S40807 (TG thyroglobulin)	Follow up of thyroid cancer patients
PTH	HSTHYR (PTH parathyroid hormone)	Parathyroid Hormone. Syndromes of calcium management
Insulin/Pre Insulin	HSPPI (INS insulin)	Diabetes
Gastrin	HSGAST (GAS gastrin)	Peptic ulcers
Oxytocin	HUMOTCB (OXT oxytocin, prepro-(neurophysin I))	Endocrine syndromes related to lactation
AVP	HUMVPC (AVP arginine vasopressin (neurophysin II, antidiuretic hormone, diabetes insipidus, neurohypophyseal))	Arginine Vasopressin. Endocrine syndromes related to the osmotic pressure of body fluids
ACTH	HUMPOMCMTTC (POMC: proopiomelanocortin (adrenocorticotropin/ beta-lipotropin/ alpha-melanocyte stimulating hormone/ beta-melanocyte stimulating hormone/ beta-endorphin))	Secreted from the anterior pituitary gland. Regulation of cortisol. Abnormalities are indicative of Cushing's disease, addison's disease and adrenal tumors
BNP	HUMNATPEP (NPPB: natriuretic peptide precursor B)	Heart failure

Blood Clotting

<i>Test</i>	<i>Gencarta Contig</i>	<i>Comments</i>
Protein C	S50739 (PROC protein C (inactivator of coagulation factors Va and VIIIa))	Inherited Clotting disorders
Protein S	HSSPROTR (PROS1 protein S (alpha))	Inherited Clotting disorders
Fibrinogen	D11940 (FGA: fibrinogen, A alpha polypeptide) HUMFBRB (FGB: fibrinogen, B beta polypeptide) T24021 (FGG: fibrinogen, gamma polypeptide)	Clotting disorders
Factors 2, 5, 7, 9, 10, 11, 12, 13	HUMPTHROM (F2 coagulation factor II (thrombin)) HUMTFPC (F3 coagulation factor III (thromboplastin, tissue factor)) HUMF5A (F5 coagulation factor V (proaccelerin, labile factor)) M78203 (F7 coagulation factor VII (serum prothrombin conversion accelerator)) HUMF8C (F8 coagulation factor VIII, procoagulant component (hemophilia A)) HUMCFIX (F9 coagulation factor IX (plasma thromboplastic component, Christmas disease, hemophilia B)) HUMCFX (F10: coagulation factor X) HUMFXI (F11 coagulation factor XI (plasma thromboplastin antecedent)) HUMCFXIIA (F12 coagulation factor XII (Hageman factor)) HUMFXIIIA (F13A1 coagulation factor XIII,	Inherited Clotting disorders

144

	A1 polypeptide) R28976 (F13B coagulation factor XIII, B polypeptide)	
vWF	HUMVWF (VWF von Willebrand factor)	Von Willebrand factor. Inherited Clotting disorders
Antithrombin III	T62060 (SERPINC1 serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1)	Inherited Clotting disorders
Cancer Markers		
Test	Gencarta Contig	Comments
AFP	D11581 (AFP alpha-fetoprotein)	Pregnancy, testicular cancer and hepatocellular cancer
CA125	HSIAI3B (M17S2 membrane component, chromosome 17, surface marker 2 (ovarian carcinoma antigen CA125))	Ovarian cancer
CA-15-3	HSMUC1A (MUC1 mucin 1, transmembrane)	Breast cancer
CA-19-9	HSAFUT3 (FUT3: fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group included))	Gastrointestinal cancer, pancreatic cancer
CEA	T10888 HUMCEA (CEA CAM3 carcinoembryonic antigen-related cell adhesion molecule 3)	Carcinoembryonic Antigen. Colorectal cancer
PSA	HSCDN9 (KLK3: kallikrein 3, (prostate specific antigen))	
PSMA	HUMPSM (FOLH1: folate hydrolase (prostate-specific membrane antigen) 1)	
TPA, TATI, OVX1, LASA, CA54/81	HSPSTI (SPINK1: serine protease inhibitor, Kazal type 1)	Ovarian cancer
BRCA 1	H90415 (BRCA1: breast cancer 1, early onset)	
BRCA 2	H47777 (BRCA2: breast cancer 2, early onset)	Breast cancer (ovarian cancer?)
HER2/Neu	S57296 (ERBB2: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian))	Breast cancer
Estrogen receptor	HSERG5UTA (ESR1: estrogen receptor 1) HSRNERB (ESR2: estrogen receptor 2 (ER beta))	Breast cancer
Progesterone receptor	T09102 (PGRMC1: progesterone receptor membrane component 1) Z32891 (PGRMC2: progesterone receptor membrane component 2)	Breast cancer

Note:

- (i) Small portion of these "markers" are also drug targets, whether already for approved drugs (such as alpha1 antiTrypsin) or under development (e.g., GOT).
- (ii) Some of these "markers" are also used as therapeutic proteins (e.g., Erythropoietin).
- (iii) All markers are found in the blood/serum unless otherwise specified.

#DRUG_DRUG_INTERACTION: refers to proteins involved in a biological process which mediates the interaction between at least two consumed drugs. Novel splice variants of known proteins involved in interaction between drugs may be used, for example, to modulate such drug-drug interactions. Examples of proteins involved in drug-drug interactions are presented in Table 9 together with the corresponding internal gene contig name, enabling to allocate the new splice variants within the data files in the attached CD-ROMs 1 and 3-PLEASE COMPLETE.

Table 9

Contig	Gene Symbol	Description
HUMANTLA	SLC3A2	4f2 cell-surface antigen heavy chain
Z43093	HTR6	5-hydroxytryptamine 6 receptor
HSXLALDA	ABCD1	Adrenoleukodystrophy protein
R35137	GPT	Alanine aminotransferase
D11683	ALDH1	Aldehyde dehydrogenase, cytosolic
T53833	AOX1	Aldehyde oxidase
HUMD4G08M3	ORM1	Alpha-1-acid glycoprotein 1
HUMD4G08M3	ORM2	Alpha-1-acid glycoprotein 2
HUMABPA	ABP1	Amiloride-sensitive amine oxidase [copper-containing]
S62734	MAOB	Amine oxidase [flavin-containing] b
AA526963	SLC6A14	Amino acid transporter b0+
HSAE2	SLC4A2	Anion exchange protein 2
M78110	SLC4A3	Anion exchange protein 3
M78052	ABCB2	Antigen peptide transporter 1
HUMMHCIAB	ABCB3	Antigen peptide transporter 2
F02693	APOD	Apolipoprotein d
M62234	ASNA1	Arsenical pump-driving ATPase
HUMNORTR	NAT1	Arylamine n-acetyltransferase 1
T67129	NAT1	Arylamine n-acetyltransferase 1
A1262683	NAT2	Arylamine n-acetyltransferase 2
Z39550	ABCB9	ATP-binding cassette protein abcb9
Z44377	ABCA1	ATP-binding cassette, sub-family a, member 1
M78056	ABCA2	ATP-binding cassette, sub-family a, member 2
T05334	ABCA3	ATP-binding cassette, sub-family a, member 3
T79973	ABCB6	ATP-binding cassette, sub-family b, member 6, mitochondrial
T78010	ABCB7	ATP-binding cassette, sub-family b, member 7, mitochondrial
R89046	ABCB8	ATP-binding cassette, sub-family b, member 8, mitochondrial
H64439	ABCD2	ATP-binding cassette, sub-family d, member 2
M85760	ABCD3	ATP-binding cassette, sub-family d, member 3
Z21904	ABCD4	ATP-binding cassette, sub-family d, member 4
Z39977	ABCG1	ATP-binding cassette, sub-family g, member 1
Z45628	ABCG2	ATP-binding cassette, sub-family g, member 2
T80665	SLC7A9	B(0,+)-type amino acid transporter 1
AF091582	ABCB11	Bile salt export pump
Z38696	BLMH	Bleomycin hydrolase
T08127	BNPI	Brain-specific na-dependent inorganic phosphate cotransporter
F00545	SLC12A2	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2
HSU07969	CDH17	Cadherin-17
T10238	SLC25A12	Calcium-binding mitochondrial carrier protein aralar1
Z40674	SLC25A13	Calcium-binding mitochondrial carrier protein aralar2
T61818	ABCC2	Canalicular multispecific organic anion transporter 1

T39953	ABCC3	Canalicular multispecific organic anion transporter 2
HUMCRE	CBR1	Carbonyl reductase [nadph] 1
AA320697	CBR3	Carbonyl reductase [nadph] 3
F03362	COMT	Catechol o-methyltransferase, membrane-bound form
T11004	COMT	Catechol o-methyltransferase, membrane-bound form
T39368	SLC7A4	Cationic amino acid transporter-4
S74445	RBP5	Cellular retinol-binding protein iii
T55952	RBP5	Cellular retinol-binding protein iii
HSU39905	SLC18A1	Chromaffin granule amine transporter
R52371	SLC35A1	Cmp-sialic acid transporter
D20754	CNT3	Concentrative nucleoside transporter 3
HSMNKMMP	ATP7A	Copper-transporting ATPase 1
HUMWND	ATP7B	Copper-transporting ATPase 2
HUMCFTRM	ABCC7	Cystic fibrosis transmembrane conductance regulator
F10774	SLC7A11	Cystine/glutamate transporter
HUMCYPADA	CYP11B1	Cytochrome P450 11B1, mitochondrial
HUMARM	CYP19	Cytochrome P450 19
HUMCYP145	CYP1A1	Cytochrome P450 1A1
R21282	CYP26	Cytochrome P450 26
AF209774	CYP2A13	Cytochrome P450 2A13
HSC45B2C	CYP2A6	Cytochrome P450 2A6
HSC45B2C	CYP2A7	Cytochrome P450 2A7
HSP452B6	CYP2B6	Cytochrome P450 2B6
HUM2C18	CYP2C18	Cytochrome P450 2C18
HSCP450	CYP2C19	Cytochrome P450 2C19
HUM2C18	CYP2C19	Cytochrome P450 2C19
HUMCYPAX	CYP2C8	Cytochrome P450 2C8
HSCP450	CYP2C9	Cytochrome P450 2C9
HSP450	CYP2D6	Cytochrome P450 2D6
M77918	CYP2E1	Cytochrome P450 2E1
HUMCYP11F	CYP2F1	Cytochrome P450 2F1
H09076	CYP2J2	Cytochrome P450 2J2
R07010	CYP3A1	Cytochrome P450 3A1
HUMCYPHLP	CYP3A3	Cytochrome P450 3A3
HUMCYPHLP	CYP3A4	Cytochrome P450 3A4
AA416822	CYP3A43	Cytochrome P450 3A43
HUMCYP3A	CYP3A5	Cytochrome P450 3A5
T82801	CYP3A7	Cytochrome P450 3A7
HSCYP4AA	CYP4A11	Cytochrome P450 4A11
S67580	CYP4A11	Cytochrome P450 4A11
HUMCP45IV	CYP4B1	Cytochrome P450 4B1
T98002	CYP4F12	Cytochrome P450 4F12
AA377259	CYP4F2	Cytochrome P450 4F2
AI400898	CYP4F8	Cytochrome P450 4F8
HSU09178	DPYD	Dihydropyrimidine dehydrogenase [nadp+]
W03174	DPYD	Dihydropyrimidine dehydrogenase [nadp+]
HUMFMO1	FMO1	Dimethylaniline monooxygenase [n-oxide forming] 1
HSFLMON2R	FMO2	Dimethylaniline monooxygenase [n-oxide forming] 2
T64494	FMO2	Dimethylaniline monooxygenase [n-oxide forming] 2
T40157	FMO3	Dimethylaniline monooxygenase [n-oxide forming] 3
HSFLMON2R	FMO4	Dimethylaniline monooxygenase [n-oxide forming] 4
D12220	FMO5	Dimethylaniline monooxygenase [n-oxide forming] 5
H25503	HET	Efflux transporter like protein
T12485	HET	Efflux transporter like protein
M78151	EPHX1	Epoxide hydrolase 1
T66884	SLC29A1	Equilibrative nucleoside transporter 1

HSHNP36	SLC29A2	Equilibrative nucleoside transporter 2
T08444	SLC1A3	Excitatory amino acid transporter 1
HSU01824	SLC1A2	Excitatory amino acid transporter 2
HSU03506	SLC1A1	Excitatory amino acid transporter 3
F07883	SLC1A6	Excitatory amino acid transporter 4
N39099	SLC1A7	Excitatory amino acid transporter 5
F00548	SLC2A9	Facilitative glucose transporter family member glut9
T95337	SLC27A1	Fatty acid transport protein
Z44099	SLC27A1	Fatty acid transport protein
HUMALBP	FABP4	Fatty acid-binding protein, adipocyte
S67314	FABP3	Fatty acid-binding protein, heart
AW605378	FABP2	Fatty acid-binding protein, intestinal
L25227	SLC19A1	Folate transporter 1
HSI15PGN1	FABP6	Gastrotropin
Z40427	G6PT1	Glucose 5-phosphate transporter
D11793	SLC2A1	Glucose transporter type 1, erythrocyte/brain
N27535	SLC2A10	Glucose transporter type 10
T52633	SLC2A11	Glucose transporter type 11
HUMLGTPA	SLC2A2	Glucose transporter type 2, liver
HUMLGTPA	SLC2A2	Glucose transporter type 2, liver
T07239	SLC2A3	Glucose transporter type 3, brain
HUMIRGT	SLC2A4	Glucose transporter type 4, insulin-responsive.
M62105	SLC2A5	Glucose transporter type 5, small intestine
T59518	SLC2A8	Glucose transporter type 8
HUMLGTH1	GSTA1	Glutathione s-transferase a1
HUMLGTH1	GSTA2	Glutathione s-transferase a2
T98291	GSTA3	Glutathione s-transferase a3-3
Z21581	GSTA4	Glutathione s-transferase a4-4
HSGST4	GSTM1	Glutathione s-transferase mu 1
D31291	GSTM2	Glutathione s-transferase mu 2
HSGST4	GSTM2	Glutathione s-transferase mu 2
T08311	GSTM3	Glutathione s-transferase mu 3
HUMGSTM4B	GSTM4	Glutathione s-transferase mu 4
HUMGSTM5	GSTM5	Glutathione s-transferase mu 5
T05391	GSTP1	Glutathione s-transferase p
AA346312	GSTT1	Glutathione s-transferase theta 1
R08187	GSTT2	Glutathione s-transferase theta 2
Z25318	GSTK1	Glutathione s-transferase, mitochondrial
H03163	SLC37A1	Glycerol-3-phosphate transporter
AA363955	SLC5A7	High affinity choline transporter
HSRRMRNA	SLC7A1	High-affinity cationic amino acid transporter-1
R22196	SLC31A1	High-affinity copper uptake protein 1
AA918012	SLC10A2	Ileal sodium/bile acid transporter
F00840	SLC7A5	Large neutral amino acid transporter small subunit 1
M79133	SLC7A5	Large neutral amino acid transporter small subunit 1
Z38621	SLC7A8	Large neutral amino acids transporter small subunit 2
HUMCARAA	CES1	Liver carboxylesterase
S52379	CES1	Liver carboxylesterase
T55488	SLC21A6	Liver-specific organic anion transporter
W78748	SLC5A4	Low affinity sodium-glucose cotransporter
T54842	SLC7A2	Low-affinity cationic amino acid transporter-2
T87799	ABCA7	Macrophage abc transporter
Z17844	LRP	Major vault protein
Z24885	GSTZ1	Maleylacetoacetate isomerase
T39939	MT1A	Metallothionein-IA
R99207	MT1B	Metallothionein-IB

T39939	MT1E	Metallothionein-IE
D11725	MT1F	Metallothionein-IF
S68949	MT1G	Metallothionein-IG
S68954	MT1G	Metallothionein-IG
HSFMET	MT1H	Metallothionein-IH
S52379	MT2A	Metallothionein-II
M78846	MT3	Metallothionein-III
AA570216	MT1K	Metallothionein-IK
S68954	MT1K	Metallothionein-IK
D11725	MT1L	Metallothionein-IL
HSPP15	MT1L	Metallothionein-IL
HSPP15	MT1R	Metallothionein-IR
NM032935	MT4	Metallothionein-IV
HUMGST	MGST1	Microsomal glutathione s-transferase 1
H59104	MGST2	Microsomal glutathione s-transferase 2
T47062	MGST3	Microsomal glutathione s-transferase 3
SSMPCP	SLC25A3	Mitochondrial phosphate carrier protein
R14814	SULT1A3	Monoamine-sulfating phenol sulfotransferase
HUMARYTRAB	SULT1A3	Monoamine-sulfating phenol sulfotransferase
M62141	SLC16A1	Monocarboxylate transporter 1
H90048	SLC16A6	Monocarboxylate transporter 2
F02520	SLC16A2	Monocarboxylate transporter 3
AI005004	SLC16A8	Monocarboxylate transporter 4
T59354	SLC16A3	Monocarboxylate transporter 5
R22416	SLC16A4	Monocarboxylate transporter 6
T78890	SLC16A5	Monocarboxylate transporter 7
F01173	SLC16A7	Monocarboxylate transporter 8
Z41819	ABCB1	Multidrug resistance protein 1
AL041030	ABCB4	Multidrug resistance protein 3
SATHRMRP	ABCC1	Multidrug resistance-associated protein 1
R00050	ABCC4	Multidrug resistance-associated protein 4
M78673	ABCC5	Multidrug resistance-associated protein 5
R99091	ABCC6	Multidrug resistance-associated protein 6
T69749	ABCC6	Multidrug resistance-associated protein 6
D11495	DIA4	Nad(p)h dehydrogenase [quinone] 1
HUMNRAMP	SLC11A1	Natural resistance-associated macrophage protein 1
Z38360	SLC11A2	Natural resistance-associated macrophage protein 2
HUMASCT1A	SLC1A4	Neutral amino acid transporter a
AW237674	SLC1A5	Neutral amino acid transporter b(0)
M78631	SLC3A1	Neutral and basic amino acid transport protein rbat
HSU08021	NNMT	Nicotinamide n-methyltransferase
T87759	SLC22A4	Novel organic cation transporter 1
Z41935	SLC15A2	Oligopeptide transporter, kidney isoform
HSU21936	SLC15A1	Oligopeptide transporter, small intestine isoform
M62053	OAT1	Organic anion transporter 1
H18607	OAT3	Organic anion transporter 3
R16970	OAT4	Organic anion transporter 4
T39111	SLC21A9	Organic anion transporter b
Z41576	SLC21A11	Organic anion transporter oATP-d
T23657	SLC21A12	Organic anion transporter oATP-e
Z21041	SLC21A14	Organic anion transporting polypeptide 14
H75435	SLC21A8	Organic anion transporting polypeptide 8
HSU77086	SLC22A1	Organic cation transporter 1
HSOCTK	SLC22A2	Organic cation transporter 2
R00207	SLC22A3	Organic cation transporter 3
H30224	ORCTL4	Organic cation transporter like 4

H25503	ORCTL2	Organic cation transporter-like 2
Z38659	SLC22A5	Organic cation/carnitine transporter 2
AB010438	ORCTL3	Organic-cation transporter like 3
T95621	ORNT1	Ornithine transporter
AA398593	ORNT2	Ornithine transporter 2
R79412	NTT5	Orphan sodium- and chloride-dependent neurotransmitter transporter ntt5
H82347	NTT73	Orphan sodium- and chloride-dependent neurotransmitter transporter ntt73
Z43484	NTT73	Orphan sodium- and chloride-dependent neurotransmitter transporter ntt73
Z44749	SLC25A17	Peroxisomal membrane protein pmp34
HUMARYLSUL	SULT1A1	Phenol-sulfating phenol sulfotransferase 1
HUMARYLSUL	SULT1A2	Phenol-sulfating phenol sulfotransferase 2
D12243	RBP4	Plasma retinol-binding protein
HUMATPAD	ATP12A	Potassium-transporting ATPase alpha chain 2
Z40030	ATP8A1	Potential phospholipid-transporting ATPase ia
Z40188	FIC1	Potential phospholipid-transporting ATPase ic
T86800	SLC31A2	Probable low-affinity copper uptake protein 2
Z41717	PTGIS	Prostacyclin synthase
S78220	PTGS1	Prostaglandin g/h synthase 1
HUMENDOSYN	PTGS2	Prostaglandin g/h synthase 2
T85296	SLC21A2	Prostaglandin transporter
M62053	SLC22A6	Renal organic anion transport protein 1
HSU26209	SLC13A2	Renal sodium/dicarboxylate cotransporter
Z40774	SLC13A2	Renal sodium/dicarboxylate cotransporter
HSNAPII	SLC17A1	Renal sodium-dependent phosphate transport protein 1
HUMNAPI3X	SLC34A1	Renal sodium-dependent phosphate transport protein 2
H85361	ABCA4	Retinal-specific ATP-binding cassette transporter
S74445	CRABP1	Retinoic acid-binding protein i, cellular
HUMCRABP	CRABP2	Retinoic acid-binding protein ii, cellular
HUMCRBP	RBP1	Retinol-binding protein i, cellular
S57153	RBP1	Retinol-binding protein i, cellular
T07054	RBP2	Retinol-binding protein ii, cellular
T63266	RBP2	Retinol-binding protein ii, cellular
HUMBGT1R	SLC6A12	Sodium- and chloride-dependent betaine transporter
HUMCRTR	SLC6A8	Sodium- and chloride-dependent creatine transporter 1
R20043	SLC6A13	Sodium- and chloride-dependent gaba transporter 2
S70609	SLC6A9	Sodium- and chloride-dependent glycine transporter 1
AA625644	SLC6A5	Sodium- and chloride-dependent glycine transporter 2
M78677	SLC6A6	Sodium- and chloride-dependent taurine transporter
T10761	SLC4A4	Sodium bicarbonate cotransporter nbc1
AA452802	NBC4	Sodium bicarbonate cotransporter nbc4a
HUMCNC	SLC8A1	Sodium/calcium exchanger 1
R20720	SLC8A2	Sodium/calcium exchanger 2
T07666	SLC8A3	Sodium/calcium exchanger 3
T07666	SLC8A3	Sodium/glucose cotransporter 1
HUMSGLCT	SLC5A2	Sodium/glucose cotransporter 2
S83549	SLC9A2	Sodium/hydrogen exchanger 2
HSU66088	SLC5A5	Sodium/iodide cotransporter
HSU62966	SLC28A1	Sodium/nucleoside cotransporter 1
AA358822	SLC28A2	Sodium/nucleoside cotransporter 2
HUMNTCP	SLC10A1	Sodium/taurocholate cotransporting polypeptide
HSGAT1MR	SLC6A1	Sodium-and chloride-dependent gaba transporter 1
F05686	SLC6A11	Sodium-and chloride-dependent gaba transporter 3
AA604857	SVCT1	Sodium-dependent vitamin c transporter 1

T27309	SVCT2	Sodium-dependent vitamin c transporter 2
S44626	SLC6A3	Sodium-dependent dopamine transporter
Z39412	NADC3	Sodium-dependent high-affinity dicarboxylate transporter
T77525	SLC5A6	Sodium-dependent multivitamin transporter
HUMNORTR	SLC6A2	Sodium-dependent noradrenaline transporter
HSZ83953	SLC17A3	Sodium-dependent phosphate transport protein 3
R06460	SLC17A3	Sodium-dependent phosphate transport protein 3
HSZ83953	SLC17A4	Sodium-dependent phosphate transport protein 4
HSY10506	SLC17A4	Sodium-dependent phosphate transport protein 4
H40741	SLC6A7	Sodium-dependent proline transporter
HSSERT	SLC6A4	Sodium-dependent serotonin transporter
T64950	SLC21A3	Sodium-independent organic anion transporter
M79233	EPHX2	Soluble epoxide hydrolase
Z39813	SLC25A18	Solute carrier
HUMSTAR	STAR	Steroidogenic acute regulatory protein
Z20453	STAR	Steroidogenic acute regulatory protein
R69741	SLC26A2	Sulfate transporter
T08860	ABCC8	Sulfonylurea receptor 1
R73927	ABCC9	Sulfonylurea receptor 2
T84623	SULT1C1	Sulfotransferase 1C1
R58632	SULT1C2	Sulfotransferase 1C2
T95810	SLC18A2	Synaptic vesicle amine transporter
AF080246	TRAG3	Taxol resistant associated protein 3
R20880	SLC19A2	Thiamine transporter 1
HSU44128	SLC12A3	Thiazide-sensitive sodium-chloride cotransporter
S62904	TPMT	Thiopurine s-methyltransferase
HSPBX2	G17	Transporter protein
T62038	G17	Transporter protein
R53836	SLC35A3	UDP n-acetylglucosamine transporter
T60594	SLC35A2	UDP-galactose translocator
HUMUGT1FA	UGT1	UDP-glucuronosyltransferase 1-1, microsomal
HUMUGT1FA	UGT1A10	UDP-glucuronosyltransferase 1A10
HUMUGT1FA	UGT1A7	UDP-glucuronosyltransferase 1A7
HUMUGT1FA	UGT1A8	UDP-glucuronosyltransferase 1A8
HUMUGT1FA	UGT1A9	UDP-glucuronosyltransferase 1A9
HSUGT2BIO	UGT2B10	UDP-glucuronosyltransferase 2B10, microsomal
HSUDPGT	UGT2B11	UDP-glucuronosyltransferase 2B11, microsomal
N70316	UGT2B11	UDP-glucuronosyltransferase 2B11, microsomal
HSU08854	UGT2B15	UDP-glucuronosyltransferase 2B15, microsomal
T24450	UGT2B17	UDP-glucuronosyltransferase 2B17, microsomal
HSUDPGT	UGT2B4	UDP-glucuronosyltransferase 2B4, microsomal
HUMUDPGTA	UGT2B7	UDP-glucuronosyltransferase 2B7, microsomal
AI002801	SLC14A1	Urea transporter, erythrocyte
Z19313	SLC14A1	Urea transporter, erythrocyte
AI002801	SLC14A2	Urea transporter, kidney
HSU09210	SLC18A3	Vesicular acetylcholine transporter
HUMKCHB	KCNA4	Voltage-gated potassium channel protein kv1.4
R09608	XDH	Xanthine dehydrogenase/oxidase
T64266	SLC7A7	Y+L amino acid transporter 1
T10628	SLC30A1	Zinc transporter 1
AA322641	SLC30A4	Zinc transporter 4

#DISEASE_RELATED_CLINICAL_PHENOTYPE – This field denotes the possibility of using biomolecular sequences of the present invention for the diagnosis

and/or treatment of genetic diseases such as listed in the following URL:

www.geneclinics.org/servlet/access?id=8888891&key=X9D790O5re1Az&db=genete&sts&res=&fcn=b&grp=g&genesearch=true&testtype=both&ls=1&type=e&qry=&submit=Search and in Table 10, below. This list includes genetic diseases and genes

- 5 which may be used for the detection and/or treatment thereof. As such, newly uncovered variants of these genes may be used for improved diagnosis and/or treatment when used singly or in combination with the previously described genes.

Table 10

Gencarta Config	Gene Symbol	Disease
HSCFTRMA	CFTR	Congenital Bilateral Absence of the Vas Deferens ;Cystic Fibrosis
HUMCFTR M	CFTR	Congenital Bilateral Absence of the Vas Deferens ;Cystic Fibrosis
HUMFGFR3	FGFR3	Achondroplasia ;Crouzon Syndrome with Acanthosis Nigricans ;FGFR-Related Craniosynostosis Syndromes ;Hypochondroplasia ;Muenke Syndrome ;Severe Achondroplasia with Developmental Delay and Acanthosis Nigricans (SADDAN) ;Thanatophoric Dysplasia
T07012	FGD1	Aarskog Syndrome
HSCA1III	COL3A1	Ehlers-Danlos Syndrome, Vascular Type
HUMCOL2 A1B	COL2A1	Achondrogenesis Type 2 ;Kniest Dysplasia ;Spondyloepimetaphyseal Dysplasia, Strudwick Type ;Spondyloepiphyseal Dysplasia, Congenita ;Stickler Syndrome ;Stickler Syndrome Type I
R68817	APRT	Adenine Phosphoribosyltransferase Deficiency
HUMAMPD I	AMPD1	Adenosine Monophosphate Deaminase 1
M62124	PXR1	Zellweger Syndrome Spectrum
HSXLALDA	ABCD1	Adrenoleukodystrophy, X-Linked
T28718	BTK	X-Linked Agammaglobulinemia
R91110	IL2RG	X-Linked Severe Combined Immunodeficiency
HUMPEDG	OCA2	Oculocutaneous Albinism Type 2
HSU01873	TYR	Oculocutaneous Albinism Type 1
HSOA1MRN A	OA1	Ocular Albinism, X-Linked
R14843	TYRP1	Oculocutaneous Albinism Type 3 (TRP1 Related)
HSALDAR	ALDOA	Aldolase A Deficiency
T40633	HBA1	Alpha-Thalassemia
T40633	HBA2	Alpha-Thalassemia ;Hemoglobin Constant Spring
HSU09820	ATRX	Alpha-Thalassemia X-Linked Mental Retardation Syndrome
HUMCOL4 A5	COL4A5	Alport Syndrome ;Alport Syndrome, X-Linked
T61627	APOE	Apolipoprotein E Genotyping ;Familial Combined Hyperlipidemia ;Hyperlipoproteinemia Type III
T89701	PSEN1	Alzheimer Disease Type 3 ;Early-Onset Familial Alzheimer Disease

R05822	PSEN2	Alzheimer Disease Type 4 ;Early-Onset Familial Alzheimer Disease
HSTTRM	TTR	Transthyretin Amyloidosis
T23978	SOD1	Amyotrophic Lateral Sclerosis
HUMANDR EC	AR	Androgen Insensitivity Syndrome ;Spinal and Bulbar Muscular Atrophy
Z19491	UBE3A	Angelman Syndrome
HUMPAX6 AN	PAX6	Aniridia ;Anophthalmia ;Isolated Aniridia ;Peters Anomaly ;Peters Anomaly with Cataract ;Wilms Tumor-Aniridia-Genital Anomalies-Retardation Syndrome
HUMKGFR A	FGFR2	Apert Syndrome ;Beare-Stevenson Syndrome ;Crouzon Syndrome ;FGFR-Related Craniosynostosis Syndromes ;Jackson-Weiss Syndrome ;Pfeiffer Syndrome Type 1, 2, and 3
HSU03272	FBN2	Congenital Contractural Arachnodactyly
Z19459	AMCD1	Arthrogryposis Multiplex Congenita, Distal, Type I
T88756	ATM	Ataxia-Telangiectasia
H30056	BBS1	Bardet-Biedl Syndrome
Z25009	BBS2	Bardet-Biedl Syndrome
T64876	BBS4	Bardet-Biedl Syndrome
N27125	PTCH	Nevoid Basal Cell Carcinoma Syndrome
N25339	VMD2	Best Vitelliform Macular Dystrophy
N71795	VMD2	Best Vitelliform Macular Dystrophy
HUMHBB3E	HBB	Beta-Thalassemia ;Hemoglobin E ;Hemoglobin S Beta-Thalassemia ;Hemoglobin SC ;Hemoglobin SD ;Hemoglobin SO ;Hemoglobin SS ;Sickle Cell Disease
H53763	BLM	Bloom Syndrome
N22283	EYA1	Branchiootorenal Syndrome
H90415	BRCA1	BRCA1 and BRCA2 Hereditary Breast/Ovarian Cancer ;BRCA1 Hereditary Breast/Ovarian Cancer
H47777	BRCA2	BRCA1 and BRCA2 Hereditary Breast/Ovarian Cancer ;BRCA2 Hereditary Breast/Ovarian Cancer
Z33575	SOX9	Campomelic Dysplasia
S67156	ASPA	Canavan Disease
T52465	CPS1	Carbamoylphosphate Synthetase I Deficiency
HSVD3HYD	CYP27A1	Cerebrotendinous Xanthomatosis
S66705	MPZ	Charcot-Marie-Tooth Neuropathy Type 1 ;Charcot-Marie-Tooth Neuropathy Type 1B ;Congenital Hypomyelination
HSGAS3MR	PMP22	Charcot-Marie-Tooth Neuropathy Type 1 ;Charcot-Marie-Tooth Neuropathy Type 1A ;Charcot-Marie-Tooth Neuropathy Type 1E ;Hereditary Neuropathy with Liability to Pressure Palsies
T93208	PMP22	Charcot-Marie-Tooth Neuropathy Type 1 ;Charcot-Marie-Tooth Neuropathy Type 1A ;Charcot-Marie-Tooth Neuropathy Type 1E ;Hereditary Neuropathy with Liability to Pressure Palsies
HSGAPJR	GJB1	Charcot-Marie-Tooth Neuropathy Type X
HSXCGD	CYBB	Chronic Granulomatous Disease
S67289	CYBB	Chronic Granulomatous Disease
HSASD	ASS	Citrullinemia
HUMPAX2 A	PAX2	Anophthalmia ;Renal-Coloboma Syndrome
HUMP45C2 1	CYP21A2	21-Hydroxylase Deficiency

S74720	NR0B1	Complex Glycerol Kinase Deficiency ;Dosage-Sensitive Sex Reversal ;Isolated X-Linked Adrenal Hypoplasia Congenita ;X-Linked Adrenal Hypoplasia Congenita
HSKERTRNS	TGM1	Autosomal Recessive Congenital Ichthyosis
BF928311	CPO	Hereditary Coproporphyrria
HSCPPOX	CPO	Hereditary Coproporphyrria
HUMTGFBIG	TGFBIG	Avellino Corneal Dystrophy ;Granular Corneal Dystrophy ;Lattice Corneal Dystrophy Type I
R08437	MSX2	Craniosynostosis Type II ;Parietal Foramina 1
HUMPRP0A	PRNP	Prion Diseases
T08652	DRPLA	DRPLA
Z46151	DRPLA	DRPLA
HSWT1	WT1	Denys-Drash Syndrome ;Wilms Tumor ;Wilms Tumor-Aniridia-Genital Anomalies-Retardation Syndrome ;WT1-Related Disorders
T52050	WT1	Denys-Drash Syndrome ;Wilms Tumor ;Wilms Tumor-Aniridia-Genital Anomalies-Retardation Syndrome ;WT1-Related Disorders
M78080	ATP2A2	Darier Disease
Z30219	DCR	Down Syndrome Critical Region
T11279	DKC1	Dyskeratosis Congenita
T08131	DYT1	Early-Onset Primary Dystonia (DYT1)
T50729	ED1	Hypohidrotic Ectodermal Dysplasia ;Hypohidrotic Ectodermal Dysplasia, X-Linked
HUMPA1V	COL5A1	Ehlers-Danlos Syndrome, Classic Type
HUMLYSYL	PLOD	Ehlers-Danlos Syndrome, Kyphoscoliotic Form
HSCOLIA	COL1A2	Ehlers-Danlos Syndrome, Arthrochalasia Type ;Osteogenesis Imperfecta
HUMCG1PA1	COL1A1	Ehlers-Danlos Syndrome, Arthrochalasia Type ;Osteogenesis Imperfecta
Z30171	TAZ	3-Methylglutaconic Aciduria Type 2 ;Cardiomyopathy ;Dilated Cardiomyopathy ;Endocardial Fibroelastosis ;Familial Isolated Noncompaction of Left Ventricular Myocardium
Z39302	TAZ	3-Methylglutaconic Aciduria Type 2 ;Cardiomyopathy ;Dilated Cardiomyopathy ;Endocardial Fibroelastosis ;Familial Isolated Noncompaction of Left Ventricular Myocardium
HUMKERK5A	KRT5	Epidermolysis Bullosa Simplex
R72295	KRT14	Epidermolysis Bullosa Simplex
HUMKTEP2A	KRT1	Epidermolytic Hyperkeratosis ;Nonepidermolytic Palmoplantar Hyperkeratosis
HUMK10A	KRT10	Epidermolytic Hyperkeratosis
M78482	CHS1	Chediak-Higashi Syndrome
HSTCD1	CHM	Choroideremia
HSAGALAR	GLA	Fabry Disease
T79651	GLA	Fabry Disease
HUMF5A	F5	Factor V Leiden Thrombophilia ;Factor V R2 Mutation Thrombophilia
HUMFXI	F11	Factor XI Deficiency

M79108	APC	Colon Cancer (APC I1307K related) ;Familial Adenomatous Polyposis
T10619	IKBKAP	Familial Dysautonomia
HUMFMR1	FMR1	Fragile X Syndrome
M78417	FMR2	FRAXE Syndrome
R06415	FRDA	Friedreich Ataxia
HSALDOBR	ALDOB	Hereditary Fructose Intolerance
HUMALFU C	FUCA1	Fucosidosis
M85904	FH	Fumarate Hydratase Deficiency
H85361	ABCA4	Age-Related Macular Degeneration ;Retinitis Pigmentosa, Autosomal Recessive ;Stargardt Disease 1
R31596	GALK1	Galactokinase Deficiency
T53762	GALT	Galactosemia
HUMGCB	GBA	Gaucher Disease
T48672	GBA	Gaucher Disease
HSGCRAR	NR3C1	Glucocorticoid Resistance
S58359	G6PD	Glucose-6-Phosphate Dehydrogenase Deficiency
HSGKTS1	GK	Glycerol Kinase Deficiency
HSRNAGLK	GK	Glycerol Kinase Deficiency
U01120	G6PC	Glycogen Storage Disease Type Ia
HUMGAAA	GAA	Glycogen Storage Disease Type II
F00985	AGL	Glycogen Storage Disease Type III
HUMHGBE	GBE1	Glycogen Storage Disease Type IV
HSPHOSR1	PYGM	Glycogen Storage Disease Type V
D12179	PYGL	Glycogen Storage Disease Type VI
HSHMPFK	PFKM	Glycogen Storage Disease Type VII
HUMGLI3A	GLI3	GLI3-Related Disorders ;Greig Cephalopolysyndactyly Syndrome ;Pallister-Hall Syndrome
F09335	ATP2C1	Hailey-Hailey Disease
M62210	CCM1	Angiokeratoma Corporis Diffusum with Arteriovenous Fistulas ;Familial Cerebral Cavernous Malformation
T59431	HFE	HFE- Associated Hereditary Hemochromatosis
HSALK1A	ACVRL1	Hereditary Hemorrhagic Telangiectasia
HUMENDO	ENG	Hereditary Hemorrhagic Telangiectasia
HUMF8C	F8	Hemophilia A
HUMFVIII	F8	Hemophilia A
HUMCFIX	F9	Hemophilia B
HSU03911	MSH2	Hereditary Non-Polyposis Colon Cancer
Z24775	MLH1	Hereditary Non-Polyposis Colon Cancer
HSRETTT	RET	Hirschsprung Disease ;Multiple Endocrine Neoplasia Type 2
HUMSHH	SHH	Holoprosencephaly 3
N81026	TBX5	Holt-Oram Syndrome
M78262	CBS	Homocystinuria
T06035	IDS	Mucopolysaccharidosis Type II
T03828	HD	Huntington Disease
H27612	IDUA	Mucopolysaccharidosis Type I
M62205	GFAP	Alexander Disease
HUMCD40L	TNFSF5	Hyper IgM Syndrome, X-Linked
HUMPTHR OM	F2	Prothrombin G20210A Thrombophilia
T61466	MTHFR	MTHFR Deficiency ;MTHFR Thermolabile Variant

HUMSKM1 A	SCN4A	Hyperkalemic Periodic Paralysis Type 1 ;Hypokalemic Periodic Paralysis ;Hypokalemic Periodic Paralysis Type 2 ;Myotonia Congenita, Dominant ;Paramyotonia Congenita
HSU09784	CACNA1S	Hypokalemic Periodic Paralysis ;Hypokalemic Periodic Paralysis Type 1 ;Malignant Hyperthermia Susceptibility
HUMLPLA A	LPL	Familial Lipoprotein Lipase Deficiency
HUMPEX	PHEX	Hypophosphatemic Rickets, X-Linked Dominant
M78626	STS	Ichthyosis, X-Linked
R56102	IKBKKG	Incontinentia Pigmenti
Z39843	IVD	Isovaleric Acidemia
S60085S1	KAL1	Kallmann Syndrome, X-Linked
T55061	KEL	Kell Antigen Genotyping
HUMGALC	GALC	Krabbe Disease
HUMZFPSR EB	ZNF9	Myotonic Dystrophy Type 2
Z19342	KIF1B	Charcot-Marie-Tooth Neuropathy Type 2
T11351	NPC2	Niemann-Pick Disease Type C
Z39096	NDRG1	Charcot-Marie-Tooth Neuropathy Type 4
AA984421	PRX	Charcot-Marie-Tooth Neuropathy Type 4 ;Charcot-Marie-Tooth Neuropathy Type 4F
HUMRETG C	GUCY2D	Leber Congenital Amaurosis
HSU18991	RPE65	Leber Congenital Amaurosis ;Retinitis Pigmentosa, Autosomal Recessive
C16899	MTND6	Leber Hereditary Optic Neuropathy ;Mitochondrial Disorders ;Mitochondrial DNA-Associated Leigh Syndrome and NARP
AA069417	MTND4	Leber Hereditary Optic Neuropathy ;Mitochondrial Disorders ;Mitochondrial DNA-Associated Leigh Syndrome and NARP
HUMCYP3A	MTND4	Leber Hereditary Optic Neuropathy ;Mitochondrial Disorders ;Mitochondrial DNA-Associated Leigh Syndrome and NARP
HSCPHC22	MTND1	Leber Hereditary Optic Neuropathy ;Mitochondrial Disorders ;Mitochondrial DNA-Associated Leigh Syndrome and NARP
HUMHPRT	HPRT1	Lesch-Nyhan Syndrome
HUMLHHC GR	LHCGR	Leydig Cell Hypoplasia/Agenesis ;Male-Limited Precocious Puberty
HSP53	TP53	Li-Fraumeni Syndrome
Z19198	HADHB	Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency
M79018	HADHA	Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency
R72332	HADHA	Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency
W93500	KCNQ1	Atrial Fibrillation ;Jervell and Lange-Nielsen Syndrome ;LQT 1 ;Romano-Ward Syndrome
S62085	OCRL	Lowe Syndrome
T48981	FBN1	Marfan Syndrome
HUMASFB	ARSB	Mucopolysaccharidosis Type VI

M62202	GNAS	Albright Hereditary Osteodystrophy ;McCune-Albright Syndrome ;Osseus Heteroplasia, Progressive
N46342	SACS	ARSACS
T81605	FANCD2	Fanconi Anemia
H47777	FANCD1	Fanconi Anemia
T23877	ACADM	Medium Chain Acyl-Coenzyme A Dehydrogenase Deficiency
AA906866	PARK2	Parkin Type of Juvenile Parkinson Disease
BE140729	GJB4	Erythrokeratoderma Variabilis
HSU26727	CDKN2A	Familial Malignant Melanoma
T47218	SPINK5	Netherton Syndrome
HSMNKMBP	ATP7A	ATP7A-Related Copper Transport Disorders
R37821	SHFM4	Ectrodactyly
Z38987	GSN	Amyloidosis V
HSARYA	ARSA	Chromosome 22q13.3 Deletion Syndrome ;Metachromatic Leukodystrophy
S68531	COL10A1	Metaphyseal Chondrodysplasia, Schmid Type
T59742	CACNA1A	Episodic Ataxia Type 2 ;Familial Hemiplegic Migraine ;Spinocerebellar Ataxia Type 6
HSCP2	HPS3	Hermansky-Pudlak Syndrome ;Hermansky-Pudlak Syndrome 3
R21301	HPS3	Hermansky-Pudlak Syndrome ;Hermansky-Pudlak Syndrome 3
HUMB GAL RP	GLB1	GM1 Gangliosidosis ;Mucopolysaccharidosis Type IVB
HSU12507	KCNJ2	Andersen Syndrome
R28488	MEN1	Multiple Endocrine Neoplasia Type I
HUMCOMP	COMP	COMP-Related Multiple Epiphyseal Dysplasia ;Multiple Epiphyseal Dysplasia, Dominant ;Pseudoachondroplasia
H30258	COL9A2	Multiple Epiphyseal Dysplasia, Dominant
T48133	EXT1	Hereditary Multiple Exostoses ;Multiple Exostoses, Type I
T06129	EXT2	Hereditary Multiple Exostoses ;Multiple Exostoses, Type II
T05624	LAMA2	Congenital Muscular Dystrophy with Merosin Deficiency
HSDYSTIA	DMD	Duchenne/Becker Muscular Dystrophy ;Dystrophinopathies ;X-Linked Dilated Cardiomyopathy
HSSTA	EMD	Emery-Dreifuss Muscular Dystrophy, X-Linked
HSU20165	BMPT2	Primary Pulmonary Hypertension
M79239	CAPN3	Calpainopathy ;Limb-Girdle Muscular Dystrophies, Autosomal Recessive
HSU34976	SGCG	Gamma-Sarcoglycanopathy ;Limb-Girdle Muscular Dystrophies, Autosomal Recessive ;Sarcoglycanopathies
HUMADHA	SGCA	Alpha-Sarcoglycanopathy ;Limb-Girdle Muscular Dystrophies, Autosomal Recessive ;Sarcoglycanopathies
AI340083	SGCA	Alpha-Sarcoglycanopathy ;Limb-Girdle Muscular Dystrophies, Autosomal Recessive ;Sarcoglycanopathies
Z25374	SGCB	Beta-Sarcoglycanopathy ;Limb-Girdle Muscular Dystrophies, Autosomal Recessive ;Sarcoglycanopathies

N29439	SGCD	Delta-Sarcoglycanopathy ;Dilated Cardiomyopathy ;Limb-Girdle Muscular Dystrophies, Autosomal Recessive ;Sarcoglycanopathies
N56180	CASQ2	Catecholaminergic Ventricular Tachycardia, Autosomal Recessive
T23560	CHRNA2	Nocturnal Frontal Lobe Epilepsy, Autosomal Dominant
HSCHRNA4 4	CHRNA4	Nocturnal Frontal Lobe Epilepsy, Autosomal Dominant
M78654	CHRNA4	Nocturnal Frontal Lobe Epilepsy, Autosomal Dominant
T86329	CDH23	Usher Syndrome Type 1
D11677	PABPN1	Oculopharyngeal Muscular Dystrophy
AW449267	PCDH15	Usher Syndrome Type 1
HUMCLC	CLCN1	Myotonia Congenita, Dominant ;Myotonia Congenita, Recessive
S86455	DMPK	Myotonic Dystrophy Type 1
T70260	MTM1	Myotubular Myopathy, X-Linked
T12579	LMX1B	Nail-Patella Syndrome
HSTRKT1	TPM3	Nemaline Myopathy
HUMTROP K	TPM3	Nemaline Myopathy
Z19248	NEB	Nemaline Myopathy
AF030626	AVPR2	Nephrogenic Diabetes Insipidus ;Nephrogenic Diabetes Insipidus, X-Linked
AA780862	NPHS1	Congenital Finnish Nephrosis
T08860	ABCC8	ABCC8-Related Hyperinsulinism ;Familial Hyperinsulinism
AA679741	KCNJ11	Familial Hyperinsulinism ;KCNJ11-Related Hyperinsulinism
M77935	NF1	Neurofibromatosis 1
HSMEORPR A	NF2	Neurofibromatosis 2
T08995	CLN3	CLN3-Related Neuronal Ceroid-Lipofuscinosis ;Neuronal Ceroid-Lipofuscinoses
T72120	CLN2	CLN2-Related Neuronal Ceroid-Lipofuscinosis ;Neuronal Ceroid-Lipofuscinoses
T41059	GRHPR	Hyperoxaluria, Primary, Type 2
HUMGCRF C	FCGR3A	Neutrophil Antigen Genotyping
R21657	NPC1	Niemann-Pick Disease Type C ;Niemann-Pick Disease Type C1
M77961	SMPD1	Niemann-Pick Disease Due to Sphingomyelinase Deficiency
T87256	SUOX	Sulfocysteinuria
D79813	SOST	SOST-Related Sclerosing Bone Dysplasias
T94707	MATN3	Multiple Epiphyseal Dysplasia, Dominant
HSCOL9AL	COL9A1	Multiple Epiphyseal Dysplasia, Dominant
S69208	TNNT1	Nemaline Myopathy
Z19459	TPM2	Nemaline Myopathy
D11793	SLC2A1	Glucose Transporter Type 1 Deficiency Syndrome
HSCHRX	NDP	Norrie Disease
T62791	OPA1	Optic Atrophy 1
Z24812	OFD1	Oral-Facial-Digital Syndrome Type I
HUMOTC	OTC	Ornithine Transcarbamylase Deficiency
R66505	MKKS	Bardet-Biedl Syndrome ;McKusick-Kaufman Syndrome
Z19438	CHAC	Choreoacanthocytosis

HUMRDSA	RDS	Patterned Dystrophy of Retinal Pigment Epithelium ;Retinitis Pigmentosa, Autosomal Dominant
Z30072	PLP1	Hereditary Spastic Paraplegia, X-Linked ;PLP-Related Disorders
HSFGR1IG	FGFR1	FGFR-Related Craniosynostosis Syndromes ;Pfeiffer Syndrome Type 1, 2, and 3
HUMPHH	PAH	Phenylalanine Hydroxylase Deficiency
HSKITCR	KIT	Gastrointestinal Stromal Tumor ;Piebaldism
HSGROW1	GH1	Pituitary Dwarfism I
F00079	GHR	Pituitary Dwarfism II
HSPIT1	POU1F1	Pituitary-Specific Transcription Factor Defects (PIT1)
T58874	SDHD	Familial Nonchromaffin Paragangliomas
HUMNTB3	ITGB3	Integrin, Beta 3 ;Platelet Antigen Genotyping
T09245	PKD1	Polycystic Kidney Disease 1, Autosomal Dominant ;Polycystic Kidney Disease, Autosomal Dominant
T55657	PKD2	Polycystic Kidney Disease 2, Autosomal Dominant ;Polycystic Kidney Disease, Autosomal Dominant
T77325	PKD2	Polycystic Kidney Disease 2, Autosomal Dominant ;Polycystic Kidney Disease, Autosomal Dominant
W27963	PKD2	Polycystic Kidney Disease 2, Autosomal Dominant ;Polycystic Kidney Disease, Autosomal Dominant
R05352	PKHD1	Polycystic Kidney Disease, Autosomal Recessive
M77871	PCLD	Polycystic Liver Disease
M78097	UROD	Porphyria Cutanea Tarda
HUMPBG	HMBS	Acute Intermittent Porphyria
HUMRODS A	UROS	Congenital Erythropoietic Porphyria
T10891	AGT	Angiotensinogen
T67463	CTSK	Pycnodysostosis
M77954	PDHA1	Pyruvate Dehydrogenase Deficiency, X-linked
Z19400	PHYH	Refsum Disease, Adult
R07476	PEX1	Zellweger Syndrome Spectrum
Z24965	RCA1	Renal Cell Carcinoma
H37900	RHO	Retinitis Pigmentosa, Autosomal Dominant ;Retinitis Pigmentosa, Autosomal Recessive
T24020	RB1	Retinoblastoma
Z44098	RS1	X-Linked Juvenile Retinoschisis
H84683	RS1	X-Linked Juvenile Retinoschisis
HSRH30A	RHCE	Rh C Genotyping ;Rh E Genotyping
S57971	RHCE	Rh C Genotyping ;Rh E Genotyping
AI282496	RHCE	Rh C Genotyping ;Rh E Genotyping
T11224	RHCE	Rh C Genotyping ;Rh E Genotyping
R60192	PEX7	Refsum Disease, Adult ;Rhizomelic Chondrodysplasia Punctata Type 1
HUMMLC1 AA	MLC1	Megalencephalic Leukoencephalopathy with Subcortical Cysts
M79106	MLC1	Megalencephalic Leukoencephalopathy with Subcortical Cysts
T64905	PITX2	Anophthalmia ;Peters Anomaly ;Rieger Syndrome
Z41163	CREBBP	Rubinstein-Taybi Syndrome
HSBHLH	TWIST1	Saethre-Chotzen Syndrome
F00367	EIF2B1	Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter

Z20030	EIF2B2	Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter
Z41323	EIF2B3	Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter
Z17882	EIF2B4	Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter
R13846	EIF2B5	Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter ;Cree Leukoencephalopathy
T03917	HEXB	Sandhoff Disease
HUMSRYA	SRY	XX Male Syndrome ;XY Gonadal Dysgenesis
HUMSCAD	ACADS	Short Chain Acyl-CoA Dehydrogenase Deficiency
HSALAS2R	ALAS2	Sideroblastic Anemia, X-Linked
T47846	GPC3	Simpson-Golabi-Behmel Syndrome
T11069	GUSB	Mucopolysaccharidosis Type VII
T08813	SPG3A	Hereditary Spastic Paraplegia, Dominant ;SPG 3
Z21409	SPG3A	Hereditary Spastic Paraplegia, Dominant ;SPG 3
M77964	SPG4	Hereditary Spastic Paraplegia, Dominant ;SPG 4
N36808	SMN1	Spinal Muscular Atrophy
Z38265	SMN1	Spinal Muscular Atrophy
T06490	SCA1	Spinocerebellar Ataxia Type 1
T55469	SCA2	Spinocerebellar Ataxia Type 2
Z41764	SCA2	Spinocerebellar Ataxia Type 2
T61453	MJD	Spinocerebellar Ataxia Type 3
HUMELASF	ELN	Cutis Laxa, Autosomal Dominant ;Supravalvular Aortic Stenosis
T05970	HEXA	Hexosaminidase A Deficiency
M79184	THRB	Thyroid Hormone Resistance
Z20729	TCOF1	Treacher Collins Syndrome
R48739	TRPS1	Trichorhinophalangeal Syndrome Type I
T77655	TSC1	Tuberous Sclerosis 1 ;Tuberous Sclerosis Complex
M78940	TSC2	Tuberous Sclerosis 2 ;Tuberous Sclerosis Complex
HSFAA	FAH	Tyrosinemia Type I
T39510	TBX3	Ulnar-Mammary Syndrome
HUMM7AA	MYO7A	Usher Syndrome Type 1
W22160	USH1C	Usher Syndrome Type 1
T08506	ACADVL	Very Long Chain Acyl-CoA Dehydrogenase Deficiency
HUMHIPLI ND	VHL	Von Hippel-Lindau Syndrome
HUMVWF	VWF	Von Willebrand Disease
HSU02368	PAX3	Waardenburg Syndrome Type I
N64051	WRN	Werner Syndrome
HUMWND	ATP7B	Wilson Disease
T40645	WAS	WAS-Related Disorders
HSLAL	LIPA	Wolman Disease
HSASL1	ASL	Argininosuccinicaciduria
HSAGAGEN E	AGA	Aspartylglycosaminuria
T88756	ATD	Asphyxiating Thoracic Dystrophy
Z19164	ASAH	Farber Disease
HUMALD	FBP1	Fructose 1,6 Bisphosphatase Deficiency
HSLDHAR	LDHA	Lactate Dehydrogenase Deficiency
M77886	LDHB	Lactate Dehydrogenase Deficiency
HSU13680	LDHC	Lactate Dehydrogenase Deficiency
Z46189	MAN2B1	Alpha-Mannosidosis

M79249	MANBA	Beta-Mannosidosis
H26723	GALNS	Mucopolysaccharidosis Type IVA
H23053	SLC26A4	DFNB 4 ;Enlarged Vestibular Aqueduct Syndrome ;Nonsyndromic Hearing Loss and Deafness, Autosomal Recessive ;Pendred Syndrome
HSPGK1	PGK1	Phosphoglycerate Kinase Deficiency
HSU08818	MET	Papillary Renal Carcinoma
M79231	PRCC	Papillary Renal Carcinoma
T08200	GNS	Mucopolysaccharidosis Type IIID
HUMNAGB	NAGA	Schindler Disease
T08881	NEU1	Mucopolipidosis I
R81783	SLC17A5	Free Sialic Acid Storage Disorders
HUMAUTO NH	MTATP6	Mitochondrial Disorders ;Mitochondrial DNA-Associated Leigh Syndrome and NARP
F09306	SCA7	Spinocerebellar Ataxia Type 7
AF248482	DAZ	Y Chromosome Infertility
HSU21663	DAZ	Y Chromosome Infertility
T47024	JAG1	Alagille Syndrome
HSRYRRM1	RBM1A1	Y Chromosome Infertility
HSRYRRM2	RBM1A1	Y Chromosome Infertility
HSVD3R	VDR	Osteoporosis ;Rickets-Alopecia Syndrome
T40157	FMO3	Trimethylaminuria
HUMPHOSL IP	PPGB	Galactosialidosis
HUMPPR	PPGB	Galactosialidosis
H22222	FANCC	Fanconi Anemia
D12009	RPS6KA3	Coffin-Lowry Syndrome
M78282	PTEN	PTEN Hamartoma Tumor Syndrome (PHTS)
M78802	FY	Duffy Antigen Genotyping
HSU04270	KCNH2	LQT 2 ;Romano-Ward Syndrome
T19733	SCN5A	Brugada Syndrome ;LQT 3 ;Romano-Ward Syndrome
HSTFIIDX	TBP	Spinocerebellar Ataxia Type17
HUMKCHA	KCNA1	Episodic Ataxia Type 1
HSU78110	NRTN	Hirschsprung Disease
HSET3AA	EDN3	Hirschsprung Disease
Z17351	ECE1	Hirschsprung Disease
T47284	DHCR7	Smith-Lemli-Opitz Syndrome
HUMXIHb	HBZ	Alpha-Thalassemia
HSCP2	CP	Aceruloplasminemia
N25320	CLN6	CLN6-Related Neuronal Ceroid-Lipofuscinosis ;Neuronal Ceroid-Lipofuscinoses
T11340	NBS1	Nijmegen Breakage Syndrome
Z40114	NBS1	Nijmegen Breakage Syndrome
HSU03688	CYP1B1	Glaucoma, Recessive (Congenital) ;Peters Anomaly
D62980	MYOC	Glaucoma, Dominant (Juvenile Onset)
T98453	NAGLU	Mucopolysaccharidosis Type IIIB
AA779817	RUNX2	Cleidocranial Dysplasia
HUMCBFA	RUNX2	Cleidocranial Dysplasia
HSMAREN O	MEFV	Familial Mediterranean Fever
F02180	PHKB	Phosphorylase Kinase Deficiency of Liver and Muscle
D11905	HPS1	Hermansky-Pudlak Syndrome ;Hermansky-Pudlak Syndrome I
R95987	CRX	Retinitis Pigmentosa, Autosomal Dominant
T05762	EVC	Ellis-van Creveld Syndrome

T12126	FLNA	Frontometaphyseal Dysplasia ;Melnick-Needles Syndrome ;Otopalatodigital Syndrome ;Periventricular Heterotopia, X-Linked
T60913	EBP	Chondrodysplasia Punctata, X-Linked Dominant
HSHNF4	HNF4A	Maturity-Onset Diabetes of the Young Type I
HUMBGLU KIN	GCK	Familial Hyperinsulinism ;GCK-Related Hyperinsulinism ;Maturity-Onset Diabetes of the Young Type II
M62026	GCK	Familial Hyperinsulinism ;GCK-Related Hyperinsulinism ;Maturity-Onset Diabetes of the Young Type II
R94860	CIAS1	Chronic Infantile Neurological Cutaneous and Articular Syndrome ;Familial Cold Urticaria ;Muckle-Wells Syndrome
T08221	SMARCA1	Schimke Immunoosseous Dysplasia
T95621	SLC25A15	Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome
HUMOATC	OAT	Ornithine Aminotransferase Deficiency
R08989	MLYCD	Malonyl-CoA Decarboxylase Deficiency
N35888	PMM2	Congenital Disorders of Glycosylation
HSRPMI	MPI	Congenital Disorders of Glycosylation
HSSRECV6	MGAT2	Congenital Disorders of Glycosylation
T91755	MGAT2	Congenital Disorders of Glycosylation
HSCPTI	CPT1A	Carnitine Palmitoyltransferase IA (liver) Deficiency
D12096	CPT2	Carnitine Palmitoyltransferase II Deficiency
HSA1ATCA	SERPINA1	Alpha-1-Antitrypsin Deficiency
N36808	SMN2	Spinal Muscular Atrophy
Z38265	SMN2	Spinal Muscular Atrophy
HUMACAD L	ACADL	Long Chain Acyl-CoA Dehydrogenase Deficiency
Z25247	CACT	Carnitine-Acylcarnitine Translocase Deficiency
HUMETFA	ETFA	Glutaricacidemia Type 2
HSETFBS	ETFB	Glutaricacidemia Type 2
S69232	ETFDH	Glutaricacidemia Type 2
T09377	MEB	Muscle-Eye-Brain Disease
Z40427	G6PT1	Glycogen Storage Disease Type Ib
AI002801	SLC14A1	Kidd Genotyping
Z19313	SLC14A1	Kidd Genotyping
HUMPGAM M	PGAM2	Phosphoglycerate Mutase Deficiency
H86930	MPP4	Retinitis Pigmentosa, Autosomal Recessive
HSU14910	RGR	Retinitis Pigmentosa, Autosomal Recessive
AA775466	CARD15	Crohn Disease
AA306952	GAN	Giant Axonal Neuropathy
T99245	CLCN5	Dent Disease
T23537	NR3C2	Pseudohypoaldosteronism Type 1, Dominant
HSLASNA	SCNN1A	Pseudohypoaldosteronism Type 1, Recessive
H26938	SCNN1B	Pseudoaldosteronism ;Pseudohypoaldosteronism Type 1, Recessive
HUMGAMM	SCNN1G	Pseudoaldosteronism ;Pseudohypoaldosteronism Type 1, Recessive
HSP450AL	CYP11B2	Familial Hyperaldosteronism Type 1 ;Familial Hypoaldosteronism Type 2
HUMCYPA DA	CYP11B1	Familial Hyperaldosteronism Type 1
AF017089	COL11A1	Stickler Syndrome ;Stickler Syndrome Type II

HUMCA1XI A	COL11A1	Stickler Syndrome ;Stickler Syndrome Type II
HUMA2XIC OL	COL11A2	Stickler Syndrome
S61523	PIGA	Paroxysmal Nocturnal Hemoglobinuria
T58881	PHKA2	Glycogen Storage Disease Type IX
Z39614	DHAPAT	Rhizomelic Chondrodysplasia Punctata Type 2
N89899	SH2D1A	Lymphoproliferative Disease, X-Linked
HUMUGT1F A	UGT1A1	Gilbert Syndrome
HUMNC1A	COL7A1	Epidermolysis Bullosa Dystrophica, Bart Type ;Epidermolysis Bullosa Dystrophica, Cockayne-Touraine Type ;Epidermolysis Bullosa Dystrophica, Hallopeau-Siemens Type ;Epidermolysis Bullosa Dystrophica, Pasini Type ;Epidermolysis Bullosa, Pretibial
T49684	ITGB4	Epidermolysis Bullosa Letalis with Pyloric Atresia
S66196	ITGA6	Epidermolysis Bullosa Letalis with Pyloric Atresia
T10988	LAMC2	Epidermolysis Bullosa Junctional, Herlitz-Pearson Type
HUMLAMA A	LAMA3	Epidermolysis Bullosa Junctional, Herlitz-Pearson Type
Z24848	LAMA3	Epidermolysis Bullosa Junctional, Herlitz-Pearson Type
T10484	LAMB3	Epidermolysis Bullosa Junctional, Disentis Type ;Epidermolysis Bullosa Junctional, Herlitz-Pearson Type
HUMBP180 AA	COL17A1	Epidermolysis Bullosa Junctional, Disentis Type
M78889	PLEC1	Epidermolysis Bullosa with Muscular Dystrophy
Z38659	SLC22A5	Carnitine Deficiency, Systemic
T85099	CTNS	Cystinosis
W27253	CNGA3	Achromatopsia ;Achromatopsia 2
HSU66088	SLC5A5	Thyroid Hormonogenesis Defect I
HUMTEKRP TK	TEK	Venous Malformation, Multiple Cutaneous and Mucosal
R69741	SLC26A2	Achondrogenesis Type 1B ;Atelosteogenesis Type 2 ;Diastrophic Dysplasia ;Multiple Epiphyseal Dysplasia, Recessive
R70146	PEX10	Zellweger Syndrome Spectrum
S55790	COL4A3	Alport Syndrome ;Alport Syndrome, Autosomal Recessive
HSCOL4A4	COL4A4	Alport Syndrome ;Alport Syndrome, Autosomal Recessive
T10559	SHFM3	Ectrodactyly
T99040	FANCA	Fanconi Anemia
H47777	FANCB	Fanconi Anemia
AA542822	FANCE	Fanconi Anemia
HUMPSPB	PSAP	Metachromatic Leukodystrophy
HUMSAPA1	PSAP	Metachromatic Leukodystrophy
S69686	PSAP	Metachromatic Leukodystrophy
AA252786	NCF1	Chronic Granulomatous Disease
HUMNCF1A	NCF1	Chronic Granulomatous Disease
HSTGFB1	TGFB1	Camurati-Engelmann Disease
R24242	CYBA	Chronic Granulomatous Disease
HUMNOXF	NCF2	Chronic Granulomatous Disease
S41458	PDE6B	Retinitis Pigmentosa, Autosomal Recessive
AA002150	PDE6B	Retinitis Pigmentosa, Autosomal Recessive
R21727	DYSF	Dysferlinopathy ;Limb-Girdle Muscular Dystrophies, Autosomal Recessive
AF055580	USH2A	Usher Syndrome Type 2 ;Usher Syndrome Type 2A

N36632	MITF	Waardenburg Syndrome Type II ; Waardenburg Syndrome Type IIA
M78027	MYH9	DFNA 17 ; Epstein Syndrome ; Fechtner Syndrome ; May-Hegglin Anomaly ; Sebastian Syndrome
Z40194	HPS4	Hermansky-Pudlak Syndrome
AA333774	GP1BA	Platelet Antigen Genotyping
M79110	GP1BB	Platelet Antigen Genotyping
HUMGPIIB A	ITGA2B	Platelet Antigen Genotyping
T29174	ITGA2	Glycoprotein 1a Deficiency ; Platelet Antigen Genotyping
HSGST4	GSTM1	Lung Cancer
AA773443	CHEK2	Li-Fraumeni Syndrome
T78869	CHEK2	Li-Fraumeni Syndrome
T03839	SH3BP2	Cherubism
T67412	IRF6	IRF6-Related Disorders
AB037973	FGF23	Hypophosphatemic Rickets, Dominant
T60199	FBLN5	Cutis Laxa, Autosomal Recessive
T03890	ARX	ARX-Related Disorders
M79175	NSD1	Sotos Syndrome
T07860	NSD1	Sotos Syndrome
M79181	COH1	Cohen Syndrome
MIHS75KD A	NDUFS1	Leigh Syndrome (nuclear DNA mutation) ; Mitochondrial Respiratory Chain Complex I Deficiency
T09312	NDUFV1	Leigh Syndrome (nuclear DNA mutation) ; Mitochondrial Respiratory Chain Complex I Deficiency
AA399371	SALL4	Acrorenooocular Syndrome ; Okiihiro Syndrome
HUMA8SEQ	TIMP3	Pseudoinflammatory Fundus Dystrophy
Z40623	GDAP1	Charcot-Marie-Tooth Neuropathy Type 4 ; Charcot-Marie-Tooth Neuropathy Type 4A
AA128030	FOXL2	Blepharophimosis, Epicanthus Inversus, Ptosis
HUMCRTR	SLC6A8	Creatine Deficiency Syndrome, X-Linked
T08882	JPH3	Huntington Disease-Like 2
T07283	SNRPN	Autistic Disorder ; Pervasive Developmental Disorders
Z38837	SPR	Sepiapterin Reductase Deficiency (SR)
HUMANTIR	AGTR1	Angiotensin II Receptor, Type 1
T46961	SEPN1	Congenital Muscular Dystrophy with Early Spine Rigidity ; Multiminicore Disease
Z43954	TRIM32	Limb-Girdle Muscular Dystrophies, Autosomal Recessive
Z19219	TTID	Limb-Girdle Muscular Dystrophies, Autosomal Dominant
HSECADH	CDH1	Hereditary Diffuse Gastric Cancer
Z41199	WFS1	Nonsyndromic Low-Frequency Sensorineural Hearing Loss ; Wolfram Syndrome
HUMLORA A	LOR	Progressive Symmetric Erythrodermatoderma
Z38324	HR	Alopecia Universalis ; Papular Atrichia
T09039	RYR1	Central Core Disease of Muscle ; Malignant Hyperthermia Susceptibility ; Multiminicore Disease
T10442	GALE	Galactose Epimerase Deficiency
D82541	PDB2	Paget Disease of Bone
HSU20759	CASR	Autosomal Dominant Hypocalcemia ; Familial Hypocalciuric Hypercalcemia, Type I ; Familial Isolated Hypoparathyroidism ; Neonatal Severe Primary Hyperparathyroidism
AA071082	SALL1	Townes-Brocks Syndrome

T81692	EDAR	Hypohidrotic Ectodermal Dysplasia ;Hypohidrotic Ectodermal Dysplasia, Autosomal
HUMHPA1B	HP	Anhaptoglobinemia
HSU01922	TIMM8A	Deafness-Dystonia-Optic Neuronopathy Syndrome
HUMHSDI	HSD3B2	Prostate Cancer
HSU05659	HSD17B3	Prostate Cancer
Z38915	NPHP4	Nephronophthisis 4 ;Senior-Loken Syndrome
HSC1INHR	SERPING1	Hereditary Angioneurotic Edema
D62739	BBS7	Bardet-Biedl Syndrome
T64266	SLC7A7	Lysinuric Protein Intolerance
S52028	CTH	Cystathioninuria
Z30254	EFEMP1	Doyne Honeycomb Retinal Dystrophy ;Patterned Dystrophy of Retinal Pigment Epithelium
D59254	ELOVL4	Stargardt Disease 3
S43856	GCH1	Dopa-Responsive Dystonia ;GTP Cyclohydrolase 1-Deficient DRD ;GTP Cyclohydrolase-1 Deficiency (GTPCH)
M78468	PAFAH1B 1	17-Linked Lissencephaly
M78473	PAFAH1B 1	17-Linked Lissencephaly
S51033	MID1	Opitz Syndrome, X-Linked
Z40343	MID1	Opitz Syndrome, X-Linked
HUM6PTHS	PTS	Pyruvoyltetrahydropterin Synthase Deficiency
M62103	CIRH1A	North American Indian Childhood Cirrhosis
HSDHPR	QDPR	Dihydropteridine Reductase Deficiency (DHPR)
T23665	FKRP	Congenital Muscular Dystrophy Type 1C ;Limb-Girdle Muscular Dystrophies, Autosomal Recessive
T60498	LRPPRC	Leigh Syndrome, French-Canadian Type
BG772870	LRPPRC	Leigh Syndrome, French-Canadian Type
HSACHRA	CHRNA1	Congenital Myasthenic Syndromes
HSACHRB	CHRNA1	Congenital Myasthenic Syndromes
HSACHRG	CHRNA1	Congenital Myasthenic Syndromes
HSACETR	CHRNA1	Congenital Myasthenic Syndromes
HSACRAP	CHRNA1	Congenital Myasthenic Syndromes
M78334	COLQ	Congenital Myasthenic Syndromes
S56138	CHAT	Congenital Myasthenic Syndromes
D11584	SDHC	Familial Nonchromaffin Paragangliomas
HSPSTI	SPINK1	Hereditary Pancreatitis
HSSPROTR	PROS1	Protein S Heerlen Variant
HUMLAP	ITGB2	Leukocyte Adhesion Deficiency, Type 1
T12572	ADAMTS1 3	Familial Thrombotic Thrombocytopenia Purpura
HUMCOMII P	SDHB	Carotid Body Tumors and Multiple Extraadrenal Pheochromocytomas
NM005912	MC4R	Obesity
HUMPAX8 A	PAX8	Congenital Hypothyroidism
AA037119	FOXE1	Bamforth-Lazarus Syndrome ;Congenital Hypothyroidism
AV754057	FSHB	Isolated Follicle Stimulating Hormone Deficiency
HUMHOME OA	PCBD	Pterin-4a Carbinolamine Dehydratase Deficiency (PCD)
HSTHR	TH	Dopa-Responsive Dystonia ;Tyrosine Hydroxylase-Deficient DRD
AA219596	ZIC3	Heterotaxy Syndrome

HSU20324	CSRP3	Dilated Cardiomyopathy
HUMPHLAM	PLN	Dilated Cardiomyopathy
F10219	ALMS1	Alstrom Syndrome
T06612	VCL	Dilated Cardiomyopathy
AF388366	USH3A	Usher Syndrome Type 3
Z40797	SGCE	Myoclonus-Dystonia
T08448	RAB7	Charcot-Marie-Tooth Neuropathy Type 2
D12383	GARS	Charcot-Marie-Tooth Neuropathy Type 2
Z36734	HRPT2	HRPT2-Related Disorders
H19914	EDARAD D	Hypohidrotic Ectodermal Dysplasia ;Hypohidrotic Ectodermal Dysplasia, Autosomal
T08852	PPT1	Neuronal Ceroid-Lipofuscinoses ;PPT1-Related Neuronal Ceroid- Lipofuscinosis
HUMDRA	SLC26A3	Familial Chloride Diarrhea
R16324	AGPAT2	Berardinelli-Seip Congenital Lipodystrophy
Z41967	BSCL2	Berardinelli-Seip Congenital Lipodystrophy
W28410	OPN1MW	Blue-Mono-Cone-Monochromatic Type Colorblindness
T27896	OPN1LW	Blue-Mono-Cone-Monochromatic Type Colorblindness
AI469991	PHOX2A	Congenital Fibrosis of Extraocular Muscles
HSFSTHR	FSHR	Premature Ovarian Failure, Autosomal Recessive
HSLPH	LCT	Hypolactasia, Adult Type
Z41000	BCS1L	Gracile Syndrome ;Mitochondrial Respiratory Chain Complex III Deficiency
HSCGJP	GJA1	Oculodentodigital Dysplasia
HSPERFP1	PRF1	Familial Hemophagocytic Lymphohistiocytosis 2
M78112	GLUD1	Familial Hyperinsulinism ;GLUD1-Related Hyperinsulinism
Z39336	GLUD1	Familial Hyperinsulinism ;GLUD1-Related Hyperinsulinism
W79230	RAX	Anophthalmia
AF041339	PITX3	Anophthalmia
AA151708	HESX1	Anophthalmia
HSSOXB	SOX3	Anophthalmia ;Mental Retardation, X-Linked, with Growth Hormone Deficiency
HUMHMGBOX	SOX2	Anophthalmia
HSGM2APA	GM2A	GM2 Activator Deficiency
Z19280	GLC1E	Glaucoma, Dominant (Adult Onset)
T20165	PHF6	Borjeson-Forssman-Lehmann Syndrome
Z40394	CMT4B2	Charcot-Marie-Tooth Neuropathy Type 4
HUMIHH	IHH	Brachydactyly Type A1
HUMCDPK	CDK4	Familial Malignant Melanoma
T39355	SBDS	Shwachman-Diamond Syndrome
HSHMPLK	MPL	Amegakaryocytic Thrombocytopenia, Congenital
Z38860	TRIM37	Mulibrey Nanism
M62027	DTNA	Familial Isolated Noncompaction of Left Ventricular Myocardium
Z39175	DDB2	Xeroderma Pigmentosum
T09329	MUTYH	MYH-Associated Polyposis
HUMAPA	APP	Alzheimer Disease Type 1 ;Early-Onset Familial Alzheimer Disease
M79090	GSS	5-Oxoprolinuria
Z26981	OXCT	3-Oxoacid CoA Transferase
D12046	PMS1	Hereditary Non-Polyposis Colon Cancer
T08186	PMS2	Hereditary Non-Polyposis Colon Cancer
R20984	MSH6	Hereditary Non-Polyposis Colon Cancer

T60457	NDUFS4	Leigh Syndrome (nuclear DNA mutation) ;Mitochondrial Respiratory Chain Complex I Deficiency
D30864	NDUFS8	Leigh Syndrome (nuclear DNA mutation)
M78107	SDHA	Leigh Syndrome (nuclear DNA mutation)
R15290	NDUFS7	Leigh Syndrome (nuclear DNA mutation)
HUMPCBA	PC	Pyruvate Carboxylase Deficiency
R11095	AASS	Hyperlysinemia
T23789	PEX3	Zellweger Syndrome Spectrum
T09086	STK11	Peutz-Jeghers Syndrome
T87335	HAL	Histidinemia
Z19082	ALDH4A1	Hyperprolinemia, Type II
Z25227	MADH4	Juvenile Polyposis Syndrome
M78130	XPB	Xeroderma Pigmentosum
T08987	XPD	Xeroderma Pigmentosum
D81449	XPF	Xeroderma Pigmentosum
HSXPGAA	XPG	Xeroderma Pigmentosum
HSAUHR	AUH	3-Methylglutaconic Aciduria Type 1
T19530	MMAB	Methylmalonicaciduria
Z40169	MMAA	Methylmalonicaciduria
T93695	BCAT1	Hyperleucine-Isoleucinemia
Z41266	BCAT2	Hyperleucine-Isoleucinemia
HSU03506	SLC1A1	Dicarboxylicaminoaciduria
R88591	PRODH	Hyperprolinemia, Type I
T05380	EPM2A	Progressive Myoclonus Epilepsy, Lafora Type
T27227	FANCF	Fanconi Anemia
H49070	FANCF	Fanconi Anemia
Z41736	FANCG	Fanconi Anemia
R66178	ED4	Ectodermal Dysplasia, Margarita Island Type
L25197	KCNE1	Jervell and Lange-Nielsen Syndrome ;LQT 5 ;Romano-Ward Syndrome
HUMUMOD	UMOD	Familial Nephropathy with Gout ;Medullary Cystic Kidney Disease 2
HSU66583	CRYGD	Cataract, Crystalline Aculeiform
HSPHR	PTHR1	Chondrodysplasia, Blomstrand Type
T97980	MTRR	Homocystinuria-Megaloblastic Anemia
S60710	ADSL	Adenylosuccinase deficiency
Z38216	SLC25A19	Amish Lethal Microcephaly
T35049	SLC25A19	Amish Lethal Microcephaly
T11501	DBH	Dopamine Beta-Hydroxylase Deficiency
H11439	NLGN3	Autistic Disorder ;Pervasive Developmental Disorders
R12551	NLGN4	Autistic Disorder ;Pervasive Developmental Disorders
M78212	ATP1A2	Familial Hemiplegic Migraine
T96957	SPCH1	Severe Speech Delay
AI266171	PHOX2B	Congenital Central Hypoventilation Syndrome
BG723199	DSG4	Localized Autosomal Recessive Hypotrichosis
T46918	HSD11B2	Apparent Mineralocorticoid Excess Syndrome
HUMFERLS	FTL	Hyperferritinemia Cataract Syndrome
HUMCKRA SA	KRAS2	Familial Pancreatic Cancer
S39383	PTPN11	LEOPARD Syndrome ;Noonan Syndrome
HUMSTAR	STAR	Cholesterol Desmolase Deficiency
Z20453	STAR	Cholesterol Desmolase Deficiency
HUMVPC	AVP	Neurohypophyseal Diabetes Insipidus
M62144	MECP2	Rett Syndrome
HSCA2VR	COL5A2	Ehlers-Danlos Syndrome, Classic Type

HUMGENX	TNXB	Ehlers-Danlos-like Syndrome Due to Tenascin-X Deficiency
R02385	TNXB	Ehlers-Danlos-like Syndrome Due to Tenascin-X Deficiency
T39901	LITAF	Charcot-Marie-Tooth Neuropathy Type 1
AA621310	FOXE3	Anophthalmia
H18132	CFC1	Heterotaxy Syndrome
R36719	EBAF	Heterotaxy Syndrome
HSACTIURE	ACVR2B	Heterotaxy Syndrome
T52017	CRELD1	Heterotaxy Syndrome
D11851	LMNA	Dilated Cardiomyopathy ;Emery-Dreifuss Muscular Dystrophy, Autosomal Dominant ;Familial Partial Lipodystrophy, Dunnigan Type ;Hutchinson-Gilford Progeria Syndrome ;Limb-Girdle Muscular Dystrophies, Autosomal Dominant ;Mandibuloacral Dysplasia
D12062	DSP	Cardiomyopathy, Dilated, with Woolly Hair and Keratoderma ;Keratosis Palmoplantaris Striata
H99382	MSH3	Hereditary Non-Polyposis Colon Cancer
AW205295	NOG	Multiple Synostoses Syndrome
AA135181	GJB3	Erythrokeratoderma Variabilis
F10278	PEO1	Mitochondrial DNA Deletion Syndromes
M62022	MASS1	Febrile Seizures
HUMQBPC A	UQCRB	Mitochondrial Respiratory Chain Complex III Deficiency
HUMEGR2 A	EGR2	Charcot-Marie-Tooth Neuropathy Type 1 ;Charcot-Marie-Tooth Neuropathy Type 1D ;Charcot-Marie-Tooth Neuropathy Type 4 ;Charcot-Marie-Tooth Neuropathy Type 4E
HSFLT4X	FLT4	Milroy Congenital Lymphedema
Z24968	PEX26	Zellweger Syndrome Spectrum
AA338362	ANKH	Craniometaphyseal Dysplasia, Dominant
HUMRPS24 A	RPS19	Diamond-Blackfan Anemia
T11633	RPS19	Diamond-Blackfan Anemia
HSACMHCP	MYH7	Dilated Cardiomyopathy ;Familial Hypertrophic Cardiomyopathy
Z25920	TNNT2	Dilated Cardiomyopathy ;Familial Hypertrophic Cardiomyopathy
HUMTRO	TPM1	Dilated Cardiomyopathy ;Familial Hypertrophic Cardiomyopathy
Z18303	MYBPC3	Dilated Cardiomyopathy ;Familial Hypertrophic Cardiomyopathy
HSU09466	COX10	Leigh Syndrome (nuclear DNA mutation)
S72487	ECGF1	Mitochondrial Neurogastrointestinal Encephalopathy Syndrome
M62196	KIF5A	Hereditary Spastic Paraplegia, Dominant
T07578	KIF5A	Hereditary Spastic Paraplegia, Dominant
D11648	HSPD1	Hereditary Spastic Paraplegia, Dominant
T47330	SOX18	Hypotrichosis-Lymphedema-Telangiectasia Syndrome
AA448334	CAV3	Caveolinopathy ;Limb-Girdle Muscular Dystrophies, Autosomal Dominant
AW071529	ALX4	Parietal Foramina 2
M61973	CD2AP	Focal Segmental Glomerulosclerosis
W21801	NR2E3	Enhanced S-Cone Syndrome

Z20305	TREM2	PLOSL
T05421	ANK2	LQT 4 ;Romano-Ward Syndrome
HUMROR2 A	ROR2	ROR2-Related Disorders
Z25920	CMD1D	Dilated Cardiomyopathy
AA887962	HLXB9	Currarino Syndrome
R00281	ALDH5A1	Succinic Semialdehyde Dehydrogenase Deficiency
HSPCCAR	PCCA	Propionic Acidemia
N43992	DLL3	Spondylocostal Dysostosis, Autosomal Recessive ;Syndactyly, Type IV
Z39790	MUT	Methylmalonicaciduria
HUMARGL	ARG1	Argininemia
M78631	SLC3A1	Cystinuria
T80665	SLC7A9	Cystinuria
T27286	HGD	Alkaptonuria
HUMBCKD H	BCKDHA	Maple Syrup Urine Disease
HUMBCKD HA	BCKDHB	Maple Syrup Urine Disease
HSTRANSP	DBT	Maple Syrup Urine Disease
Z44722	HLCS	Holocarboxylase Synthetase Deficiency
Z38396	BTB	Biotinidase Deficiency
T48178	POMT1	Walker-Warburg Syndrome
T28737	GJB2	DFNA 3 Nonsyndromic Hearing Loss and Deafness ;DFNB 1 Nonsyndromic Hearing Loss and Deafness ;GJB2-Related DFNA 3 Nonsyndromic Hearing Loss and Deafness ;GJB2-Related DFNB 1 Nonsyndromic Hearing Loss and Deafness ;Nonsyndromic Hearing Loss and Deafness, Autosomal Dominant ;Nonsyndromic Hearing Loss and Deafness, Autosomal Recessive ;Vohwinkel Syndrome
T05861	COCH	DFNA 9 (COCH) ;Nonsyndromic Hearing Loss and Deafness, Autosomal Dominant
HSBRN4	POU3F4	DFN 3
HSU21938	TPPA	Ataxia with Vitamin E Deficiency (AVED)
T93783	KIAA1985	Charcot-Marie-Tooth Neuropathy Type 4
BE735997	SANS	Usher Syndrome Type 1
AA548783	HOXD13	Syndactyly, Type II
R33750	HOXA13	Hand-Foot-Uterus Syndrome
HUMPP	GLDC	GLDC-Related Glycine Encephalopathy ;Glycine Encephalopathy
F04230	AMT	AMT-Related Glycine Encephalopathy ;Glycine Encephalopathy
T54795	DECR	2,4-Dienoyl-CoA Reductase Deficiency
R07295	ACAT1	Ketothiolase Deficiency
S70578	ACAT1	Ketothiolase Deficiency
HUMMEVK IN	MVK	Hyper IgD Syndrome ;Mevalonicaciduria
T11245	HMGCL	3-Hydroxy-3-Methylglutaryl-Coenzyme A Lyase Deficiency
Z41427	GCDH	Glutaricacidemia Type 1
HSSHXA	SHOX	Langer Mesomelic Dwarfism ;Leri-Weill Dyschondrosteosis ;Short Stature
HUMDOPA DC	DDC	Aromatic L-Amino Acid Decarboxylase Deficiency

HSCOL3A4	COL6A3	Limb-Girdle Muscular Dystrophies, Autosomal Dominant
HSCOL1A4	COL6A1	Limb-Girdle Muscular Dystrophies, Autosomal Dominant
HSCOL2C2	COL6A2	Limb-Girdle Muscular Dystrophies, Autosomal Dominant
H16770	RECQL4	Rothmund-Thomson Syndrome
H11473	SGSH	Mucopolysaccharidosis Type IIIA
H67137	MCCC1	3-Methylcrotonyl-CoA Carboxylase Deficiency
R88931	MCCC2	3-Methylcrotonyl-CoA Carboxylase Deficiency
Z24865	TCAP	Dilated Cardiomyopathy ;Limb-Girdle Muscular Dystrophies, Autosomal Recessive
M86030	DCX	DCX-Related Malformations
HUMACTA SK	ACTA1	Nemaline Myopathy
HSDBGIGLY	DSG1	Keratosis Palmoplantaris Striata
HSRETS	SAG	Retinitis Pigmentosa, Autosomal Recessive
HSAPHOL	ALPL	Hypophosphatasia
N73784	XPA	Xeroderma Pigmentosum
T28958	XPC	Xeroderma Pigmentosum
N69543	POLH	Xeroderma Pigmentosum
T54103	POLH	Xeroderma Pigmentosum
H56484	CKN1	Cockayne Syndrome
Z38185	ERCC6	Cockayne Syndrome
F07041	PI12	Familial Encephalopathy with Neuroserpin Inclusion Bodies
AA633404	KCNE2	LQT 6 ;Romano-Ward Syndrome
AF302095	KCNE2	LQT 6 ;Romano-Ward Syndrome
HSTITINC2	CMD1G	Dilated Cardiomyopathy
N99115	NPHP1	Nephronophthisis 1 ;Senior-Loken Syndrome
HUMELAN AA	ELA2	ELA2-Related Neutropenia
S67325	PCCB	Propionic Acidemia
HSGA7331	MIS1	Corneal Dystrophy, Gelatinous Drop-Like
HSACE	ACE	Angiotensin I Converting Enzyme 1
S49816	TSHR	Congenital Hypothyroidism ;Familial Non-Autoimmune Hyperthyroidism
Z30221	VMGLOM	Multiple Glomus Tumors
H88042	COL9A3	Multiple Epiphyseal Dysplasia, Dominant
M78119	ADA	Adenosine Deaminase Deficiency
T55785	GAMT	Guanidinoacetate Methyltransferase Deficiency
HUMCST4B A	CSTB	Myoclonic Epilepsy of Unverricht and Lundborg
S73196	AQP2	Nephrogenic Diabetes Insipidus ;Nephrogenic Diabetes Insipidus, Autosomal
HSU76388	NR5A1	XY Sex Reversal with Adrenal Failure
HSCPHC22	MTRNR1	MTRNR1-Related Hearing Loss and Deafness
H21596	PPARG	Diabetes Mellitus with Acanthosis Nigricans and Hypertension
D56550	FOXC1	Anophthalmia ;Rieger Syndrome
M78868	AP3B1	Hermansky-Pudlak Syndrome
T47068	NOTCH3	CADASIL
HSHMF1C	TCF1	Maturity-Onset Diabetes of the Young Type III
AA223508	TCF1	Maturity-Onset Diabetes of the Young Type III
AF049893	IPF1	Maturity-Onset Diabetes of the Young Type IV
HSU30329	IPF1	Maturity-Onset Diabetes of the Young Type IV
HSVHNF1	TCF2	Maturity-Onset Diabetes of the Young Type V
HUMLDLRF	LDLR	Familial Hypercholesterolemia

MT		
HSAPOBR2	APOB	Familial Hypercholesterolemia Type B
T78010	ABCB7	Sideroblastic Anemia and Ataxia
AF076215	PROP1	PROP1-Related Combined Pituitary Hormone Deficiency
S99468	ALAD	Acute Hepatic Porphyria
T61818	ABCC2	Dubin-Johnson Syndrome
HUMLCAT	LCAT	Lecithin Cholesterol Acyltransferase Deficiency
Z38510	HADHSC	Short Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, Liver
AF041240	PPOX	Variegate Porphyria
T77011	PPOX	Variegate Porphyria
Z40014	ALDH10	Sjogren-Larsson Syndrome
S79867	KRT16	Nonepidermolytic Palmoplantar Hyperkeratosis ;Pachyonychia Congenita
HUMKER56 K	KRT6A	Pachyonychia Congenita
HSKERELP	KRT17	Pachyonychia Congenita ;Steatocystoma Multiplex
R11850	KRT6B	Pachyonychia Congenita
S69510	KRT9	Epidermolytic Palmoplantar Keratoderma
HSCYTK	KRT13	White Sponge Nevus of Cannon
T92918	KRT4	White Sponge Nevus of Cannon
S54769	SPG7	Hereditary Spastic Paraplegia, Recessive ;SPG 7
T50707	FECH	Erythropoietic Protoporphyrria
HUMPOMM	PXMP3	Zellweger Syndrome Spectrum
R05392	PEX6	Zellweger Syndrome Spectrum
Z38759	PEX12	Zellweger Syndrome Spectrum
R14480	PEX16	Zellweger Syndrome Spectrum
R10031	PEX13	Zellweger Syndrome Spectrum
R13532	PXF	Zellweger Syndrome Spectrum
Z30136	AGPS	Rhizomelic Chondrodysplasia Punctata Type 3
HSU07866	ACOX	Pseudoneonatal Adrenoleukodystrophy
N63143	ALG6	Congenital Disorders of Glycosylation
HSTNFR1A	TNFRSF1 A	Familial Hibernian Fever
AA018811	RP1	Retinitis Pigmentosa, Autosomal Dominant
HSG11	RP1	Retinitis Pigmentosa, Autosomal Dominant
T07942	RP1	Retinitis Pigmentosa, Autosomal Dominant
H28658	PRPF31	Retinitis Pigmentosa, Autosomal Dominant
T07062	PRPF8	Retinitis Pigmentosa, Autosomal Dominant
T05573	RP18	Retinitis Pigmentosa, Autosomal Dominant
HUMNRLG P	NRL	Retinitis Pigmentosa, Autosomal Dominant
T87786	CRB1	Retinitis Pigmentosa, Autosomal Recessive
H92408	TULP1	Retinitis Pigmentosa, Autosomal Recessive
S42457	CNGA1	Retinitis Pigmentosa, Autosomal Recessive
H30568	PDE6A	Retinitis Pigmentosa, Autosomal Recessive
M78192	RLBP1	Retinitis Pigmentosa, Autosomal Recessive ;Retinitis Pigmentosa, Autosomal Recessive, Bothnia Type
T10761	SLC4A4	Proximal Renal Tubular Acidosis with Ocular Abnormalities

N64339	GJB6	DFNA 3 Nonsyndromic Hearing Loss and Deafness ;DFNB 1 Nonsyndromic Hearing Loss and Deafness ;GJB6-Related DFNB 1 Nonsyndromic Hearing Loss and Deafness ;GJB6-Related DFNA 3 Nonsyndromic Hearing Loss and Deafness ;Hidrotic Ectodermal Dysplasia 2 ;Nonsyndromic Hearing Loss and Deafness, Autosomal Dominant ;Nonsyndromic Hearing Loss and Deafness, Autosomal Recessive
T67968	MAT1A	Isolated Persistent Hypermethioninemia
HUMUMPS	UMPS	Oroticaciduria
HSPNP	NP	Purine Nucleoside Phosphorylase Deficiency
AB006682	AIRE	Autoimmune Polyendocrinopathy Syndrome Type 1
BE871354	JUP	Naxos Disease
T08214	JUP	Naxos Disease
F00120	DES	Dilated Cardiomyopathy
R28506	MOCS1	Molybdenum Cofactor Deficiency
T70309	MOCS2	Molybdenum Cofactor Deficiency
T08212	SNCA	Parkinson Disease
R99091	ABCC6	Pseudoxanthoma Elasticum
T69749	ABCC6	Pseudoxanthoma Elasticum
AA207040	PRG4	Arthropathy Camptodactyly Syndrome
T57014	PRG4	Arthropathy Camptodactyly Syndrome
F07016	OPPG	Osteoporosis Pseudoglioma Syndrome
H27782	SCO2	Fatal Infantile Cardioencephalopathy due to COX Deficiency
S54705S1	PRKAR1A	Carney Complex
Z25903	SCA10	Spinocerebellar Ataxia Type10
AA592984	WISP3	Progressive Pseudorheumatoid Arthropathy of Childhood
Z39666	MCOLN1	Mucopolidosis IV
HSEMX2	EMX2	Familial Schizencephaly
HUMSP18A	SFTPB	Pulmonary Surfactant Protein B Deficiency
Z40188	ATP8B1	Benign Recurrent Intrahepatic Cholestasis ;Progressive Familial Intrahepatic Cholestasis ;Progressive Familial Intrahepatic Cholestasis 1
U46845	CYP27B1	Pseudovitamin D Deficiency Rickets
Z21585	MAPT	Frontotemporal Dementia with Parkinsonism-17
HSPPD	HPD	Tyrosinemia Type III
HUMUGT1F A	UGT1A	Crigler-Najjar Syndrome
R20880	SLC19A2	Thiamine-Responsive Megaloblastic Anemia Syndrome
H42203	TFAP2B	Char Syndrome
Z30126	RYR2	Catecholaminergic Ventricular Tachycardia, Autosomal Dominant
HSSPYRAT	AGXT	Hyperoxaluria, Primary, Type 1
T80758	SEDL	Spondyloepiphyseal Dysplasia Tarda, X-Linked
T89449	SEDL	Spondyloepiphyseal Dysplasia Tarda, X-Linked
AA373083	FOXC2	Lymphedema with Distichiasis
HUMPROP2 AB	SCA12	Spinocerebellar Ataxia Type12
Z30145	ACTC	Dilated Cardiomyopathy
HS1900	GDNF	Hirschsprung Disease
M62223	NEFL	Charcot-Marie-Tooth Neuropathy Type 1F/2E ;Charcot-Marie-Tooth Neuropathy Type 2 ;Charcot-Marie-Tooth Neuropathy Type 2E/1F
T10920	SERPINE1	Plasminogen Activator Inhibitor I

HSNCAML1	L1CAM	Hereditary Spastic Paraplegia, X-Linked ;L1 Syndrome
T11074	L1CAM	Hereditary Spastic Paraplegia, X-Linked ;L1 Syndrome
HUMHPRO T	GCSH	Glycine Encephalopathy
HSTATR	TAT	Tyrosinemia Type II
Z19514	CPT1B	Carnitine Palmitoyltransferase IB (muscle) Deficiency
BE149388	CPT1B	Carnitine Palmitoyltransferase IB (muscle) Deficiency
HSALK3A	BMPR1A	Juvenile Polyposis Syndrome
T78581	CLN5	CLN5-Related Neuronal Ceroid-Lipofuscinosis ;Neuronal Ceroid-Lipofuscinoses
N32269	CLN8	CLN8-Related Neuronal Ceroid-Lipofuscinosis ;Neuronal Ceroid-Lipofuscinoses
HSU44128	SLC12A3	Gitelman Syndrome
AI590292	NPHS2	Focal Segmental Glomerulosclerosis ;Steroid-Resistant Nephrotic Syndrome
M62209	ACTN4	Focal Segmental Glomerulosclerosis
H53423	CNGB3	Achromatopsia ;Achromatopsia 3
HSEPAR	HCI	Hemangioma, Hereditary
R14741	ZIC2	Holoprosencephaly 5
H84264	SIX3	Anophthalmia ;Holoprosencephaly 2
T10497	TGIF	Holoprosencephaly 4
Z30052	USP9Y	Y Chromosome Infertility
N85185	DBY	Y Chromosome Infertility
T11164	SPTLC1	Hereditary Sensory Neuropathy Type I
T68440	GNE	GNE-Related Myopathies ;Sialuria, French Type
HSPROPER D	PFC	Properdin Deficiency, X-Linked
T46865	SURF1	Leigh Syndrome (nuclear DNA mutation)
AI015025	VAX1	Anophthalmia
BM727523	VAX1	Anophthalmia
AA310724	SIX6	Anophthalmia
R37821	TP63	TP63-Related Disorders
AF091582	ABCB11	Progressive Familial Intrahepatic Cholestasis
HUMHOX7	MSX1	Hypodontia, Autosomal Dominant ;Tooth-and-Nail Syndrome
R15034	CACNB4	Episodic Ataxia Type 2
T52100	TYROBP	PLOSL
F09012	MTMR2	Charcot-Marie-Tooth Neuropathy Type 4
T08510	APTX	Ataxia with Oculomotor Apraxia ;Ataxia with Oculomotor Apraxia 1
HUMHAAC	HF1	Hemolytic-Uremic Syndrome
C16899	MTND5	Leber Hereditary Optic Neuropathy ;Mitochondrial DNA-Associated Leigh Syndrome and NARP

#AUTOANTIGEN_IN_AUTOIMMUNE_DISEASE -Secreted splice variants of known autoantigens associated with a specific autoimmune syndrome, as for example, these listed in table 11, can be used to treat the syndrome. The proposed therapeutic mechanism is that the secreted splice variant would bind the auto-antibodies which formed against the autoantigen, therefore reduce their circulating levels, that would lead

to less binding of the autoantigen by auto antibodies and as a consequence diminish the autoimmune clinical symptoms.

Examples of proteins which are involved in autoimmune diseases are presented in Table 11 together with the corresponding internal gene contig name, enabling to allocate the new splice variants within the data files in the attached CD-ROMs 1 and 3.

Table 11

Contig	Disease	Description
HUMROSSA	Sjogren's syndrome	52 kDa Ro protein
HUMI69KAA	Insulin dependent diabetes Mellitus	69 kDa islet cell autoantigen
S55790	Goodpasture's syndrome	alpha 3 chain of collagen IV
HSACHRA	Myasthenia Gravis	Alpha chain of nicotinic Acetyl Choline receptor
Z21711	Rheumatoid Arthritis	Annexin A11
Z21711	Sjogren's syndrome	Annexin A11
Z21711	SLE	Annexin A11
S38729	SLE	ATP-dependent DNA helicase II, 70 kDa subunit
M77907	SLE	ATP-dependent DNA helicase II, 80 kDa subunit
T08224	scleroderma	Autoantigen p27
T08224	Sjogren's syndrome	Autoantigen p27
M85815	Pemphigus	bullous pemphigoid antigen 1
HUMROSSAA	SLE	calreticulin
HUMCENPRO	General autoimmune response	Centromere autoantigen C
HSU14518	General autoimmune response	Centromere protein A
M62116	dermatomyositis	Chromodomain helicase-DNA-binding protein 3
T05980	dermatomyositis	Chromodomain helicase-DNA-binding protein 4
H18687	Autoimmune demyelinating disease	claudin 11
M79258	dermatomyositis	Dermatomyositis associated with cancer putative autoantigen-1
HSDGIGLY	Pemphigus foliaceus	Desmoglein 1
HUMPVA	Pemphigus vulgaris	Desmoglein 3
BG723199	Pemphigus vulgaris	desmoglein 4
M77924	Primary billiary cirrhosis	Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial
D11598	Polymyositis	Exosome complex exonuclease RRP45
D11598	scleroderma	Exosome complex exonuclease RRP45
HUMACTNBI	Grave's disease	Filamin B
Z17837	Rheumatoid Arthritis	follistatin-like 1
HUMGAD	Insulin dependent diabetes Mellitus	glutamate decarboxylase 1 (GAD 1)
HSGLAD2A	Insulin dependent diabetes Mellitus	glutamate decarboxylase 2 (GAD 2)
D12383	dermatomyositis	glycyl-tRNA synthetase
D12383	Polymyositis	glycyl-tRNA synthetase
Z40013	Sjogren's syndrome	Golgi autoantigen, golgin subfamily A member 1
N28220	Rheumatoid Arthritis	Golgi autoantigen, golgin subfamily B member 1

N28220	Sjogren's syndrome	Golgi autoantigen, golgin subfamily B member 1
HUMMSCA	Grave's disease	Grave's disease carrier protein
HUMGRAVIN	Myasthenia Gravis	gravin
HUMRNPSMBA	SLE	Homo sapiens small nuclear ribonucleoprotein polypeptides B and B1
HUMNSR	Insulin resistant diabetes Mellitus	insulin receptor
HSRNAIFMH	Pernicious Anemia	intrinsic factor
D12018	dermatomyositis	isoleucine-tRNA synthetase
D12018	Polymyositis	isoleucine-tRNA synthetase
T97710	Pemphigus	ladinin 1
HSAUTAN64	Autoimmune thyroid disease	Leiomodin 1
HSLAANT	SLE	Lupus La protein
HUM60RO	SLE	Lupus Ro Protein
F02808	dermatomyositis	lysyl-tRNA synthetase
F02808	Polymyositis	lysyl-tRNA synthetase
F01282	General autoimmune response	Major centromere autoantigen B
M78010	multiple sclerosis	myelin basic protein
R89508	Autoimmune demyelinating disease	Myelin oligodendrocyte glycoprotein (MOG)
HUMHSTNBP	Autoimmune infertility	Nuclear autoantigenic sperm protein
S80305	Antiphospholipid syndrome	Phospholipid beta 2 glycoprotein 1 complex
D11598	Polymyositis	polymyositis/scleroderma autoantigen 1
D11598	scleroderma	polymyositis/scleroderma autoantigen 1
HUMAUA	Polymyositis	Polymyositis/scleroderma autoantigen 2
HUMAUA	scleroderma	Polymyositis/scleroderma autoantigen 2
HUMMCH	Vitiligo	Pro-melanin-concentrating hormone
T05361	Insulin dependent diabetes Mellitus	protein tyrosine phosphatase
HSP3MY	Wegener's granulomatosis	Proteinase 3 (ANCA - antineutrophil cytoplasmic antibody)
F02560	Insulin dependent diabetes Mellitus	Protein-tyrosine phosphatase-like N [Precursor]
T05361	Insulin dependent diabetes Mellitus	Receptor-type protein-tyrosine phosphatase N2
HUM60RO	Sjogren's syndrome	Sjogren syndrome antigen A2
H81770	Sjogren's syndrome	Sjogren's syndrome nuclear autoantigen 1
HUMSNRNP	SLE	Small nuclear ribonucleoprotein Sm D1
HUMMSCA	Grave's disease	solute carrier family 25
Z17347	Insulin dependent diabetes Mellitus	SOX-13 protein
N79953	Autoimmune infertility	Sperm surface protein Sp17
T08224	scleroderma	SSSCA1
T08224	Sjogren's syndrome	SSSCA1
R54783	interstitial cystitis	synaptonemal complex protein SC65 (SC65)
S40807	Hashimoto's thyroiditis	thyroglobulin
S38729	Autoimmune thyroid disease	thyroid autoantigen 70kDa
HUMTPOA	Hashimoto's thyroiditis	Thyroid peroxidase
HUMBF7A	Celiac disease	transglutaminase 2
S49816	Grave's disease	TSH receptor

Differentially expressed biomolecular sequences - field description

#TS – This field denotes tissue-specific genes which gene products are upregulated in at least one tissue. Such gene products might be used as tissue or pathological markers. Therapeutic uses of such gene products vary and may include, for example, anti-cancer vaccination and drug-targeting. Other exemplary uses are described hereinabove. It will be appreciated that every differentially expressed gene product can be assigned to higher hierarchies of classification. Thus, for example, a prostate cancer specific gene product may be used as a diagnostic marker for this cancer, but may be also used as epithelial cancer marker and as a general cancer marker. See for example, Table 12, below.

Table 12

Tissue-tumor searched	Cancer sub-type	Cancer type	Cancer - general
All tumor types			All tumor types
prostate-tumor	prostate-tumor	All epithelial tumors	All tumor types
lung-tumor	lung-tumor	All epithelial tumors	All tumor types
head and neck-tumor	head and neck-tumor	All epithelial tumors	All tumor types
stomach-tumor	stomach-tumor	All epithelial tumors	All tumor types
colon-tumor	colon-tumor	All epithelial tumors	All tumor types
mammary-tumor	mammary-tumor	All epithelial tumors	All tumor types
kidney-tumor	kidney-tumor	All epithelial tumors	All tumor types
ovary-tumor	ovary-tumor	All epithelial tumors	All tumor types
uterus/cervix-tumor	uterus/cervix-tumor	All epithelial tumors	All tumor types
thyroid-tumor	thyroid-tumor	All epithelial tumors	All tumor types
adrenal-tumor	adrenal-tumor	All epithelial tumors	All tumor types
pancreas-tumor	pancreas-tumor	All epithelial tumors	All tumor types
liver-tumor	liver-tumor	All epithelial tumors	All tumor types
skin-tumor	skin-tumor	All epithelial tumors	All tumor types
brain-tumor	brain-tumor		All tumor types
eye-tumor	eye-tumor		All tumor types
bone-tumor	bone-tumor	Sarcoma	All tumor types
bone marrow-tumor	bone marrow-tumor	Blood cancer	All tumor types
blood-cancer	blood-cancer	Blood cancer	All tumor types
T-cells-tumor	T-cells-tumor	Blood cancer	All tumor types
lymph nodes-tumor	lymph nodes-tumor	Blood cancer	All tumor types
muscle-tumor	muscle-tumor	Sarcoma	All tumor types
testis-tumor	testis-tumor		All tumor types

The annotation format of differentially expressed gene products is as follows.

#TS tissue-name – where the “tissue name” field specifies the list of tissues for which tissue-specific genes/variants were searched, as follows: amniotic+placenta; Blood; Bone; Bone marrow; Brain; Cervix+uterus; Colon; Endocrine, adrenal gland; Endocrine, pancreas; Endocrine, parathyroid+thyroid; Gastrointestinal tract;

Genitourinary; Head and neck; Immune, T-cells; Kidney; Liver; Lung; Lymph node; Mammary gland; Muscle; Ovary; Prostate; Skin; Thymus.

#TAA – This field denotes genes or transcript sequences over-expressed in cancer. The annotation format is as follows.

- 5 #TAA tissue-name - - where the “tissue name” field specifies the list of tissues for which tissue-tumor specific genes/variants were searched, as follows: All tumor types; All epithelial tumors; prostate-tumor; lung-tumor; head and neck-tumor; stomach-tumor; colon-tumor; mammary-tumor; kidney-tumor; ovary-tumor; uterus/cervix-tumor; thyroid-tumor; adrenal-tumor; pancreas-tumor; liver-tumor; 10 skin-tumor; brain-tumor; bone-tumor; bone marrow-tumor; blood-cancer; T-cells-tumor; lymph nodes-tumor; muscle-tumor.

EXAMPLE 11

Modulating Nicastrin activity using COPA inhibitors

- 15 The present inventors uncovered that coatomer protein complex, subunit α (COPA, GenBank Accession No. NM_004371) and Nicastrin (NCSTN, GenBank Accession No. NM_015331) are a 5'-5' antisense pair. Sequence alignment is illustrated in Figure 24a. Expression patterns of NCSTN and COPA show positive correlation (see Figure 24b).

- 20 Nicastrin is a crucial member in the membrane-associated γ -secretase complex which is responsible for the specific proteolysis of beta-Amyloid that cause Alzheimer Disease (AD). It is well-established that the stability of the γ -secretase complex is essential for its function (Takasugi et al. Nature. 2003 Mar 27;422(6930):438-41. Epub 2003 Mar 16.) . Coatomer proteins are responsible for the 25 stability and transport of complexes to the membrane. This observation makes AD a disease of complex stability rather than a disease of proteolysis. Databases such as LocusLINK show a linkage between nicastrin and Alzheimer's disease, but not between COPA and Alzheimer's disease. Therefore, this finding represents a new linkage and also a potential new therapeutic modality.

- 30 Since COPA protein (long form see Figure 24b) clearly stabilizes NCSTN, it is suggested that downregulation of COPA even in combination with other treatment

methods against the gamma-secretase members, will be very efficient in combating AD.

EXAMPLE 12

5 *Enhancing a therapeutic efficacy of IL-24 using a TOSO inhibitor*

The present inventors uncovered that TOSO (GenBank Accession No. NM_005449) is a naturally occurring antisense transcript of IL-24 (GenBank Accession No. NM_006850); overlap alignment between TOSO and IL-24 is provided in Figure 25a. Products of TOSO and IL-24 regulate apoptosis in an
10 opposite manner, as implied from their inverse expression patterns (see Figure 25b). Essentially, while IL-24 induces selective apoptosis in various cancer cells, TOSO is a potent inhibitor of FAS-induced apoptotic signaling through its extracellular domain (see for example information at LocusLINK, which may be obtained by entering the above names to the database).

15 Since TOSO and IL-24 exhibit opposing functions at the protein level, it is logical that expression levels thereof follow an inverse relationship. To ensure such inverse expression patterns, TOSO mRNA functions as a negative regulator (antisense) of IL-24 by preventing or reducing IL-24 mRNA translation.

Due to this sense/antisense agonist/antagonist relationship between TOSO and
20 IL-24 it is highly likely that therapeutic efficacy of IL-24 can be enhanced by inhibiting the expression of TOSO, by using, for example, a small molecule inhibitor to inhibit TOSO expression or expression or activity of endogenous TOSO regulators.

Although the invention has been described in conjunction with specific
25 embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents, patent applications and sequences identified by their accession numbers mentioned in this specification are
30 herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent, patent application or sequence identified by their accession number was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any

178

reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.

CD-ROM Content

The following CD-ROMs are attached herewith:

Information provided as: File name/byte size/date of creation /operating system/machine format

CD-ROM1:

1. AS_patent_data_description.doc/ 2 KB/ July 31, 2003/ Microsoft Windows Internet Explorer/ PC.
2. seqs_125/ 335,513 Kb/ November 15, 2001/ Microsoft Windows Internet Explorer/ PC.
3. seqs_133/ 253,406 Kb / April 8, 2003/ Microsoft Windows Internet Explorer/ PC.

CD-ROM2:

1. alignments_125/ 391,693 Kb/ November 15, 2001/ Microsoft Windows Internet Explorer/ PC.
2. table_125/ 13,926 Kb/ November 15, 2001/ Microsoft Windows Internet Explorer/ PC.
3. Table_S1.txt/ 41 Kb bytes/ July 31, 2003/ Microsoft Windows / PC.
4. Table_S2.txt/ 135 Kb/ July 31,, 2003/ Microsoft Windows / PC.

CD-ROM3:

1. alignments_133/ 454,180 Kb/ April 8, 2003/ Microsoft Windows Internet Explorer/ PC.
2. table_133/ 10,741 Kb/ April 8, 2003/ Microsoft Windows Internet Explorer/ PC.
3. annotations_133 / 5,065 Kb/ May 17, 2004/ Microsoft Windows Internet Explorer/ PC.
4. pep_seqs_133/6,470 Kb/ May 17, 2004/ Microsoft Windows Internet Explorer/ PC.
5. Trans2Pep/565 Kb/ May 17, 2004/ Microsoft Windows Internet Explorer/ PC.

WHAT IS CLAIMED IS:

1. A method of identifying putative naturally occurring antisense transcripts, the method comprising:

- (a) computationally aligning a first database including sense-oriented polynucleotide sequences with a second database including expressed polynucleotide sequences; and
- (b) identifying expressed polynucleotide sequences from said second database being capable of forming a duplex with at least one sense-oriented polynucleotide sequence of said first database according to at least one sequence criterion, thereby identifying putative naturally occurring antisense transcripts, wherein said at least one sequence criterion includes one or more of sequence length, sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

2. The method of claim 1, wherein said first database includes sequences of a type selected from the group consisting of genomic sequences, expressed sequence tags, contigs, intron sequences, complementary DNA (cDNA) sequences, pre-messenger RNA (mRNA) sequences and mRNA sequences.

3. The method of claim 1, wherein said second database includes sequences of a type selected from the group consisting of expressed sequence tags, contigs, complementary DNA (cDNA) sequences, pre-messenger RNA (mRNA) sequences and mRNA sequences.

4. The method of claim 1, wherein an average sequence length of said expressed polynucleotide sequences of said second database is selected from a range of 0.02 to 0.8 Kb.

5. The method of claim 1, wherein said second database is generated by:
- (i) providing a library of expressed polynucleotides;
 - (ii) obtaining sequence information of said expressed polynucleotides;

181

- (iii) computationally selecting at least a portion of said expressed polynucleotides according to at least one sequence criterion; and
- (iv) storing said sequence information of said at least a portion of said expressed polynucleotides thereby generating said second database.

6. The method of claim 1 further comprising the step of testing the putative naturally occurring antisense transcripts for an ability to form said duplex with said at least one sense oriented polynucleotide sequence under physiological conditions.

7. The method of claim 1 further comprising the step of computationally testing the putative naturally occurring antisense transcripts according to at least one criterion selected from the group consisting of sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

8. A kit for quantifying at least one mRNA transcript of interest, the kit comprising at least one oligonucleotide being designed and configured so as to be complementary to a sequence region of the mRNA transcript of interest, said sequence region not being complementary with a naturally occurring antisense transcript.

9. The kit of claim 8, wherein a length of said at least one oligonucleotide is selected from a range of 15-200 nucleotides.

10. The kit of claim 8, wherein said at least one oligonucleotide is a single stranded oligonucleotide.

11. The kit of claim 8, wherein said at least one oligonucleotide is a double stranded oligonucleotide.

12. The kit of claim 8, wherein a guanidine and cytosine content of said at least one oligonucleotide is at least 25 %.
13. The kit of claim 8, wherein said at least one oligonucleotide is labeled.
14. The kit of claim 8, wherein said at least one oligonucleotide is attached to a solid substrate.
15. The kit of claim 14, wherein said solid substrate is configured as a microarray and whereas said at least one oligonucleotide includes a plurality of oligonucleotides each attached to said microarray in a regio-specific manner.
16. A kit for quantifying at least one mRNA transcript of interest, the kit comprising at least one pair of oligonucleotides including a first oligonucleotide capable of binding the at least one mRNA transcript of interest and a second oligonucleotide being capable of binding a naturally occurring antisense transcript complementary to the mRNA of interest.
17. The kit of claim 16, wherein a length of each of said first and second oligonucleotides is selected from a range of 15-200 nucleotides
18. The kit of claim 16, wherein said first and second oligonucleotides are single stranded oligonucleotides.
19. The kit of claim 16, wherein said first and second oligonucleotides are double stranded oligonucleotide.
20. The kit of claim 16, wherein a guanidine and cytosine content of each of said first and second oligonucleotides is at least 25 %.
21. The kit of claim 16, wherein said first and second oligonucleotides are labeled.

22. The kit of claim 16, wherein said first and second oligonucleotides are attached to a solid substrate.

23. The kit of claim 22, wherein said solid substrate is configured as a microarray and whereas each of said first and second oligonucleotides includes a plurality of oligonucleotides each attached to said microarray in a regio-specific manner.

24. A kit for quantifying at least one naturally occurring antisense transcript of interest, the kit comprising at least one oligonucleotide being designed and configured so as to be complementary to a sequence region of the at least one naturally occurring antisense transcript of interest, said sequence region not being complementary with a naturally occurring mRNA transcript.

25. The kit of claim 24, wherein a length of said at least one oligonucleotide is selected from a range of 15-200 nucleotides.

26. The kit of claim 24, wherein said at least one oligonucleotide is a single stranded oligonucleotide.

27. The kit of claim 24, wherein said at least one oligonucleotide is a double stranded oligonucleotide.

28. The kit of claim 24, wherein a guanidine and cytosine content of said at least one oligonucleotide is at least 25 %.

29. The kit of claim 24, wherein said at least one oligonucleotide is labeled.

30. The kit of claim 24, wherein said at least one oligonucleotide is attached to a solid substrate.

31. The kit of claim 30, wherein said solid substrate is configured as a microarray and whereas said at least one oligonucleotide includes a plurality of oligonucleotides each attached to said microarray in a regio-specific manner.

32. A method of designing artificial antisense transcripts, the method comprising:

- (a) providing a database of naturally occurring antisense transcripts;
- (b) extracting from said database criteria governing structure and/or function of said naturally occurring antisense transcripts, wherein said criteria governing structure and/or function of said naturally occurring antisense transcripts include one or more of antisense length, complementarity length, complementarity position, intron molecules, alternative splicing sites, tissue specificity, pathological abundance, chromosomal mapping, open reading frames, promoters, hairpin structures, helix structures, stem and loops, pseudoknots and tertiary interactions, guanidine and/or cytosine content, guanidine tandems, adenosine content, thermodynamic criteria, RNA duplex melting point, RNA modifications, protein-binding motifs, palindromic sequence and predicted single stranded and double stranded regions.; and
- (c) designing the artificial antisense transcripts according to said criteria.

33. The method of claim 32, wherein said step of providing said database of naturally occurring antisense transcripts is effected by:

- (a) computationally aligning a first database including sense-oriented polynucleotide sequences with a second database including expressed polynucleotide sequences; and
- (b) identifying expressed polynucleotide sequences from said second database being capable of forming a duplex with at least one sense-oriented polynucleotide sequence of said first database,

185

- (c) storing a sequence of said expressed polynucleotide sequences identified in step (b), thereby providing said database of said naturally occurring antisense transcripts..

34. The method of claim 33, wherein said first database includes sequences of a type selected from the group consisting of genomic sequences, expressed sequence tags, contigs, intron sequences, complementary DNA (cDNA) sequences, pre-messenger RNA (mRNA) sequences and mRNA sequences.

35. The method of claim 33, wherein said second database includes sequences of a type selected from the group consisting of expressed sequence tags, contigs, complementary DNA (cDNA) sequences, pre-messenger RNA (mRNA) sequences and mRNA sequences.

36. The method of claim 33, wherein an average sequence length of said expressed polynucleotide sequences of said second database is selected from a range of 0.02 to 0.8 Kb.

37. The method of claim 33, wherein said second database is generated by:
- (i) providing a library of expressed polynucleotides;
 - (ii) obtaining sequence information of said expressed polynucleotides;
 - (iii) computationally selecting at least a portion of said expressed polynucleotides according to at least one sequence criterion; and
 - (iv) storing said sequence information of said at least a portion of said expressed polynucleotides thereby generating said second database.

38. The method of claim 37, wherein said at least one sequence criterion for computationally selecting said at least a portion of said expressed polynucleotide is selected from the group consisting of sequence length, sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

39. The method of claim 33, further comprising the step of testing said putative naturally occurring antisense transcripts for an ability to form said duplex with said at least one sense oriented polynucleotide sequence under physiological conditions.

40. The method of claim 33 further comprising the step of computationally testing said putative naturally occurring antisense transcripts according to at least one criterion selected from the group consisting of sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

41. A computer readable storage medium comprising a database including a plurality of sequences, wherein each sequence is of a naturally occurring antisense transcript.

42. The computer readable storage medium of claim 41, wherein said database further includes information pertaining to each sequence of said naturally occurring antisense transcripts, said information is selected from the group consisting of related sense gene, antisense length, complementarity length, complementarity position, intron molecules, alternative splicing sites, tissue specificity, pathological abundance, chromosomal mapping, open reading frames, promoters, hairpin structures, helix structures, stem and loops, pseudoknots and tertiary interactions, guanidine and/or cytosine content, guanidine tandems, adenosine content, thermodynamic criteria, RNA duplex melting point, RNA modifications, protein-binding motifs, palindromic sequence and predicted single stranded and double stranded regions.

43. The computer readable storage medium of claim 41, wherein said database further includes information pertaining to generation of said database and potential uses of said database.

44. A method of generating a database of naturally occurring antisense transcripts, the method comprising:

- (a) computationally aligning a first database including sense-oriented polynucleotide sequences with a second database including expressed polynucleotide sequences;
- (b) identifying expressed polynucleotide sequences from said second database being capable of forming a duplex with at least one sense-oriented polynucleotide sequence of said first database so as to identify putative naturally occurring antisense transcripts; and
- (c) storing sequence information of said identified naturally occurring antisense transcripts, thereby generating the database of the naturally occurring antisense transcripts.

45. The method of claim 44, wherein said first database includes sequences of a type selected from the group consisting of genomic sequences, expressed sequence tags, contigs, intron sequences, complementary DNA (cDNA) sequences, pre-messenger RNA (mRNA) sequences and mRNA sequences.

46. The method of claim 44, wherein said second database includes sequences of a type selected from the group consisting of expressed sequence tags, contigs, complementary DNA (cDNA) sequences, pre-messenger RNA (mRNA) sequences and mRNA sequences.

47. The method of claim 44, wherein an average sequence length of said expressed polynucleotide sequences of said second database is selected from a range of 0.02 to 0.8 Kb.

48. The method of claim 44, wherein said second database is generated by:
- (i) providing a library of expressed polynucleotides;
 - (ii) obtaining sequence information of said expressed polynucleotides;
 - (iii) computationally selecting at least a portion of said expressed polynucleotides according to at least one sequence criterion; and

- (iv) storing said sequence information of said at least a portion of said expressed polynucleotides thereby generating said second database.

49. The method of claim 48, wherein said at least one sequence criterion for computationally selecting said at least a portion of said expressed polynucleotide is selected from the group consisting of sequence length, sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

50. The method of claim 44 further comprising the step of testing the putative naturally occurring antisense transcripts for an ability to form said duplex with said at least one sense oriented polynucleotide sequence under physiological conditions.

51. The method of claim 44 further comprising the step of computationally testing the putative naturally occurring antisense transcripts according to at least one criterion selected from the group consisting of sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

52. A system for generating a database of a plurality of putative naturally occurring antisense transcripts, the system comprising a processing unit, said processing unit executing a software application configured for:

- (a) computationally aligning a first database including sense-oriented polynucleotide sequences with a second database including expressed polynucleotide sequences; and
- (b) identifying expressed polynucleotide sequences from said second database being capable of forming a duplex with at least one sense-oriented polynucleotide sequence of said first database according to at least one sequence criterion, wherein said at least one sequence criterion includes at least one of sequence length, sequence

annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

53. The system of claim 52, wherein said first database includes sequences of a type selected from the group consisting of genomic sequences, expressed sequence tags, contigs, intron sequences, complementary DNA (cDNA) sequences, pre-messenger RNA (mRNA) sequences and mRNA sequences.

54. The system of claim 52, wherein said second database includes sequences of a type selected from the group consisting of expressed sequence tags, contigs, complementary DNA (cDNA) sequences, pre-messenger RNA (mRNA) sequences and mRNA sequences.

55. The system of claim 52, wherein an average sequence length of said expressed polynucleotide sequences of said second database is selected from a range of 0.02 to 0.8 Kb.

56. The system of claim 52, wherein said second database is generated by:

- (i) providing a library of expressed polynucleotides;
- (ii) obtaining sequence information of said expressed polynucleotides;
- (iii) computationally selecting at least a portion of said expressed polynucleotides according to at least one sequence criterion; and
- (iv) storing said sequence information of said at least a portion of said expressed polynucleotides thereby generating said second database.

57. The system of claim 56, wherein said at least one sequence criterion for computationally selecting said at least a portion of said expressed polynucleotide is selected from the group consisting of sequence length, sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

58. The system of claim 52 further comprising the step of testing the putative naturally occurring antisense transcripts for an ability to form said duplex with said at least one sense oriented polynucleotide sequence under physiological conditions.

59. The system of claim 52 further comprising the step of computationally testing the putative naturally occurring antisense transcripts according to at least one criterion selected from the group consisting of sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

60. A method of identifying putative naturally occurring antisense transcripts, the method comprising screening a database of expressed polynucleotide sequences according to at least one sequence criterion, said at least one sequence criterion being selected to identify putative naturally occurring antisense transcripts.

61. The method of claim 60, wherein said database includes sequences of a type selected from the group consisting of expressed sequence tags, contigs, complementary DNA (cDNA) sequences, pre-messenger RNA (mRNA) sequences and mRNA sequences.

62. The method of claim 61, wherein an average sequence length of said expressed polynucleotide sequences of said second database is selected from a range of 0.02 to 0.8 Kb.

63. The method of claim 61, wherein said at least one sequence criterion is selected from the group consisting of sequence length, sequence annotation, sequence information, intron splice consensus site, intron sharing, sequence overlap, rare restriction site, poly(T) head, poly(A) tail, and poly(A) signal.

64. The method of claim 61 further comprising the step of testing the putative naturally occurring antisense transcripts for an ability to form a duplex with at least one sense oriented polynucleotide sequence under physiological conditions.

65. A method of quantifying at least one mRNA of interest in a biological sample, the method comprising:

- (a) contacting the biological sample with at least one oligonucleotide capable of binding with the at least one mRNA of interest, wherein said at least one oligonucleotide is designed and configured so as to be complementary to a sequence region of the mRNA transcript of interest, said sequence region not being complementary with a naturally occurring antisense transcript; and
- (b) detecting a level of binding between the at least one mRNA of interest and said at least one oligonucleotide to thereby quantify the at least one mRNA of interest in the biological sample.

66. The method of claim 65, wherein said at least one oligonucleotide is attached to a solid substrate.

67. The method of claim 66, wherein said solid substrate is configured as a microarray and whereas said at least one oligonucleotide includes a plurality of oligonucleotides each attached to said microarray in a regio-specific manner.

68. The method of claim 65, wherein said at least one oligonucleotide is labeled and whereas step (b) is effected by quantifying said label.

69. The method of claim 65, wherein a length of said at least one oligonucleotide is selected from a range of 15-200 nucleotides.

70. The method of claim 65, wherein said at least one oligonucleotide is a single stranded oligonucleotide.

71. The method of claim 65, wherein said at least one oligonucleotide is a double stranded oligonucleotide.

72. The method of claim 65, wherein a guanidine and cytosine content of said at least one oligonucleotide is at least 25 %.

73. A method of quantifying the expression potential of at least one mRNA of interest in a biological sample, the method comprising:

- (a) contacting the biological sample with at least one pair of oligonucleotides including a first oligonucleotide capable of binding the at least one mRNA of interest and a second oligonucleotide being capable of binding a naturally occurring antisense transcript complementary to the mRNA of interest; and
- (b) detecting a level of binding between the at least one mRNA of interest and said first oligonucleotide and a level of binding between said naturally occurring antisense transcript complementary to the mRNA of interest and said second oligonucleotide to thereby quantify the expression potential of the at least one mRNA of interest in the biological sample.

74. The method of claim 73, wherein a length of each of said first and second oligonucleotides is selected from a range of 15-200 nucleotides

75. The method of claim 73, wherein said first and second oligonucleotides are single stranded oligonucleotides.

76. The method of claim 73, wherein said first and second oligonucleotides are double stranded oligonucleotide.

77. The method of claim 73, wherein a guanidine and cytosine content of each of said first and second oligonucleotides is at least 25 %.

78. The method of claim 73, wherein said first and second oligonucleotides are labeled and whereas step (b) is effected by quantifying said label.

79. The method of claim 73, wherein said first and second oligonucleotides are attached to a solid substrate.

80. The method of claim 79, wherein said solid substrate is configured as a microarray and whereas each of said first and second oligonucleotides includes a plurality of oligonucleotides each attached to said microarray in a regio-specific manner.

81. A method of quantifying at least one naturally occurring antisense transcript of interest in a biological sample, the method comprising:

- (a) contacting the biological sample with at least one oligonucleotide capable of binding with the at least one naturally occurring antisense transcript of interest, wherein said at least one oligonucleotide is designed and configured so as to be complementary to a sequence region of the naturally occurring antisense transcript of interest, said sequence region not being complementary with a naturally occurring mRNA transcript; and
- (b) detecting a level of binding between the at least one naturally occurring antisense transcript of interest and said at least one oligonucleotide to thereby quantify the at least one naturally occurring antisense transcript of interest in the biological sample.

82. The method of claim 81, wherein said at least one oligonucleotide is attached to a solid substrate.

83. The method of claim 82, wherein said solid substrate is configured as a microarray and whereas said at least one oligonucleotide includes a plurality of oligonucleotides each attached to said microarray in a regio-specific manner.

84. The method of claim 81, wherein said at least one oligonucleotide is labeled and whereas step (b) is effected by quantifying said label.

85. The method of claim 81, wherein a length of said at least one oligonucleotide is selected from a range of 15-200 nucleotides.

86. The method of claim 81, wherein said at least one oligonucleotide is a single stranded oligonucleotide.

87. The method of claim 81, wherein said at least one oligonucleotide is a double stranded oligonucleotide.

88. The method of claim 81, wherein a guanidine and cytosine content of said at least one oligonucleotide is at least 25 %.

89. A method of identifying a novel drug target, the method comprising:

- (a) determining expression level of at least one naturally occurring antisense transcript of interest in cells characterized by an abnormal phenotype; and
- (b) comparing said expression level of said at least one naturally occurring antisense transcript of interest in said cells characterized by an abnormal phenotype to an expression level of said at least one naturally occurring antisense transcript of interest in cells characterized by a normal phenotype, to thereby identify the novel drug target.

90. The method of claim 89, wherein said abnormal phenotype of said cells is selected from the group consisting of biochemical phenotype, morphological phenotype and nutritional phenotype.

91. The method of claim 89, wherein said determining expression level of at least one naturally occurring antisense transcript of interest is effected by at least one oligonucleotide designed and configured so as to be complementary to a sequence

195

region of said at least one naturally occurring antisense transcript of interest, said sequence region not being complementary with a naturally occurring mRNA transcript.

92. The method of claim 91, wherein a length of said at least one oligonucleotide is selected from a range of 15-200 nucleotides.

93. The method of claim 91, wherein said at least one oligonucleotide is a single stranded oligonucleotide.

94. The method of claim 91, wherein said at least one oligonucleotide is a double stranded oligonucleotide.

95. The method of claim 91, wherein a guanidine and cytosine content of said at least one oligonucleotide is at least 25 %.

96. The method of claim 91, wherein said at least one oligonucleotide is labeled and whereas step (b) is effected by quantifying said label.

97. The method of claim 91, wherein said at least one oligonucleotide is attached to a solid substrate.

98. The method of claim 97, wherein said solid substrate is configured as a microarray and whereas said at least one oligonucleotide includes a plurality of oligonucleotides each attached to said microarray in a regio-specific manner.

99. A method of treating or preventing a disease, condition or syndrome associated with an upregulation of a naturally occurring antisense transcript complementary to a naturally occurring mRNA transcript, the method comprising administering a therapeutically effective amount of an agent for regulating expression of the naturally occurring antisense transcript.

100. The method of claim 99, wherein said agent for regulating expression of the naturally occurring antisense transcript is at least one oligonucleotide designed and configured so as to hybridize to a sequence region of said at least one naturally occurring antisense transcript.

101. The method of claim 100, wherein said at least one oligonucleotide is a ribozyme.

102. The method of claim 100, wherein said at least one oligonucleotide is a sense transcript.

103. A method of diagnosing a disease, condition or syndrome associated with a substandard expression ratio of an mRNA of interest over a naturally occurring antisense transcript complementary to the mRNA of interest, the method comprising:

- (a) quantifying expression level of the mRNA of interest and the naturally occurring antisense transcript complementary to the mRNA of interest;
- (b) calculating the expression ratio of the mRNA of interest over the naturally occurring antisense transcript complementary to the mRNA of interest, thereby diagnosing the disease, condition or syndrome.

104. The method of claim 103, wherein quantifying said expression level of the mRNA of interest and the naturally occurring antisense transcript complementary to the mRNA of interest is effected by at least one pair of oligonucleotides including a first oligonucleotide capable of binding the mRNA of interest and a second oligonucleotide being capable of binding the naturally occurring antisense transcript complementary to the mRNA of interest.

105. The method of claim 104, wherein a length of each of said first and second oligonucleotides is selected from a range of 15-200 nucleotides

106. The method of claim 104, wherein said first and second oligonucleotides are single stranded oligonucleotides.

107. The method of claim 104, wherein said first and second oligonucleotides are double stranded oligonucleotides.

108. The method of claim 104, wherein a guanidine and cytosine content of each of said first and second oligonucleotides is at least 25 %.

109. The method of claim 104, wherein said first and second oligonucleotides are labeled.

110. The method of claim 104, wherein said first and second oligonucleotides are attached to a solid substrate.

111. The method of claim 110, wherein said solid substrate is configured as a microarray and whereas each of said first and second oligonucleotides includes a plurality of oligonucleotides each attached to said microarray in a regio-specific manner.

112. A computer readable storage medium comprising data stored in a retrievable manner, said data including sequence information of co-regulated human polynucleotide sequences as set forth in files seqs_125 and/or seqs_133 of enclosed CD-1, polypeptide sequences encoded by said polynucleotide sequences as set forth in the file pep_seqs_133 of enclosed CD-ROM-3 and sequence annotations as set forth in the file annotations_133 of enclosed CD-ROM-3.

113. A method of modulating an activity or expression of a gene product, the method comprising upregulating or down regulating expression or activity of a naturally occurring antisense transcript of the gene product, thereby modulating the activity or expression of the gene product.

114. The method of claim 113, wherein said naturally occurring antisense transcript of the gene product is any of the nucleic acid sequences set forth in the file seqs_125 or seqs_133 of the enclosed CD-ROM1.

115. The method of claim 113, further comprising upregulating or down regulating expression or activity of the gene product.

116. An isolated polynucleotide comprising any of the nucleic acid sequences set forth in the file seqs_125 or seqs_133 of the enclosed CD-ROM1.

117. An isolated polypeptide comprising any of the amino acid sequences set forth in the file pep_seqs_133 of enclosed CD-ROM 3.

118. A method of enhancing a therapeutic efficacy of a therapeutic agent, the method comprising providing to a subject in need thereof a naturally occurring antisense transcript of a gene encoding an expression product targeted by the therapeutic agent prior to, concomitant with, or following provision of the therapeutic agent, thereby enhancing the therapeutic efficacy of the therapeutic agent.

119. A method of enhancing a therapeutic efficacy of a therapeutic agent, the method comprising providing to a subject in need thereof a naturally occurring antisense transcript of a gene encoding an expression product capable of inhibiting therapeutic activity of the therapeutic agent, prior to, concomitant with, or following provision of the therapeutic agent thereby enhancing the therapeutic efficacy of the therapeutic agent.

120. A method of enhancing a therapeutic efficacy of a therapeutic agent, the method comprising providing to a subject in need thereof a polynucleotide complementary to a naturally occurring antisense transcript of a gene encoding an expression product capable of upregulating activity or expression of the therapeutic agent prior to, concomitant with, or following provision of the therapeutic agent, thereby enhancing the therapeutic efficacy of the therapeutic agent.

121. An isolated polynucleotide, comprising a polynucleotide selected according to any of claims 118-120.

122. The isolated polynucleotide of claim 121, comprising any of the nucleic acid sequences set forth in the file seqs_125 or seqs_133 of the enclosed CD-ROM1, selected according to any of claims 118-120.




Fig. 1




Figure 2




Figure 3

4/53

Fig. 4a

570_0 AV705532_0 190 Z44352_15 783 OL: 52
 Query: 1 ggaccacaggatatgagcggaaaacactttctctacttagatacaactttttc 52
 ||||||||||||||||||||||||||||||||||||||||
 Sbjct: 52 ggaccacaggatatgagcggaaaacactttctctacttagatacaactttttc 1

Fig. 4b

570_1 AV705532_0 190 Z44352_14 1649 OL: 52
 Query: 1 ggaccacaggatatgagcggaaaacactttctctacttagatacaactttttc 52
 ||||||||||||||||||||||||||||||||||||||||
 Sbjct: 52 ggaccacaggatatgagcggaaaacactttctctacttagatacaactttttc 1

Fig. 4c

570_2 AV705532_0 190 Z44352_13 1861 OL: 52
 Query: 1 ggaccacaggatatgagcggaaaacactttctctacttagatacaactttttc 52
 ||||||||||||||||||||||||||||||||||||||||
 Sbjct: 52 ggaccacaggatatgagcggaaaacactttctctacttagatacaactttttc 1

Fig. 4d

571_0 AW070860_0 214 T81142_7 1934 OL: 54
 Query: 1 gtaagggaactttggcgacttagtgcgatcactgggagaattgtagagtccact 54
 ||||||||||||||||||||||||||||||||||||||||
 Sbjct: 1215 gtaagggaactttggcgacttagtgcgatcactgggagaattgtagagtccact 1162

Score = 22.3 bits (11), Expect = 0.66
 Identities = 11/11 (100%)
 Strand = Plus / Minus

Query: 146 acttccagagg 156
 |||||||||||
 Sbjct: 760 acttccagagg 750

Fig. 4e

571_1 AW070860_0 214 T81142_6 2353 OL: 54
 Query: 1 gtaagggaactttggcgacttagtgcgatcactgggagaattgtagagtccact 54
 ||||||||||||||||||||||||||||||||||||||||
 Sbjct: 1215 gtaagggaactttggcgacttagtgcgatcactgggagaattgtagagtccact 1162

Score = 22.3 bits (11), Expect = 0.66
 Identities = 11/11 (100%)
 Strand = Plus / Minus

Query: 146 acttccagagg 156
 |||||||||||
 Sbjct: 760 acttccagagg 750

5/53

Score = 22.3 bits (11), Expect = 0.66
 Identities = 11/11 (100%)
 Strand = Plus / Plus

Query: 100 ggaaaacacac 110
 |||||
 Sbjct: 1900 ggaaaacacac 1910

Fig. 4f

571_2 AW070860_0 214 T81142_4 2500 OL: 54
 Query: 1 gtaagggaactttggcgacttagtgcgatcactgggagaattgtagagtccact 54
 |||||
 Sbjct: 1317 gtaagggaactttggcgacttagtgcgatcactgggagaattgtagagtccact 1264

Score = 22.3 bits (11), Expect = 0.66
 Identities = 11/11 (100%)
 Strand = Plus / Minus

Query: 146 acttccagagg 156
 |||||
 Sbjct: 862 acttccagagg 852

Score = 22.3 bits (11), Expect = 0.66
 Identities = 11/11 (100%)
 Strand = Plus / Plus

Query: 100 ggaaaacacac 110
 |||||
 Sbjct: 2047 ggaaaacacac 2057

Fig. 4g

571_3 AW070860_0 214 T81142_3 947 OL: 54
 Query: 1 gtaagggaactttggcgacttagtgcgatcactgggagaattgtagagtccact 54
 |||||
 Sbjct: 224 gtaagggaactttggcgacttagtgcgatcactgggagaattgtagagtccact 171

Fig. 4h

571_4 AW070860_0 214 T81142_2 1366 OL: 54
 Query: 1 gtaagggaactttggcgacttagtgcgatcactgggagaattgtagagtccact 54
 |||||
 Sbjct: 224 gtaagggaactttggcgacttagtgcgatcactgggagaattgtagagtccact 171

Score = 22.3 bits (11), Expect = 0.66

6/53

Identities = 11/11 (100%)
Strand = Plus / Plus

Query: 100 ggaaaacacac 110
 |||||
Sbjct: 913 ggaaaacacac 923

Fig. 4i

572_0 BE046369_0 422 W26553_3 1532 OL: 52
Query: 1 aatcttcataatcccatgtgtcaaaggagagaccaggtggaggttaactgaa 52
 |||||
Sbjct: 1481 aatcttcataatcccatgtgtcaaaggagagaccaggtggaggttaactgaa 1532

Fig. 4j

572_1 BE046369_0 422 W26553_2 1753 OL: 52
Query: 1 aatcttcataatcccatgtgtcaaaggagagaccaggtggaggttaactgaa 52
 |||||
Sbjct: 1702 aatcttcataatcccatgtgtcaaaggagagaccaggtggaggttaactgaa 1753

Fig. 4k

572_2 BE046369_0 422 W26553_1 1832 OL: 52
Query: 1 aatcttcataatcccatgtgtcaaaggagagaccaggtggaggttaactgaa 52
 |||||
Sbjct: 1781 aatcttcataatcccatgtgtcaaaggagagaccaggtggaggttaactgaa 1832

7/53

53BP1_76P 53BP1 10394 76P 6837 OL: 3046 OF1: 5463
OF2: 2018

Score = 1659 bits (837), Expect = 0.0
Identities = 840/841 (99%)
Strand = Plus / Minus

Query: 7432 gagacggaatttcgctcttgttgcccaggctggaatgcaatggcacaatctcagctcact
7491
|||||
Sbjct: 3113 gagacggaatttcgctcttgttgcccaggctggaatgcaatggcacaatctcagctcact
3054

Query: 7492 gcagcgtctgcttcccagggtcaagcaattctcctgtctcagcctcctgagtagctggga
7551
|||||
Sbjct: 3053 gcagcgtctgcttcccagggtcaagcaattctcctgtctcagcctcctgagtagctggga
2994

Query: 7552 ttacaggcacatgccaccacacctggctaatttttgtatttttagtagaatcgaggtttc
7611
|||||
Sbjct: 2993 ttacaggcacatgccaccacacctggctaatttttgtatttttagtagaatcgaggtttc
2934

Query: 7612 atcatgttggtcaggctggtctcaaactcctgacttcagggtgatccgcccgcctcggcct
7671
|||||
Sbjct: 2933 atcatgttggtcaggctggtctcaaactcctgacttcagggtgatccgcccgcctcggcct
2874

Query: 7672 cccaaagtgtctgggattacagggtgtgagccaccatgcccgccctaagaaataacttttaag
7731
|||||
Sbjct: 2873 cccaaagtgtctgggattacagggtgtgagccaccatgcccgccctaagaaataacttttaag
2814

Query: 7732 tatattttcattagctagaattgcccaatctgtgtaggtataaataacttggtatagggga
7791
|||||
Sbjct: 2813 tatattttcattagctagaattgcccaatctgtgtaggtataaataacttggtatagggga
2754

Query: 7792 gagagaaagcctatcttacctgttgctttcttacttggtggtaacatccagcagttagtc
7851
|||||
Sbjct: 2753 gagagaaagcctatcttacctgttgctttcttacttggtggtaacatccagcagttagtc
2694

Fig. 5a

8/53

Query: 7852 tatttataaacataattactttttcacatatgaaccataaaatatttaactttctgctct
7911
|||||
Sbjct: 2693 tatttataaacataattactttttcacatatgaaccataaaatatttaactttctgctct
2634

Query: 7912 atattgtttgtttaccgctgtatctcccacagcttgaacagtaccaaggtacgtagtagg
7971
|||||
Sbjct: 2633 atattgtttgtctaccgctgtatctcccacagcttgaacagtaccaaggtacgtagtagg
2574

Query: 7972 tgctcaataaatgactattgaataaatgaacatatccaacaaatgttctcaatgtaaagg
7971
|||||
Sbjct: 2573 tgctcaataaatgactattgaataaatgaacatatccaacaaatgttctcaatgtaaagg
2514

Query: 8032 atcagagatgccacatgttctccttgatgggagagacccttccacatgggaatgatggga
8091
|||||
Sbjct: 2513 atcagagatgccacatgttctccttgatgggagagacccttccacatgggaatgatggga
2454

Query: 8092 aggagttgtactcctggatgttcagtaactgcttctaggagaaaaggtagagtcctatca
8151
|||||
Sbjct: 2453 aggagttgtactcctggatgttcagtaactgcttctaggagaaaaggtagagtcctatca
2334

Query: 8152 ctaagccgcagatatttatttgtgtgtggctagaatgggatgttttgaatcttctgttac
8211
|||||
Sbjct: 2393 ctaagccgcagatatttatttgtgtgtggctagaatgggatgttttgaatcttctgttac
2334

Query: 8212 aaccttggaacgtggctgttatttcaatttatgagccagaaattttcacatcccgaaac
8271
|||||
Sbjct: 2333 aaccttggaacgtggctgttatttcaatttatgagccagaaattttcacatcccgaaac
2274

Query: 8272 t 8272
|
Sbjct: 2273 t 2273

Score = 1655 bits (835), Expect = 0.0
Identities = 849/856 (99%)
Strand = Plus / Minus

Fig. 5a continued

9/53

Query: 5903 agatattgctttaggggtatttgatgtggtggtgacggacccctcatgccagcctcggt
5962

|||||
Sbjct: 4642 agatattgctttaggggtatttgatgtggtggtgacggacccctcatgccagcctcggt
4583

Query: 5963 gctgaagtgtgctgaagcattgcagctgcctgtggtgtcacaagagtgggtgatccagt
6022

|||||
Sbjct: 4582 gctgaagtgtgctgaagcattgcagctgcctgtggtgtcacaagagtgggtgatccagt
4523

Query: 6023 cctcattgttggggagagaattggattcaagcagcatccaaaatataaacacgattatgt
6082

|||||
Sbjct: 4522 cctcattgttggggagagaattggattcaagcagcatccaaaatataaacacgattatgt
4463

Query: 6083 ttctcactaaagatacttgggtcttactgggttttattccctgctatcgtggagattgtgtt
6142

|||||
Sbjct: 4462 ttctcactaaagatacttgggtcttactgggttttattccctgctatcgtggagattgtgtt
4403

Query: 6143 ttaaccagggttttaaagtgtgtcttgtgtgtaactggattccttgcatggatcctgtatat
6202

|||||
Sbjct: 4402 ttaaccagggttttaaagtgtgtcttgtgtgtaactggattccttgcatggatcctgtatat
4343

Query: 6203 agttttatttgctgaacttttatgataaaataaatgttgaatctctttggttgtagtaac
6262

|||||
Sbjct: 4342 agttttatttgctgaacttttatgataaaataaatgttgaatctctttggttgtagtaac
4283

Query: 6263 tgggatttcttcatctgtnnnnnngagcttaatctcagaacaaatgacaagacatagtac
6322

|||||
Sbjct: 4282 tgggatttcttcatctgttttttgagcttaatctcagaacaaatgacaagacatagtac
4223

Query: 6323 tttctctgagtcctttcaacaggcttattcacttacggaggacagctcaccaaggaaattg
6382

|||||
Sbjct: 4222 tttctctgagtcctttcaacaggcttattcacttacggaggacagctcaccaaggaaattg
4163

Query: 6383 aaaagttaagagtgaactttattctgtggcatcattcccaaaaggttattccagggtgtc
6442

Fig. 5a continued

10/53

|||||
Sbjct: 4162 aaaagttaagagtgaactttattctgtggcatcattcccaaaagggtattccagggtgtc
4103

Query: 6443 taaaatgctatgcttgagaaactcagtttaaggtaggtgaaggcccagattaacagttg
6502

|||||
Sbjct: 4102 taaaatgctatgcttgagaaactcagtttaaggtaggtgaaggcccagattaacagttg
4043

Query: 6503 tgccaaaagttgagtgggaattgggcacagctctgtttcctgacagttaaaaaagacctca
6562

|||||
Sbjct: 4042 tgccaaaagttgagtgggaattgggcacagctctgtttcctgacagttaaaaaagacctca
3983

Query: 6563 tgctctctctctgagctgagatcacagctcacctgtgggtactccccaactcttagagct
6622

|||||
Sbjct: 3982 tgctctctctctgagctgagatcacagctcacctgtgggtactccccaactcttagagct
3923

Query: 6623 aaaggggagaacgaaaggaccaactgccatgaaggggacagtgaccataagcttgatggaat
6682

|||||
Sbjct: 3922 aaaggggagaacgaaaggaccaactgccatgaaggggacagtgaccataagcttgatggaat
3863

Query: 6683 gaccttccgtaagataaacatgggaagcacaagtgagaacacctggaaatgttacacgtt
6742

|||||
Sbjct: 3862 gaccttccgtaagataaacatgggaagcacaagtgagaacacctggaaatgttacacgtt
3803

Query: 6743 ctagtcaaagacccaa 6758

|||||
Sbjct: 3802 ctagtcaaagacccaa 3787

Score = 1211 bits (611), Expect = 0.0
Identities = 625/632 (98%)
Strand = Plus / Minus

Query: 6778 gtcacaatagctggaagcagttccttcccttcctctggcatcactgatccctgcatggct
6837

|||||
Sbjct: 3767 gtcacaatagctggaagcagttccttcccttcctctggcatcactgatccctgcatggct
3708

Fig. 5a continued

11/53

Query: 6838 tctcattctctaaagcaggggtcaacaaggnnnnnnnctgtaaagggtaaagagtaa
6897

|||||
Sbjct: 3707 tctcattctctaaagcaggggtcaacaaggttttttctgtaaagggtaaagagtaa
3648

Query: 6898 atttcaggctttgtgggccatttgatccatcacaaactactcgcctttgctgtgagggcat
6957

|||||
Sbjct: 3647 atttcaggctttgtgggccatttgatccatcacaaactactcgcctttgctgtgagggcat
3588

Query: 6958 gaaagcaaccatagacaatgagtaaacaatgggcacggctgtgtttcagtaaaactgta
7017

|||||
Sbjct: 3587 gaaagcaaccatagacaatgagtaaacaatgggcacggctgtgtttcagtaaaactgta
3528

Query: 7018 caaaaacagacagcaggccatagtttgccagctcctgctccagagacagcagtggaaagg
7077

|||||
Sbjct: 3527 caaaaacagacagcaggccatagtttgccagctcctgctccagagacagcagtggaaagg
3468

Query: 7078 gtgatcttttagttgataatagcaggggaataagtgtgcagagcttcccagtggtgtagaa
7137

|||||
Sbjct: 3467 gtgatcttttagttgataatagcaggggaataagtgtgcagagcttcccagtggtgtagaa
3408

Query: 7138 tatgtagtgatgaaaaccagatgcagtgactataacctgatgccagaacactgcattctt
7197

|||||
Sbjct: 3407 tatgtagtgatgaaaaccagatgcagtgactataacctgatgccagaacactgcattctt
3348

Query: 7198 tttcagtttgaggggcggtgttcagtgaaatatttcttttacttacactgatatgaatat
7257

|||||
Sbjct: 3347 tttcagtttgaggggcggtgttcagtgaaatatttcttttacttacactgatatgaatat
3288

Query: 7258 tgattaccagtgatggctgggcatattaagataaacttcaaccctatggtttggtgaag
7317

|||||
Sbjct: 3287 tgattaccagtgatggctgggcatattaagataaacttcaaccctatggtttggtgaag
3228

Query: 7318 atgggtaattgggcctgcaatcttcagtatttaaaaatctaacaacttgatctcaatttt
7377

Fig. 5a continued

12/53

|||||
Sbjct: 3227 atgggtaattgggcctgcaatcttcagatatttaaaaatctaacaacttgatctcaatttt
3168

Query: 7378 ttcttaaggacctttttcttgagaataatac 7409
|||||
Sbjct: 3167 ttcttaaggacctttttcttgagaataatac 3136

Score = 404 bits (204), Expect = e-115
Identities = 204/204 (100%)
Strand = Plus / Minus

Query: 5556 cagtgtaacacagcttaccagtgctcttaattgcggatcagcattgtcgaacccggaag
5615

|||||
Sbjct: 6169 cagtgtaacacagcttaccagtgctcttaattgcggatcagcattgtcgaacccggaag
6110

Query: 5616 tacttcctgtgccttgccagtggttccctgtgtgtctcatgtctgggtccatgatagt
5675

|||||
Sbjct: 6109 tacttcctgtgccttgccagtggttccctgtgtgtctcatgtctgggtccatgatagt
6050

Query: 5676 tgccatgccaaccagctccagaactaccgtaattatctgttgccagctgggtacagcctt
5735

|||||
Sbjct: 6049 tgccatgccaaccagctccagaactaccgtaattatctgttgccagctgggtacagcctt
5990

Query: 5736 gaggagcaaagaattctggactgg 5759

|||||
Sbjct: 5989 gaggagcaaagaattctggactgg 5966

Score = 291 bits (147), Expect = 1e-80
Identities = 147/147 (100%)
Strand = Plus / Minus

Query: 5758 ggcaaccccgtaaaaatcctttccagaatctgaagggtactcttggtatcagaccaacagc
5817

|||||
Sbjct: 5159 ggcaaccccgtaaaaatcctttccagaatctgaagggtactcttggtatcagaccaacagc
5100

Query: 5818 agaacttcctggagctctggtctgagatcctcatgactgggtgggtgcagcctctgtgaagc
5877

|||||
Sbjct: 5099 agaacttcctggagctctggtctgagatcctcatgactgggtgggtgcagcctctgtgaagc
5040

Fig. 5a continued

13/53

Query: 5878 agcaccattcaagtgcccataacaaag 5904
|||||
Sbjct: 5039 agcaccattcaagtgcccataacaaag 5013

Score = 281 bits (142), Expect = 9e-78
Identities = 142/142 (100%)
Strand = Plus / Minus

Query: 8920 ctgccagagttccaccagcctgggtatagtagttttgttataatctagtcgtaacagtagt
8979
|||||
Sbjct: 2274 ctgccagagttccaccagcctgggtatagtagttttgttataatctagtcgtaacagtagt
2215

Query: 8980 tgagccaaatctgagttgatctgatgattccgaacactggagagaatcttgaacaggagt
9039
|||||
Sbjct: 2214 tgagccaaatctgagttgatctgatgattccgaacactggagagaatcttgaacaggagt
2155

Query: 9040 gaagactggcggtctaaagccct 9061
|||||
Sbjct: 2154 gaagactggcggtctaaagccct 2133

Score = 226 bits (114), Expect = 5e-61
Identities = 117/118 (99%)
Strand = Plus / Minus

Query: 9673 ccttcacgagaatgctcagctgggaggctccacgctcatccagtgggcctagggtctgac
9732
|||||
Sbjct: 2135 ccttcacgagaatgctcagctgggaggctccacgctcatccagtgggcctagggtctgac
2076

Query: 9733 tgaccagcgaacaaaaactgtgacagagatctaggatttcattcaggcagtgaaacac 9790
|||||
Sbjct: 2075 tgaccagcgaacaaaaactgtgacagagatctaggatttcattcaggcagtgaaacac 2018

Score = 190 bits (96), Expect = 3e-50
Identities = 96/96 (100%)
Strand = Plus / Minus

Query: 5463 gaatttttggaattcctcctttcaacaagcagtatacagaatcccagcttcgagcagga
5522
|||||
Sbjct: 6812 gaatttttggaattcctcctttcaacaagcagtatacagaatcccagcttcgagcagga
6753

Fig. 5a continued

14/53

```
Query: 5523 gctggctatatccttgaagatttcaatgaagcccag 5558
          |||
Sbjct: 6752 gctggctatatccttgaagatttcaatgaagcccag 6717
```

Score = 52.0 bits (26), Expect = 2e-08
Identities = 26/26 (100%)
Strand = Plus / Minus

```
Query: 7668 gcctcccaaagtgctgggattacagg 7693
          |||
Sbjct: 5312 gcctcccaaagtgctgggattacagg 5287
```

Fig. 5a continued

15/53

CIDEB1 BLTR2 CIDEB1 2289 BLTR2 6530 OL: 2254 OF1: 17 OF2:
 1

Score = 2727 (753.8 bits), Expect = 0.0, Sum P(13) = 0.0
 Identities = 547/549 (99%), Positives = 547/549 (99%), Strands Minus /
 Plus

Query: 2250 TTTTGTAGTTTGAGGGGAAGGGTATGAAGACAGATCTCAAGGTAAAGTCAGAGAGGGCT
 2191
 Sbjct: 1 TTTTGTAGTTTGAGGGGAAGGGTATGAAGACAGATCTCAAGGTAAAGTCAGAGAGGGCT 60

Query: 2190 GTCATCAGTATGCTGGGGAGTTTAGGGACAGGAGGCATTGGTAGGGGATTAGATGTAGCA
 2131
 Sbjct: 61 GTCATCAGTATGCTGGGGAGTTTAGGGACAGGAGGCATTGGTAGGGGATTAGATGTAGCA
 120

Query: 2130 GCAGTCAGGCTGGGATCAAGATGCCTGGGGGACATCTTGATCTTGGCCTTTCAGGGCAAG
 2071
 Sbjct: 121 GCAGTCAGGCTGGGATCAAGATGCCTGGGGGACATCTTGATCTTGGCCTTTCAGGGCAAG
 180

Query: 2070 TGGGAGGCTAGAAAGGTGGCTAGGAAAGAACAGCATTCCTTCAGGTAAGGGTATAGACTTG
 2011
 Sbjct: 181 TGGGAGGCCAGAAAGGTGGCTAGGAAAGAACAGCATTCCTTCAGGTAAGGGTATAGACTTG
 240

Query: 2010 GGATGTGAGGCGTTATGCTGAAAGGTTCTGTACGAGGGGATCAGAGGACAGTGGGGAAA
 1951
 Sbjct: 241 GGATGTGAGGCGTTATGCTGAAAGGTTCTGTACGAGGGGATCAGAGGACAGTGGGGAAA
 300

Query: 1950 TTGGGTGGGTATCTAGCCTGTACTGTCTGCAGGTCCTGAAATTTGATGCTGTCATAGTC
 1891
 Sbjct: 301 TTGGGTGGGTATCTAGCCTGTACTGTCTGCAGGTCCTGAAATTTGATGCTGTCATAGTC
 360

Query: 1890 TTTGCAGTGGGTCGGTTGGGAATGATTCTGGGGGCAGAGCTCAGAGCCCCCTTAGTAGGAA
 1831
 Sbjct: 361 TTTGCAGTGGGTCGGTTGGGAATGATTCTGGGGGCAGAGCTCAGAGCCCCCTTAGTAGGAA
 420

Query: 1830 TGGAGGCGGCCCTTCTGCTGCCACTGCTCAGCCCCCTCCACTGCATGACGAAGGGTGGAG
 1771
 Sbjct: 421 TGGAGGCGGCCCTTCTGCTGCCACTGCTCAGCCCCCTCCACTGCATGACGAAGGGTGGAG
 480

Query: 1770 GAAATTCAGCAACATATGGCCCAGGCCTTGACAGAGTGTGGAGGTCCAACGAAGGAGC
 1711
 Sbjct: 481 GAAATTCAGCAACATATGGCCCAGGCCTTGACAGAGTGTGGAGGTCCAACGAAGGAGC
 540

Fig. 5b

16/53

Query: 1710 TCCCTGAGT 1702
|||||||
Sbjct: 541 TCCCTGAAT 549

Score = 1322 (365.4 bits), Expect = 0.0, Sum P(13) = 0.0
Identities = 266/268 (99%), Positives = 266/268 (99%), Strands Minus /
Plus

Query: 757 CCTGTAGGCCCAGAAGGATGTCGGTCTGCTACCGTCCCCAGGGAACGAGACACTGCTGA
698
|||||||
Sbjct: 5426 CCTGTAGGCCCAGAAGGATGTCGGTCTGCTACCGTCCCCAGGGAACGAGACACTGCTGA
5485

Query: 697 GCTGGAAGACTTCGCGGGCCACAGGCACAGCCTTCCTGCTGCTGGCGGCGCTGCTGGGGC
638
|||||||
Sbjct: 5486 GCTGGAAGACTTCGCGGGCCACAGGCACAGCCTTCCTGCTGCTGGCGGCGCTGCTGGGGC
5545

Query: 637 TGCCTGGCAACGGCTTCGTGGTGTGGAGCTTGGCGGGCTGGCAGCCTGCACGGGGGCGAC
578
|||||||
Sbjct: 5546 TGCCTGGCAACGGCTTCGTGGTGTGGAGCTTGGCGGGCTGGCAGCCTGCACGGGGGCGAC
5605

Query: 577 CGCTGGCGGCCACGCTTGTGCTGCACCTGGCGCTGGCCGACGGCGCGGTGCTGCTGCTCA
518
|||||||
Sbjct: 5606 CGCTGGCGGCCACGCTTGTGCTGCACCTGGCGCTGGCCGACGGCGCGGTGCTGCTGCTCA
5665

Query: 517 CGCCGCTCTTTGTGGCCTTCCTGACCGG 490
|||||||
Sbjct: 5666 CGCCGCTCTTTGTGGCCTTCCTGACCCG 5693

Score = 1316 (363.8 bits), Expect = 0.0, Sum P(13) = 0.0
Identities = 264/265 (99%), Positives = 264/265 (99%), Strands Minus /
Plus

Query: 421 CAAGCGTGCTGCTCACCAGCCTGCTCAGCCTGCAGCGCTGCCTCGCAGTCACCCGCCCT
362
|
Sbjct: 5762 CCAGCGTGCTGCTCACCAGCCTGCTCAGCCTGCAGCGCTGCCTCGCAGTCACCCGCCCT
5821

Query: 361 TCCTGGCGCCTCGGCTGCGCAGCCCGGCCCTGGCCCGCCGCTGCTGCTGGCGGTCTGGC
302
|||||||
Sbjct: 5822 TCCTGGCGCCTCGGCTGCGCAGCCCGGCCCTGGCCCGCCGCTGCTGCTGGCGGTCTGGC
5881

Query: 301 TGGCCGCCCTGTTGCTCGCCGTCCCGGCCGCCGTCTACCGCCACCTGTGGAGGGACCGCG
242
|||||||
Sbjct: 5882 TGGCCGCCCTGTTGCTCGCCGTCCCGGCCGCCGTCTACCGCCACCTGTGGAGGGACCGCG
5941

Fig. 5b continued

17/53

Query: 241 TATGCCAGCTGTGCCACCCGTCGCCGGTCCACGCCGCCGCCACCTGAGCCTGGAGACTC
182
Sbjct: 5942 TATGCCAGCTGTGCCACCCGTCGCCGGTCCACGCCGCCGCCACCTGAGCCTGGAGACTC
6001

Query: 181 TGACCGCTTTCGTGCTTCCTTTCGG 157
Sbjct: 6002 TGACCGCTTTCGTGCTTCCTTTCGG 6026

Score = 920 (254.3 bits), Expect = 0.0, Sum P(13) = 0.0
Identities = 188/193 (97%), Positives = 188/193 (97%), Strands Minus /
Plus

Query: 1708 CCTGAGTACTTTCTTTGGGCCAAGTCCTTGAAAGTCACAACCTCATAGAGTAGAGCCCGTA
1649
Sbjct: 724 CCTGAGTACTTTCTTTGGGCCAAGTCCTTGAAAGTCACAACCTCATAGAGTAGAGCCCGTA
783

Query: 1648 GAATGTGGCTTTGACATTCAGGCTGCCAAAGAGGTCTCGAGGGTTTGTCTGTACACGTC
1589
Sbjct: 784 GAATGTGGCTTTGACATTCAGGCTGCCAAAGAGGTCTCGAGGGTTTGTCTGTACACGTC
843

Query: 1588 AAAGGTGAATCGGCCGATGTCCTTGCTGTGCTTGGGGCTCTCCCGTCCAGGCCCATATGA
1529
Sbjct: 844 AAAGGTGAATCGGGCGATGTCCTTGCTGTGCTTGGGGCTCTCCCGTCCAGGCCCATATGA
903

Query: 1528 CAGCACTCCACTC 1516
Sbjct: 904 CAGCACTCCACTC 916

Score = 753 (208.2 bits), Expect = 0.0, Sum P(13) = 0.0
Identities = 157/165 (95%), Positives = 157/165 (95%), Strands Minus /
Plus

Query: 1529 ACAGCACTCCACTCCTTGTTAGGGCTCCAGCTCTGACCAGACTGCAACACCATCAGGCACG
1470
Sbjct: 1139 ATAGGCCTCTTACCTTGTTAGGGCTCCAGCTCTGACCAGACTGCAACACCATCAGGCACG
1198

Query: 1469 TGTCATCCTCCAGCAGCTGGAAGAAGTCCTCACTGTCCACTGCAGTTCCATCCTCCTCTA
1410
Sbjct: 1199 TGTCATCCTCCAGCAGCTGGAAGAAGTCCTCACTGTCCACTGCAGTTCCATCCTCCTCTA
1258

Query: 1409 GCACCAGGGTTAGCACTCCATTGAGCAGTAGGGTCTCCAATGCTT 1365
Sbjct: 1259 GCACCAGGGTTAGCACTCCATTGAGCAGTAGGGTCTCCAATGCCT 1303

Score = 746 (206.2 bits), Expect = 0.0, Sum P(13) = 0.0

Fig. 5b continued

Identities = 150/151 (99%), Positives = 150/151 (99%), Strands Minus / Plus

Sbjct: 2146 TACTTTGGCTAGCAGCTCCTGGCGGGTGGCAGCTGTGAGGCCTTTCCGGATGGTCCGCTT
2205

Sbjct: 2206 GTGATCACAGACACGAAAGGTCGCTGGGGTGGTGGAGCTGAGGTCCAGACCCCTCCGTCC
2265

Sbjct: 2266 AAAC TCCGAGCTTATATTAGATACTGACCTG 2296

Sbjct: 3257; CTGCTCTTTCCTTCCTTGGTCGGAGGAGGGGCTGGCTCACTGCTCTGGCTTCATTTT
3316

Sbjct: 3317 CCAGAGCTGCCTGCTGCAGTCACACTTAGGTCATCTTCTCTCACTTTTCTCCTTTTGCCG
3376

Sbjct: 3377 ATTAGTGGACGTGACAGAGATGTGAATGGG 3406

Sbjct: 6018 TCCTTTCGGGCTGATGCTCGGCTGCTACAGCGTGACGCTGGCACGGCTGCGGGGCGCCCG
6077

Sbjct: 6078 CTGGGGCTCCGGGCGGCACGGGGCGCGGTGGGCCGGCTGGTGAGCGCCATCGTGCTTGC
6137

Sbjct: 6138 CTTCTGGCTTGCTCTGGGCCCCCTACCACGC 6167

Fig. 5b continued

19/53

Score = 638 (176.4 bits), Expect = 0.0, Sum P(13) = 0.0
 Identities = 130/133 (97%), Positives = 130/133 (97%), Strands Minus / Plus

Query: 962 GGGCAGGGGATGTCCTTTGATGGCATCAAGACTTTAGCTTCTGGTGCGCTGTGTCCCAGC
 903

Sbjct: 3404 GGGCAGGGGATGTCCTTTGATGGCATCAAGACTTTAGCTTCTGGTGCGCTGTGTCCCAGC
 3463

Query: 902 TCTGATTTCAGTTGCAGCCGTGATGGACAGTTGCATGGAAGCTGAGACTCTCACTGACAG
 843

Sbjct: 3464 TCTGATTTCAGTTGCAGCCGTGATGGACAGTTGCATGGAAGCTGAGACTCTCACTGACAG
 3523

Query: 842 TGAAACCCTCAAA 830

Sbjct: 3524 TGAAACCCTCAAA 3536

Score = 537 (148.4 bits), Expect = 0.0, Sum P(13) = 0.0
 Identities = 109/111 (98%), Positives = 109/111 (98%), Strands Minus / Plus

Query: 1227 ACTGACCTGAGTAAGTCACTGGGGTTCAGAGCTGAGAGGTACTCCATGGTGGACCGGAGA
 1168

Sbjct: 2590 AGTCACCTGAGTAAGTCACTGGGGTTCAGAGCTGAGAGGTACTCCATGGTGGACCGGAGA
 2649

Query: 1167 GTTCCTTCCCTGGAACCTTCTGGGCTGGGTGGTTCTCTCCTGTGCTGGGGCT 1117

Sbjct: 2650 GTTCCTTCCCTGGAACCTTCTGGGCTGGGTGGTTCTCTCCTGTGCTGGGGCT 2700

Score = 394 (108.9 bits), Expect = 0.0, Sum P(13) = 0.0
 Identities = 82/86 (95%), Positives = 82/86 (95%), Strands Minus / Plus

Query: 839 AACCCCTCAAAATGAACACAATCCCTGCTTTCCTGCCAAGGATCCTTGTAGGGTCCCCCAG
 780

Sbjct: 3526 AAACCCTCAAAATGAACACAATCCCTGCTTTCCTGCCAAGGATCCTTGTAGGGTCCCCCAG
 3585

Query: 779 CTTCCCCACTTTTTTCTGTGTCTG 754

Sbjct: 3586 CTTCCCCACTTTTTTCTGTGTCTG 3611

Score = 370 (102.3 bits), Expect = 0.0, Sum P(13) = 0.0
 Identities = 74/74 (100%), Positives = 74/74 (100%), Strands Minus / Plus

Query: 493 CCGGCAGGCCTGGCCGCTGGGCCAGGCGGGCTGCAAGGCGGTGTACTACGTGTGCGCGCT
 434

Sbjct: 5691 CCGGCAGGCCTGGCCGCTGGGCCAGGCGGGCTGCAAGGCGGTGTACTACGTGTGCGCGCT
 5750

Query: 433 CAGCATGTACGCCA 420

Sbjct: 5751 CAGCATGTACGCCA 5764

Fig. 5b continued

20/53

CIDEB2_BLTR2 CIDEB2 1511 BLTR2 6530 OL: 1410 OF1: 1 OF2:
1

Score = 2736 (756.0 bits), Expect = 0.0, Sum P(5) = 0.0
Identities = 548/549 (99%), Positives = 548/549 (99%), Strands Minus /
Plus

Query: 1384 TTTTGTAGTTTGAGGGGAAGGGTATGAAGACAGATCTCAAGGTAAAGTCAGAGAGGGCT
1325
Sbjct: 1 TTTTGTAGTTTGAGGGGAAGGGTATGAAGACAGATCTCAAGGTAAAGTCAGAGAGGGCT 60
Query: 1324 GTCATCAGTATGCTGGGGAGTTTAGGGACAGGAGGCATTGGTAGGGGATTAGATGTAGCA
1265
Sbjct: 61 GTCATCAGTATGCTGGGGAGTTTAGGGACAGGAGGCATTGGTAGGGGATTAGATGTAGCA
120
Query: 1264 GCAGTCAGGCTGGGATCAAGATGCCTGGGGGACATCTTGATCTTGGCCTTTCAGGGCAAG
1205
Sbjct: 121 GCAGTCAGGCTGGGATCAAGATGCCTGGGGGACATCTTGATCTTGGCCTTTCAGGGCAAG
180
Query: 1204 TGGGAGGCCAGAAAGGTGGCTAGGAAAGAACAGCATTCTTCAGGTAAGGGTATAGACTTG
1145
Sbjct: 181 TGGGAGGCCAGAAAGGTGGCTAGGAAAGAACAGCATTCTTCAGGTAAGGGTATAGACTTG
240
Query: 1144 GGATGTGAGGCGTTATGCTGAAAGGTTCTGTACGAGGGGATCAGAGGACAGTGGGGAAA
1085
Sbjct: 241 GGATGTGAGGCGTTATGCTGAAAGGTTCTGTACGAGGGGATCAGAGGACAGTGGGGAAA
300
Query: 1084 TTGGGTGGGTTATCTAGCCTGTACTGTCTGCAGGTCCTGAAATTTGATGCTGTCATAGTC
1025
Sbjct: 301 TTGGGTGGGTTATCTAGCCTGTACTGTCTGCAGGTCCTGAAATTTGATGCTGTCATAGTC
360
Query: 1024 TTTGCAGTGGGTGCGTTGGAATGATTCTGGGGGCAGAAGCTCAGAGCCCCTTAGTAGGAA
965
Sbjct: 361 TTTGCAGTGGGTGCGTTGGAATGATTCTGGGGGCAGAAGCTCAGAGCCCCTTAGTAGGAA
420
Query: 964 TGGAGGCGGCCCTTCTGCTGCCACTGCTCAGCCCCCTCCACTGCATGACGAAGGGTGGAG
905
Sbjct: 421 TGGAGGCGGCCCTTCTGCTGCCACTGCTCAGCCCCCTCCACTGCATGACGAAGGGTGGAG
480
Query: 904 GAAATTCAGCAACATATGGCCCAGGCCTTGCAGCAGTGTGGAGGTCCAACGAAGGAGC
845
Sbjct: 481 GAAATTCAGCAACATATGGCCCA(:GAAGGAGC
540

Fig. 5c

21/53

Query: 844 TCCCTGAGT 836
|||||||
Sbjct: 541 TCCCTGAAT 549

Score = 1787 (493.8 bits), Expect = 0.0, Sum P(5) = 0.0
Identities = 359/361 (99%), Positives = 359/361 (99%), Strands Minus /
Plus

Query: 361 ACTGACCTGAGTAAGTCACTGGGGTTTCAGAGCTGAGAGGTACTCCATGGTGGACCGGAGA
302

Sbjct: 2590 AGTCACCTGAGTAAGTCACTGGGGTTTCAGAGCTGAGAGGTACTCCATGGTGGACCGGAGA
2649

Query: 301 GTTCCTTCCCTGGAACCTTCTGGGCTGGGTGGTTCTCTCCTGTGCTGGGGCTTTAGTGGTG
242

Sbjct: 2650 GTTCCTTCCCTGGAACCTTCTGGGCTGGGTGGTTCTCTCCTGTGCTGGGGCTTTAGTGGTG
2709

Query: 241 TTTTCTGTTACAAACCTGGGATCTCAGCCCAGGACAAGGTGGGAATGAGTCAAGCCTGGA
182

Sbjct: 2710 TTTTCTGTTACAAACCTGGGATCTCAGCCCAGGACAAGGTGGGAATGAGTCAAGCCTGGA
2769

Query: 181 CTCTGGCCCCCTGCCTGGCCAGTAAGAAGGGCAAAGTCCAAGGGGAGGGATGAGGGAGG
122

Sbjct: 2770 CTCTGGCCCCCTGCCTGGCCAGTAAGAAGGGCAAAGTCCAAGGGGAGGGATGAGGGAGG
2829

Query: 121 GGCCAGATGGGGTCCTGGAGGAAGAATTGCCTGGCAAAGCCATTGGAGCTTGTATGTGT 62

Sbjct: 2830 GGCCAGATGGGGTCCTGGAGGAAGAATTGCCTGGCAAAGCCATTGGAGCTTGTATGTGT
2889

Query: 61 GTCTTTGGTGATGACATGTGTTGTGAGGGTAGATGGGAACCATGTAAAAGGATGAAATGT 2

Sbjct: 2890 GTCTTTGGTGATGACATGTGTTGTGAGGGTAGATGGGAACCATGTAAAAGGATGAAATGT
2949

Query: 1 G 1

Sbjct: 2950 G 2950

Score = 965 (266.6 bits), Expect = 0.0, Sum P(5) = 0.0
Identities = 193/193 (100%), Positives = 193/193 (100%), Strands Minus /
Plus

Query: 842 CCTGAGTACTTTCTTTGGGCCAAGTCCTTGAAAGTCACAACCTCATAGAGTAGAGCCCGTA
783

Sbjct: 724 CCTGAGTACTTTCTTTGGGCCAAGTCCTTGAAAGTCACAACCTCATAGAGTAGAGCCCGTA
783

Query: 782 GAATGTGGCTTTGACATTCAAGGCTGCCAAAGAGGTCTCGAGGGTTTTGCTTGACACGTC
723

Fig. 5c continued

22/53

```

Sbjct: 784 GAATGTGGCTTTGACATTGAGGCTGCCAAAGAGGTCTCGAGGGTTTGTGTACACGTC
843
Query: 722 AAAGGTGAATCGGGCGATGTCCTTGCTGTGCTTGGGCCTCTCCCGTCCCAGGCCATATGA
663
Sbjct: 844 AAAGGTGAATCGGGCGATGTCCTTGCTGTGCTTGGGCCTCTCCCGTCCCAGGCCATATGA
903
Query: 662 CAGCACTCCACTC 650
Sbjct: 904 CAGCACTCCACTC 916

Score = 757 (209.2 bits), Expect = 0.0, Sum P(5) = 0.0
Identities = 161/173 (93%), Positives = 161/173 (93%), Strands Minus /
Plus

Query: 671 GCCATATGACAGCACTCCACTCCTTGTTAGGGCTCCAGCTCTGACCAGACTGCAACACCAT
612
Sbjct: 1131 GCCCCAGTATAGGCCTCTTACCCTTGTTAGGGCTCCAGCTCTGACCAGACTGCAACACCAT
1190
Query: 611 CAGGCACGTGTCATCCTCCAGCAGCTGGAAGAAGTCTCACTGTCCACTGCAGTTCCATC
552
Sbjct: 1191 CAGGCACGTGTCATCCTCCAGCAGCTGGAAGAAGTCTCACTGTCCACTGCAGTTCCATC
1250
Query: 551 CTCCTCTAGCACCAGGGTTAGCACTCCATTGAGCAGTAGGGTCTCCAATGCTT 499
Sbjct: 1251 CTCCTCTAGCACCAGGGTTAGCACTCCATTGAGCAGTAGGGTCTCCAATGCCT 1303

Score = 746 (206.1 bits), Expect = 0.0, Sum P(5) = 0.0
Identities = 150/151 (99%), Positives = 150/151 (99%), Strands Minus /
Plus

Query: 503 TGCTTTGGCTAGCAGCTCCTGGCGGGTGGCAGCTGTCAGGCCTTTCCGGATGGTCCGCTT
444
Sbjct: 2146 TACTTTGGCTAGCAGCTCCTGGCGGGTGGCAGCTGTCAGGCCTTTCCGGATGGTCCGCTT
2205
Query: 443 GTGATCACAGACACGGAAAGGTCGCTGGGGTGGTGGAGCTGAGGTCCAGACCCTCCGTCC
384
Sbjct: 2206 GTGATCACAGACACGGAAAGGTCGCTGGGGTGGTGGAGCTGAGGTCCAGACCCTCCGTCC
2265
Query: 383 AAATCCGAGCTTATATTAGATACTGACCTG 353
Sbjct: 2266 AAATCCGAGCTTATATTAGATACTGACCTG 2296
```

Fig. 5c continued

23/53

APAF1_EB1 APAF1 7042 EB1a 1752 OL: 141 OF1: 6889
OF2: 1612

Score = 705 (194.8 bits), Expect = 3.9e-52, P = 3.9e-52
Identities = 141/141 (100%), Positives = 141/141 (100%), Strands Minus /
Plus

Query: 7029 TGTTTTTCAAACAATTTTGTGAATTTATTTTACAAAAATTTTAAATTCATATTTT
6970

|||||
Sbjct: 1612 TGTTTTTCAAACAATTTTGTGAATTTATTTTACAAAAATTTTAAATTCATATTTT
1671

Query: 6969 AAAATGTATACCAAGGCAAAAAATCATATAAGCTATATCATAAATACAAGAGTTTCAA
6910

|||||
Sbjct: 1672 AAAATGTATACCAAGGCAAAAAATCATATAAGCTATATCATAAATACAAGAGTTTCAA
1731

Query: 6909 ACATACAAGAGACATATAATG 6889

|||||
Sbjct: 1732 ACATACAAGAGACATATAATG 1752

Fig. 5d

24/53

Hum_AChR_MINK2 AChR 2457 MINK2 4863 OL: 236 OF1: 2175
OF2: 4583

Score = 218 bits (110), Expect = 2e-59
Identities = 110/110 (100%)
Strand = Plus / Minus

Query: 2254 aagggttacttgctgctcacactatatacagatgcaagcaaggggcgtggagagtgaggg
2313

|||||
Sbjct: 4787 aagggttacttgctgctcacactatatacagatgcaagcaaggggcgtggagagtgaggg
4728

Query: 2314 ctccctgctccctccctccaccggggaagggcatgggctagaagaggaga 2363

|||||
Sbjct: 4727 ctccctgctccctccctccaccggggaagggcatgggctagaagaggaga 4678

Score = 133 bits (67), Expect = 9e-34
Identities = 74/75 (98%), Gaps = 1/75 (1%)
Strand = Plus / Minus

Query: 2384 aatgttttgctg-cgggggtccccctccattccctggagtttgggggaaggggaatcat
2442

|||||
Sbjct: 4657 aatgttttgctggcgggggtccccctccattccctggagtttgggggaaggggaatcat
4598

Query: 2443:taaagtgtttcaga 2457

|||||
Sbjct: 4597 taaagtgtttcaga 4583

Score = 103 bits (52), Expect = 8e-25
Identities = 52/52 (100%)
Strand = Plus / Minus

Query: 2175 agctggttgaattgtctttattaacaaacaggatatccaaggccactacatt 2226

|||||
Sbjct: 4863 agctggttgaattgtctttattaacaaacaggatatccaaggccactacatt 4812

Fig. 5e

25/53

Mus_AChR Mus_AChR 1590 Anti_Mus_AChR 2227 OL: 672 OF1:
934 OF2: 506

Score = 1221 (337.4 bits), Expect = 3.7e-254, Sum P(4) = 3.7e-254
Identities = 245/246 (99%), Positives = 245/246 (99%), Strands Minus /
Plus

Query: 1587 AGTTCACAAACCAGATTTATTGTCAGCGGCCTGTTTCAAATCTCTTTCTTGGGGGGTG
1528

Sbjct: 506 AGTTCACAAACCAGATTTATTGTCAGCGGCCTGTTTCAAATCTCTTTCTTGGGGGGTG
565

Query: 1527 GGGGAGAGGTGGGTGCCAGTGCAGGCTCATGGTTGGATGCACGGTGGGTAAGGGAGATCA
1468

Sbjct: 566 GGGGAGAGGTGGGTGCCAGTGCAGGCTCATGGTTGGATGCACGGTGGGTAAGGGAGATCA
625

Query: 1467 GGAACCTGGTTGAAGTAACCCCCAAGGAAGATGAGAGTAGAACCAACGCTGAAGAGCACC
1408

Sbjct: 626 GGAACCTGGTTGAAGTAACCCCCAAGGAAGATGAGAGTAGAACCAACGCTGAAGAGCACC
685

Query: 1407 AAAGCTGCCCCAAAAACAGACATTGTCCAGGGCCTTCCCCATACGCACCCAGTCGGACAGT
1348

Sbjct: 686 AAAGCTGCCCCAAAAACAGACATTGTCCAGGGCCTTCCCCATACGCACCCAGTCGGACAGT
745

Query: 1347 TCCTCT 1342

Sbjct: 746 TCCTGT 751

Score = 954 (263.6 bits), Expect = 3.7e-254, Sum P(4) = 3.7e-254
Identities = 198/207 (95%), Positives = 198/207 (95%), Strands Minus /
Plus

Query: 1249 GCAGAGGGCTGCGGTCCAAGTTCCGTGCCGATGCCTCTGACCCTCAAACACGAGTTCGCT
1190

Sbjct: 1007 GCAGTGCTTACCGGTCCAAGTTCCGTGCCGATGCCTCTGACCCTCAAACACGAGTTCGCT
1066

Query: 1189 CCGCGGCTTTTCAAGATGAGCTCCTCCGCTCTGAGCAGAATGCCACAGACGAGGCACG
1130

Sbjct: 1067 CCGCGGCTTTTCAAGATGAGCTCCTCCGCTCTGAGCAGAATGCCACAGACGAGGCACG
1126

Query: 1129 CCTCGCTGGTGAGGCAGTTCGGGGATCCTCTGGGGGTGGGCTCGAGCCCAGGAGACGCGG
1070

Sbjct: 1127 CCTCGCTGGTGAGGCAGTTCGGGGATCCTCTGGGGGTGGGCTCGAGCCCAGGAGACGCGG
1186

Query: 1069 CAGCAGCTCTAATAAAATCTGGCGCAG 1043

|||||

Fig. 5f

```

Sbjct: 1187 CAGCAGCTCTAATAAAAATCTGCAGCCG 1213

Score = 591 (163.3 bits), Expect = 3.7e-254, Sum P(4) = 3.7e-254
Identities = 119/120 (99%), Positives = 119/120 (99%), Strands Minus /
Plus

Query: 1053 ATCTGGCGCAGCCGAGGGGATGTAGCATGAGTCGTTGGCGTCCTCAAAGATACGTTGAGC
994
      | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 1277 ACCTGGCGCAGCCGAGGGGATGTAGCATGAGTCGTTGGCGTCCTCAAAGATACGTTGAGC
1336

Query: 993 ACGATGACGCAATTCATGACAATGAGCGTGGCAACCACCATGACGAATATAAGATACCTG
934
      | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 1337 ACGATGACGCAATTCATGACAATGAGCGTGGCAACCACCATGACGAATATAAGATACCTG
1396

Score = 546 (150.9 bits), Expect = 3.7e-254, Sum P(4) = 3.7e-254
Identities = 110/111 (99%), Positives = 110/111 (99%), Strands Minus /
Plus

Query: 1346 CCTCTCCAGTGGCTTCTCTGGTCTCTTGTGCTCTCAGCCACAAAGTTCACAGCATCCACAC
1287
      | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 826 CCTCTCCAGTGGCTTCTCTGGTCTCTTGTGCTCTCAGCCACAAAGTTCACAGCATCCACAC
885

Query: 1286 AGCAGCGGATTTCTGGGGCTGCAGCACCCAGGTTCTGGCAGAGGGCTGCGG 1236
      | |||||||||||||||||||||||||||||||||||||||
Sbjct: 886 AGCAGCGGATTTCTGGGGCTGCAGCACCCAGGTTCTGGCAGAGGGCTGCTG 936

```

Fig. 5f continued

27/53

CyclinE2 CyclinE2 2714 Anti_CyclinE2 6773 OL: 1855
OF1: 865 OF2: 2006

Score = 7885 (2178.8 bits), Expect = 0.0, Sum P(4) = 0.0
Identities = 1577/1577 (100%), Positives = 1577/1577 (100%), Strands Minus
/ Plus

Query: 2714 TACAGCTGGCAGCGCAGAGAAGGAAAAAAGTTTCTCCAAGCAATGGCAAAACTTTACT
2655
|||||
Sbjct: 2006 TACAGCTGGCAGCGCAGAGAAGGAAAAAAGTTTCTCCAAGCAATGGCAAAACTTTACT
2065

Query: 2654 TTTAAGCAGTTAAATTTTTTAACTTTTATTTTTTAAACAATGGGCTAAAAATAAACAGT
2595
|||||
Sbjct: 2066 TTTAAGCAGTTAAATTTTTTAACTTTTATTTTTTAAACAATGGGCTAAAAATAAACAGT
2125

Query: 2594 ATTAAAAGGTTAAGTTTATATAATACATATGTACACAATTAGTGGTGTTCCTTTTCAGA
2535
|||||
Sbjct: 2126 ATTAAAAGGTTAAGTTTATATAATACATATGTACACAATTAGTGGTGTTCCTTTTCAGA
2185

Query: 2534 CAAAATACTGAAACAAATATTAGTTTAAAAACAACTATACAGAAGACTTCATACCGTAA
2475
|||||
Sbjct: 2186 CAAAATACTGAAACAAATATTAGTTTAAAAACAACTATACAGAAGACTTCATACCGTAA
2245

Query: 2474 CAATAAATGTATAGTTTCTTCAAAGGGAGAAGAGATTCACATATCTGATAACAAAATAAA
2415
; |||||
Sbjct: 2246 CAATAAATGTATAGTTTCTTCAAAGGGAGAAGAGATTCACATATCTGATAACAAAATAAA
2305

Query: 2414 CTAGCAATCTAGTTTCTAATCTACTTTATGAGGCTGGATTTTTTTTTTAGAAAAGCTAA
2355
|||||
Sbjct: 2306 CTAGCAATCTAGTTTCTAATCTACTTTATGAGGCTGGATTTTTTTTTTAGAAAAGCTAA
2365

Query: 2354 TTTAAAATATTTAGAAATAGCTAGCCTATGTACAGCAAGTTTCATGTCTTTTTTTAATA
2295
|||||
Sbjct: 2366 TTTAAAATATTTAGAAATAGCTAGCCTATGTACAGCAAGTTTCATGTCTTTTTTTAATA
2425

Query: 2294 AATAGATTTCTAGGAGTCAGTATATATTTAATACTCTTCTTCCTTAAGAAAATAGAAGTT
2235
|||||
Sbjct: 2426 AATAGATTTCTAGGAGTCAGTATATATTTAATACTCTTCTTCCTTAAGAAAATAGAAGTT
2485

Query: 2234 TAGGTCAAGTGTTAAGCTTTATCACTTTGACACTGTCCTTATCTCACAATGGAGGAATTT
2175
|||||

Fig. 5g

28/53

Sbjct: 2486 TAGGTCAAGTGTTAAGCTTTATCACTTTGACACTGTCCTTATCTCACAATGGAGGAATTT
2545

Query: 2174 AGAAAGGACCTTAACAGTTTCACAAACATAAATAAGCCTTAGTCACACTAAATTAAAAA
2115

Sbjct: 2546 AGAAAGGACCTTAACAGTTTCACAAACATAAATAAGCCTTAGTCACACTAAATTAAAAA
2605

Query: 2114 AAAAAATTCCTTAGGGATATCTTAGAGTAGTAAAGTGACTTCCTCATATAAATAGTTTGA
2055

Sbjct: 2606 AAAAAATTCCTTAGGGATATCTTAGAGTAGTAAAGTGACTTCCTCATATAAATAGTTTGA
2665

Query: 2054 AAGGGTACTTAAGTTTTTCACCCAAATTGTGATATACAAAAGGTTATTACCAAGCAACC
1995

Sbjct: 2666 AAGGGTACTTAAGTTTTTCACCCAAATTGTGATATACAAAAGGTTATTACCAAGCAACC
2725

Query: 1994 TACATGTCAAGAAAGCCCCAGTTAGGAAGGAGCCACAGCATTTATCTTGTTTATAATTC
1935

Sbjct: 2726 TACATGTCAAGAAAGCCCCAGTTAGGAAGGAGCCACAGCATTTATCTTGTTTATAATTC
2785

Query: 1934 TTTGGTACTCCCACTGTTTAGAGCACAGGTTGAACACCATGTTTCATCTAAGCCTTATTAG
1875

Sbjct: 2786 TTTGGTACTCCCACTGTTTAGAGCACAGGTTGAACACCATGTTTCATCTAAGCCTTATTAG
2845

Query: 1874 TTAAAAATGTGTTATGGCAAGGCAAATAAACTAGTTTAAAAACATTAAATTTACCCAT
1815

Sbjct: 2846 TTAAAAATGTGTTATGGCAAGGCAAATAAACTAGTTTAAAAACATTAAATTTACCCAT
2905

Query: 1814 TTGTAGAAATTCAAGTTTTATAATAGCTTGCTATAGCAGCTATAGATAAATTAGTCACCT
1755

Sbjct: 2906 TTGTAGAAATTCAAGTTTTATAATAGCTTGCTATAGCAGCTATAGATAAATTAGTCACCT
2965

Query: 1754 TATTACAAAACCTAAACCTTTGTAAACAAGTTTAAATTTAATTTTCAAGAACCAAATTGCA
1695

Sbjct: 2966 TATTACAAAACCTAAACCTTTGTAAACAAGTTTAAATTTAATTTTCAAGAACCAAATTGCA
3025

Query: 1694 CTAGTCAAGAGTGTAGGAATTTTGAGAATCTAACAACCTAGATTCAAAGTACTGTATCACT
1635

Sbjct: 3026 CTAGTCAAGAGTGTAGGAATTTTGAGAATCTAACAACCTAGATTCAAAGTACTGTATCACT
3085

Query: 1634 TAGTATACCCCTTTAAGGTAGCACTTATCCAGTCCAAAACCTCCAGTGACAAAATTCCTAGT
1575

Fig. 5g continued

29/53

```
|||||
Sbjct: 3086 TAGTATACCCCTTTAAGGTAGCACTTATCCAGTCCAAACTCCAGTGACAAAATTCCTAGT
3145
Query: 1574 TTATCAAGATAAACACAGTAACACTGGATTAAAGGAAAAACATTGCTATGGTATAGACTG
1515
|||||
Sbjct: 3146 TTATCAAGATAAACACAGTAACACTGGATTAAAGGAAAAACATTGCTATGGTATAGACTG
3205
Query: 1514 TGGTTGGCTTCTATCCAGTAACCTTGGGAATGAAGACATCTTTGTAAACAAGTCCTGCTG
1455
|||||
Sbjct: 3206 TGGTTGGCTTCTATCCAGTAACCTTGGGAATGAAGACATCTTTGTAAACAAGTCCTGCTG
3265
Query: 1454 TTTCTTTAACAGCTAACATAGGAAATAATTAAATGTATTCTTTAGTGCCAATTGTAAGTT
1395
|||||
Sbjct: 3266 TTTCTTTAACAGCTAACATAGGAAATAATTAAATGTATTCTTTAGTGCCAATTGTAAGTT
3325
Query: 1394 TTAAATCAGAATGGCAGTGTAACCTTGTGAATTGGCTAGGGCAATCAATCACAGCACTAC
1335
|||||
Sbjct: 3326 TTAAATCAGAATGGCAGTGTAACCTTGTGAATTGGCTAGGGCAATCAATCACAGCACTAC
3385
Query: 1334 TTTCTGTAAACTTTAGTAGTTCAGTGATACCAGTTCTACCCAATCTTGGTGAATTCCAA
1275
|||||
Sbjct: 3386 TTTCTGTAAACTTTAGTAGTTCAGTGATACCAGTTCTACCCAATCTTGGTGAATTCCAA
3445
Query: 1274 CTTGTTTGCTTAGTTATCTTCTTTAGTGTTTTCTGGTGGTTTTTCAGTGCTCTTCGGTG
1215
|||||
Sbjct: 3446 CTTGTTTGCTTAGTTATCTTCTTTAGTGTTTTCTGGTGGTTTTTCAGTGCTCTTCGGTG
3505
Query: 1214 GTGTCATAATGCCTCCATTGCACACTGGTGACAACTGTCCCCCTTTTCTGAAGGTGTTTA
1155
|||||
Sbjct: 3506 GTGTCATAATGCCTCCATTGCACACTGGTGACAACTGTCCCCCTTTTCTGAAGGTGTTTA
3565
Query: 1154 TGTAATTTACTTCCTCC 1138
|||||
Sbjct: 3566 TGTAATTTACTTCCTCC 3582

Score = 805 (222.4 bits), Expect = 0.0, Sum P(4) = 0.0
Identities = 161/161 (100%), Positives = 161/161 (100%), Strands Minus /
Plus

Query: 1139 CCAGCATAGCCAAATAGTTTGTATGTGTCTGGATATTATGTCTGTCTTCCATAGGAATCT
1080
|||||
```

Fig. 5g continued

30/53

Sbjct: 3967 CCAGCATAGCCAAATAGTTTGTATGTGTCTGGATATTATGTCTGTCTTCCATAGGAATCT
4026

Query: 1079 TCTTAAAAGTCTTCAGCTTCACTGGACTAGTACTTTTTACTACATTGACAAAAGGTACCA
1020

|||||

Sbjct: 4027 TCTTAAAAGTCTTCAGCTTCACTGGACTAGTACTTTTTACTACATTGACAAAAGGTACCA
4086

Query: 1019 TCCAATCTACACATTCTGAAATACTGTCCCACTCCAAACCT 979
|||||

Sbjct: 4087 TCCAATCTACACATTCTGAAATACTGTCCCACTCCAAACCT 4127

Score = 581 (160.5 bits), Expect = 0.0, Sum P(4) = 0.0
Identities = 117/118 (99%), Positives = 117/118 (99%), Strands Minus /
Plus

Query: 982 ACCTGAGGCTTTCTTAACCACTTCAATGGAGGTAAAATGGCACAAGGCAGCAGCAGTCAG
923

|||||

Sbjct: 4615 ACCTGAGGCTTTCTTAACCACTTCAATGGAGGTAAAATGGCACAAGGCAGCAGCAGTCAG
4674

Query: 922 TATTCTGTACTGGAACCTAATGAATCAATGGCTAGAATACACAGATCTAAAAGCTGA 865
|||||

Sbjct: 4675 TATTCTGTACTGGAACCTAATGAATCAATGGCTAGAATACACAGATCTAAAAGCTAA 4732

Fig. 5g continued




Fig. 6

32/53




Fig. 7




Fig. 8

33/53




Fig. 9




Fig. 10




Fig. 11

34/53




Fig. 12

35/53




Fig. 13

36/53




Fig. 14

37/53




Fig. 15b




Fig. 15a




Fig. 16

39/53

Fig. 17a

AChR- ϵ




Fig. 17b

Mink




Fig. 18

41/53




Fig. 19a

Fig. 19b







Fig. 20



43/53




Fig. 22a




Fig. 22b

44/53




Fig. 22c




Fig. 22d

45/53




Fig. 22e




Fig. 22f

46/53




Fig. 22g




Fig. 22h

47/53




Fig. 22i




Fig. 22j

48/53

Probe	Probe pass thres hold	Anti sen se pair ver.	Actu al pool	Virtu al pool	Y79	ES-2	HEK -293	K-562	HT-29	SK-N DZ	MG-63	SNU1	NI564	HeLa	MCF10
					28 52b	29 53	30b 78	31b 55b	33b 56	34b 89	35 58	36b 79	45 63	46b 64	50b
Actin lum	+	+	CTRL	472 442	0.56 0.71	0.89 0.89	0.62 0.95	0.71 0.73	0.41 0.47	0.66 0.62	0.78 0.8	1.01 1.12	2.24 2.6	0.91 1.09	0.92
GAPDH 30um	+	+	CTRL	1847 1710	0.97 0.96	0.82 0.78	0.53 0.51	0.97 0.86	0.47 0.52	0.87 0.73	1.03 0.8	1.88 1.65	1.28 0.87	1.38 1.33	0.84
HUMM	+	+	CTRL	2245 2282	1.43 1.42	0.85 0.78	1.16 1.06	1.26 1.02	0.82 0.88	1.1 0.95	1.95 1.28	0.88 0.75	0.91 0.54	1.37 1.25	1.14
Known 10AC	+	VER.	378 426	1.82 1.49	0.65 0.54	0.94 0.91	0.91 0.91	1.32 0.82	1.03 0.66	1.61 1.57	2.34 2.37	0.8 0.65	1.06 0.55	1.15 0.9	0.79
Known 10C	+	VER.	95 103	1.04 1.27	0.78 0.84	-1	1.51 1	-1	1 1.16	-1 1.78	1	0.74 1.01	0.79 1	1.49 1	0.58
Known 9AC	+	VER.	852 959	2 1.84	0.81 0.69	1.07 1.26	1.56 1.14	1.14	1.11 0.85	1.55 1.27	1.14 0.83	0.76 0.63	0.89 0.49	1.28 1.25	0.77
260AC	+		154 197	1.34 1.95	0.35 1	0.9 1.79	0.84 1	0.84	0.71 1.42	0.87 1.35	0.47 1	0.59 1.3	0.78 1	1.14 1	1.31
260C	-		33 48	1 1	0.93 1	-1	1.8 1	-1	1 1	1 -1	-1 -1	1 1	1 1	1 1	1
261AC	+	VER.	344 357	-1 1	0.65 0.53	1.34 1.22	1.76 1.09	1.09	1 0.69	1.65 1	1.04 0.71	0.86 0.64	1.32 0.39	2.09 1.01	1
72C	-	IND. VER.	63 69	1.28 1.15	0.46 0.78	1	1	-1	1 2.32	1.14 1.78	-1 -1	1 1	1 1	1 1	0.6

Fig. 23

49/53

	Lung		Testis		Placenta		DU 145		T24		G-361		Jurkat		HepG2		MCF7		PANC-1	H1299	Brain	
	70	74	71	75	72b	76	82	83	69	51	80	60	88	66	86b	67b	85	84	37	43	77	
68b	0.98	1.34	1.37	0.45	0.55	1.51	1	1.19	1.1	1.52	0.94	1.41	1.36	1.33	1	0.34	0.55	1.32	1.13	0.86	0.9	1.16
	0.82	0.37	0.31	0.36	0.28	0.55	0.44	0.93	0.69	0.96	0.57	1.4	1.19	1.36	0.91	0.85	0.81	0.78	0.5	0.62	2.16	0.86
	1.04	1.44	0.9	1.16	0.71	1.19	0.9	1.12	0.82	0.97	0.55	0.95	0.71	1.13	0.62	1.37	1.32	1.31	0.83	1.13	1.65	0.66
	0.78	1.74	1.22	1.87	1.34	1.42	1.13	1.17	0.95	0.77	0.35	1.42	1	0.94	0.84	1.12	1.16	0.96	0.59	1.76	1.48	1.43
	1.61	1.59	1	0.89	1	1	1	1	1	1	0.57	1	1	1	1	0.85	1.3	1	1	1.65	1.55	1
	0.84	2.11	1.27	1.54	1.16	1.04	0.67	1.05	0.9	0.86	0.52	1.38	0.79	1.34	1.1	1.03	1.09	1.48	1.11	1.52	1.29	1.2
	3.64	1.01	2.58	1.43	3.45	1.52	3.07	1.02	1	0.56	0.72	0.84	0.5	1	1	0.84	1.55	1.1	1.09	1	1.04	4.89
	1	1	1	1	1	1	2.46	1	-1	1	-1	1	1	1	1	1	1.68	1	1	-1	-1	1
	1	1	1	2.17	1.31	1.39	0.83	1.36	0.72	0.96	0.52	1	0.58	1.95	1	1.5	0.94	1.86	1	-1	-1	1
	1.05	1	1	-1	1	1	1	1.02	1	1	0.99	1	1	-1	1.83	1	1	1	1	1	1	1

Fig. 23 (Cont.)

50/53

FIG. 24a

2091_0 Z19505_0 5019 M78914_25 801 OL: 187
Query: 222 accccctgccgtagccatcttgccctctctgctgagcggaagcccccggttcggctcctgtc 281
|||||
Sbjct: 160 accccctgccgtagccatcttgccctctctgctgagcggaagcccccggttcggctcctgtc 101

Query: 282 tgtttagcggcctctctaggctaccactgacaccgtctctgtggcccgagcctaagagac 341
|||||
Sbjct: 100 tgtttagcggcctctctaggctaccactgacaccgtctctgtggcccgagcctaagagac 41

Query: 342 cggaagttcgtggttccaggcgc 364
|||||
Sbjct: 40 cggaagttcgtggttccaggcgc 18

Score = 87.7 bits (44), Expect = 1e-18
Identities = 44/44 (100%)
Strand = Plus / Minus

Query: 183 acctgctagtaggacgcagaaagacagaaggcgaaggagacccc 226
|||||
Sbjct: 229 acctgctagtaggacgcagaaagacagaaggcgaaggagacccc 186

51/53




FIG. 24b

52/53

FIG. 25a

3673_0 T24746_0 3068 N31850_0 1705 OL: 585

Query: 2480 tgagttatgttgtcttttatttagcaggggaatgtcatcacagattggatagtagtacatccagg 2539
|||||

Sbjct: 1705 tgagttatgttgtcttttatttagcaggggaatgtcatcacagattggatagtagtacatccagg 1646

Query: 2540 tgcaatgtcaccatcagcaaggtcagcttgacactcaagtgggaagattaggggaagaatga 2599
|||||

Sbjct: 1645 tgcaatgtcaccatcagcaaggtcagcttgacactcaagtgggaagattaggggaagaatga 1586

Query: 2600 ctaggatnnnnnnnnnggagggcaccaagggaaagggatgatggggtgagctggcgagt 2659
|||||

Sbjct: 1585 ctaggataaaaaaaaaggagggcaccaagggaaagggatgatggggtgagctggcgagt 1526

Query: 2660 gtgggtgggaaatgaaatgtttattgaggatctgctttgtgctgggcactttaatccaca 2719
|||||

Sbjct: 1525 gtgggtgggaaatgaaatgtttattgaggatctgctttgtgctgggcactttaatccaca 1466

Query: 2720 ttttatcgttttactttttcaaacagatgcaccttacccccaccccaatgctctgtccctgc 2779
|||||

Sbjct: 1465 ttttatcgttttactttttcaaacagatgcaccttacccccaccccaatgctctgtccctgc 1406

Query: 2780 agatatcagaagacagtggtgattttcatgctctgaagttcagttttacatccaagcatcc 2839
|||||

Sbjct: 1405 agatatcagaagacagtggtgattttcatgctctgaagttcagttttacatccaagcatcc 1346

Query: 2840 ctctctgttttttaacaatccaaagacaggccnnnnnnngcaccacagttttattaagtac 2899
|||||

Sbjct: 1345 ctctctgttttttaacaatccaaagacaggccaaaaaaagcaccacagttttattaagtac 1286

Query: 2900 ttactaagcaccatccactgccccacactgtggcaaggattgtgaggggtaagaagca 2959
|||||

Sbjct: 1285 ttactaagcaccatccactgccccacactgtggcaaggattgtgaggggtaagaagca 1226

Query: 2960 tggggcacaatattctgctgccttcatgtaacttacagtctcacaataaatagaacttc 3019
|||||

Sbjct: 1225 tggggcacaatattctgctgccttcatgtaacttacagtctcacaataaatagaacttc 1166

Query: 3020 agttgaaatactgacattaattaataatagagttgtaataaatacaa 3064
|||||

Sbjct: 1165 agttgaaatactgacattaattaataatagagttgtaataaatacaa 1121

53/53

Fig.25b

```
>45499 T24746_1 (45497 T24746_P2) #GENE_SYMBOL IL24 ;MDA7 ;ST16 #GO_F
#GO_Acc 5125 #GO_Desc cytokine activity #CL 1 #DB sp #EN IL24_HUMAN
#GO_P #GO_Acc 6915 #GO_Desc apoptosis #CL 1 #DB sp #EN IL24_HUMAN #GO_P
#GO_Acc 6955 #GO_Desc immune response #CL 1 #DB sp #EN IL24_HUMAN #GO_C
#GO_Acc 5576 #GO_Desc extracellular #CL 3 #DB PROLOC #EN PROLOC #GO_C
#GO_Acc 5576 #GO_Desc extracellular #CL 1 #DB sp #EN IL24_HUMAN
>45290 W01276_0 (45289 W01276_P1) #GENE_SYMBOL TOSO #TAA blood-tumor
#GO_F #GO_Acc 8189 #GO_Desc apoptosis inhibitor activity #CL 1 #DB sp
#EN O60667 #GO_P #GO_Acc 6916 #GO_Desc anti-apoptosis #CL 1 #DB sp #EN
O60667 #GO_P #GO_Acc 6968 #GO_Desc cellular defense response #CL 1 #DB
sp #EN O60667 #GO_C #GO_Acc 16020 #GO_Desc membrane #CL 3 #DB PROLOC
#EN PROLOC
```

1

SEQUENCE LISTING

<110> Levanon Erez, et al.

<120> METHODS AND SYSTEMS FOR IDENTIFYING NATURALLY OCCURRING ANTISENSE
TRANSCRIPTS AND METHODS AND KITS UTILIZING SAME

<130> 27987

<150> US 09/718,407

<151> 2000-11-24

<150> US 09/732,938

<151> 2000-12-11

<150> US 09/785,439

<151> 2001-02-20

<150> US 09/907,923

<151> 2001-07-18

<150> US 009/993,398

<151> 2001-11-06

<150> US 10/201,605

<151> 2002-7-24

<160> 44

<170> PatentIn version 3.1

<210> 1

<211> 190

<212> DNA

<213> Homo sapiens

<400> 1
ggaccagga tatgagcga aaacactttc tctacttaga tacaactttt tcctgtgcgc 60
atgcctgtaa tcccagctac tcaggaggct gaggcaggag aatcccttga acccaggagg 120

2

cagaggttgc ggtgagccaa gatctcacca ttgcactcca gcctgggcaa taagaacaaa 180
actccgtctc 190

<210> 2

<211> 783

<212> DNA

<213> Homo sapiens

<400> 2

gaaaaagtgt tatctaagta gagaaagtgt tttccgctca taccctgggt ccacatcgaa 60
gaattcagtc cttgtggatg aactgtaaac agcacccttc ctctaagatg ccgaagatca 120
tagtttgtgg tttttttctt tcaggcgggtg gaagcagggc agagccgaag cagcccgtc 180
ctcaagaggc cgggtcggac ccaggcgggtg ctggaccagt cagatgtgta caccatgtc 240
ctgtcagcct tcgtggaaaa gaaggtgggc cgcagcttcc cgcctcttct ggactgagaa 300
tgctcaaaac aaggaagtgt ctgaaaacga ggagacttca tgtgattaga gtcacttgaa 360
gtgattagaa tcaactggagt ttccttgggt gaggccctag agctggtagt ttggcttcta 420
atgctgaggc ctaaagcata attgttgacg ggtggttctg gagcgatttg tgcaaaacca 480
gtgaaagatg aacactgggc cattttaaga tggaaacaag gtgggggttg gatagagagt 540
tatatgcagc ctcttttgca cctcgttgggt atttgaaga ccacattttt ttctccctag 600
gagatgcctc ataaatttgt gatagccgtg ctgatggaat acattcgttc tcttaaccag 660
tttcagattg cagtacagct atgtaactga gtaagacagg gagaaatatt aatccgtgag 720
tggtctccag taagaccatg gccaaataca tcctgaagta gaatatctgg aaaatttgag 780
att 783

<210> 3

<211> 1649

<212> DNA

<213> Homo sapiens

<400> 3

gaaaaagtgt tatctaagta gagaaagtgt tttccgctca taccctgggt ccacatcgaa 60
gaattcagtc cttgtggatg aactgtaaac agcacccttc ctctaagatg ccgaagatca 120
tagtttgtgg tttttttctt tcaggcgggtg gaagcagggc agagccgaag cagcccgtc 180
ctcaagaggc cgggtcggac ccaggcgggtg ctggaccagt cagatgtgta caccatgtc 240
ctgtcagcct tcgtggaaaa gaaggtgggc cgcagcttcc cgcctcttct ggactgagaa 300
tgctcaaaac aaggaagtgt ctgaaaacga ggagacttca tgtgattaga gtcacttgaa 360
gtgattagaa tcaactggagt ttccttgggt gaggccctag agctggtagt ttggcttcta 420

3

atgctgaggc	ctaaagcata	attgttgacg	ggtaggttctg	gagcgatttg	tgcaaaacca	480
gtgaaagatg	aacactgggc	cattttaaga	tggaacaag	gtgggggttg	gatagagagt	540
tatatgcagc	ctcttttgca	cctcggttgg	atttgtaaga	ccacatTTTT	ttctccctag	600
gagatgcctc	ataaatttgt	gatagccgtg	ctgatggaat	acattcggtc	tcttaaccag	660
tttcagattg	cagtacagcc	ttcaaatcat	ctgggcccaa	gttaaacag	aaggaattta	720
aaaaaaaaac	acagtcactg	tcttagaaga	tgactcatat	gctaagacag	gtctgcctcc	780
ctgactcaga	atgctgagtg	actcctgaca	ttattagttg	gaatgggaag	tgtaagggtca	840
agttggggtc	tttacctgca	tgacgaaacc	acttcttgta	atgacagact	tttactgtgt	900
tggttagaat	agccagtcct	tggggagcct	ctagtctgtt	gtagctgaat	gatttggaag	960
tggtctttca	ctttttactt	ttgtcctcag	cattacctac	atgaacttgt	tatcaaaacc	1020
cttgctccagc	acaacctctt	ttatatgctg	catcagttcc	tgtagtacca	cgtcctcagc	1080
gactccaaac	ctttggcctg	tctgctgtta	tccttagaga	gtttctatcc	tcctgctcat	1140
cagctatctc	tgtagcatgct	gaaggtaact	ctgatgtgtg	aggttttaga	ctatggaaac	1200
taactctgtt	cctgttgttt	gcactgacct	ggacttctct	cccttactgc	tagcgacttt	1260
caacagcaaa	tgatgaaata	gtagaagttc	tcctttccaa	acaccaagtg	ttagctgcct	1320
taaggtttat	cgggggcatt	ggtggccatg	acaacatttc	tgacgaaaa	tttttagatg	1380
ctgcaaagca	gactgaagac	aacatgcttt	tctatacaat	attccgcttt	tttgaacagc	1440
gaaaccagcg	tttgcgaggg	agccccaatt	tcacaccagg	ggaacactgt	gaagaacatg	1500
ttgctttttt	caaacagatt	tttgagagacc	aagctctaata	gaggcctaca	acattctgaa	1560
atcacttgct	gttttttttat	ataaaaatgt	gtacaaaagt	aatttattgc	attaataaag	1620
ctctttaaac	tataaaatgt	taaaaagt				1649

<210> 4

<211> 1861

<212> DNA

<213> Homo sapiens

<400> 4

gaaaaagttg	tatctaagta	gagaaagtgt	tttccgctca	tatcctgggt	ccacatcgaa	60
gaattcagtc	cttgtggatg	aactgtaaac	agcacccttc	ctctaagatg	ccgaagatca	120
tagtttgtgg	tttttttctt	tcaggcggtg	gaagcagggc	agagccgaag	cagcccgtct	180
ctcaagaggc	cgggtcggac	ccaggcggtg	ctggaccagt	cagatgtgta	cacctatgtc	240
ctgtcagcct	tcgtggaaaa	gaagggtggc	cgcagctttc	cgcctcttct	ggactgagaa	300
tgctcaaaac	aaggaagttg	ctgaaaacga	ggagacttca	tgtgattaga	gtcacttgaa	360
gtgattagaa	tactggagtg	ttccttgggt	gaggccctag	agctggtagt	ttggcttcta	420
atgctgaggc	ctaaagcata	attgttgacg	ggtaggttctg	gagcgatttg	tgcaaaacca	480
gtgaaagatg	aacactgggc	cattttaaga	tggaacaag	gtgggggttg	gatagagagt	540

tatatgcagc ctcttttgca cctcgttggt atttgtaaga ccacatTTTT ttctccctag 600
 gagatgcctc ataaatttgt gatagccgtg ctgatggaat acattcgttc tcttaaccag 660
 tttcagattg cagtacagcc ttcaaatacat ctgggcccac gttaaaacag aaggaattta 720
 aaaaaaaaaac acagtcaactg tcttagaaga tgactcatat gctaagacag gtctgcctcc 780
 ctgactcaga atgctgagtg actcctgaca ttattagttg gaatgggaag tgtaagggtca 840
 agttgggggc tttacctgca tgacgaaacc acttcttgta atgacagact tttactgtgt 900
 tggttagaat agccagtcct tggggagcct ctagtctgtt gtagctgaat gatttggaag 960
 tgttctttca ctttttactt ttgtcctcag cattacctac atgaacttgt tatcaaaacc 1020
 cttgtccagc acaacctctt ttatatgctg catcagttcc tgcagtacca cgtcctcagc 1080
 gactccaaac ctttggttg tctgctgtta tccctagaga gtttctatcc tctgctcat 1140
 cagctatctc tggacatgct gaaggtaact ctgatgtgtg aggttttaga ctatggaaac 1200
 taactctgtt cctgttggtt gcactgacct ggacttctct cccttactgc tagcgacttt 1260
 caacagcaaa tgatgaaata gtagaagttc tcttttcaa acaccaagtg ttagctgcct 1320
 taaggtttat ccggggcatt ggtggccatg acaacatttc tgcacgaaa tttttagatg 1380
 ctgcaaagca gactgaagac aacatgcttt tctatacaat attcgccttt tttgaacagc 1440
 gaaaccagcg tttgcgagg agcccaatt tcacaccagg tgagaatgca atgaaaagac 1500
 ttggggtaac catagcctca aagagtagca gagggcactg gcagctggtg ggcgaggacc 1560
 ctgggttagc atttttgtaa acaacacaat ttgataacag cccacctagc ccttggccca 1620
 ttattttag tagagtgaat tcagtatact gacagaatct ggattatgct ctggaactca 1680
 ccgaggaggt gtgttttgag tcaagacaca tttaggaccc agatcaggca cagcccatct 1740
 cttatagcag atcttggaat atctcttaaa gccaggaata agacggcaaa tgggtggctaa 1800
 gggttttaaa gggctcgggg cttattaagg tttcagtttt atgaagtata cattgggtga 1860
 t 1861

<210> 5

<211> 214

<212> DNA

<213> Homo sapiens

<400> 5

gtaagggaaac tttggcgact tagtgcgatc actgggagaa ttgtagagtc cactggagag 60
 aaagaaaaat ggtcaaaaag agcccagaga gttcctgggg gaaaacacac cgcagcccag 120
 acctattcat aactgcacag ctggtacttc cagaggcaca tgcaccaggg gcacgtggtt 180
 ctctttgctg acaagattta ttaaaagaaa agag 214

<210> 6

<211> 1934

<212> DNA

<213> Homo sapiens

<400> 6

```

aagtcaacga aaggttcctg tgtccttgac cacgtattcc atcacgtaaa ccttgtggag      60
atagattatt ttgggctacg ttactgtgac agaagccatc agacgtattg gctggatcct      120
gcaaaaaccc ttgctgaaca caaagaactg atcaacactg gacctccata tactttgtat      180
tttggattta aattctatgc tgaagatcca tgtaaaactta aagaagaaat aaccagatat      240
cagtttttct tgcaggtgaa gcaagatgtc cttcagggcc gtctgccctg tcccgtaaac      300
actgctgctc agctgggagc gtatgccatc cagtcggagc ttggagatta tgacccatat      360
aaacatactg caggatatgt atctgagtac cggtttggtc ctgatcagaa ggaagaactt      420
gaagaagcca tagaaaggat tcataaaact ctaatgggtc agattccttc tgaggctgag      480
ctgaattact tgaggactgc caaatccctg gagatgtatg gcgttgacct ccatcccgtc      540
tatggagaaa acaagtctga gtatttctta ggattaactc cggttgggtg tgttgtgtac      600
aagaataaaa agcaagtggg gaagtatttc tggcctcgga ttacaaaggc tcacttcaag      660
gagactcaat ttgaactcag agtactggga aaagattgta acgaaacctc attctttttt      720
gaagctcgga gtaaaactgc ttgcaagcac ctctggaagt gcagtgtgga acatcataca      780
tttttttaga tgccagaaaa tgaatccaat tcactgtcaa gaaaactcag caagtttgga      840
tccatacgtt ataagcaccg ctacagtggc aggacagctt tgcaaatgag ccgagatctt      900
tctattcagc ttccccggcc tgatcagaat gtgacaagaa gtcgaagcaa gacttacctt      960
aagcgaatag cacaacacac gccagctgaa tcaaacacca tcagtaggat aactgcaaac     1020
atggaaaatg gagaaaatga aggaacaatt aaaattattg caccttcacc agtaaaaagc     1080
tttaagaaag caaagaatga aaatagccct gataccctaa gaagcaaata tcatgcaccg     1140
tggaagaaa atggccccc gagtggactc tacaattctc ccagtgatcg cactaagtcg     1200
ccaaagttcc cttacacgcg tcgccgaaac cctcctgtg gaagtgacaa tgattctgta     1260
cagcctgtga ggaggaggaa agcccataac agtggtgaag attcagatct taagcaaagg     1320
aggaggtcac gttcacgctg taacaccagc agtggtagtg aatcagaaaa ttctaataga     1380
gaacaccgga aaaagagaaa cagaatacgg caggagaatg atatggttga ttcagcgcct     1440
cagtgggaag ctgtattaag gagacaaaag gaaaaaaacc aagccgacct caacagcagg     1500
cgatccagac acagatctcg ttcgagaagc cccgatatcc aagcaaaaga agagttatgg     1560
aagcacattc aaaaagaact tgtggatcca tccggattgt ccgaagaaca attaaaagag     1620
attccatata ctaaaataga gtgagtgcct ttcagaatct tctcacctaa gctttattag     1680
tgcttgtgag taatccattc taattcttca atttgtttcc agacagtgtc ttaatttgtc     1740
tttacatttt aaccaaact aggtgacagt agcgaaagag gaagaaaagt gtgcattaaa     1800
gctacttatt ctacactata atcactatca tctcttatta gccacctctt tgtacttggg     1860
aggtacaagg gggcttttcc tgattaatgt cagtttttaa ataaattctt ttctgagatt     1920

```

ctcactgaaa aaat

1934

<210> 7

<211> 2353

<212> DNA

<213> Homo sapiens

<400> 7

aagtcaacga aaggttccgt tgtccttgac cacgtattcc atcacgtaaa ccttgtggag	60
atagattatt ttgggctacg ttactgtgac agaagccatc agacgtattg gctggatcct	120
gcaaaaaccc ttgtcgaaca caaagaactg atcaacactg gacctccata tactttgtat	180
tttgggtatta aattctatgc tgaagatcca tgtaaaacta aagaagaaat aaccagatat	240
cagtttttct tgcaggtgaa gcaagatgtc cttcagggcc gtctgccctg tcccgtcaac	300
actgctgctc agctgggagc gtatgccatc cagtcggagc ttggagatta tgaccatat	360
aaacatactg caggatatgt atctgagtac cggtttggtc ctgatcagaa ggaagaactt	420
gaagaagcca tagaaaggat tcataaaact ctaatgggtc agattccttc tgaggctgag	480
ctgaattact tgaggactgc caaatccctg gagatgtatg gcgttgacct ccatcccgtc	540
tatggagaaa acaagtctga gtatttctta ggattaactc cggttgggtg tgttgtgtac	600
aagaataaaa agcaagtggg gaagtatttc tggcctcgga ttacaaaggc tcacttcaag	660
gagactcaat ttgaactcag agtactggga aaagattgta acgaaacctc attctttttt	720
gaagctcgga gtaaaactgc ttgcaagcac ctctggaagt gcagtgtgga acatcataca	780
tttttttagaa tgccagaaaa tgaatccaat tcactgtcaa gaaaactcag caagtttggg	840
tccatacggt ataagcaccg ctacagtggc aggacagctt tgcaaagag cggagatctt	900
tctattcagc ttccccggcc tgatcagaat gtgacaagaa gtcgaagcaa gacttacctt	960
aagcgaatag cacaacaca gccagctgaa tcaaacacca tcagtaggat aactgcaaac	1020
atggaaaatg gagaaaatga aggaacaatt aaaattattg caccttcacc agtaaaaagc	1080
tttaagaaag caaagaatga aaatagccct gatacccaa gaagcaaata tcatgcaccg	1140
tgggaagaaa atggccccc gagtggactc tacaattctc ccagtgatcg cactaagtcg	1200
ccaaagtctc cttacacgcg tcgccgaaac ccctcctgtg gaagtgacaa tgattctgta	1260
cagcctgtga ggaggaggaa agcccataac agtgggtgaag attcagatct taagcaaagg	1320
aggaggtcac gttcacgctg taacaccagc agtggtagtg aatcagaaaa ttctaataga	1380
gaacaccgga aaaagagaaa cagaatacgg caggagaatg atatggttga ttcagcgctt	1440
cagtgggaag ctgtattaag gagacaaaag gaaaaaaacc aagccgacct caacagcagg	1500
cgatccagac acagatctcg ttcgagaagc cccgatatcc aagcaaaaga agagttatgg	1560
aagcacattc aaaaagaact tgtggatcca tccggattgt ccgaagaaca attaaaagag	1620
attccataca ctaaaataga gacacaaggc gacccaatcc gcatcaggca ttctcattcg	1680

7

```

ccacgaagtt accgccagta tcgcagggtcc cagtgttcag atggggagcg atcagttctc 1740
tcggaagtga attcaaaaac agatcttgta ccaccacttc cggtgacca ttcttcggat 1800
gctcaggggt ctgggggatgc tacagttcat cagagaagaa atgggtctaa agatagcctg 1860
atggaagaaa aacctcagac atctacaaac aacctggctg gaaaacacac agcaaaaaca 1920
ataaaaacta tacaagcttc ccgcctcaag acagagactt gatcctgatg aagggtcaag 1980
ggtaggggtg ggaaggttgt gtgcgccact ggtacttttg aaactgtgaa ataggtatct 2040
taattcaaat ctacagacctg caagtatttc ttcagcatga gaaaatacat tatcttttgc 2100
ttcttttttt tttttttttg agatgttata actctgtcgc ccaggctgga gtgcagcggc 2160
accgtgtcag ctaccgcag cctccactta ctgggttaag cgattctcct gtctcaggct 2220
accgagcagc tgggattaca ggcgtgcacc acaacacccg gctaattctt tttgtatttt 2280
tagtagagac agggctttgc catgttgag gctggtctcg aactcctgac ctcaagtgat 2340
ccgcctgcct cag 2353

```

<210> 8

<211> 2500

<212> DNA

<213> Homo sapiens

<400> 8

```

gacatgggct gtttctgcgc tgttccggaa gaattttact gcgaagtttt gtcctcggat 60
gaatccaagt taacccttac caccagcag cagggcatca agaagtcaac gaaagggtcc 120
gttgtccttg accacgtatt ccatcacgta aaccttgttg agatagatta ttttgggcta 180
cgttactgtg acagaagcca tcagacgtat tggctggatc ctgcaaaaac ccttgctgaa 240
cacaaagaac tgatcaacac tggacctcca tatactttgt attttgggat taaattctat 300
gctgaagatc catgtaaact taaagaagaa ataaccagat atcagttttt cttgcaggtg 360
aagcaagatg tccttcaggg ccgtctgccc tgtcccgta aactgctgc tcagctggga 420
gcgtatgcca tcagtcgga gcttgagat tatgacccat ataaacatac tgcaggatat 480
gtatctgagt accggtttgt tcctgatcag aaggaagaac ttgaagaagc catagaaagg 540
attcataaaa ctctaattggg tcagattcct tctgaggctg agctgaatta cttgaggact 600
gccaaatccc tggagatgta tggcgttgac ctccatcccg tctatggaga aaacaagtct 660
gagtatttct taggattaac tccggttggt gttgttgtgt acaagaataa aaagcaagtg 720
gggaagtatt tctggcctcg gattacaaag gttcacttca aggagactca atttgaaact 780
agagtactgg gaaaagattg taacgaaacc tcattctttt ttgaagctcg gagtaaaact 840
gcttgcaagc acctctggaa gtgcagtgtg gaacatcata catttttttag aatgccagaa 900
aatgaatcca attcactgtc aagaaaactc agcaagtttg gatccatacg ttataagcac 960
cgctacagtg gcaggacagc tttgcaaatg agccgagatc tttctattca gcttccccgg 1020
cctgatcaga atgtgacaag aagtcgaagc aagacttacc ctaagcgaat agcacaaca 1080

```


cagccagctg aatcaaacac catcagtagg ataactgcaa acatggaaaa tggagaaaat 1140
 gaaggaacaa ttaaaattat tgcaccttca ccagtaaaaa gctttaagaa agcaaagaat 1200
 gaaaatagcc ctgataccca aagaagcaaa tctcatgcac cgtgggaaga aaatggcccc 1260
 cagagtggac tctacaattc tcccagtgat cgcactaagt cgccaaagtt cccttacacg 1320
 cgtcgccgaa acccctcctg tggagtgac aatgattctg tacagcctgt gaggaggagg 1380
 aaagcccata acagtgggtga agattcagat cttaagcaaa ggaggagggtc acgttcacgc 1440
 tgtaacacca gcagtggtag tgaatcagaa aattctaata gagaacaccg gaaaaagaga 1500
 aacagaatac ggcaggagaa tgatatgggt gattcagcgc ctcatgggga agctgtatta 1560
 aggagacaaa aggaaaaaaa ccaagccgac cccaacagca ggcgatccag acacagatct 1620
 cgttcgagaa gccccgatat ccaagcaaaa gaagagttat ggaagcacat tcaaaaagaa 1680
 cttgtggatc catccggatt gtccgaagaa caattaaaag agattccata cactaaaata 1740
 gagtgagtg ctttcagaat cttctcacca aagctttatt agtgcttgac acaagggtgac 1800
 ccaatccgca tcaggcatto tcattcgcca cgaagttacc gccagtatcg cagggtccag 1860
 tgttcagatg gggagcgatc agttctctcg gaagtgaatt caaaaacaga tcttgtagca 1920
 ccacttccg tgaccttc ttcggatgct caggggttctg gggatgctac agttcatcag 1980
 agaagaaatg ggtctaaaga tagcctgatg gaagaaaaac ctgagacatc tacaacaac 2040
 ctggctggaa aacacacagc aaaaacaata aaaactatac aagcttccc cctcaagaca 2100
 gagacttgat cctgatgaag ggtcaagggt aggggtggga aggttggtg cgccactggt 2160
 acttttgaaa ctgtgaaata ggtatottaa ttcaaactc agacctgcaa gtatttcttc 2220
 agcatgagaa aatacattat cttttgcttc tttttttttt ttttttgaga tggtatcact 2280
 ctgtcgccca ggctggagtg cagcggcacc gtgtcagctc accgcagcct ccacttactg 2340
 ggttaagcga ttctcctgtc tcaggctacc gagcagctgg gattacaggc gtgcaccaca 2400
 acaccggct aattcttttt gtatttttag tagagacagg gctttgccat gttggaggct 2460
 ggtctcgaac tcctgacctc aagtgatccg cctgcctcag 2500

<210> 9

<211> 947

<212> DNA

<213> Homo sapiens

<400> 9

gaaagatgat actaggtcag gaaatagcat ttgaaagtca ttctcatctg gagggatgaa 60
 gccaaagataa ggcggaacca gggaaaagct ttaagaaagc aaagaatgaa aatagccctg 120
 atacccaaag aagcaaattc catgcaccgt ggggaagaaa tggccccag agtggactct 180
 acaattctcc cagtgatcgc actaagtcgc caaagttccc ttacacgcgt cgccgaaacc 240
 cctcctgtgg aagtgacaat gattctgtac agcctgtgag gaggaggaaa gcccataac 300

9

```

agtgggtgaag tttcagatct taaggcaaag ggagggaggt cacgttcacg ctgtaacacc 360
agcagtggtta gtgaatcaga aaattctaata agagaacacc ggaaaaagag aaacagaata 420
cggcaggaga atgatatggt tgattcagcg cctcagtggg aagctgtatt aaggagacaa 480
aaggaaaaaa accaagccga cccaacagc aggcgatcca gacacagatc tcgttcgaga 540
agccccgata tccaagcaaa agaagagtta tggaagcaca ttcaaaaaga acttgtggat 600
ccatccggat tgtccgaaga acaattaaaa gagattccat aactaaaaat agagtgagtg 660
cctttcagaa tcttctcacc aaagctttat tagtgcttgt gagtaatcca ttctaattct 720
tcaatttgtgt tccagacagt gctttaattt gtctttacat tttaaccaa actaggtgac 780
agtagcgaaa gaggaagaaa agtgtgcatt aaagctactt attctacact ataatacacta 840
tcattctctta ttagccacct ctttgtactt ggtaggtaca agggggcttt tcctgattaa 900
tgtcagtttt aaaataaatt cttttctgag attctcactg aaaaaat 947

```

<210> 10

<211> 1366

<212> DNA

<213> Homo sapiens

<400> 10

```

gaaagatgat actaggtcag gaaatagcat ttgaaagtca ttctcatctg gagggatgaa 60
gccaaagataa ggcggaacca gggaagagct ttaagaaagc aaagaatgaa aatagccctg 120
atacccaaag aagcaaatct catgcaccgt gggaagaaaa tggcccccag agtggactct 180
acaattctcc cagtgatcgc actaagtcgc caaagttccc ttacacgcgt cgccgaaacc 240
cctcctgtgg aagtgacaat gattctgtac agcctgtgag gaggaggaaa gccattaac 300
agtgggtgaag tttcagatct taaggcaaag ggagggaggt cacgttcacg ctgtaacacc 360
agcagtggtta gtgaatcaga aaattctaata agagaacacc ggaaaaagag aaacagaata 420
cggcaggaga atgatatggt tgattcagcg cctcagtggg aagctgtatt aaggagacaa 480
aaggaaaaaa accaagccga cccaacagc aggcgatcca gacacagatc tcgttcgaga 540
agccccgata tccaagcaaa agaagagtta tggaagcaca ttcaaaaaga acttgtggat 600
ccatccggat tgtccgaaga acaattaaaa gagattccat aactaaaaat agagacacaa 660
ggtgacccaa tccgcatcag gcattctcat tcgccacgaa gttaccgcca gtatcgcagg 720
tcccagtggt cagatgggga gcgatcagtt ctctcgaag tgaattcaaa aacagatctt 780
gtaccaccac ttccggtgac ccattctctg gatgctcagg gttctgggga tgctacagtt 840
catcagagaa gaaatgggtc taaagatagc ctgatggaag aaaaacctca gacatctaca 900
aacaacctgg ctggaaaaca cacagcaaaa acaataaaaa ctatacaagc ttcccgcctc 960
aagacagaga cttgatcctg atgaagggtc aagggtaggg gtgggaaggt tgtgtgcgcc 1020
actggtactt ttgaaactgt gaaataggta tcttaattca aatctcagac ctgcaagtat 1080
ttcttcagca tgagaaaata cattatcttt tgcttctttt tttttttttt ttgagatggt 1140

```

10

atcactctgt	cgcccaggct	ggagtgcagc	ggcaccgtgt	cagctcaccg	cagcctccac	1200
ttactggggt	aagcgattct	cctgtctcag	gctaccgagc	agctgggatt	acaggcgtgc	1260
accacaacac	ccggctaatt	ctttttgtat	ttttagtaga	gacagggctt	tgccatgttg	1320
gaggctggtc	tcgaactcct	gacctcaagt	gatccgcctg	cctcag		1366

<210> 11

<211> 422

<212> DNA

<213> Homo sapiens

<400> 11

aatcttcata	atcccatgt	gtcaaaggag	agaccagggtg	gaggtaactg	aatcatgggg	60
gtggtttccc	caggctgttt	ttgtgatagt	gagtgagttc	tcagagatc	tgatggtttt	120
ataaggggct	cttccctcct	ttgcttgtga	agaagggtgcc	ttttttcccc	tttgccttct	180
gcatgattg	taagtttcct	gaggcctccc	cagccaagct	gaactgtgag	tcaattaaac	240
ctcttttctt	cgtaaattac	ccagtcttga	gcagttcttt	acagcagtg	gaaaacagag	300
gaatacacc	atacatgcta	ttctctgccc	agaagccagg	gggagcctgc	cattaaaatg	360
aaagtcactc	cttgactcag	aaccctcaaa	tagctttcat	ctcaccacga	aaaaaaagaa	420
aa						422

<210> 12

<211> 1532

<212> DNA

<213> Homo sapiens

<400> 12

aggtttctgc	acaggaatat	cgagagcgtc	atgaaccoga	gctatagaga	aaggagatga	60
ggcgtgagcc	accgcacccg	gctgacaagt	gtccttctaa	gaaacacaca	gaggagaaga	120
cacagaagag	gagagcacca	tgtgatggta	gacacagaaa	ttggagttct	acagccacaa	180
gccaaaggaac	tcttgagacc	accaggagat	ggaagatgca	aagaactgat	tttctctcag	240
agcctctgga	gggagtgtgg	ccctgggtgac	accttgattt	tggacttctg	gcctacagaa	300
ccatgcacac	aggaggactt	catttcccag	gtctccttgc	agtgaagttg	aggccatgtg	360
actggtcttg	ggccaatgga	atgggtgcag	aagggaacaca	gccatttctt	agactcagcc	420
tgaaatgtcc	tccataatcc	ttactctttc	tcccttcact	cactggctgc	aggaagctga	480
gaattatcct	tggacttaca	taaagcattt	tggactttat	gtaagtaaca	acctgttgta	540
ttaagctact	aagattttac	ggttggttgt	taaatcagct	aaccttaaac	atcctaacaa	600
ctacaaatag	aatacctgtt	actgcataca	taaaaatata	aaaattagct	ggatgtggtc	660

11

ccacctgtag	tcccagctac	tcgggaggct	gaggcaggag	aattgcttga	acctgggagg	720
cggagggttg	ggtgagctga	gacgcacca	ctgcactgca	gcctgggcaa	cagagcagga	780
ctctatctca	aaaaaaaaac	acaataaaca	tttcttacct	actgtagttt	ttgtgggtca	840
ggaatctggg	agcagcttag	ttggatgatt	tctgctcaca	gtgttttatg	aggttgcagt	900
caagatgttg	gctggggctg	tagtcactctg	gagatttaac	tacggctgga	ggatccactt	960
caccatgggt	cactcacctg	gtgctgggtg	ctggcaggaa	atttcagctc	ttctcttata	1020
tggatctctt	cacagattgc	ttgagtgtcc	tcaccgtatg	gtgactggct	tcctttacag	1080
aaatcagttg	aagggaaatgg	gcaagtaaga	aacagcaatg	ctttttatga	cctagtctctg	1140
aagttcccca	ccattactta	tgttcattgg	aagccagttg	ctaaggagag	cctgcactca	1200
aagattgggg	aaatagactt	tatctttcaa	agtgttgaag	aatttgcaga	cgtatttttaa	1260
aaccaccaca	caatccatca	acacatcatg	tcggctctat	tcttgaaata	gatccagaat	1320
ttgaccactt	ttcaccatct	ccattgctat	taccagatc	taatcaacac	catcacttgc	1380
ctggactaga	gatttctctc	tcactgggct	ctctgcttct	atctttagcc	cattgctatg	1440
atttggctgt	gtccccaccc	aaaatctcat	cttgaattat	aatcttcata	atccccatgt	1500
gtcaaaggag	agaccaggtg	gaggtaactg	aa			1532

<210> 13

<211> 1753

<212> DNA

<213> Homo sapiens

<400> 13

tttcttaggg	tttttttttg	agttggagcc	tcgctctgtc	ccccaggetg	gagtgcagtg	60
atgtgatctc	ggctcactgc	aacctctgcc	tcccagggtc	aagtgattct	cctgcctcag	120
cctccctagt	agctgcgact	acaggcatgt	gccaccatgc	ctggctaacg	ttttgtattt	180
ttgagtagag	acagggtttc	accatgttgg	ccaggctatt	ctcgaactcc	tgacctcaag	240
tgatccacct	gcctcggctt	cccaaagttt	ctgggattac	aggcgtgagc	caccgcaccc	300
ggctgacaag	tgtccttcta	agaaacacac	agaggagaag	acacagaaga	ggagagcacc	360
atgtgatggg	agacacagaa	attggagttc	tacagccaca	agccaaggaa	ctcctggagc	420
caccaggaga	tggaagatgc	aaagaactga	ttttctctca	gagcctctgg	agggagtggtg	480
gccctgggtg	caccttgatt	ttggacttct	ggcctacaga	accatgcaca	caggaggact	540
tcatttccca	ggtctccttg	cagtgaagtt	gaggccatgt	gactgggtctt	gggccaatgg	600
aatgggtgca	gaagggacac	agccatttct	tagactcagc	ctgaaatgtc	ctccataatc	660
cttactcttt	ctcccttcac	tcactggctg	caggaagctg	agaattatcc	ttggacttac	720
ataaagcatt	ttggacttta	tgtaaagtaac	aacctgttgt	attaagctac	taagatttta	780
cggttgtttg	ttaaatacagc	taaccttaaa	catcctaaca	actacaaata	gaatacctgt	840
tactgcatac	ataaaaatac	aaaaattagc	tggatgtggg	cccacctgta	gtcccagcta	900

12

```

ctcgggagggc tgaggcagga gaattgcttg aacctgggag gcgagggttg tggtagctg      960
agatcgacacc actgcactgc agcctgggca acagagcagg actctatctc aaaaaaaaaa 1020
cacaataaac atttcttacc tactgtagtt tttgtgggtc aggaatctgg gagcagctta 1080
gttgatgat ttctgctcac agtgttttat gaggttgag tcaagatggt ggctggggct 1140
gtagtcatct ggagatttaa ctacggctgg aggatccact tcaccatggt tcaactcacct 1200
ggtgctgggt gctggcagga aatttcagct cttctcttat atggatctct tcacagattg 1260
cttgagtgtc ctcaccgtat ggtgactggc ttcctttaca gaaatcagtt gaagggaatg 1320
ggcaagtaag aaacagcaat gctttttatg acctagtcct gaagttcccc accattactt 1380
atgttcattg gaagccagtt gctaaggaga gcctgcactc aaagattggg gaaatagact 1440
ttatctttca aagtgttgaa gaatttgag acgtatttta aaaccaccac acaatccatc 1500
aacacatcat gtgggtctta ttcttgaaat agatccagaa tttgaccact tttcaccatc 1560
tccattgcta ttaccagat ctaatcaaca ccatcacttg cctggactag agatttcctc 1620
ctcactgggc tctctgcttc tatcttttagc ccattgctat gatttggttg tgtccccacc 1680
caaaatctca tcttgaatta taatcttcat aatccccatg tgtcaaagga gagaccaggt 1740
ggaggtaact gaa
                                                                 1753

```

<210> 14

<211> 1832

<212> DNA

<213> Homo sapiens

<400> 14

```

gggttttgcg ggtataatta cattcaggat ctcaggatac tgcattatct gtgtgacccc      60
taaattctgat gacaagtgtc tgttttttgt ttttgttttt gagacagagc ctgctctgt 120
caccagggt ggagtgtgt ggtgtgatct cggtcactg caacctccgc ctcccagggt 180
caagcaattc tctgcctcag cctcccgagt aaatgtgatt acaggcaggc gcctgccagc 240
acaccagct gattttagta tttttagtag agatgggggt tcaccatctt ggccaggctg 300
gtcttgaatt cctgacctcg tgatccaccc acttcagctt cccaaagtto tgggattaca 360
ggcgtgagcc accgcacccg gctgacaagt gtccttctaa gaaacacaca gaggagaaga 420
cacagaagag gagagcacca tgtgatggta gacacagaaa ttggagtctt acagccacaa 480
gccaaaggaac tcttgagcc accaggagat ggaagatgca aagaactgat tttctctcag 540
agcctctgga gggagtgtgg ccctggtgac accttgattt tggacttctg gcctacagaa 600
ccatgcacac aggaggactt catttcccag gtctccttgc agtgaagttg aggccatgtg 660
actggtcttg ggccaatgga atgggtgcag aaggacaca gccatttct agactcagcc 720
tgaaatgtcc tccataatcc ttactcttcc tcccttcaact cactggctgc aggaagctga 780
gaattatcct tggacttaca taaagcattt tggactttat gtaagtaaca acctgttgta 840

```

13

ttaagctact	aagatTTTtac	ggttgTTTgt	taaatCagct	aacCTTaaac	atcctaaca	900
ctacaaatag	aatacctgtt	actgcataca	taaaaataca	aaaattagct	ggatgtggtc	960
ccacctgtag	tcccagctac	tcgggaggct	gaggcaggag	aattgcttga	acctgggagg	1020
cggaggTTgt	ggtgagctga	gatcgcacca	ctgcactgca	gcctgggcaa	cagagcagga	1080
ctctatctca	aaaaaaaaac	acaataaaca	tttcttacct	actgtagttt	ttgtgggtca	1140
ggaatctggg	agcagcttag	ttggatgatt	tctgctcaca	gtgttttatg	aggttgca	1200
caagatgttg	gctggggctg	tagtcatctg	gagattTaaac	tacggctgga	ggatccactt	1260
caccatgggt	cactcacctg	gtgctgggtg	ctggcaggaa	atttcagctc	ttctcttata	1320
tggatctctt	cacagattgc	ttgagtgtcc	tcaccgtatg	gtgactggct	tcctttacag	1380
aaatcagttg	aagggaaatg	gcaagtaaga	aacagcaatg	ctttttatga	cctagtccctg	1440
aagttcccca	ccattactta	tgttcattgg	aagccagttg	ctaaggagag	cctgcactca	1500
aagattgggg	aaatagactt	tatctttcaa	agtgttgaag	aatttgCaga	cgtattttaa	1560
aaccaccaca	caatccatca	acacatcatg	tcggctctat	tcttgaaata	gatccagaat	1620
ttgaccactt	ttcaccatct	ccattgctat	taccagatc	taatcaacac	catcacttgc	1680
ctggactaga	gatttctctc	tcactgggct	ctctgcttct	atctttagcc	cattgctatg	1740
atTTggctgt	gtccccaccc	aaaatctcat	cttgaattat	aatcttcata	atccccatgt	1800
gtcaaaggag	agaccaggtg	gaggtaaactg	aa			1832

<210> 15

<211> 10394

<212> DNA

<213> Homo sapiens

<400> 15

cgTTgtttgg	cgTgtTTTTt	TTTTgtttt	ttgtcactgc	ctgcctgggt	cctgccccgag	60
gtctccatcc	tcggtttccc	tgtccttgcc	ccgggccctg	ggagtgtctc	ggaaggctgc	120
gcagtattgg	aggggacaga	atgaccttcc	ggccttgagt	ccctggggag	cagatggacc	180
ctactggaag	tcagttggat	tcagatttct	ctcagcaaga	tactccttgc	ctgataaattg	240
aagattctca	gcctgaaagc	caggttctag	aggatgatcc	tggttctcac	ttcagtatgc	300
tatctcgaca	ccttccta	ctccagacgc	acaaagaaaa	tcctgtgttg	gatgttgtgt	360
ccaatcctga	acaaacagct	ggagaagaac	gaggagacgg	taatagtggg	ttcaatgaac	420
atTTgaaaga	aaacaagggt	gcagaccctg	tggattcttc	taacttggac	acatgtgggt	480
ccatcagtca	ggtcattgag	cagttacctc	agccaaacag	gacaagcagt	gttctgggaa	540
tgtcagtgga	atctgtcctc	gctgtggagg	aagagaaggg	agaagagttg	gaacagaagg	600
agaaagagaa	ggaagaagat	acttcaggca	atactacaca	ttcccttggg	gctgaagata	660
ctgcctcatc	acagttgggt	tttgggggtc	tggaaactctc	ccagagccag	gatgttgagg	720
aaaatactgt	gccatatgaa	gtggacaaaag	agcagctaca	atcagtaacc	accaactctg	780

gttataccag	gctgtctgat	gtggatgcta	atactgcaat	taagcatgaa	gaacagtcca	840
acgaagatat	ccccatagca	gaacagtcca	gcaaggacat	ccctgtgaca	gcacagccca	900
gtaaggatgt	acatgttgta	aaagagcaaa	atccaccacc	tgcaaggcca	gaggacatgc	960
cttttagccc	caaagcatct	gttgctgcta	tggaagcaaa	agaacagttg	tctgcacaag	1020
aacttatgga	aagtggactg	cagattcaga	agtcaccaga	gcctgaggtt	ttgtcaactc	1080
aggaagactt	gtttgaccag	agcaataaaa	cagtatcttc	tgatgggtgc	tctactcctt	1140
caagggagga	agggtgggtg	tctttggctt	ccactcctgc	caccactctg	catctcctgc	1200
agctctctgg	tcagaggtcc	cttggttcagg	acagtctttc	cacgaattct	tcagatcttg	1260
ttgctccttc	tcctgatgct	ttccgatcta	ctccttttat	cgttcctagc	agtcccacag	1320
agcaagaagg	gagacaagat	aagccaatgg	acacgtcagt	gttatctgaa	gaaggaggag	1380
agccttttca	gaagaaactt	caaagtgggtg	aaccagtggg	gttagaaaac	ccccctctcc	1440
tgcttgagtc	cactgtatca	ccacaagcct	caacaccaat	atctcagagc	acaccagtct	1500
tccctcctgg	gtcacttcct	atcccatccc	agcctcagtt	ttctcatgac	attttttattc	1560
cttccccaag	tctggaagaa	caatcaaattg	atgggaagaa	agatggagat	atgcatagtt	1620
catctttgac	agttgagtg	tctaaaactt	cagagattga	accaaagaat	tcccttgagg	1680
atcttgggct	atctttgaca	ggggattctt	gcaagttgat	gctttctaca	agtgaatata	1740
gtcagtcctc	aaagatggag	agcttgagtt	ctcacagaat	tgatgaagat	ggagaaaaca	1800
cacagattga	ggatacggaa	cccatgtctc	cagttctcaa	ttctaaattt	gttcctgctg	1860
aaaatgatag	tatcctgatg	aatccagcac	aggatgggtg	agtacaactg	agtcagaatg	1920
atgacaaaac	aaagggagat	gatacagaca	ccagggatga	cattagtatt	ttagccactg	1980
gttgcaaggg	cagagaagaa	acggtagcag	aagatgtttg	tattgatctc	acttggtgatt	2040
cggggagtc	ggcagttccg	tcaccagcta	ctcgatctga	ggcactttct	agtgtgttag	2100
atcaggagga	agctatggaa	attaaagaac	accatccaga	ggaggggtct	tcaggggtctg	2160
agggtgaaga	aatccctgag	acaccttggtg	aaagtcaagg	agaggaactc	aaagaagaaa	2220
atatggagag	tggtccgttg	cacctttctc	tgactgaaac	tcagtcccaa	gggttggtgc	2280
ttcaaaagga	aatgccaaaa	aaagaatgct	cagaagctat	ggaagttgaa	accagtgtga	2340
ttagtattga	ttccctcaa	aagttggcaa	tacttgacca	agaattggaa	cataaggaac	2400
aggaagcttg	ggaagaagct	acttcagagg	actccagtg	tgatcattga	gatgtgaaag	2460
agccatctcc	cagagttgat	gtttcttggtg	aacctttgga	gggagtgagg	aagtgtctcag	2520
attcccagtc	atgggaggat	attgctccag	aaatagaacc	atgtgctgag	aatagattag	2580
acaccaagga	agaaaagagt	gtagaatatg	aaggagatct	gaaatcaggg	actgcagaaa	2640
cagaacctgt	agagcaagat	tcttcacagc	cttccttacc	tttagtgaga	gcagatgatc	2700
ctttaagact	tgaccaggag	ttgcagcagc	cccaaactca	ggagaaaaca	agtaattcat	2760
taacagaaga	ctcaaaaatg	gctaattgcaa	agcagctaag	ctcagatgca	gaggcccaga	2820
agctggggaa	gccctctgcc	catgcctcac	aaagcttctg	tgaaagttct	agtgaacccc	2880

catttcattt	cactttgcct	aaagaagggtg	atatcatccc	accattgact	ggtgcaaccc	2940
cacctcttat	tgggcaccta	aaattggagc	ccaagagaca	cagtactcct	attgggtatta	3000
gcaactatcc	agaaagcacc	atagcaacca	gtgatgtcat	gtctgaaagc	atgggtggaga	3060
cccatgatcc	catacttggg	agtggaaaag	gggattcttg	ggctgcccc	gacgtggatg	3120
ataaattatg	tctaagaatg	aaactgggta	gtcctgagac	tgaggcgagt	gaagagtctt	3180
tgcagttcaa	cctggaaaag	cctgcaactg	gtgaaagaaa	aaatggatct	actgctgttg	3240
ctgagtctgt	tgccagtccc	cagaagacca	tgtctgtgtt	gagctgtatc	tgtgaagcca	3300
ggcaagagaa	tgaggctcga	agtgaggatc	ccccaccac	acccatcagg	gggaacttgc	3360
tccactttcc	aagttctcaa	ggagaagagg	agaaagaaaa	attggagggt	gaccatacaa	3420
tcaggcagag	tcaacagcct	atgaagccca	ttagtcctgt	caaggacctt	gtttctcctg	3480
cttcccagaa	gatggtcata	caagggccat	ccagtcctca	aggagaggca	atggtgacag	3540
atgtgctaga	agaccagaaa	gaaggacgga	gtactaataa	ggaaaatcct	agtaaggcct	3600
tgattgaaag	gcccagccaa	aataacatag	gaatccaaac	catggagtgt	tccttgaggg	3660
tcacagaaac	tgtttcagca	gcaaccagca	ctataaagaa	tgtgtgtgag	caggggacca	3720
gtacagtgga	ccagaacttt	ggaaagcaag	atgccacagt	tcagactgag	agggggagtg	3780
gtgagaaacc	agtcagtgtc	cctgggggatg	atacagagtc	gctccatagc	cagggagaag	3840
aagagtttga	tatgcctcag	cctccacatg	gccatgtctt	acatcgtcac	atgagaacaa	3900
tcggggaagt	acgcacactt	gtcactcgtg	tcattacaga	tgtgtattat	gtggatggaa	3960
cagaagtaga	aagaaaagta	actgaggaga	ctgaagagcc	aattgtagag	tgtcaggagt	4020
gtgaaactga	agtttccctt	tcacagactg	ggggctcctc	aggtgacctg	ggggatatca	4080
gtccttcttc	ctccaaggca	tcagctttac	accgcacatc	aagtgggaca	agtctctcag	4140
ctatgcacag	cagtggagc	tcagggaaag	gagccggacc	actcagaggg	aaaaccagcg	4200
ggacagaacc	cgcagatttt	gccttaccca	gctcccagag	aggcccagga	aaactgagtc	4260
ctagaaaagg	ggtcagtcat	acagggacgc	cagtgtgtga	ggaggatggg	gatgcaggcc	4320
ttggcatcag	acagggaggg	aaggctccag	tcacgcctcg	tgggcgtggg	cgaaggggcc	4380
gcccaccttc	tcggaccact	ggaaccagag	aaacagctgt	gcctggcccc	ttgggcatag	4440
aggacatttc	acctaacttg	tcaccagatg	ataaatcctt	cagccgtgtc	gtgccccgag	4500
tgccagactc	caccagacga	acagatgtgg	gtgctgggtg	tttgctcgtg	agtgactctc	4560
cagaaattcc	tttccaggct	gtgctgggcc	cttctgatgg	cttagatgcc	tcctctccag	4620
gaaatagctt	tgtagggtc	cgtgtttag	ccaagtggtc	atccaatggc	tacttttact	4680
ctgggaaaat	cacacgagat	gtcggagctg	ggaagtataa	attgctcttt	gatgatgggt	4740
acgaatgtga	tgtgttgggc	aaagacattc	tgttatgtga	ccccatcccg	ctggacactg	4800
aagtgcggc	cctctcggag	gatgagtatt	tcagtgcagg	agtggtgaaa	ggacatagga	4860
aggagtctgg	ggaactgtac	tacagcattg	aaaaagaagg	ccaaagaaag	tggtataagc	4920
gaatggctgt	catcctgtcc	ttggagcaag	gaaacagact	gagagagcag	tatgggcttg	4980
gcccctatga	agcagtaaca	cctcttataa	aggcagcaga	tatcagctta	gacaatttgg	5040

tggaagggaa gcggaaacgg cgcagtaacg tcagctcccc agccaccctt actgcctcca 5100
gtagcagcag cacaaccctt acccgaaaga tcacagaaag tcctcgtgcc tccatgggag 5160
ttctctcagg caaaagaaaa cttatcactt ctgaagagga acgggtccctt gccaaagcag 5220
gtcgcaagtc tgccacagta aaacctgggtg cagtaggggc aggagagttt gtgagccctt 5280
gtgagagtgg agacaacacc ggtgaaccct ctgccctgga agagcagaga gggcctttgc 5340
ctctcaacaa gaccttgttt ctgggctacg cttttctcct taccatggcc acaaccagt 5400
acaagttggc cagccgctcc aaactgccag atggtcctac aggaagcagt gaagaagagg 5460
aggaattttt ggaaattcct cttttcaaca agcagtatac agaatcccag cttcgagcag 5520
gagctggcta tctccttgaa gatttcaatg aagcccagtg taacacagct taccagtgtc 5580
ttctaattgc ggatcagcat tgtcgaaccc ggaagtactt cctgtgcctt gccagtggga 5640
ttccttggtg gtctcatgtc tgggtccatg atagttgcca tgccaaccag ctccagaact 5700
accgtaatta tctgttgcca gctgggtaca gccttgagga gcaaagaatt ctggactggc 5760
aaccctgta aaatcctttc cagaatctga aggtactctt ggtatcagac caacagcaga 5820
acttcctgga gctctggtct gagatcctca tgactggtgg tgcagcctct gtgaagcagc 5880
accattcaag tgcccataac aaagatattg ctttaggggt atttgatgtg gtggtgacgg 5940
accctcatg cccagcctcg gtgctgaagt gtgctgaagc attgcagctg cctgtggtgt 6000
cacaagagtg ggtgatccag tgcctcattg ttggggagag aattggattc aagcagcatc 6060
caaaatataa acacgattat gtttctcact aaagatactt ggtcttactg gttttattcc 6120
ctgctatcgt ggagattgtg ttttaaccag gttttaaatg tgtcttggtg gtaactggat 6180
tccttgcatg gatcctgtat atagttttat ttgctgaact tttatgataa aataaatgtt 6240
gaatctcttt ggtttagta actgggattt cttcatctgt ttttttgagc ttaatctcag 6300
aacaatgac aagacatagt actttctctg agtctttcaa caggcttatt cacttacgga 6360
ggacagctca ccaaggaaat tgaaaagtta agagtgaact ttattctgtg gcatcattcc 6420
caaaagggtta ttccaggggtg tctaaaatgc tatgcttgca gaaactcagt ttaaggtagg 6480
tgaaggccca gattaacagt tgtgccaaaa gttgagtgga attgggcaca gctctgtttc 6540
ctgacagtta aaaaagacct catgctctct ctctgagctg agatcacagc tcacctgtgg 6600
gtactcccca actcttagag ctaaagggtg aacgaaagga ccaactgcca tgaagggaca 6660
gtgaccataa gcttgatgga atgaccttcc gtaagataaa catgggaagc acaagtgaga 6720
acacctggaa atgttacacg ttctagtcaa agaccaata ttattattat tattattgtc 6780
acaatagctg gaagcagttc cttcccttcc tctggcatca ctgatccctg catggcttct 6840
cattctctaa agcaggggtc aacaagggtt ttttctgtaa aggggtcaaag agtaaatatt 6900
tcaggctttg tgggccattt gatccatcac aactactcgc ctttgctgtg agggcatgaa 6960
agcaaccata gacaatgagt aaacaaatgg gcacggctgt gtttcagtaa aactgtacaa 7020
aaacagacag caggccatag tttgccagct cctgctccag agacagcagt ggaaaggggtg 7080
atcttttagtt gataatagca ggggaataagt tgtcagagct tcccagtgtg tgtagaatat 7140

17

gtagtgatga aaaccagatg cagtgactat aacctgatgc cagaacactg cattcttttt	7200
cagtttggag ggcgttggtc agtgaatatt tctttttact tacactgata tgaatattga	7260
ttaccagtga tggctgggcc atattaagat aacttcaacc cctatggttt gtgtaagatg	7320
ggtaattggg cctgcaatct tcagtattta aaaatctaac aacttgatct caattttttc	7380
ttaaggacct ttttcttgga gaataatact tttttttttt tttttttttt tgagacggaa	7440
tttcgctctt gttgcccagg ctggaatgca atggcacaat ctcagctcac tgcagcgtct	7500
gcttcccagg ttcaagcaat tctcctgtct cagcctcctg agtagctggg attacaggca	7560
catgccacca cacctggcta atttttgtat ttttagtaga atcgaggttt catcatgttg	7620
gtcaggctgg tctcaaactc ctgacttcag gtgatccgcc cgcctcggcc tcccaaagt	7680
ctgggattac aggtgtgagc caccatgccc ggcctaagaa atacttttaa gtatattttc	7740
attagctaga attgccaat ctgtgtaggt ataaattact tggatatagg agagagaaag	7800
cctatcttac ctgttgcttt ctacttggg ggtaacatcc agcagttagt ctatttataa	7860
acataattac ttttccat atgaaccata aaatatttaa ctttctgctc tatattgttt	7920
gtttaccgct gtatctccca cagcttgaa agtaccagg tacgtagtag gtgctcaata	7980
aatgactatt gaataaatga acatatccaa caaatgttct caatgtaaag gatcagagat	8040
gccacatgtt ctcttgatg ggagagaccc ttccacatgg gaatgatggg aaggagtgt	8100
actcctggat gttcagtaac tgcttctagg agaaaaggta gagtccatc actaagccgc	8160
agatatttat ttgtgtgtgg ctagaatggg atgttttgaa tcttctgtta caaccttggg	8220
aacgtggctg ttatttcaat ttatgagcca gaaattttca catcccgaaa ctacaaaaga	8280
gaaaaagagc cttattaagt gtcatgcttt cccaagacta ccttcaaaga aatatgaatc	8340
aggataacct gtgatctaaa taatgtcatc ttaaaactga agagtttctt ttgactcttc	8400
tgctacaata gcttagaaaa aaatctgctt gcagacattt tagagagaaa ggacaatgaa	8460
gtgattttct gaatgggaat gacagacctc tgggaagcca gctaccactg aatctcggta	8520
tcagtttttt ttaaagttta gagttagaag ggggtgctgc ctcccttcac agatgcggaa	8580
gctagggacc agcaaggcgg ggtgcccacg gctgcacagc tagttcatat cagaattggg	8640
agtgaaggc cactgcctc ccagcatagc aatacataac ctaccaaagg acttaacacc	8700
tatctcactg tcaggttttt tagtatttta tgatgatgat gacttctact agaaaataac	8760
ctccattaaa attattaaag atggtcacac ctctatctct aagccttact tataaaatga	8820
gggtatttgg actaaagtct tcttccagtt ctagaattct acaactcatt aaaaagccac	8880
cttaaaaagt ctactgagtt acccaagggt tgctcctacc tgcccagagt tccaccagcc	8940
tgggtatagt atttgttata atctagtcgt aacagtagtt gagccaaatc tgagttgatc	9000
tgatgattcc gaacactgga gagaatcttg aacaggagtg aagactggcg gctaaagccc	9060
tgagagaga aggactcagc tgtcattcca cttcagctca ccaactctcc atatggagga	9120
tggggcgga gggaggagt tcttgaaaa gccttggtca aaattctaca gaaccacctg	9180
gccttcccac attcctattt ctattagttc ctaaaatgac ttgtaccaa tccatacatg	9240
catgacttcc tatgaaagta ctcttcatc agtaggaatt tagtagctgg tttccagtta	9300

```

atgtatTTTTg tcaagtactg ggggttgggga gaacccgttt tgattacaag cagataatta 9360
tctcagttag atggggggtta gttcaaggaa gtaaggaggg gggaggatgt gaggaagtta 9420
gaacaaccca atgcttattt gatgggctga ataaactatt caggactgaa ctatTTTTga 9480
gcaactgttag gtggcacagt aattacctgc ttcaaatca actgatacca acatTTTTat 9540
ctttgtatct tatctctgta cgtgtgtgta ttgaggaaat gctttactga ctacaggaa 9600
agatcatgaa ttctccattg gcaaaaccac ctctgtcctt tcggcaaggc tgcatacttc 9660
caggcagacg caccttcacg agaatgctca gctgggcggc tccacgctca tccagtgggc 9720
ctaggttctg actgaccagc gaacaaaaac tgtgacagag atctaggatt tcattcaggc 9780
agtgaacac ctacccggga aacagagttg gcattaggaa aggaaggaag gtacatccat 9840
gaagttaaag tgtaggaga acagtctgat taatagctga tctaattaat agctgacctc 9900
ccaaatctga caggatagac actgccacgt gcaaggcctg ccagcccctc agacgcacaa 9960
aatgcgtaaa acaaatgcat cctttcctgg ctaagcgagt attactctct tagccctgca 10020
ccaaacctcc aatctagcca catttaactc ttcatTTTctt agaccgcag agtgtcttcc 10080
tgccctctgag ctgtgagtggt tgttcccttt gcccgggatg ctcttgTTTT taataccagt 10140
tcaagtccca ctctctcagt gaagcactcc cttccctact atagccttta gtgaaccctc 10200
gtttcttgct tctttattat ctgtactgtt gtccacttgg caattgttca ggcctctgtg 10260
ttgttactga tttttgtatg tatatatata tatatgtctt gtttttccaa ctagattgtg 10320
agctccttaa gggcagagcc atgaattata cctctttgta tccccagtg cttgcataca 10380
gtaagcactc aata 10394

```

<210> 16

<211> 6837

<212> DNA

<213> Homo sapiens

<400> 16

```

agcatcgagt cggccttggt gcctactgga gtctccgcag agcccgggcg ggagtagctg 60
gtggaccccg ttgagctgcc gaacttccg gactcccccg cgacccttc ccagcttccc 120
gtccgctccg ccgcagcgat tgtctcgggt ggttgattcg gcacaaaccg cccgaccag 180
gggccggtgc gcgtgtggaa ggggaagcac tcccctcgtg gtcgcctgga ggtgcgctgg 240
aggagggggt gacataacca gggactcgag gtccgcgctg ggaatgatcc acgaactgct 300
cttggtctctg agcgggtacc ctgggtccat ttccacctgg aacaagcgga gtggcctgca 360
ggtatcgcag gacttccctt tctccaccc cagtgcagcc agtgtcctga atcgactctg 420
ccggctcggc acagactata ttcgcttcac tgagttcatt gaacagtaca cgggccatgt 480
gcaacagcag gatcaccatc catctcaaca gggccaaggt gggttacatg gaatctacct 540
gcgggccttc tgcacagggc tggattctgt ttgcagcct tatcgccaag cactgcttga 600

```

tttgaacaa	gagttcctgg	gtgatcccca	tctctccata	tcacatgtca	actacttcct	660
agaccagttc	cagcttcttt	ttccctctgt	gatggttgta	gtagaacaaa	ttaaaagtca	720
aaagattcat	ggttgtcaaa	tcctggaaac	agtctacaaa	cacagctgtg	gggggttgcc	780
tcctgttcga	agtgcactgg	aaaaaatcct	ggcgtttgt	catggggca	tgtataaaca	840
gctctcagcc	tggatgctcc	atggactcct	cttgaccag	catgaagaat	tctttatcaa	900
acaggggcc	tcttctggta	atgtcagtgc	ccagccagaa	gaggacgagg	aggatctggg	960
cattggggga	ctgacaggaa	aacaactgag	agaactgcag	gacttgcgcc	tgattgagga	1020
agagaacatg	ctggcaccat	ctctgaagca	gttttcccta	cgagtggaga	ttttgccatc	1080
ctacattcca	gtgagggttg	ctgaaaaaat	cctatttgtt	ggagaatctg	tccagatggt	1140
tgagaatcaa	aatgtgaacc	tgactagaaa	aggatccatt	ttgaaaaacc	aggaagacac	1200
ttttgctgca	gagctgcacc	gtctcaagca	gcagccactc	ttcagcttgg	tggaactttga	1260
acaggtggtg	gatcgcatc	gcagcactgt	ggctgagcat	ctctggaagt	tgatggtaga	1320
agaatccgat	ttactgggtc	agctgaagat	cattaaagac	ttttaccttc	tggaacgtgg	1380
agaactgttt	caggccttca	ttgacacagc	tcaacacatg	ttgaaaacac	cacccactgc	1440
agtaactgag	catgatgtga	atgtggcctt	tcaacagtca	gcacacaagg	tattgctaga	1500
tgatgacaac	cttctccctc	tggtgcactt	gacaatcgag	tatcacggaa	aggagcacia	1560
agcagatgct	actcaggcaa	gagaagggcc	ttctcgggaa	acttctcccc	gggaagcccc	1620
tgcatctggc	tgggcagccc	taggtctttc	ctacaaagta	cagtggccac	tacatattct	1680
cttcacccca	gctgtcctgg	aaaagtacaa	tggtgttttt	aagtacttac	tgagtgtgcy	1740
ccgggtgcaa	gctgagctgc	agcactgctg	ggccctacaa	atgcagcgca	agcacctcaa	1800
gtcgaaccag	actgatgcaa	tcaagtggcg	cctaagaaat	cacatggcat	ttttgggtgga	1860
taatcttcag	tactatctcc	aggtagatgt	gttgagatct	cagttctccc	agctgcttca	1920
tcagatcaat	tctacccgag	actttgaaag	catccgattg	gctcatgacc	acttccctgag	1980
caatttgctg	gctcaatcct	ttatcctatt	gaaacctgtg	tttactgccc	tgaatgaaat	2040
cctagatctc	tgctcacagt	tttgtttgct	ggtcagtcag	aacctaggcc	cactggatga	2100
gcgtggagcc	gcccagctga	gcattctcgt	gaagggtctt	agccgccagt	cttcactcct	2160
gttcaagatt	ctctccagtg	ttcggaatca	tcagatcaac	tcagatttgg	ctcaactact	2220
gttacgacta	gattataaca	aatactatac	ccaggctggg	ggaactctgg	gcagtttcgg	2280
gatgtgaaaa	tttctggctc	ataaattgaa	ataacagcca	cgttcccaag	gttgtaacag	2340
aagattcaaa	acatcccat	ctagccacac	acaaataaat	atctgcggct	tagtgatagg	2400
actctacctt	ttctcctaga	agcagttact	gaacatccag	gagtacaact	ccttcccatc	2460
attcccatgt	ggaagggtct	ctcccatcaa	ggagaacatg	tggcatctct	gatcctttac	2520
attgagaaca	tttggttgat	atgttcattt	attcaatagt	cattttattga	gcacctacta	2580
cgtaccttgg	tactgttcaa	gctgtgggag	atacagcggt	agacaaacaa	tatagagcag	2640
aaagttaa	attttatggg	tcatatgtga	aaaagtaatt	atgtttataa	atagactaac	2700
tgctggatgt	taccaccaag	taagaaagca	acaggttaaga	taggctttct	ctctccctat	2760

accaagtaat ttatacctac acagattggg caattctagc taatgaaaat atacttaaaa	2820
gtattttctta ggccgggcat ggtggctcac acctgtaatc ccagcacttt gggaggccga	2880
ggcggggcgga tcacctgaag tcaggagttt gagaccagcc tgaccaacat gatgaaacct	2940
cgattctact aaaaatacaa aaattagcca ggtgtggtgg catgtgcctg taatcccagc	3000
tactcaggag gctgagacag gagaattgct tgaacctggg aagcagacgc tgcagtgagc	3060
tgagattgtg ccattgcatt ccagcctggg caacaagagc gaaattccgt ctcaaaaaaa	3120
aaaaaaaaaa aaaaagtatt attctccaag aaaaagggtcc ttaagaaaaa attgagatca	3180
agttgttaga tttttaaata ctgaagattg caggcccaat taccatctt acacaaacca	3240
taggggttga agttatctta atatggccca gccatcactg gtaatcaata ttcatatcag	3300
tgtaagtaaa aagaaatatt cactgaacaa cgccctccaa actgaaaaag aatgcagtgt	3360
tctggcatca ggttatagtc actgcatctg gttttcatca ctacatattc tacacacact	3420
gggaagctct gacaacttat tccctgctat tatcaactaa agatcacctt ttccactgct	3480
gtctctggag caggagctgg caaactatgg cctgctgtct gttttgttac agttttactg	3540
aaacacagcc gtgcccattt gtttactcat tgtctatggt tgctttcatg ccctcacagc	3600
aaaggcgagt agttgtgatg gatcaaattg ccacaaagc ctgaaatatt tactctttga	3660
ccctttacag aaaaaaacct tgttgacccc tgcttttagag aatgagaagc catgcaggga	3720
tcagtgtatg cagaggaagg gaaggaactg cttccagcta ttgtgacaat aataataata	3780
ataatattgg gtctttgact agaacgtgta acatttccag gtgttctcac ttgtgcttcc	3840
catgtttatc ttacggaagg tcattccatc aagcttatgg tcaactgtccc ttcatggcag	3900
ttggctccctt cgttctccct ttagctctaa gagttgggga gtaccacag gtgagctgtg	3960
atctcagctc agagagagag catgaggtct tttttaactg tcaggaaaca gagctgtgcc	4020
caattccact caacttttgg cacaactggt aatctgggcc ttcacctacc ttaaactgag	4080
tttctgcaag catagcattt tagacacctt ggaataacct tttgggaatg atgccacaga	4140
ataaagttca ctcttaactt ttcaatttcc ttggtgagct gtcctccgta agtgaataag	4200
cctgttgaaa gactcagaga aagtactatg tcttgtcatt tgttctgaga ttaagctcaa	4260
aaaaacagat gaagaaatcc cagttactac aaccaaagag attcaacatt tattttatca	4320
taaaagttca gcaataaaaa ctatatataa gatccatgca aggaatccag ttacacacaa	4380
gacacattta aaacctgggt aaaacacaaat ctccacgata gcagggaata aaaccagtaa	4440
gaccaagtat ctttagtgag aaacataatc gtgtttatat tttggatgct gcttgaatcc	4500
aattctctcc ccaacaatga ggcactggat caccactct tgtgacacca caggcagctg	4560
caatgcttca gcacacttca gcaccgaggc tgggcatgag gggcccgta ccaccacatc	4620
aaatcccct aaagcaatat ctgcaaggag caagggaaag tgaagaagga aaggacactc	4680
aacttagccc tccattagaa agagagattt gattctaacc aatacatccc actctgcaca	4740
aaccaaagcc ctattatgtc aaacacactg ctactgatca tgaccaaagg cagagttata	4800
atcactatgt gctgacctg tagaaatatt taacaaatat acgtccagtg cttcacttat	4860

21

gttgactcac ctcttgaagg tggtaactttt cttctctaag aaacatggat acgggtcaacc 4920
tattaggcct gagccttggg ccacaaggcc taacacctac aggtctaagg agatccctgg 4980
aacaagagaca ctacacacac tcttttcaggt accctttgtta tgggcacttg aatggtgctg 5040
cttcacagag gctgcaccac cagtcacgag gatctcagac cagagctcca ggaagttctg 5100
ctgttgggtct gataccaaga gtaccttcag attctggaaa ggattttcac ggggttgctt 5160
atgaaggaga caggaaagga ccttagcatg acaagtaata tccaacaaac tgcctttctg 5220
caaagggact catgtacatc tgaatgcttt caaaaataaa tgcccatca gacatagtgt 5280
ctcaagcctg taatcccagc actttgggag gctgtcgtgg ttggatctct tgggcctggg 5340
agttcgagac cagcctgggc aatgtggtga gaccccatct ctacaaaaga caacaaaaaa 5400
attagctggg tgtggtggcg agtgcctgta gtccagcag cttgggaggc tgaggtaggg 5460
ggatcacttc agcctgggag gttgaggctg cagtaagtcg tcaactgcgc actgtactcc 5520
agcctagggt acagagcaag acttcactct aaaaaactaa gccctatatt aggggtcccc 5580
ttctcttctt tctttctatg aatgatctgt attccttgca ttcttgctt tctaatttcc 5640
atgtttgttc tggggctgag aataatccaa atcatgctcc tgagcctata tatttttaat 5700
gcttgcttaa aacttagttc tctgacttta cagggtgaga atattgaacc tatatacaaa 5760
tcttcacaca tttgcaaaag gttcctagcc aatgtaacct agggaaataa actagataaa 5820
ctcctgaagt catttcaaac ccactcaaat ttatcccaca gacattccaa tttctagaaa 5880
gctttactct ctcacctaga ttctcttccc tccaaagctt gctgtcctcc tgcctataca 5940
attctggatg ggcttcaaat acttaccagt ccagaattct ttgctcctca aggtgtacc 6000
cagctggcaa cagataatta cggtagttct ggagctgggt ggcatggcaa ctatcatgga 6060
cccagacatg agacacacaa ggaatcccac tggcaaggca cagggaagta ttcggggttc 6120
gacaatgctg atccgcaatt agaagacact ggtaagctgt gttacactgc aagaaaagaa 6180
gcagagccaa tgggttttgt gacttctgtg gaaagctcct aagcagcagc cataatgagc 6240
catgaagagc agatctgaag actcccaact actacccaaa atgtgattta gtctatcctg 6300
cccaaggcca ctcttctcac tgggaaggccc aagtaatttc catagatgtt ctctctgcct 6360
cacctgcagc atactgagga cctaaatcct caacggacaa ccaaaccta tgaactcagc 6420
ctttcaggct aaaaatcagc aaccctaata ggggtttcta ctactaaaca taaacatcaa 6480
tcttcttttg tcccagcaac agaaccatag ccattaacta acccaaggct ctaccttctc 6540
ttccctatac acaacaaaaa ttctatttca tgcaaaaaca ttttggcagt ttctcagttc 6600
ctgaaatctc tggctacttt atccagggtc cccaaccct cccaggcctc ttctcaacac 6660
agcaagttgg ctcttatcat tgccactata ttaggttaca caaagaaact cctcacctgg 6720
gcttcattga aatcttcaag gatatagcca gctcctgctc gaagctggga ttctgtatac 6780
tgcttggtga aaggaggaat ttccaaaaat tctatattaa aaaaaaac caagata 6837

<210> 17

<211> 733

22

<212> DNA

<213> Artificial sequence

<220>

<223> Probe

<400> 17

cacaatctcc acgatagcag ggaataaaac cagtaagacc aagtatcttt agtgagaaac	60
ataatcgtgt ttatatcttg gatgctgctt gaatccaatt ctctcccaa caatgaggca	120
ctggatcacc cactcttggt acaccacagg cagctgcaat gcttcagcac acttcagcac	180
cgaggctggg catgaggggt ccgtcaccac cacatcaaat acccctaaag caatatctgc	240
aaggagcaag ggaaagtga gaaggaaagg aactcaact tagccctcca ttagaaagag	300
agatttgatt ctaaccaata catcccactc tgcacaaacc aaagccctat tatgtcaaac	360
acactgctac tgatcatgac caaaggcaga gttataatca ctatgtgctg accttgtaga	420
aatatttaac aaatatacgt ccagtgtctt acttatgttg actcaactct tgaagggtgt	480
acttttcttc tctaagaaac atggatacgg tcaacctatt aggcctgagc cttggaccac	540
aaggcctaac acctacaggt ctaaggagat ccctggaaca aagacactac acacactctt	600
tcaggtagct ttgttatggg cacttgaatg gtgctgcttc acagaggctg caccaccagt	660
catgaggatc tcagaccaga gctccaggaa gttctgctgt tggcttgata ccaagagtac	720
cttcagattc tgg	733

<210> 18

<211> 734

<212> DNA

<213> Artificial sequence

<220>

<223> Probe

<400> 18

gctagaattg cccaatctgt gtaggtataa attacttggg atagggagag agaaagccta	60
tcttacctgt tgctttctta cttgggtggt acatccagca gttagtctat ttataaacat	120
aattactttt tcacatatga accataaaat atttaacttt ctgctctata ttgtttgtct	180
accgctgtat ctcccacagc ttgaacagta ccaaggtagc tagtaggtgc tcaataaatg	240
actattgaat aaatgaacat atccaacaaa tgttctcaat gtaaaggatc agagatgcca	300
catgttctcc ttgatgggag agacccttcc acatgggaat gatgggaagg agttgtactc	360
ctggatgttc agtaactgct tctaggagaa aaggtagagt cctatcacta agccgcagat	420
atatttttgt gtgtggctag aatgggatgt tttgaatctt ctgttacaac cttgggaacg	480
tggctgttat ttcaatttat gagccagaaa ttttcacatc ccgaaactgc ccagagttcc	540

23

accagcctgg gtatagtatt tgttataatc tagtcgtaac agtagttgag ccaaactctga 600
 gttgatctga tgattccgaa cactggagag aatcttgaac aggagtgaag actggcggct 660
 aaagcccttc acgagaatgc tcagctgggc ggctccacgc tcatccagtg ggcctaggtt 720
 ctgactgacc agca 734

<210> 19

<211> 2289

<212> DNA

<213> Homo sapiens

<400> 19

tcgcggccgc gtcrcgcgt ggtagggggc ccagagcaag ccgaaggcaa gcacgatggc 60
 gctcaccagc cggcccaccc gcgcccgtg ccgcccggag ccccagcggg cggcccgcag 120
 ccgtgccagc gtcacgctgt agcagccgag catcagccga aaggaagcac gaaagcggtc 180
 agagtctcca ggctcaggtg ggcgcgggcg tggaccggcg acgggtggca cagctggcat 240
 acgcgggtccc tccacaggtg gcggtagacg gcggccggga cggcgagcaa cagggcggcc 300
 agccagaccg ccagcagcag gcggcggggc agggccgggc tgcgagccg aggcgccagg 360
 aaggggaggg tgactgcgag gcagcgctgc aggtgagca ggccggtgag cagcacgctt 420
 ggcgtacatg ctgagcgcg acacgtagta caccgccttg cagcccgctt ggcccagcgg 480
 ccaggcctgc cggtcaggaa ggccacaaag agcggcggtg gcagcagcac cgcgccgtcg 540
 gccagcgcca ggtgcagcac aagcgtggcc gccagcggtc gcccccgctg aggttgccag 600
 cccgccaagc tccacaccac gaagccgttg ccaggcagcc ccagcagcgc cgcagcagc 660
 aggaaggctg tgctgtggc ccgcgaagtc ttccagctca gcagtgtctc gttccctggg 720
 ggacggtagc agaccgacat ccttctgggc ctacaggaca cagaaaaaaa gtggggaagc 780
 tgggggaccc tacaaggatc cttggcagga aagcagggat tgtgttcatt ttgaggggtt 840
 cactgtcagt gagagtctca gcttccatgc aactgtccat cacggctgca actgaaatca 900
 gagctgggac acagcgcacc agaagctaaa gtcttgatgc catcaaagga catcccctgc 960
 cccattcaca yattcacatc tctgtcacgt ccactaatcg gcaaaaggag aaaagtgaga 1020
 gaagatgacc taagtgtgac tgcagcaggc agctctggaa aatgaagcca gagcagtgag 1080
 ccagcccctc ctccgaccaa ggaggaagga aagagcagcc ccagcacagg agagaaccac 1140
 ccagcccaga agttccaggg aaggaaactct ccggtccacc atggagtacc tctcagctct 1200
 gaaccccagt gacttactca ggtcagtatc taatataagc tcggagtttg gacggagggg 1260
 ctggacctca gctccaccac cccagcgacc tttccgtgtc tgtgatcaca agcggaccat 1320
 ccggaaaggc ctgacagctg ccacccgcca ggagctgcta gccaaagcat tggagaccct 1380
 actgctgaat ggagtgttaa ccctgggtgct agaggaggat ggaactgcag tggacagtga 1440
 ggacttcttc cagctgctgg aggatgacac gtgcctgatg gtgttgagc ctggtcagag 1500
 ctggagccct acaaggagtg gagtgtgtc atatgggcct ggacgggaga gcccgaagca 1560

cagcaaggac atcggccgat tcacctttga cgtgtacaag caaaaccctc gagacctctt	1620
tggcagcctg aatgtcaaag ccacattcta cgggctctac tctatgagtt gtgactttca	1680
aggacttggc ccaaagaaag tactcagggg gctccttcgt tggacctcca cactgctgca	1740
aggcctgggc catatgttgc tgggaatttc ctccaccctt cgtcatgcag tggagggggc	1800
tgagcagtgg cagcagaagg gccgcctcca ttccactactaa ggggctctga gcttctgccc	1860
ccagaatcat tccaaccgac ccactgcaaa gactatgaca gcatcaaatt tcaggacctg	1920
cagacagtac aggctagata acccaaccaa tttcccact gtccctctgat cccctcgtga	1980
cagaaccttt cagcataacg cctcacatcc caagtctata cccttacctg aagaatgctg	2040
ttctttccta gccaccttcc tagcctccca cttgccctga aaggccaaga tcaagatgtc	2100
ccccaggcat cttgatccca gcctgactgc tgctacatct aatcccctac caatgcctcc	2160
tgccctaaa ctcccagca tactgatgac agccctctct gactttacct tgagatctgt	2220
cttcataccc ttccctcaa actaacaaaa acatttccaa taaaaatattc aaatatttac	2280
cgtcaacctc	2289

<210> 20

<211> 1511

<212> DNA

<213> Homo sapiens

<400> 20

cacatttcat ccttttcat ggttcccatc taccctcaca acacatgtca tcaccaaaga	60
cacacataca agctccaatg gcttttgcca ggcaattctt cctccaggac cccatctggc	120
ccctccctca tccctccctc tggactttgc ccttcttact ggccaggcag gggggccaga	180
gtccaggcct gactcattcc caccttgtcc tgggctgaga tcccaggttt gtaacagaaa	240
acaccactaa agccccagca caggagagaa ccaccagcc cagaagttcc aggaaggaa	300
ctctccggtc caccatggag tacctctcag ctctgaacct cagtactta ctcaggctag	360
tatctaatat aagctcggag tttggacgga gggctctggac ctcagctcca ccacccagc	420
gacctttccg tgtctgtgat cacaagcgga ccattccgga aggcctgaca gctgccacct	480
gccaggagct gctagccaaa gcattggaga ccctactgct gaattggagt ctaaccctgg	540
tgctagagga ggatggaact gcagtggaca gtgaggactt cttccagctg ctggaggatg	600
acacgtgcct gatggtgttg cagtctggtc agagctggag ccctacaagg agtggagtgc	660
tgctcatatgg cctgggacgg gagaggccca agcacagcaa ggacatcgcc cgattcacct	720
ttgacgtgta caagcaaac cctcgagacc tctttggcag cctgaatgtc aaagccacat	780
tctacgggct ctactctatg agttgtgact ttcaaggact tggcccaaag aaagtactca	840
gggagctcct tcgttggacc tccacactgc tgcaaggcct gggccatatg ttgctgggaa	900
tttccctcac ccttcgtcat gcagtggagg gggctgagca gtggcagcag aagggccgcc	960

25

tccattccta	ctaaggggct	ctgagcttct	gccccagaa	tcattccaac	cgacccactg	1020
caaagactat	gacagcatca	aatttcagga	cctgcagaca	gtacaggcta	gataaacccac	1080
ccaatttccc	cactgtcctc	tgatccccctc	gtgacagaaac	ctttcagcat	aacgcctcac	1140
atcccaagtc	tataaccctta	cctgaagaat	gctgttcttt	cctagccacc	tttctggcct	1200
cccacttgcc	ctgaaaggcc	aagatcaaga	tgtccccccag	gcattcttgat	cccagcctga	1260
ctgctgctac	atctaataccc	ctaccaatgc	ctcctgtccc	taaactcccc	agcatactga	1320
tgacagccct	ctctgacttt	accttgagat	ctgtcttcat	acccttcccc	tcaaactaac	1380
aaaaacattt	ccaataaaaa	tatcaaatat	ttaccactaa	gacttctgac	tccaatttaa	1440
accaggaaaag	ggatgggggtg	gataccccat	tttgccctcc	cccatcaaca	cccagtccca	1500
gatccaaagc	c					1511

<210> 21

<211> 6530

<212> DNA

<213> Homo sapiens

<400> 21

ttttgttagt	ttgaggggaa	gggtatgaag	acagatctca	aggtaaagtc	agagagggct	60
gtcatcagta	tgctggggag	tttagggaca	ggaggcattg	gtaggggatt	agatgtagca	120
gcagtcaggc	tgggatcaag	atgcctgggg	gacatcttga	tcttggcctt	tcagggcaag	180
tgggaggcca	gaaaggtggc	taggaaagaa	cagcattctt	caggtaaggg	tatagacttg	240
ggatgtgagg	cgttatgctg	aaaggttctg	tcacgagggg	atcagaggac	agtggggaaa	300
ttgggtgggt	tatctagcct	gtactgtctg	caggtcctga	aatttgatgc	tgtcatagtc	360
tttgagtggt	gtcggttgga	atgattctgg	gggcagaagc	tcagagcccc	ttagtaggaa	420
tggaggcggc	ccttctgctg	ccactgctca	gccccctcca	ctgcatgacg	aagggtggag	480
gaaattccca	gcaacatatg	gcccaggcct	tgcagcagtg	tggaggtcca	acgaaggagc	540
tccctgaatg	gcagagacaa	gaggaaatca	gatgatttgg	aaaacttggg	aggaagccat	600
caagctggga	gatgaggact	ttccacaagc	aagagctaac	taggggtagg	tgggtgcaag	660
aggacgaatt	atggggacta	tccaactgta	ggggatgggg	cagtatgaca	tgttgatttc	720
tgacctgagt	actttctttg	ggccaagtcc	ttgaaagtca	caactcatag	agtagagccc	780
gtagaatgtg	gctttgacat	tcaggctgcc	aaagaggtct	cgagggtttt	gcttgtagac	840
gtcaaagggtg	aatcgggcga	tgtccttgct	gtgcttgggc	ctctcccgtc	ccaggccata	900
tgacagcact	ccactctgta	ggacaccctt	gtcagtgcag	tagatcctca	taccagacac	960
ccaccactaa	tctccatcag	cactgggtca	gacctccct	cgcttggact	ttctgtccac	1020
tgtgtgacat	ccttgacaat	tccacaactc	ctcctgcacc	tgggtccccag	gatcagggtt	1080
aagctagaga	ggaagcccgg	gaaagctcta	aaggacaggc	attggaagca	gccccagtat	1140
aggcctctta	cccttgtagg	gctccagctc	tgaccagact	gcaacaccat	caggcacgtg	1200

tcacccctcca	gcagctggaa	gaagtcctca	ctgtccactg	cagttccatc	ctcctctagc	1260
accaggggta	gcactccatt	cagcagtagg	gtctccaatg	cctgccaat	ggcaagaagc	1320
aagaagggca	ggctcttatcc	catgccccctt	ccctcttttag	ctgccaaca	tccatcagtt	1380
ggctctagac	attggctgat	gtcccacttt	gactttccgg	cactttgata	cctcctaaag	1440
gttgacagctc	tccgtgttct	tcagtttttg	ggggatccta	gctagaggct	gacctttttc	1500
ctcttttgctc	ctaccatgtc	attggcatct	ccccttgctc	ccctccaagt	cacttctggg	1560
ttggaattgg	aaagcaagcc	aggttctcac	gaagtcacc	cttctgtctt	atctacaatg	1620
ctgcacctca	cttcccacac	cctcaagagt	tctccagaag	tgttttcagt	aatagtgttt	1680
aacctttttg	agtccttact	ctgtgccagg	tatgaggact	ttacctacat	tatcctctta	1740
ctcctttcaa	caaccctagg	aggatgatga	ttattattgc	ctttttatag	ttgaagaaac	1800
tgagggtttg	gtagggttgaa	caacttccca	aggtttgaca	ggcaggaagt	ggcagaatca	1860
gaatttgaac	ttgatttgtc	acacaaatca	cctttccata	ctagcttctg	aattctgtcc	1920
ctcgaactct	ccctatctcc	tgctaaccctc	tgctccata	gaaaagctca	ctcggtgga	1980
aatgaacaaa	ttgaccagag	ctcattaggg	ccactccgct	gcttttagcc	ctcagagggg	2040
ggggcagctg	tgtgacttca	gccctctgct	ccatcatcac	aagttgccac	tgttgaggag	2100
ccccttggtc	acccttgcta	taggaaccga	ggaacttggc	ctacttactt	tggctagcag	2160
ctcctggcgg	gtggcagctg	tcaggccttt	ccgatggctc	cgcttctgat	cacagacacg	2220
gaaaggtcgc	tgggggtggtg	gagctgaggt	ccagaccctc	cgtccaaaat	ccgagcttat	2280
attagatact	gacctggtag	ttgagaagaa	aagtcaagaa	ggggcgagga	ggggcttggt	2340
gagtgtaaag	ggcatgatga	gggtagagtg	gctagagggc	tagggagggg	gagatctagg	2400
tttatcgatt	agggatgagg	gagagaccat	ggagtgcagg	tgggggcggg	tggctcagga	2460
gcttgacaag	cccactgtgg	agtggggagc	aggagaggaa	gggggtactg	ttagtctcct	2520
aggggctgag	tggagtattg	ttgccctgcc	tatatccct	aaaggtggag	ggtagagcgg	2580
aggggttagca	gtcacctgag	taagtcactg	gggttcagag	ctgagaggta	ctccatgggtg	2640
gaccggagag	ttccttccct	ggaacttctg	ggctgggtgg	ttctctcctg	tgctggggct	2700
ttagtgggtg	tttctgttac	aaacctggga	tctcagccca	ggacaagggtg	ggaatgagtc	2760
aagcctggac	tctggccccc	ctgcctggcc	agtaagaagg	gcaaagtcca	aggggagggg	2820
tgaggggagg	gccagatggg	gtcctggagg	aagaattgcc	tggcaaaagc	cattggagct	2880
tgtatgtgtg	tctttggtga	tgacatgtgt	tgtgagggtg	gatgggaacc	atgtaaaagg	2940
atgaaatgtg	acttctgggtg	tttttttatt	tctatggagg	gaatttctgg	ggacgggttc	3000
tggctctcag	gctctgagaa	gctgcagttt	atgagtggct	ctgtgtgtgc	tgccacctac	3060
tggagaagcc	ataagctgca	gctttaggaa	aaggggaacc	ggggcagagt	gtggggaagt	3120
gggatggcag	catggcaggg	ctttggaaaa	tgagaggtga	gactgtgtcc	aggaaggggtg	3180
taaggagagg	atggatcctg	atacatggat	tcaggatcat	tagggctcctg	tctgggacac	3240
tggccttctc	gcttacctgc	tctttccttc	ctccttggtc	ggaggagggg	ctggctcact	3300

gctctggcctt	cattttccag	agctgcctgc	tgcagtcaca	cttaggtcat	cttctctcac	3360
ttttctcctt	ttgccgatta	gtggacgtga	cagagatgtg	aatggggcag	ggatgtcctt	3420
tgatggcatc	aagacttttag	cttctgggtgc	gctgtgtccc	agctctgatt	tcagttgcag	3480
ccgtgatgga	cagttgcatg	gaagctgaga	ctctcactga	cagtgaacc	ctcaaataaa	3540
cacaatccct	gctttcctgc	caaggatcct	tgtagggtcc	cccagcttcc	ccactttttt	3600
tctgtgtcct	gacaaaagaaa	cacagagtaa	cttgattgcc	ctgtgacctg	gccagttgca	3660
tttcccctgc	aggcttgagc	ccaagccaga	gccttgaaaa	ggatttcagg	ttgttgccca	3720
aaacactgaa	aaaaactggc	cctggccctg	aaccaaatac	cttgaaccct	cgtaaacctc	3780
ataccctgac	ccccttggtt	tggatatacc	caggtagaac	aactctctct	cactgtctgt	3840
tgtgaggata	cgctgtagcc	cactcattaa	gtacattctc	ctaataaatg	ctttggactg	3900
atcacccctgc	cagtcttttg	tcttgggcaa	tctatacttt	tctcagaggt	tcccaaggcc	3960
tactgaagg	acttaacata	ctcttaatgg	ctttcctctc	tcttgtttta	ccttatgccc	4020
tcacttctctg	agttaacctc	caaataacag	gatcacctgt	accaagccc	ttagctcaag	4080
aatacaggat	cacctgtacc	caagccctta	gctcaagctc	tgctttggaa	gaacccaaac	4140
taagacagt	ctcctgggtg	cctccccaag	caacctcaag	ttctggctgt	tacttgagca	4200
gaggcctttc	ttttcccttc	cccagctct	atccatctgc	caggccccc	tcaaatactct	4260
tcatttccaa	gttttgcttg	acttttccaa	gaggagagg	ctgcttctta	gtatgtccct	4320
actcatcctt	tcctttcttg	tcttgtatcc	tgggtgcagc	tggtaatggg	gcctcttcat	4380
ggttgtgtgt	catgactccc	taaccattat	gcctccatgc	atcccctgtt	cctcctggaa	4440
cctagcacca	tgctttacat	ggaaaagctg	tcattgacag	cccgttgaga	gccctgagg	4500
tggagtgact	ggggcagggc	ctgaggcaag	aggtgggagg	aggtaggagg	ccaggggctc	4560
agccggacca	ggagactgga	aacaggcaag	gataaggcag	gtgggggact	gagttgtttg	4620
ggtcacctct	gcaggccaga	gagaccaggc	aacatacaca	ctgcagaagg	tgggctggga	4680
ggattggggc	cagagctggg	ggagggatga	gaacagaagc	aggaccagga	ttcagcagag	4740
tcctcctatt	tccttccacc	accagggaat	cttactgccc	cacttcagct	tgtgctgttt	4800
cctggcaagg	caggctctca	catgcctgga	cgcctgggtg	cgttgggtgat	gggaaggagc	4860
agggtagagg	aggggcccc	ggagaggccc	aggatgagcc	tcactctgtc	cctccccatt	4920
cttgtcttac	cctctgcaaa	tgtgatagcc	acaggacagg	agtaggcacc	tcgcctactg	4980
ctgcttaacc	tttcagcttc	tccaggcccc	caatcctgct	tgctcccagc	ttggtaagta	5040
gatctgtgca	cgctccctta	cacccaccca	tccagttttg	cccagatgtg	ctagaatggg	5100
gctggacaaa	gaaggagggg	ccagactaga	ggagtgggtg	tagagatagt	gacagcctgg	5160
ggtgatgact	ttatgcctgt	ttaccactga	gctctgggaa	ggaggccagg	agtggggcag	5220
gtcaactgac	tgggagcagg	ggatctgggt	tccaagaagg	agttgtgttt	gaggtgggt	5280
ctgggtcctc	gtggaagtca	ggactcccag	gcagaaaaga	ggcaggctgc	aggggaagtaa	5340
ggaggaggca	tggcaccttc	tcacgggca	tcacaggtgg	ggttttgccc	caccctgaa	5400
cgccctctgt	ggcgcccttc	accacctgt	aggcccagaa	ggatgtcgg	ctgctaccgt	5460

```

ccccagggga acgagacact gctgagctgg aagacttcgc gggccacagg cacagccttc 5520
ctgctgctgg cggcgctgct ggggctgcct ggcaacggct tcgtgggtgtg gagcttggcg 5580
ggctggcggc ctgcacgggg gcgacggctg ggggccacgc ttgtgctgca cctggcgctg 5640
gccgacggcg cgggtgctgct gctcacggcg ctctttgtgg ccttcctgac ccggcaggcc 5700
tgcccgctgg gccaggcggg ctgcaaggcg gtgtactacg tgtgcgcgct cagcatgtac 5760
gccagcgtgc tgctcacggc cctgctcagc ctgcagcgct gcctcgagc caccgcccc 5820
ttcctggcgc ctcggtgctg cagcccgggc ctggcccgcc gcctgctgct ggcggctctg 5880
ctggccgccc tgttgcctgc cgtcccggcc gccgtctacc gccacctgtg gagggaccgc 5940
gtatgccagc tgtgccaccc gtgcgggtc cacgccgcgc ccacctgag cctggagact 6000
ctgaccgctt tcgtgcttcc tttcgggctg atgctcggt gctacagcgt gacgctggca 6060
cggctgcggg gcgcccgtg gggctccggg cggcacgggg cgcgggtggg ccggctggtg 6120
agcgccatcg tgcttgctt cggcttgctc tgggccccct accacgcagt caaccttctg 6180
caggcggtcg cagcgctggc tccaccggaa ggggccttgg cgaagctggg cggagccggc 6240
caggcggcgc gagcgggaa tacggccttg gccttcttca gttctagcgt caaccgggtg 6300
ctctacgtct tcaccgctgg agatctgctg ccccgggcag gtcccgttt cctcacgcgg 6360
ctcttcgaag gctctgggga ggccgaggg ggcggccgct ctagggaagg gaccatggag 6420
ctccgaacta cccctcagct gaaagtgtg gggcagggcc gcggcaatgg agaccgggg 6480
ggtgggatgg agaaggacgg tccggaatgg gacctttgac agcagaccct 6530

```

<210> 22

<211> 424

<212> DNA

<213> Artificial sequence

<220>

<223> Probe

<400> 22

```

ggattagatg tagcagcagt caggctggga tcaagatgcc tgggggacat cttgatcttg 60
gcctttcagg gcaagtggga ggctagaaag gtggctagga aagaacagca ttcttcagg 120
aagggtatag acttgggatg tgaggcgta tgctgaaagg ttctgtcacg aggggatcag 180
aggacagtgg ggaaattggg tgggttatct agcctgtact gtctgcaggc cctgaaattt 240
gatgctgtca tagtctttgc agtgggtcgg ttggaatgat tctgggggca gaagctcaga 300
gcccttagt aggaatggag gcggcccttc tgctgccact gctcagcccc ctccactgca 360
tgacgaaggg tggaggaaat tcccagcaac atatggcca ggccctgcag cagtgtggag 420
gtcc 424

```

<210> 23

<211> 424

<212> DNA

<213> Artificial sequence

<220>

<223> Probe

<400> 23

```

ggacctccac actgctgcaa ggcctgggccc atatgttgct gggaatttcc tccaccttc      60
gtcatgcagt ggagggggct gagcagtggc agcagaaggc ccgcctccat tcctactaag      120
gggctctgag cttctgcccc cagaatcatt ccaaccgacc cactgcaaag actatgacag      180
catcaaattt caggacctgc agacagtaca ggctagataa cccacccaat ttccccactg      240
tcctctgata ccctcgtgac agaacctttc agcataacgc ctcacatccc aagtctatac      300
ccttacctga agaatgctgt tctttcctag ccacctttct agcctccac ttgccctgaa      360
aggccaagat caagatgtcc ccaggcatc ttgatccag cctgactgct gctacatcta      420
atcc                                             424

```

<210> 24

<211> 7042

<212> DNA

<213> Homo sapiens

<400> 24

```

aagaagaggt agcgagtgga cgtgactgct ctatcccgcc caaaagggat agaaccagag      60
gtggggagtc tgggcagtcg gcgaccgcgc aagacttgag gtgccgcagc ggcacccgga      120
gtagcgcccg gctccctccg ggggtgcagc gccgtcgggg gaaggcgccc acaggccggg      180
aagacctcct ccctttgtgt ccagtagtgg ggtccaccgc agggcgggcc gtgggcccgg      240
cctcaccgcg gcgctccggg actgtggggg caggctgcgt tgggtggacg cccacctcgc      300
caaccttcgg aggtccctgg gggctctcgt gcgccccggg gctgcagaga tccaggggag      360
gcgcctgtga ggcccgacc tgccccgggg cgaagggtat gtggcgagac agagccctgc      420
accctaatt cccggtggaa aactcctgtt gccgtttccc tccaccggcc tggagtctcc      480
cagtcctgtc ccggcagtcg cgcctcccc actaagacct aggcgcaaag gcttggtcca      540
tggttgacag ctacagagaga gaaagatctg aggggaagat gatgcaaaag ctcgaaattg      600
tttgcttcaa catagagaag ctctggaaaa ggacatcaag acatcctaca tcatggatca      660
catgattagt gatggatttt taacaatatc agaagaggaa aaagtaagaa atgagcccac      720
tcaacagcaa agagcagcta tgctgattaa aatgatactt aaaaaagata atgattccta      780
cgtatcattc tacaatgtc tactacatga aggatataaa gatcttgctg cccttctcca      840
tgatggcatt cctgttgtct cttcttcag tgtaaggaca gtcctgtgtg aagggtggag      900

```

accacagagg	ccagttgttt	ttgtcacaag	gaagaagctg	gtgaatgcaa	ttcagcagaa	960
gctctccaaa	ttgaaaggtg	aaccaggatg	ggtcaccata	catggaatgg	caggctgtgg	1020
gaagtctgta	ttagctgcag	aagctgttag	agatcattcc	cttttagaag	gttgtttccc	1080
agggggagtg	cattgggttt	cagttgggaa	acaagacaaa	tctgggcttc	tgatgaaact	1140
gcagaatctt	tgcacacggg	tggatcagga	tgagagtttt	tcccagaggg	ttccacttaa	1200
tattgaagag	gctaaagacc	gtctccgcat	tctgatgctt	cgcaaacacc	caaggctctt	1260
cttgatcttg	gatgatgttt	gggactcttg	gggtgtgaaa	gcttttgaca	gtcagtggtca	1320
gattcttctt	acaaccagag	acaagagtgt	tacagattca	gtaatgggtc	ctaaatatgt	1380
agtccttggtg	gagagtccct	taggaaagga	aaaaggactt	gaaattttat	ccctttttgt	1440
taatatgaag	aaggcagatt	tgcagaaca	agctcatagt	attataaaag	aatgtaaagg	1500
ctctcccctt	gtagtatctt	taattgggtg	acttttacgt	gattttccca	atcgctggga	1560
gtactacctc	aaacagcttc	agaataagca	gtttaagaga	ataaggaaat	cttcgtctta	1620
tgattatgag	gctctagatg	aagccatgtc	tataagtgtt	gaaatgctca	gagaagacat	1680
caaagattat	tacacagatc	tttccatcct	tcagaaggac	gttaagggtg	ctacaaaggt	1740
gttatgtatt	ctctgggaca	tggaaactga	agaagttgaa	gacatactgc	aggagtttgt	1800
aaataagtct	cttttattct	gtgatcggaa	tggaaagtcg	tttcgttatt	atttacatga	1860
tcttcaagta	gattttctta	cagagaagaa	ttgcagccag	cttcaggatc	tacataagaa	1920
gataatcact	cagtttcaga	gatatcacca	gccgcatact	ctttcaccag	atcaggaaga	1980
ctgtatgtat	tggtacaact	ttctggccta	tcacatggcc	agtgccaaga	tgcaacaagga	2040
actttgtgct	ttaatgtttt	ccctggattg	gattaaagca	aaaacagaac	ttgtaggccc	2100
tgctcatctg	attcatgaat	ttgtggaata	cagacatata	ctagatgaaa	aggattgtgc	2160
agtcagtgag	aattttcagg	agtttttatc	tttaaagtga	caccttcttg	gacgacagcc	2220
atttccta	attgtacaac	tgggtctctg	tgagccggaa	acttcagaag	tttatcagca	2280
agctaagctg	caggccaagc	aggaggtcga	taatggaatg	ctttacctgg	aatggataaa	2340
caaaaaaac	atcacgaatc	tttcccgtt	agttgtccgc	ccccacacag	atgctgttta	2400
ccatgcctgc	ttttctgagg	atggtcagag	aatagcttct	tgtggagctg	ataaaacctt	2460
acaggtgttc	aaagctgaaa	caggagagaa	acttctagaa	atcaaggctc	atgaggatga	2520
agtgtttgt	tgtgcattct	ctacagatga	cagatttata	gcaacctgct	cagtggataa	2580
aaaagtgaag	atttggaatt	ctatgactgg	ggaactagta	cacacctatg	atgagcactc	2640
agagcaagtc	aattgctgcc	atttcaccaa	cagtagtcat	catcttctct	tagccactgg	2700
gtcaagtgac	tgttctctca	aactttggga	tttgaatcaa	aaagaatgtc	gaaataccat	2760
gtttgggtcat	acaatttcag	tcaatcactg	cagattttca	ccagatgata	agcttttggc	2820
tagttgttca	gctgatggaa	ccttaaagct	ttgggatgcg	acatcagcaa	atgagaggaa	2880
aagcattaat	gtgaaacagt	tcttcctaaa	tttggaggac	cctcaagagg	atatggaagt	2940
gatagtgaag	tggtgttcgt	ggctctgctga	tggtgcaagg	ataatggtgg	cagcaaaaaa	3000

31

taaaatcttt	ttgtggaata	cagactcacg	ttcaaagggtg	gctgattgca	gaggacattt	3060
aagttgggtt	catggtgtga	tgttttctcc	tgatggatca	tcatttttga	catcttctga	3120
tgaccagaca	atcaggctct	gggagacaaa	gaaagtatgt	aagaactctg	ctgtaatgtt	3180
aaagcaagaa	gtagatgttg	tgtttcaaga	aaatgaagtg	atggtccttg	cagttgacca	3240
tataagacgt	ctgcaactca	ttaatggaag	aacaggtcag	attgattatc	tgactgaagc	3300
tcaagttagc	tgctgttgct	taagtccaca	tcttcagtac	attgcatttg	gagatgaaaa	3360
tggagccatt	gagatttttag	aacttgtaaa	caatagaatc	ttccagtcga	ggtttcagca	3420
caagaaaact	gtatggcaca	tccagttcac	agccgatgag	aagactctta	tttcaagttc	3480
tgatgatgct	gaaattcagg	tatggaattg	gcaattggac	aatgtatct	ttctacgagg	3540
ccatcaggaa	acagtgaag	acttttagact	cttgaaaaat	tcaagactgc	tttcttggtc	3600
atttgatgga	acagtgaagg	tatggaatat	tattactgga	aataaagaaa	aagactttgt	3660
ctgtcaccag	ggtacagtac	tttcttggtga	catttctcac	gatgctacca	agttttcatc	3720
tacctctgct	gacaagactg	caaagatctg	gagttttgat	ctccttttgc	cacttcatga	3780
attgaggggc	cacaacggct	gtgtgcgctg	ctctgccttc	tctgtggaca	gtaccctgct	3840
ggcaacggga	gatgacaatg	gagaaatcag	gatatggaat	gtctcaaacg	gtgagcttct	3900
tcatttgtgt	gctccgcttt	cagaagaagg	agctgctacc	catggaggct	gggtgactga	3960
cctttgcttt	tctccagatg	gcaaaatgct	tatctctgct	ggaggatata	ttaagtgggtg	4020
gaacgttgct	actggggaat	cctcacagac	cttctacaca	aatggaacca	atcttaagaa	4080
aatacacgtg	ccccctgact	tcaaaacata	tgtgactgtg	gataatcttg	gtattttata	4140
tattttacag	actttagaat	aaaatagtta	agcattaatg	tagttgaact	ttttaaat	4200
ttgaattgga	aaaaaattct	aatgaaacct	tgatatcaac	tttttataaa	gctcttaatt	4260
gttgtgcagt	attgcattca	ttacaaaagt	gtttgtgggt	ggatgaataa	tattaatgta	4320
gctttttccc	aatgaacat	acctttaatc	ttgtttttca	tgatcatcat	taacagtttg	4380
tccttaggat	gcaaatgaaa	atgtgaatac	ataccttggt	gtactgttgg	taaaattctg	4440
tcttgatgca	ttcaaaatgg	ttgacataat	taatgagaag	aatttggaag	aaattgggtat	4500
tttaatactg	tctgtattta	ttactgttat	gcaggctgtg	cctcagggtg	gcagtggcct	4560
gctttttgaa	ccacacttac	cccaaggggg	ttttgttctc	ctaaatacaa	tcttagaggt	4620
tttttgact	ctttaaat	gctttaaaaa	tattgtgtct	gtgtgcatag	tctgcagcat	4680
ttcctttaat	tgactcaata	agtgagtctt	ggatttagca	ggcccccca	cctttttttt	4740
ttgtttttgg	agacagagtc	ttgctttgtt	gccaggctgg	agtgcagtgg	cgcgatctcg	4800
gtcaccaca	atcgctgcct	cctgggttca	agcaattctc	ctgcctcagc	ctcccgagta	4860
gctgggacta	cagggtgtcg	cacatgccag	gctaattttt	gtatttttag	tagagacggg	4920
gtttcaccat	gttggccggg	atggctctga	tctcttgacc	tcattgatcta	cccgcccttg	4980
cctcccaaag	tgctgagatt	acaggcgtga	gccaccgtgc	ctggccaggc	cccttctctt	5040
ttaatggaga	cagggtcttg	cactatcacc	caggctggag	tgagtgga	taatcatacc	5100
tcattgcagc	ctcagactcc	tgggttcaag	caatcctcct	gcctcagcct	cccaagtagc	5160


```

tgagactgca ggcacgagcc accacaccca gctaattttt aagttttctt gtagagacag 5220
ggctctcacta tgttgtctag gctgggtcttg aactcttggc ctcaagtaat cctcctgcct 5280
cagcctccca aagtgttggg attgcagata tgagccactg gcctggcctt cagcagttct 5340
ttttgtgaag taaaacttgt atgttggaag gagtagattt tattgggtcta cccttttctc 5400
actgtagctg ctggcagccc tgtgccatat ctggactcta gttgtcagta tctgagttgg 5460
acactattcc tgctccctct tgtttcttac atatcagact tcttacttga atgaaacctg 5520
atctttccta atcctcactt ttttcttttt taaaaagcag tttctccact gctaaatggt 5580
agtcattgag gtggggccaa ttttaatcat aagccttaat aagatttttc taagaaatgt 5640
gaaatagaac aattttcatc taattccatt tacttttaga tgaatggcat tgtgaatgcc 5700
attcttttaa tgaatttcaa gagaattctc tggttttctg tgtaattcca gatgagtcac 5760
tgtaactcta gaagattaac cttocagcca acctattttc ctttcccttg tctctctcat 5820
cctcttttcc ttcttctctt cctttctctt cttttatctc caaggttaat caggaaaaat 5880
agcttttgac aggggaaaaa actcaataac tagctatttt tgacctcctg atcaggaact 5940
ttagttgaag cgtaaatcta aagaaacatt ttctctgaaa tatattatta agggcaatgg 6000
agataaatta atagtagatg tggttcccag aaaatataat caaaattcaa agattttttt 6060
tgtttctgta actggaacta aatcaaataa ttactagtgt taatagtaga taacttgttt 6120
ttattgttgg tgcatattag tataactgtg gggtaggtcg gggagagggg aagggaatag 6180
atcactcaga tgtattttag ataagctatt tagcctttga tggaatcata aatacagtga 6240
atacaatcct ttgcattggt aaggagggtt tttgttttta aatggtgggt caaggagcta 6300
gtttacaggc ttactgtgat ttaagcaaata gtgaaaagtg aaaccttaat tttatcaaaa 6360
gaaatttctg taaatggtat gtctccttag aatacccaa tcataatttt atttgtacac 6420
actgttaggg gctcatctca tgtaggcaga gtataaagta ttaccttttg gaattaaaag 6480
ccactgactg ttataaagta taacaacaca catcagggtt taaaaagcct tgaatggccc 6540
ttgtcttaaa aagaaattag gagccagggt cggtggcacg tgctgtagt cccagctcct 6600
tgaggaggct agacaggagg attccttgag ccctggaggt tgagtccagc ctgggtgaca 6660
tagcaagacc ctgtcttaaa agaaaaatgg gaagaaagac aaggtaacat gaagaaagaa 6720
gagataccta gtatgatgga gctgcaaatt tcatggcagt tcatgcagtc ggtcaagagg 6780
aggattttgt tttgtagttt gcagatgagc atttctaaag cattttccct tgctgtattt 6840
ttttgtatta taaattacat tggacttcat atatataatt tttttttaca ttatatgtct 6900
cttgtatggt ttgaaactct tgtatttatg atatagctta tatgattttt ttgccttggg 6960
atacatttta aaatatgaat ttaaaaaatt tttgtaaaaa taaaattcac aaaattgttt 7020
tgaaaaacaa aaaaaaaaaa aa 7042

```

<210> 25

<211> 3019

<212> DNA

<213> Artificial sequence

<220>

<223> Probe

<220>

<221> misc_feature

<222> (2846)..(2846)

<223> Any nucleotide

<400> 25

tttttttttt	tttttttgaa	aaacattttt	ggattgtttc	attcttttgc	tgtcatttat	60
ctgttgatta	gaccactaaa	gtgaaggatt	caagctaaat	acatcaacct	ttctatttag	120
gctttatcag	ctatatgtaa	attcaattct	atcaaaattt	tctgagtgcc	tcctcagtgt	180
gtctctctga	tggttcctgc	ccggtatggc	tggcatgaag	aagatccacg	gacttgcgaa	240
tgctaacgcg	gggcttgggg	atgggtttgg	agggtttgtt	ttcaaagctt	tctggaagtg	300
tgaggagtgt	ttcccctttt	cttgcttgta	gtgctagctg	gtaagcgact	tcgaatgcct	360
gtcccagggt	taggatgatt	tcataaggcta	aattcacatc	aaaggcagta	aacacatgac	420
agtagtggtg	attagacttc	aaatcttttg	tgatataggc	aaatgttgag	aggtcttctg	480
ggctctgggc	agcacaggag	atattacgaa	tttcatgctc	agcaattatg	ttcttatttg	540
ttgcatcaat	aaatttgact	cctttatatg	agacagaaa	aataatagta	gggaccttct	600
tcatttgctc	tgtagacttc	tgacagttag	cccgcatttt	tgacacaagca	tcttgggttg	660
attctgtccc	cctaagctct	tttatcagca	tagaacctaa	ataaaaagct	ttgtaatcac	720
acgactggaa	gataagcttt	tctgggtgat	gctgccagta	ctgtaccggg	gtagaggctg	780
tggcttcatt	cggaggtcgc	aaggtaatgg	aaggttctcc	ccagtctcct	gtctgagcca	840
tctgcctctc	cagttttgat	cggggaatat	catcaaagta	gttttcattt	cttctcctcc	900
ttgcatcgcc	ctgcatgata	atgtgaggaa	cgtctaggga	gccaccagtg	gtgtaagtgc	960
tttggctaag	tgatggagac	aactgaggag	gagtgtgatt	accactgggt	tccttgaggg	1020
tgatggaccg	agggggcttc	tgtgggggat	cgtcgtgcag	cctgtctccc	agagatgcc	1080
aaatacgttt	cctgtggcca	atcaaattga	tttttaaaac	attaataagt	tcaacctccc	1140
agattttttt	caacagggtc	atcgaagtgt	agccattaat	tagaaaggct	ttggtgtagt	1200
cgcccagttc	aatggaatcc	agccactcag	ctacagaggt	gggatggtag	ccatcatgcc	1260
caatgggtct	catcttttga	aggagctgga	ttgcctgtag	aattctttgt	ctgtgcccag	1320
aattaaggat	ttcaattttc	aacaaatcct	gatcttccat	aacattgctt	cccataaact	1380
gcacattgtc	aaatccatta	gccatcaggt	ggttctcgta	ctgaggtagc	ccaatgcttt	1440
ccaaccattg	tcccactgtt	tggacagggc	atctgggtct	tgtgggtctc	ccattcatct	1500
ctttaagtgc	gttggtgatt	ccaacatcta	tggaaactcat	tattttgtca	atttcttccc	1560

```

attccgatgt gaaggatggt gttctttcag aattcccttt agaactgtgt tcagcagtgg 1620
aagattcact ccagttaact cttgatgttt tctcattgga aggataggca atgagatcag 1680
aatcagattht agagacactt tttgacaaat gcatgtcgat caaggcttta ggcaatgacc 1740
ttattctccc cagagtacag gctctctcca caaatcccc tgcttcata acccactggt 1800
ccccattccg agatccactc ctggttgatc ttgtgccaac aatggtatgg ttttcgagtt 1860
ggttgctttt tttgtgaaaa attgttctac tgaccacttt gggtttaatt ttctttacca 1920
aaggttctga gttatthttct attggagact gcttgaaagg caaaggactg tttgccaac 1980
tgacttcac ttgtcctttt tcacattgtt ctcttttccc atagagatga aatggattht 2040
caggggactc acaggctgga gaggatccat ggagcaggcc tgcaaattgc ccaggatcat 2100
attctthttgg gggatcattg tcatcctgtc gggagaggtc atctgtatgg ttagttccct 2160
cattcttgac ttctgtggtt cccacagaag aggtgggtgg actagcagga ggactggcag 2220
taaagcttgt gcacctgta gatgtgttga tttcaaaata ttcttggttg tgattcattc 2280
ggtgaaaaac cagagaagac acaatggatg ttcgctgttt aggtctgggt cgaatgactt 2340
ttacaatatt tttgagggca gtatcagggg atggagggtga acaatcagggt gttgggcctg 2400
ttgagctgtt tctatggtta ctagtctctg gagtagtaac tgctacctca gaggcattat 2460
cagttcttgg ggaagggtgcc ctgcaattt ctaaggagca aggtttcttt gtaacagctg 2520
tgtccatgag atcacacaga aagttctcat tttctgaagg aaatgtatcc agagaagcag 2580
atggtacaat ttccatagtg taatthtctt tctthtgata ggactcctgg gcaagcatgg 2640
ggaagccaag gttcctacat ccattacacg gagttaatgc ttcccaaagt cctgatggcc 2700
cacacgtatt ttcatcatca tcctcttctt ccactctctc tggtgacaaa ttgattgtag 2760
atgaggttct tacactctgg cttccattth tcccaagttc ttctctgaa atcttgctca 2820
aattatctaa gtatgggtct gatatngtgt ggcacaagtc ttcaaacgaa taatccttht 2880
cttgacagag tthtattthca tccaagagtt ttgataatth tccagtgaag gtttacttht 2940
tggtctthtt ggaaggagac tcaacaggag atgaaatgtg tgthtcttgt gttgcatctt 3000
cctgtacagg ctcttcgag
3019

```

<210> 26

<211> 1752

<212> DNA

<213> Artificial sequence

<220>

<223> Probe

<400> 26

```

agaacgcaga ccagcccaag ctgacagctt gagtatgcct tcttctgctg cctggthttg 60
ggggctgtat gacgtactgg tcggtagtaa agattaatat gtaagaaatg tggagctagg 120

```

35

atcaagtc	cat	actccacagc	ctgcctggca	aactatgttt	tacttctgac	tttgcctct	180
cgctgaga	aac	attaatctgt	caagctggcg	ggctcctttg	atagcaactt	tcccaggggc	240
atgatgtggc	aatgccacct	ctcagcccag	gactaccgct	attaccccg	ggacggctac		300
tccctgctta	aacgcttccc	tcttcaccc	cttacaggac	ccagatgccc	tgtccaaaca		360
gtgggaca	aat	ggttgaaaag	cattgggcta	cctcagtacg	agaaccacct	gatgggcta	420
ggatttgaca	atgtgcagtt	tatgggaagc	aatgttatgg	aagatcagga	tttgttgga		480
attggaatcc	ttaattctgg	gcacagacaa	agaattctac	aggcaatcca	gctccttcca		540
aagatgagac	ccattgggca	tgatggctac	catccaccc	ctgtagctga	gtggctggat		600
tccattgaac	tgggcgacta	caccaaagcc	tttctaatta	atggctacac	ttcgatggac		660
ctgttgaaaa	aaatctggga	ggttgaaactt	attaatgttt	taaaaatcaa	tttgattggc		720
cacaggaaac	gtattttggc	atctctggga	gacaggctgc	acgacgatcc	cccacagaag		780
ccccctcggt	ccatcaccc	caggacagga	gactggggag	aaccttccat	taccttgcca		840
cctccgaatg	aagccacagc	ctctaccccg	gtacagtact	ggcagcatca	cccagaaaag		900
cttatcttcc	agtcgtgtga	ttacaaagct	ttttatttag	gttctatgct	gataaaagag		960
cttaggggga	cagaatcaac	ccaagatgct	tgtgcaaaaa	tgcgggctaa	ctgtcagaag		1020
tctacagagc	aaatgaagaa	ggtccctact	attattcttt	ctgtctcata	taaaggagtc		1080
aaattttattg	atgcaacaaa	taagaacata	attgctgagc	atgaaattcg	taatattctcc		1140
tgtgctgccc	aggaccacga	agacctctca	acatttgcct	atatcacaaa	agatttgaag		1200
tctaatacacc	actactgtca	tgtgtttact	gcctttgatg	tgaatttagc	ctatgaaatc		1260
atcctaacc	tgggacaggc	attcgaagtc	gcttaccagc	tagcactaca	agcaagaaaa		1320
gggggacact	cctccacact	tccagaaagc	tttgaaaaca	aacctccaa	acccatcccc		1380
aagccccgcg	ttagcattcg	caagtcctg	gatcttcttc	atgccagcca	taccgggcag		1440
gaaccatcag	agagacacac	tgaggaggca	ctcagaaaat	tttgatagaa	ttgaatttac		1500
atatagctga	taaagcctaa	atagaaaggt	tgatgtat	agcttgaatc	cttcacttta		1560
gtggtcta	aat	caacagataa	atgacaagca	aagaatgaaa	caatccaaaa	atgtttttca	1620
aaacaatttt	gtgaatttta	tttttacaaa	aattttttta	attcatattt	taaaatgtat		1680
accaaggcaa	aaaaatcata	taagctatat	cataaataca	agagtttcaa	aacatacaag		1740
agacataata	tg						1752

<210> 27

<211> 367

<212> DNA

<213> Artificial sequence

<220>

<223> Probe

36

<400> 27
 ccgcgttagc attcgcaagt ccgtggatct tcttcatgcc agccataccg ggcaggaacc 60
 atcagagaga cacactgagg aggcaactcag aaaattttga tagaattgaa ttacatata 120
 gctgataaag cctaaataga aaggttgatg tatttagctt gaatccttca ctttagtggt 180
 ctaatcaaca gataaatgac aagcaaagaa tgaaacaatc caaaaatggt ttcaaaaca 240
 attttgtgaa ttttattttt acaaaaattt ttttaattca tattttaaaa tgtataccaa 300
 ggcaaaaaaa tcatataagc tatatcataa atacaagagt ttcaaacat acaagagaca 360
 tataatg 367

<210> 28

<211> 367

<212> DNA

<213> Artificial sequence

<220>

<223> Probe

<400> 28
 cattatatgt ctcttgatg ttttgaaact cttgtattta tgatatactt tatatgattt 60
 ttttgccttg gtatacattt taaaatatga atttaaaaaa tttttgtaaa aataaaattc 120
 acaaaattgt tttgaaaaac atttttggat tgtttcattc tttgcttgct atttatctgt 180
 tgattagacc actaaagtga aggattcaag cttaatacat caacctttct atttaggctt 240
 tatcagctat atgtaaatc aattctatca aaattttctg agtgcctcct cagtgtgtct 300
 ctctgatggt tcctgcccg tatggctggc atgaagaaga tccacggact tgcgaatgct 360
 aacgcgg 367

<210> 29

<211> 2457

<212> DNA

<213> Homo sapiens

<400> 29
 cacgcagcag gatggcaagg gctccgcttg gggctctgct cctcttgggg cttctcggca 60
 ggggtgtggg gaagaacgag gaactgcgtc tttatcacca tctcttcaac aactatgacc 120
 caggaagccg gccagtggg gagcctgagg atactgtcac catcagcctc aaggtcaccc 180
 tgacgaatct catctcactg aatgaaaaag aggagactct caccactagc gtctggattg 240
 gaatcgattg gcaggattac cgactcaact acagcaagga cgactttggg ggtatagaaa 300
 ccctgcgagt cccttcagaa ctcggtgggc tgccagagat tgtgctggaa aacaatattg 360
 atggccagtt cggagtggcc tacgacgcca acgtgctcgt ctacgagggc ggctccgtga 420

37

cgtggctgcc tccggccatc taccgcagcg tctgcgcagt ggaggtcacc tacttcccct 480
 tcgattggca gaactgttcg cttattttcc gctctcagac gtacaatgcc gaagaggtgg 540
 agttcacttt tgccgtagac aacgacggca agaccatcaa caagatcgac atcgacacag 600
 aggcctatac tgagaacggc gagtgggcca tcgacttctg cccgggggtg atccgccgcc 660
 accacggtgg cgccaccgac ggcccagggg agactgacgt catctactcg ctcatcatcc 720
 gccggaagcc gctctttctac gtcattaaca tcatcgtgcc ctgtgtgctc atctcggggc 780
 tgggtgctgct cgcctacttc ctgccggcgc agggccggcg ccagaaatgc acggtctcca 840
 tcaacgtcct gctcgcccag accgtcttct tgttcctcat tgcccagaaa atcccagaga 900
 cttctctgag cgtgccgctc ctgggcaggt tccttatttt cgtcatgggtg gtcgccacgc 960
 tcattgtcat gaattgcgtc atcgtgctca acgtgtccca gcggacgccc accaccacgc 1020
 ccatgtcccc gcggctgcgc cacgttctcc tggagctgct gccgcgcctc ctgggctccc 1080
 cgccgcgcc cgaggcccc cgggccgcct cgcgcccaag gcgggcgtcg tcggtgggct 1140
 tattgctccg cgcggaggag ctgatactga aaaagccacg gagcgagctc gtgtttgagg 1200
 ggcagaggca ccggcagggg acctggacgg ctgccttctg ccagagcctg ggcgccgccg 1260
 cccccaggt ccgctgctgt gtggatgccg tgaacttcgt ggccgagagc acgagagatc 1320
 aggaggccac cggcgaggaa gtgtccgact ggggtgcgcat ggggaatgcc cttgacaaca 1380
 tctgcttctg ggccgctctg gtgctcttca gcgtgggctc cagcctcatc ttctcgggg 1440
 cctacttcaa ccgagtgcct gatctcccct acgcgccgtg tatccagcct tagctcgac 1500
 cgacttcaat ttcccacca tctccagtag gaaattgatt ttgaaaaagt aggctgccgc 1560
 caccacggca ttatgatccc ttccccctgc tgatcaatct gcagtttgtg aacttcacaa 1620
 gaatggtgtg tgcccgttcc ctggcggtgt taggcctggc cgcagtcag ggtcagcag 1680
 gaggaaaggg ttcacatagg ctctcaggtg ccagtcctcc agaaagcaag gactgccctt 1740
 cattcagcct tgctgacctc ccagcctttc taaggctcag cccacaggga ctctgggtggc 1800
 tgccagcttg tgagctatct atctatatc atttcatagc caaacaggag acccctttgc 1860
 aggacttgca cacagggagg ctgtagccag gaaaccctct tcttccctgg tctggctctg 1920
 ctggagcggg tgggaaccaa acaccttcag tgctggtggc cctcaggccc acaggtttaa 1980
 ggctgaggct gccctgacct ttccacagtc atttcttcta ggttttcttg gcccagcact 2040
 gccatccca ccccatgagg ctcactcatt gcagatccca gccaccctg cccctttctt 2100
 cccaccctg gaggtctctc ctgcctagtc tacagtaactg acagaaagca aggacatgcg 2160
 gcctgcatgg tgggagctgg ttgaattgtc tttattaaca aacaggatat ccaaggccac 2220
 tacattgagg aggggggagg ggggaggag gagaagggtt acttgctgct cactatat 2280
 acagatgcaa gcaaggggcg tggagagtga gggctccctg ctccctccct ccaccggga 2340
 agggcatggg ctagaagagg agaggggggt cgggaatggg gggaatgtt tggctgctgg 2400
 gtccccctc cattccctgg agtttggggg aagggaatc attaaagtgc tttcaga 2457

<211> 4863

<212> DNA

<213> Homo sapiens

<400> 30

ggagatagcg cctgtcagtc ggtgggtcgg tctctcgcgc ggccctcccc ctccccggtc	60
tccgggggag gcgcggtgga gtccgcccc ggggttctcc gatgggggag aagcggcgac	120
ggcggcagtg gagtaaccga gccggagcgt gagcggcccc ggtgccccgt tccccacgga	180
ggccatgggc gaccagccc ccgcccgcag cctggacgac atcgacctgt ccgccctgcg	240
ggacctgct gggatctttg agcttgtgga ggtggtcggc aatggaacct acggacaggt	300
gtacaagggt cggcatgtca agacggggca gctggctgcc atcaaggta tggatgtcac	360
ggaggacgag gaggaagaga tcaaacagga gatcaacatg ctgaaaaagt actctcacca	420
ccgcaacatc gccacctact acggagcctt catcaagaag agccccccgg gaaacgatga	480
ccagctctgg ctggtgatgg agttctgtgg tgetggttca gtgactgacc tggtaaagaa	540
cacaaaaggc aacgccctga aggaggactg tatcgctat atctgcaggg agatcctcag	600
gggtctggcc catctccatg cccacaaggt gatccatga gacatcaagg ggcagaatgt	660
gctgctgaca gagaatgctg aggtcaagct agtggatttt ggggtgagtg ctgagctgga	720
ccgcaccgtg ggcagacgga acactttcat tgggactccc tactggatgg ctccagaggt	780
catcgctgt gatgagaacc ctgatgccac ctatgattac aggagtata tttggtctct	840
aggaatcaca gccatcgaga tggcagaggg agccccccct ctgtgtgaca tgcaccccat	900
gcgagccctc ttcctcattc ctcggaaccc tccgcccagg ctcaagtcca agaagtggtc	960
taagaagttc attgacttca ttgacacatg tctcatcaag acttacctga gccgccacc	1020
cacggagcag ctactgaagt ttcccttcat cggggaccag cccacggagc ggcaggtccg	1080
catccagctt aaggaccaca ttgaccgatc ccggaagaag cggggtgaga aagaggagac	1140
agaatatgag tacagcggca gcgaggagga agatgacagc catggagagg aaggagagcc	1200
aagctccatc atgaacgtgc ctggagagtc gactctacgc cgggagtttc tccggctcca	1260
gcaggaaaat aagagcaact cagaggcttt aaaacagcag cagcagctgc agcagcagca	1320
gcagcgagac cccgaggcac acatcaaaca cctgctgcac cagcggcagc ggcgcataga	1380
ggagcagaag gaggagcggc gccgcgtgga ggagcaacag cggcgggagc gggagcagcg	1440
gaagctgcag gagaaggagc agcagcggcg gctggaggac atgcaggctc tgcggcggga	1500
ggaggagcgg cggcagggcg agcgcgagca ggaatacaag cggaagcagc tggaggagca	1560
gcggcagtca gaacgtctcc agaggcagct gcagcaggag catgcctacc tcaagtcctt	1620
gcagcagcag caacagcagc agcagcttca gaaacagcag cagcagcagc tctgcctgg	1680
ggacaggaag cccctgtacc attatggtcg gggcatgaat cccgctgaca aaccagcctg	1740
ggcccgcagag gtagaagaga gaacaaggat gaacaagcag cagaactctc ccttggccaa	1800
gagcaagcca ggcagcacgg ggctgagcc ccccatcccc caggcctccc caggggcccc	1860

39

aggacccctt	tcccagactc	ctcctatgca	gaggccggtg	gagccccagg	agggaccgca	1920
caagagcctg	gtggcacacc	gggtccact	gaagccatat	gcagcacctg	taccccgatc	1980
ccagtccctg	caggaccagc	ccacccgaaa	cctggctgcc	ttcccagcct	cccatgaccc	2040
cgaccctgcc	atccccgcac	ccactgccac	gcccagtgcc	cgaggagctg	tcattccgcca	2100
gaattcagac	cccacctctg	aaggacctgg	ccccagcccg	aatccccccag	cctgggtccg	2160
cccagataac	gaggccccac	ccaaggtgcc	tcagaggacc	tcattctatcg	ccactgccct	2220
taacaccagt	ggggccggag	ggtcccggcc	agcccaggca	gtccgtgcc	gtaacccga	2280
cctcaggagg	agcgaccctg	gctgggaacg	ctcggacagc	gtccttccag	cctctcacgg	2340
gcacctcccc	caggctggct	caactggagcg	gaaccgcgtg	ggagtctcct	ccaaaccgga	2400
cagctccctt	gtgctctccc	ctgggaataa	agccaagccc	gacgaccacc	gctcacggcc	2460
aggccggccc	gcaagctata	agcgagcaat	tggtagaggac	tttgtgttgc	tgaaagagcg	2520
gactctggac	gaggccccctc	ggcctcccaa	gaaggccatg	gactactcgt	cgtccagcga	2580
ggaggtggaa	agcagtgagg	acgacgagga	ggaaggcgaa	ggcgggccag	cagaggggag	2640
cagagatacc	cctggggggcc	gcagcgatgg	ggatacagac	agcgtcagca	ccatggtggt	2700
ccacgacgtc	gaggagatca	ccgggaccca	gccccatac	gggggcggca	ccatggtggt	2760
ccagcgcacc	cctgaagagg	agcggaaacct	gctgcatgct	gacagcaatg	ggtacacaaa	2820
cctgcctgac	gtggtccagc	ccagccactc	acccaccgag	aacagcaaag	gccaaagccc	2880
accctcgaag	gatgggagtg	gtgactacca	gtctcgtggg	ctggtaaagg	cccctggcaa	2940
gagctcgttc	acgatgtttg	tggatctagg	gatctaccag	cctggaggca	gtggggacag	3000
catccccatc	acagccctag	tgggtggaga	gggcactcgg	ctcgaccagc	tgcagtacga	3060
cgtgaggaag	ggttctgtgg	tcaacgtgaa	tcccaccaac	acccgggccc	acagtgagac	3120
ccctgagatc	cggaaagtaca	agaagcgatt	caactccgag	atcctctgtg	cagccctttg	3180
gggggtcaac	ctgctggtgg	gcacggagaa	cgggctgatg	ttgctggacc	gaagtgggca	3240
gggcaagggtg	tatggactca	ttggggggcg	acgcttccag	cagatggatg	tgctggaggg	3300
gctcaacctg	ctcatcacca	tctcaggga	aaggaaacaa	ctgcgggtgt	attacctgtc	3360
ctggctccgg	aacaagattc	tgcaaatga	cccagaagtg	gagaagaagc	agggctggac	3420
caccgtgggg	gacatggagg	gctgcgggca	ctaccgtgtt	gtgaaatacg	agcggattaa	3480
gttcctggtc	atgcctctca	agagctccgt	ggaggtgtat	gcctggggcc	ccaaacccta	3540
ccacaaattc	atggccttca	agtcctttgc	cgacctcccc	caccgccttc	tgctggctga	3600
cctgacagta	gaggaggggc	agcggctcaa	ggtcatctat	ggctccagtg	ctggcttcca	3660
tgctgtggat	gtcgactcgg	ggaacagcta	tgacatctac	atccctgtgc	acatccagag	3720
ccagatcacg	cccatgcc	tcattcttct	ccccaacacc	gacggcatgg	agatgctgct	3780
gtgctacgag	gacgaggggtg	tctacgtcaa	cacgtacggg	cgcattatta	aggatgtggt	3840
gctgcagtg	ggggagatgc	ctaacttctgt	ggcctacatc	tgctccaacc	agataatggg	3900
ctgggggtgag	aaagccattg	agatccgctc	tgtggagacg	ggccacctcg	acggggtctt	3960
catgcacaaa	cgagctcaga	ggctcaagtt	cctgtgtgag	cggaatgaca	aggtgttttt	4020

40

```

tgccctcagtc cgctctgggg gcagcagcca agtttacttc atgactctga accgtaactg 4080
catcatgaac tggtagacggg gccctgggct ggggctgtcc cacactggac ccagctctcc 4140
ccctgcagcc aggcttcccg ggccgcccct ctttcccctc cctgggcttt tgcttttact 4200
ggtttgattt cactggagcc tgctgggaac gtgacctctg acccctgatg ctttcgtgat 4260
cacgtgacca tctcttccc caacatgtcc tcttcccaa actgtgcctg tccccagctt 4320
ctggggaggg acacagcttc cccttcccag gaattgagtg ggcctagccc ctccccctt 4380
ttctccattt gagaggagag tgcttggggc ttgaaccctt taccctactg ctgctgactg 4440
ggcagggccc tggaccctt tatttgacg tcaggggagc cggctcccc cttgaatgta 4500
ccagaccctg gggggggtca ctgggcccta gatttttggg gggtcaccag ccactccagg 4560
ggcagggacc atttcttcat tttctgaaag cactttaatg attcccctt ccccaaactc 4620
cagggaatgg aggggggacc ccgccagcca aaacattccc ccattcccg acccccctct 4680
cctcttctag cccatgccct tcccgggtgg agggaggag caggagagccc tcactctcca 4740
cgccccttgc ttgcatctgt atatagtgtg agcagcaagt aacccttctc cctccccccc 4800
caccctcct caatgtagtg gccttgata tcctgtttgt taataaagac aattcaacca 4860
gct 4863

```

<210> 31

<211> 283

<212> DNA

<213> Artificial sequence

<220>

<223> Probe

<400> 31

```

agctggttga attgtcttta ttaacaaaca ggatatccaa ggccactaca ttgaggaggg 60
gggagggggg agggaggaga agggttactt gctgctcaca ctatatacag atgcaagcaa 120
ggggcgtgga gagtgagggc tccctgctcc ctccctccac cggggaaggg catgggctag 180
aagaggagag gggggtcggg aatgggggga atgttttggc tgcggggtcc cccctccatt 240
ccctggagtt tgggggaagg ggaatcatta aagtgctttc aga 283

```

<210> 32

<211> 283

<212> DNA

<213> Artificial sequence

<220>

<223> Probe

<400> 32
 tctgaaagca ctttaaatgat tccccctccc ccaaactcca gggaatggag gggggacccc 60
 gcagccaaaa cattcccccc attccccgacc cccctctcct cttctagccc atgcccttcc 120
 ccggtggagg gagggagcag ggagccctca ctctccacgc cccttgcttg catctgtata 180
 tagtgtgagc agcaagtaac ccttctcctc cctccccct ccccccctct caatgtagtg 240
 gccttgata tctgtttgt taataaagac aattcaacca gct 283

<210> 33

<211> 2714

<212> DNA

<213> Homo sapiens

<400> 33
 ggcacagggc gaggttttat acacctgaaa gaagagaatg tcaagacgaa gtagccgttt 60
 acaagctaag cagcagcccc agcccagcca gacggaatcc cccaagaag cccagataat 120
 ccaggccaag aagaggaaaa ctaccagga tgtcaaaaaa agaagagagg aggtcaccaa 180
 gaaacatcag tatgaaatta ggaattgttg gccacctgta ttatctgggg ggatcagttc 240
 ttgcattatc attgaaacac ctcaaaaaga aataggaaca agtgatttct ccagatttac 300
 aaattacaga tttaaaaatc tttttattaa tccttcacct ttgcctgatt taagctgggg 360
 atgttcaaaa gaagtctggc taaacatgtt aaaaaaggag agcagatatg ttcatgacaa 420
 acattttgaa gttctgcatt ctgacttggg accacagatg aggtccatac ttctagactg 480
 gcttttagag gtatgtgaag tatacacact tcatagggaa acattttatc ttgcacaaga 540
 cttttttgat agatttatgt tgacacaaaa ggatataaat aaaaatatgc ttcaactcat 600
 tggaattacc tcattattca ttgcttccaa acttgaggaa atctatgctc ctaaaactcca 660
 agagtttgct tacgtcactg atggtgcttg cagtgaagag gatattctaa ggatggaact 720
 cattatatta aaggctttaa aatgggaact ttgtcctgta acaatcatct cctggctaaa 780
 tctctttctc caagttgatg ctcttaaaga tgctcctaaa gttcttctac ctcagtattc 840
 tcaggaaaca ttcattcaaa tagctcagct tttagatctg tgtattctag ccattgattc 900
 attagagttc cagtacagaa tactgactgc tgctgccttg tgccatttta cctccattga 960
 agtgggttaag aaagcctcag gtttgaggatg ggacagtatt tcagaatgtg tagattggat 1020
 ggtacctttt gtcaatgtag taaaaagtag tagtccagtg aagctgaaga cttttaagaa 1080
 gattcctatg gaagacagac ataatatcca gacacataca aactatttgg ctatgctgga 1140
 ggaagtaaat tacataaaca ctttcagaaa agggggacag ttgtcaccag tgtgcaatgg 1200
 aggcattatg acaccaccga agagcactga aaaaccacca ggaaaacact aaagaagata 1260
 actaagcaaa caagttggaa ttcaccaaga ttgggtagaa ctggtatcac tgaactacta 1320
 aagttttaca gaaagtagtg ctgtgattga ttgccctagc caattcacia gttacactgc 1380
 cattctgatt ttaaaactta caattggcac taaagaatac atttaattat ttctatggt 1440

```

agctgttaaa gaaacagcag gacttggtta caaagatgtc ttcattccca aggttactgg 1500
atagaagcca accacagtct ataccatagc aatgtttttc ctttaatcca gtgttactgt 1560
gtttatcttg ataaactagg aattttgtca ctggagtttt ggactggata agtgctacct 1620
taaagggtat actaagtgat acagtacttt gaatctagtt gttagattct caaaattcct 1680
acactcttga ctagtgaat ttggttcttg aaaattaaat ttaaacttgt ttacaaaggt 1740
ttagttttgt aataagggtga ctaatttatc tatagctgct atagcaagct attataaaac 1800
ttgaatttct acaaatggtg aaatttaatg ttttttaaac tagtttattt gccttgccat 1860
aacacatttt ttaactaata aggcttagat gaacatggtg ttcaacctgt gctctaaaca 1920
gtgggagtac caaagaaatt ataaacaaga taaatgctgt ggctccttcc taactggggc 1980
tttcttgaca tgtaggttgc ttggttaataa cctttttgta tatcacaatt tgggtgaaaa 2040
acttaagtac cctttcaaac tatttatatg aggaagtcac tttactactc taagatatcc 2100
ctaaggaatt ttttttttta atttagtgtg actaaggctt tatttatgtt tgtgaaactg 2160
ttaaggctct ttctaaattc ctccattgtg agataaggac agtgtcaaag tgataaagct 2220
taacacttga cctaaacttc tattttctta aggaagaaga gtattaaata tatactgact 2280
cctagaaatc tatttattaa aaaaagacat gaaaacttgc tgtacatagg ctagctattt 2340
ctaaatattt taaattagct ttctaaaaa aaaaatccag cctcataaag tagattagaa 2400
aactagattg ctagtattat ttgttatcag atatgtgaat ctcttctccc tttgaagaaa 2460
ctatacattt attgttacgg tatgaagtct tctgtatagt ttgtttttta actaatattt 2520
gtttcagtat tttgtctgaa aagaaaacac cactaattgt gtacatatgt attatataaa 2580
cttaaccttt taatactgtt tatttttagc ccattgttta aaaaataaaa gttaaaaaaa 2640
tttaactgct taaaagtaaa gttttgccat tgcttgagaa aacttttttt tccttctctg 2700
cgctgccagc tgta 2714

```

<210> 34

<211> 6773

<212> DNA

<213> Homo sapiens

<400> 34

```

caagcatgtg atgttcttgt accttcttct gatagtacat ctcaacagtt gactccatat 60
agtcaagtcc atatttgttt gagatctggc aactatcagg aggtaatata gattttcatt 120
gaagacaact taaccttgag ttacctgtc cagttccgac agtcagtcct aagagaactc 180
tttaagaaag ctcaacaggg aaatgaagct ctagatgaaa tctgtttttaa agtttgtgcc 240
tgtaatacag tccgtgatat actggaaggc agaacaatta gtgttcaatt taaccagcta 300
tttcttagac caaataaaga gaaaatagac tttcttcttg aggtatgttc aagatcagta 360
aatttagaaa aagcttcaga gtctttgaaa ggaaacatgg ctgcttttct aaagaatgtg 420

```

43

tgtctggggt	tggaagatct	gcagtatggt	ttcatgat	ttt	cttcacatga	gcttttcatt	480
acattgttga	aagatgaaga	acgaaagcta	cttgttgatc	agatgaggaa	gagatcccct		540
agagtaaato	tgtgcattaa	acctgtaact	tcattttatg	atatcccagc	ttcagcaagt		600
gtcaacattg	gtcagttaga	gcatcaactt	atattgtcag	tggatccttg	gaggattaga		660
caaattttta	ttgaattaca	tggtatgact	tcagagcgcc	agttctggac	agtgtccta		720
aagtgggaag	taccttctgt	ctatagtgg	gttatcctgg	gaattaaaga	caatttaaca		780
agagatttgg	tttatattct	tatggccaaa	ggtttgact	gcagtactgt	taaggacttt		840
tcccatgcta	aacagctctt	tgctgcttgt	ttggagttgg	taacagagtt	ctcaccgaag		900
cttcgtcagg	tcagctgaa	tgagatgttg	cttttgata	ttcatacaca	cgaagctggg		960
acagggcagg	caggagagag	accgccatcc	gaccttataa	gtagagtacg	aggctatctg		1020
gaaatgaggc	ttcctgatat	tcctcttcgt	caagttatag	ctgaggaatg	tgttgccctt		1080
atgttaaaact	ggagagaaaa	tgaatacctt	acactccaag	ttcctgcatt	tttgcttcag		1140
agtaatccat	atgtaaagct	tgacagctt	ttagcagcta	catgcaaaga	acttccaggc		1200
cctaaagaaa	gcagacggac	tgccaaagac	ctttgggaag	ttgttgttca	aatctgtagt		1260
gtgtccagtc	agcacaaacg	aggaaatgat	ggcagagtta	gtttaataaa	acagagggaa		1320
tctacgttag	gtatcatgta	tcggagtga	ctgctttctt	ttatcaaaaa	attacgagaa		1380
ccactcgctt	tgactattat	tttatcactc	tttgtgaaac	ttcacaatgt	tcgggaggac		1440
attgtgaatg	atattacagc	tgaacacatt	tctatttggc	catcttccat	tcccaacctc		1500
cagtctgtgg	actttgaagc	tgtggcaatc	acagtgaag	agctagtctg	atatacactc		1560
agtataaatc	caaataacca	ttcttggtta	attatccagg	cagatattta	ctttgcaacg		1620
aatcagat	cagcagctct	tcactattac	ctccaggcag	gagctgtgtg	ttctgacttc		1680
tttaacaagg	ctgtgcccc	tgatgtttat	acagaccagg	taataaaaacg	aatgataaaa		1740
tggtgttctt	tgctgaattg	ccacacacag	gtggctat	tatgtcagtt	cctcagagaa		1800
attgactaca	aaacagcggt	taaatctctg	caagaacaaa	acagtcatga	tgctatggac		1860
tcctactacg	actacatatg	ggatgttacc	atatttggat	acttgactta	tcttcatcat		1920
aaaagaggag	aaacagataa	aagacaaatt	gcaatcaaag	ccatcggcca	gacagagttg		1980
aatgcaagca	atccagaaga	agtgttacag	ctggcagcgc	agagaaggaa	aaaaaagttt		2040
ctccaagcaa	tggaacaaact	ttacttttta	gcagttaaat	ttttttaact	tttatTTTTT		2100
aaacaatggg	ctaaaataaa	acagtattaa	aagggttaagt	ttatataata	catatgtaca		2160
caattagtgg	tgTTTTTctt	tcagacaaaa	tactgaaaca	aatattagtt	taaaaacaaa		2220
ctatacagaa	gacttcatac	cgtaacaata	aatgtatagt	ttcttcaaag	ggagaagaga		2280
ttcacatatc	tgataacaaa	ataaactagc	aatctagttt	tctaactctac	tttatgaggc		2340
tggaTTTTTt	tttttagaaaa	gctaatttaa	aatattttaga	aatagctagc	ctatgtacag		2400
caagTTTTTca	tgtctTTTTt	taataaatag	atcttctagga	gtcagtatat	atttaataact		2460
cttcttctct	aagaaaatag	aagtttaggt	caagtgttaa	gctttatcac	tttgacactg		2520
tccttatctc	acaatggagg	aatttagaaa	ggaccttaac	agtttcacaa	acataaataa		2580

agccttagtc	acactaaatt	aaaaaaaaaa	attccttagg	gatatcttag	agtagtaaag	2640
tgacttcctc	atataaatag	tttgaaagg	tacttaagtt	tttcacccaa	attgtgatat	2700
acaaaaaggt	tattaccaag	caacctacat	gtcaagaaag	cccagttag	gaaggagcca	2760
cagcatttat	cttgtttata	atttctttgg	tactccact	gtttagagca	caggttgaac	2820
accatgttca	tctaagcctt	attagttaa	aaatgtgtta	tggcaaggca	aataaactag	2880
tttaaaaaac	attaaatttc	accatttgta	gaaattcaag	ttttataata	gcttgctata	2940
gcagctatag	ataaattagt	caccttatta	caaaactaaa	cctttgtaaa	caagtttaaa	3000
tttaattttc	aagaaccaa	ttgcactagt	caagagtgt	ggaattttga	gaatctaaca	3060
actagattca	aagtactgta	tcacttagta	tacccttta	ggtagcactt	atccagtcca	3120
aaactccagt	gacaaaattc	ctagtttatc	aagataaaca	cagtaacact	ggattaaagg	3180
aaaaacattg	ctatgggtata	gactgtgggt	ggcttctatc	cagtaacctt	gggaatgaag	3240
acatctttgt	aaacaagtcc	tgctgtttct	ttaacagcta	acataggaaa	taattaaatg	3300
tattcttttag	tgccaattgt	aagttttaaa	atcagaatgg	cagtgtaaact	tgtgaattgg	3360
ctagggcaat	caatcacagc	actactttct	gtaaaacttt	agtagttcag	tgataccagt	3420
tctaoccaa	cttgggtgaat	tccaacttgt	ttgcttagtt	atcttcttta	gtgttttctt	3480
ggtgggtttt	cagtgtctct	cgggtgggtc	ataatgcctc	cattgcacac	tggtgacaac	3540
tgtccccctt	ttctgaagg	gtttatgtaa	tttacttcct	cctatacatg	ggaagaaatc	3600
atgcactgat	ttcataaatc	aaagtcaaac	cagacttctg	ggtagcttatt	tgagattatt	3660
taggccta	tttaatagtc	tttttatgtc	tttgcaagt	tgaagggtca	tattctgaaa	3720
gtttctgtaa	cgttatatat	tttttaaa	ctttatctag	actgttggca	ttgatcttga	3780
gacacttcac	aaatcttgc	ttgatttcaa	agtaatttta	ttaacttttc	tacattttga	3840
aatcagtg	ccccttagaa	ctttctttcc	cctgaaactg	cctgaaggag	tactctattc	3900
ctaccatcag	ttttgggtgac	ttactagatt	cagatagcaa	agccaaaaaa	ctcacaaaaa	3960
aacataccag	catagccaaa	tagtttgtat	gtgtctggat	attatgtctg	tcttccatag	4020
gaatcttctt	aaaagtcttc	agcttcaactg	gactagtact	ttttactaca	ttgacaaaag	4080
gtaccatcca	atctacacat	tctgaaatac	tgtccactc	caaacctaga	tagatagaaa	4140
aaagttagaa	aagcatgaag	gtgtgtacatc	agaaactatc	ttacatatgt	ctgatgtact	4200
tggtgtgtgt	tttgagatat	tttaaaagaa	accaaatacat	aaccaagaag	tttagcatgt	4260
caaaacagat	tatcactctc	aaactattta	catgactatg	ttgaagggaa	aaaggacttc	4320
agaacttctt	aaccagtacc	ttctacatat	gaaattgaaa	tgggtcaaata	ccaaagaact	4380
cttaaagcag	aactataatg	ttgattcatt	tcaactgtat	ttaaattcca	tttgggtctt	4440
ttgttgatac	acattcagga	ttggaaagta	cttctaacag	aaagataatt	actgaacagc	4500
taattttttt	tttgccaaag	ttttaaatgc	atgttttagca	gaatgttaaa	gttcagagac	4560
tgtagtccca	ttagaagttg	tgaaaaggta	agaagacaac	aaatagagag	tcttacctga	4620
ggctttctta	accacttcaa	tggaggtaaa	atggcacaag	gcagcagcag	tcagtattct	4680

45

gtactggaac	tctaataaat	caatggctag	aatacacaga	tctaaaagct	aacaggaaaa	4740
acaaaagtac	aagcaattta	ggagaaagat	gagtactaaa	tgtctcttgc	taaaacctta	4800
gggatctaga	gataaataag	ccaccacccg	gccaggcgcg	gtggctcacg	cctgtaatcc	4860
cagcactttg	ggaggccgag	gcgggtggat	cacaagggtca	cgagatcgag	accatcctgg	4920
ctaacacggt	gaaaccccg	ctctactaaa	aaatacaaaa	aattagctgg	gcttgggtggc	4980
acgcgcctgt	agtcccagct	actcgggagg	ctgaggcagg	agaatggcgt	gaaccoggga	5040
tgcagagctt	gcagtgcgca	gagatcgcg	cactgcactc	cagcctgggc	gaaagagcga	5100
gactccgtct	caaaaaaaaa	aaaaacaagc	caccaacctg	aaggaagtag	acaaggaagg	5160
actgttgcaa	tacagtgtga	catgtactag	caggaagggc	acctaatacca	gattggaaaa	5220
gatagtgatg	gcctcaaatt	gccataaatg	ggtcttaaaa	gataagggag	ccaggaagag	5280
taggaggcag	agaatgttct	aggtataggg	acattacttg	gaactcagtt	cacagtccag	5340
aactcctaag	gtgaaaaata	aataaggagt	accttcattt	cttatcaaga	aagatgaggg	5400
gtgggtggcta	gaaagaggca	tggtctagat	tggatcacia	agggtcttta	agaagtcaga	5460
attttatagg	ctgattcttg	aagctactgg	aagattttta	aatcaaagtt	ccatttttaag	5520
aaagatacct	tagaatgcag	tgaagcagac	agactagaag	aaaacatggt	tattaagcag	5580
tgagattagt	taaaaggctg	tataatctag	gcaataagag	ctgaactagt	agcagtggaa	5640
tggtatagtg	taaaaggggt	agatttcaca	gatttgagaa	gatacttggt	cagtgggaatt	5700
aaacttcaat	tctctttgtc	ctcattgggt	cagaaggtag	gagaaatggg	agaagagctg	5760
ggaattggaa	gtgaaatatt	actgttatat	acctctagaa	agtccacatt	gtttatcggc	5820
ttatcaaaga	tttaccatca	ctatcagaag	ggtatagctg	cctaggacaa	tttgggatgc	5880
taggaattct	ggatgaaaaa	attaagcttt	taataaaaaa	ttttataaaa	taaaccaatt	5940
tcagtatact	tagtggttat	ccaatttgag	tattcataat	gtgctagatt	taagcaccac	6000
tgcccacaaa	ttttaacctc	ggtgacttaa	taattatccc	caaagtgtct	ccatatgtta	6060
gattttcaca	tcccacatag	aataagaggg	tagattttct	tcacttttgt	tatatggcag	6120
atacagcagc	cttaagatta	cttacgagaa	gtaagcaaga	aagaatggga	tctcctcttt	6180
tttttttttt	ttaatttttt	gagatggagt	cttgctctgt	tgctcagggt	ggagtgcagt	6240
agtgcgatct	cggctcactg	caacctccac	ctccagggtt	ccagcgattc	tctgcctca	6300
gcctcccaag	taacatgttg	gctaggctgc	ctcagccgcc	caaactcctg	acctcaagtg	6360
atctgcctgc	ctgcctcagc	cgcctcaagt	gctgagatta	gagacctgag	ccacagtgcc	6420
cggccagatc	ctcctcctcc	tctacttact	tactttgtta	aatatgctag	cctggaaaag	6480
tttactttga	atttatgttc	taaaaaattt	ttttaacaaa	gtaattttta	ttctgatatt	6540
taacttgata	ggcactctgt	gtatccaaat	gtaaagacat	catacagaat	aattctatgc	6600
cattataaag	cttaaacaca	actggcgaaa	aaaatgcttt	tccccatttt	atatcaaaaa	6660
gagatacttt	agtttggtg	cctaaagaat	gaaagtactc	agaaaagtgt	aaggactttg	6720
tttttctaga	aatattaagc	aacataaaca	ctggggacag	aactttatgc	gtc	6773

<210> 35

<211> 1590

<212> DNA

<213> Mus musculus

<400> 35

```

ctgagaacca gacatcagga tggcaggggc tctgcttggt gccctgcttc tctgacact      60
ctttggcaga agccagggaa agaatgaaga gcttagcctg tatcaccatc tcttcgacaa      120
ttatgatcca gaatgccggc cagttaggag acctgaggac actgtcacca tcaccctcaa      180
ggtcacccta accaacctca tctcactgaa cgagaaagaa gaaactctga ccaccagtgt      240
ctggattggc attgactggc acgactatcg gctcaactac agcaaggacg attttgcagg      300
tgtaggaatc ctccgggtcc cttcagaaca tgtatggctg ccagagattg ttctagaaaa      360
caatattgat gggcagtttg gagtggccta cgacagcaat gttctagtct atgagggagg      420
ctatgtgagc tggttgcccc cagccatcta ccgcagcacc tgcgcagtgg aggtcaccta      480
tttccccttt gactggcaga actgctctct catTTTTcgc tcccagacct acaatgctga      540
ggaggtggag ttcactcttg ccgtggatga cgacggcaat accatcaaca agattgacat      600
tgacacggca gcttttaccg agaatggaga atgggccata gactactgcc caggcatgat      660
tcgccgctat gagggagggt ccacagaagg tcttgagaaa actgacgtca tctatacgct      720
catcatccgc cggaagccgc ttttttacgt cattaacatc attgtgcctt gcgtgctcat      780
ttctggcttg gtgctgctcg cttacttcct gcctgcgcag gctggtggcc agaaatgcac      840
ggtctctatc aacgtcctgc tagcccagac tgtcttcttg tttctaattg cccagaaaat      900
tccagagact tctctgagcg tgccactgct gggcaggtat cttatatctg tcatggtggt      960
tgccacgctc attgtcatga attgcgtcat cgtgctcaac gtatctttga ggacgccaac     1020
gactcatgct acatcccctc ggctgcgcca gattttatta gagctgctgc cgcgtctcct     1080
gggctcgagc ccacccccag aggatccccg aactgcctca ccagcgaggc gtgcctcgtc     1140
tgtgggcatt ctgctcagag cggaggagct catcttgaaa aagccgcgga gcgaactcgt     1200
gtttgagggg cagaggcatc ggcacggaac ttggaccgca gccctctgcc agaacctggg     1260
tgctgcagcc ccagaaatcc gctgctgtgt ggatgctgtg aactttgtgg ctgagagcac     1320
aagagaccag gaagccactg gagaggaact gtccgactgg gtgcgtatgg ggaaggccct     1380
ggacaatgtc tgtttttggg cagcttttgg gctcttcagc gttggttcta ctctcatctt     1440
ccttgggggt tacttcaacc aagtccctga tctcccttac ccaccgtgca tccaaccatg     1500
agcctgcact ggcaccacc tctccccac cccccaagaa agagattttg aaaacaggcc     1560
gctgacaata aatctggttt gtgaacttgc                                     1590

```

<210> 36

<211> 2227

<212> DNA

<213> Mus musculus

<400> 36

tgtgagcagc aagtagccct tctccctcct gtatcctttc tcaatgtagt ggccttggat	60
atatccccctt tgtaataaaa gacaattcaa ccagcttcca ccattttgag atcctactat	120
tggtctctct caatcctgga gagatttgag agttgagaat gcagagggta gaggaaggc	180
attaggctct gtgaagttac tgtgataata gagacgaagt aaggtggatg aataggccag	240
ggatcagtcg tgacacggta ggaccctttg agaatagttt ttaccagccc cagcagggcc	300
aggccagact tctggcttca gtgtttctat atctgggtct tgtaaaaacc tcattggcta	360
tcaactagat aaacattctt taggttagaa ggagccaaga gcaaaattga accaattgcc	420
tccaagtgcc tgaccaaacc acccaccat cttctacttc cctgaggagt tggaccacc	480
cacatgacca cacaaccct cgggcagttc acaaaccaga ttattgtca gcggcctgtt	540
ttcaaaatct ctttcttggg ggggtgggga gaggtgggtg ccagtgcagg ctcatggttg	600
gatgcacggt gggtaggga gatcaggaaac ttggttgaag taacccccaa ggaagatgag	660
agtagacca acgtgaaga gcaccaaagc tgcccaaaa cagacattgt ccagggcctt	720
ccccatacgc acccagtcgg acagttcctg tgagagagag cttagcgagg gaggagcctg	780
gagggcgggg catctagcac tgctccgcct caacctccca acccactct ccagtggctt	840
cctggtctct tgtgctctca gccacaaagt tcacagcatc cacacagcag cggatttctg	900
gggctgcagc acccaggttc tggcagaggg ctgctgctaa ggcaacagca agcgctaggt	960
cattaaaaga gcgtcctaac ggcgagtgtg tgcctttgac ccaagagcag tgcttaccgg	1020
tccaagttcc gtgccgatgc ctctgacct caaacacgag ttcgctccgc ggctttttca	1080
agatgagctc ctccgctctg agcagaatgc ccacagacga ggacgcctc gctggtgagg	1140
cagttcgggg atcctctggg ggtgggctcg agcccaggag acgcggcagc agctctaata	1200
aaatctgcag ccggggcaga gagagggtcc aagcccgctt cccaccctg ggcagtactt	1260
tctccaacca gcgcttacct ggcgagccg aggggatgta gcatgagtcg ttggcgctct	1320
caaagatacg ttgagcagca tgacgcaatt catgacaatg agcgtggcaa ccaccatgac	1380
gaatataaga tacctgatat acagaagcct gatgtcacag caccaccaca acaaggcact	1440
agctgcctc tacctcaca ataccacct gcacagctgg tggcgttact tcttgatcct	1500
cctcaacgat gccagtattg tcctggccct tctgcatata ccactgttg cggacatgaa	1560
ggggattccc agcaatttg acacctgct gtgggtctac cacttocaca gctccaccga	1620
ggtgagggtg ttagaatggc agaattctgga gaggtcccca gctcttcctg ctatggccct	1680
ttccatgtga tcattccact cactacctt gctcctccag gtggccttac agcctccact	1740
tctatcttcc ctggaacttg ctgtggccgc agctcacgaa tatctggtgc aaagggtcag	1800
agagcttaag tcccaggacc ccctggaatc cgacaagtcg cccaccaga aggccacct	1860
agggctggtg ctaagagaag ctgcagccag catcatgagc tttggagcca ccttggtaga	1920
ggtgctgctc tgggaggctg agggatggga ataaaagggg gagagggcta ggccaacaaa	1980

48

agcaaggacc tctagcccat atgcccgaat gtagatctcg gccctgtggc tgcagcagga 2040
 ggtgcagcga ctggacggcg gcaacgactg cccaggccca gcccagaca ctggggatcc 2100
 tggtagggcg ctggcccgtag gccctggc cgcagggcag gggattcggc aagctggaac 2160
 ggcagctggc gcaagtggc ggtacctgat ccagggggcg tggttgtacc tgtgtggacg 2220
 aggtttg 2227

<210> 37

<211> 2472

<212> DNA

<213> Homo sapiens

<400> 37

agcatcgagt cggccttgtt gcctactgga gtctccgcag agcccgggcg ggagtagctg 60
 gtggaccccg ttgagctgcc gaacttcccg gactcccccg cgacccttc ccagcttccc 120
 gtccgctccg ccgcagcgat tgtctcggcg ggttgattcg gcacaaaccg cccgaccag 180
 gggccggtgc gcgtgtggaa ggggaagcac tcccctcgtg gtcgcctgga ggtgcgctgg 240
 aggagggggg gacataacca gggactcgag gtccgccgtg ggaatgatcc acgaactgct 300
 cttggctctg agcgggtacc ctgggtccat tttcacctgg aacaagcgga gtggcctgca 360
 ggtatcgag gacttccctt tcctccacc cagtgcagacc agtgtcctga atcgactctg 420
 ccggctcggc acagactata ttcgcttcac tgagttcatt gaacagtaca cgggccatgt 480
 gcaacagcag gatcaccatc catctcaaca gggccaaggt gggttacatg gaatctacct 540
 gcgggccttc tgcacaggcg tggattctgt tttgcagcct tatcgccaag cactgcttga 600
 tttggaacaa gagttcctgg gtgatcccca tctctccata tcacatgtca actacttctt 660
 agaccagttc cagcttcttt ttcctctgt gatggttga gtagaacaaa ttaaaagtca 720
 aaagattcat ggttgtcaaa tcctggaaac agtctacaaa cacagctgtg gggggttggc 780
 tcctgttcga agtgcactgg aaaaaatcct ggccgtttgt catggggtca tgtataaaca 840
 gctctcagcc tggatgctcc atggactcct cttggaccag catgaagaat tctttatcaa 900
 acagggggcca tcttctggta atgtcagtc ccagccagaa gaggacgagg aggatctggg 960
 cattggggga ctgacaggaa aacaactgag agaactgcag gacttgcgcc tgattgagga 1020
 agagaacatg ctggcaccat ctctgaagca gttttcccta cgagtggaga ttttgccatc 1080
 ctacattcca gtgagggttg ctgaaaaaat cctatttgtt ggagaatctg tccagatgtt 1140
 tgagaatcaa aatgtgaacc tgactagaaa aggatccatt ttgaaaaacc aggaagacac 1200
 ttttgctgca gagctgcacc gtctcaagca gcagccactc ttcagcttgg tggactttga 1260
 acagggtgtg gatcgcatc gcagcactgt ggctgagcat ctctggaagt tgatggtaga 1320
 agaatccgat ttactgggtc agctgaagat cattaaagac ttttaccttc tgggacgtgg 1380
 agaactgttt caggccttca ttgacacagc tcaacacatg ttgaaaacac caccactgac 1440

49

```

agtaactgag catgatgtga atgtggcctt tcaacagtca gcacacaagg tatttgctaga 1500
tgatgacaac cttctccctc tgttgcaactt gacaatcgag tatcacggaa aggagcacia 1560
agcagatgct actcaggcaa gagaagggcc ttctcgggaa acttctcccc gggaagcccc 1620
tgcactctggc tgggcagccc taggtctttc ctacaaagta cagtggccac tacatatctt 1680
cttcacccca gctgtcctgg aaaaaaatag acaattttta aaaccaaaca gaatgggact 1740
gtcttctgca agcctaccta caaacaggta caatgttggt tttaagtact tactgagtgt 1800
gcgccgggtg caagctgagc tgcagcactg ctgggcccta caaatgcagc gcaagcacct 1860
caagtcgaac cagactgatg caatcaagtg gcgcctaaga aatcacatgg catttttggt 1920
ggataatctt cagtactatc tccaggtaga tgtgttgag tctcagttct cccagctgct 1980
tcatcagatc aattctaccc gagactttga aagcatccga ttggctcatg accacttcct 2040
gagcaatttg ctggctcaat cctttatcct attgaaacct gtgtttcact gcctgaatga 2100
aatcctagat ctctgtcaca gtttttggtc gctggtcagt cagaacctag gccactgga 2160
tgagcgtgga gccgccagc tgagcattct cgtgaagggc tttagccgcc agtcttcact 2220
cctgttcaag attctctcca gtgttcggaa tcatcagatc aactcagatt tggctcaact 2280
actgttacga ctagattata acaaatacta taccaggct ggtggaactc tgggcagttt 2340
cgggatgtga aaatttctgg ctcataaatt gaaataacag ccacgttccc aagggtgtaa 2400
cagaagattc aaaacatccc attctagcca cacacaaata aatatctgcg gcttaaaaaa 2460
aaaaaaaaaa aa 2472

```

<210> 38

<211> 4165

<212> DNA

<213> Homo sapiens

<400> 38

```

agcatcgagt cggccttggt gcctactgga gtctccgcag agccccggcg ggagtagctg 60
gtggaccccc ttgagctgcc gaacttcggg gactcccccg cgaccccttc ccagcttccc 120
gtccgctccg ccgcagcgat tgtctcgggt ggttgattcg gcacaaaccg cccgaccag 180
gggccgggtg gcgtgtggaa ggggaagcac tccccctcgt gtgcctgga ggtgcgctgg 240
aggagggggg gacataacca gggactcgag gtccgccgtg ggaatgatcc acgaactgct 300
cttggctctg agcgggtacc ctgggtccat ttacacctg aacaagcgga gtggcctgca 360
ggtatcgag gacttccctt tctccaccc cagtgcagac agtgtcctga atcgactctg 420
ccggtcggc acagactata ttgcgttcac tgagttcatt gaacagtaca cgggccatgt 480
gcaacagcag gatcaccatc catctcaaca gggccaagg gggttacatg gaatctacct 540
gcgggccttc tgcacagggc tggattctgt ttgcagcct tatcgccaag cactgcttga 600
tttgaacaa gagttcctgg gtgatccca tctctccata tcacatgtca actacttcct 660
agaccagttc cagcttcttt tccctctgt gatggttgta gtagaacaaa ttaaaagtca 720

```

aaagattcat	ggttgtcaaa	tcctggaaac	agtctacaaa	cacagctgtg	gggggttgcc	780
tcctgttcga	agtgcactgg	aaaaaatcct	ggccgtttgt	catgggggtca	tgtataaaca	840
gctctcagcc	tggatgctcc	atggactcct	cttggaccag	catgaagaat	tctttatcaa	900
acaggggcca	tcttctggta	atgtcagtgc	ccagccagaa	gaggacgagg	aggatctggg	960
cattggggga	ctgacaggaa	aacaactgag	agaactgcag	gacttgcgcc	tgattgagga	1020
agagaacatg	ctggcaccat	ctctgaagca	gttttcccta	cgagtggaga	ttttgccatc	1080
ctacattcca	gtgaggggtg	ctgaaaaaat	cctattttgt	ggagaatctg	tccagatgtt	1140
tgagaatcaa	aatgtgaacc	tgactagaaa	aggatccatt	ttgaaaaacc	aggaagacac	1200
ttttgctgca	gagctgcacc	gtctcaagca	gcagccactc	ttcagcttgg	tggactttga	1260
acaggtggtg	gategcattc	gcagcactgt	ggctgagcat	ctctggaagt	tgatggtaga	1320
agaatccgat	ttactgggtc	agctgaagat	cattaaagac	ttttaccttc	tgggacgtgg	1380
agaactgttt	caggccttca	ttgacacagc	tcaacacatg	ttgaaaacac	cacccactgc	1440
agtaactgag	catgatgtga	atgtggcctt	tcaacagtca	gcacacaagg	tattgctaga	1500
tgatgacaac	cttctccctc	tgttgacttt	gacaatcgag	tatcacggaa	aggagcacia	1560
agcagatgct	actcaggcaa	gagaagggcc	ttctcgggaa	acttctcccc	gggaagcccc	1620
tgcatctggc	tgggcagccc	taggtctttc	ctacaaagta	cagtggccac	tacatattct	1680
cttcacccca	gctgtcctgg	aaaagtacaa	tgttgttttt	aagtacttac	tgagtgtgcg	1740
ccgggtgcaa	gctgagctgc	agcactgctg	ggccctacaa	atgcagcgca	agcacctcaa	1800
gtcgaaccag	actgatgcaa	tcaagtggcg	cctaagaaat	cacatggcat	ttttgggtgga	1860
taatcttcag	tactatctcc	aggtagatgt	gttggagtct	cagttctccc	agctgcttca	1920
tcagatcaat	tctacccgag	actttgaaag	catccgattg	gctcatgacc	acttcctgag	1980
caatttgctg	gctcaatcct	ttatcctatt	gaaacctgtg	tttcaactgc	tgaatgaaat	2040
cctagatctc	tgtcacagtt	tttgtttctg	ggtcagtcat	aacctaggcc	cactggatga	2100
gcgtggagcc	gccagctga	gcattctcgt	gaagggtctt	agccgccagt	cttcactcct	2160
gttcaagatt	ctctccagtg	ttcggaatca	tcagatcaac	tcagatttgg	ctcaactact	2220
gttacgacta	gattataaca	aatactatac	ccaggctggg	ggaactctgg	gcagtttcgg	2280
gatgtgaaaa	tttctggctc	ataaattgaa	ataacagcca	cgttcccaag	gttgtaacag	2340
aagattcaaa	acatcccatt	ctagccacac	acaaataaat	atctgcccgt	tagtgatagg	2400
actctacctt	ttctcctaga	agcagttact	gaacatccag	gagtacaact	ccttcccatc	2460
attcccatgt	ggaagggctc	ctcccatcaa	ggagaacatg	tggcatctct	gaccccttac	2520
attgagaaca	tttggtggat	atgttcattt	attcaatagt	cattttattga	gcacctacta	2580
cgtaccttgg	tactgttcaa	gctgtgggag	atacagcggt	agacaaacaa	tatagagcag	2640
aaagttaaata	attttatggg	tcatatgtga	aaaagtaatt	atgtttataa	atagactaac	2700
tgctggatgt	taccaccaag	taagaaagca	acaggtaaga	taggctttct	ctctccctat	2760
accaagtaat	ttatacctac	acagattggg	caattctagc	taatgaaaat	atacttaaaa	2820

51

```

gtatttctta ggccgggcat ggtggctcac acctgtaatc ccagcacttt gggaggccga 2880
ggcggggcgga tcacctgaag tcaggagttt gagaccagcc tgaccaacat gatgaaacct 2940
cgattctact aaaaatacaa aaattagcca ggtgtggtgg catgtgcctg taatcccagc 3000
tactcaggag gctgagacag gagaattgct tgaacctggg aagcagacgc tgcagtgagc 3060
tgagattgtg ccattgcatt ccagcctggg caacaagagc gaaattccgt ctcaaaaaaa 3120
aaaaaaaaaa aaaaagtatt attctccaag aaaaagggtcc ttaagaaaaa attgagatca 3180
agttgttaga tttttaataa ctgaagattg caggcccaat taccatctt acacaaacca 3240
taggggttga agttatctta atatggccca gccatcactg gtaatcaata ttcatatcag 3300
tgtaagtaaa aagaaatatt cactgaacaa cgccctccaa actgaaaaag aatgcagtgt 3360
tctggcatca ggttatagtc actgcatctg gttttcatca ctacatatc tacacacact 3420
gggaagctct gacaacttat tccctgctat tatcaactaa agatcacccct ttccactgct 3480
gtctctggag caggagctgg caaactatgg cctgctgtct gttttgtac agttttactg 3540
aaacacagcc gtgcccattt gtttactcat tgtctatggt tgctttcatg ccctcacagc 3600
aaaggcgagt agttgtgatg gatcaaattg ccacaaagc ctgaaatatt tactctttga 3660
ccctttacag aaaaaaacct tgttgacccc tgctttagag aatgagaagc catgcagga 3720
tcagtgatgc cagaggaagg gaaggaactg cttccagcta ttgtgacaat aataataata 3780
ataatattgg gtctttgact agaacgtgta acatttccag gtgttctcac ttgtgcttcc 3840
catgtttatc ttacggaagg tcattccatc aagcttatgg tcaactgtcc ttcattggcag 3900
ttggctcctt cgttctccct ttagctctaa gagttgggga gtaccacagc gtgagctgtg 3960
atctcagctc agagagagag catgaggtct tttttaactg tcaggaaaca gagctgtgcc 4020
caattccact caacttttgg cacaactgtt aatctgggcc ttcacctacc ttaaaactgag 4080
tttctgcaag catagcattt tagacaccct ggaataacct tttgggaatg atgccacaga 4140
ataaagttca ctcttaactt ttcaa 4165

```

<210> 39

<211> 27

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 39

ggagagaacc acccagccca gaagtgc

27

<210> 40

<211> 23

<212> DNA

52

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 40

aggaatggag gcggcccttc tgc

23

<210> 41

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 41

cggaggagct catcttgaaa aag

23

<210> 42

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 42

gatcaggaac ttggttgaag taac

24

<210> 43

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic oligonucleotide

<400> 43

tgtgagcagc aagtaaccct tctcc

25

<210> 44

<211> 793

<212> DNA

<213> Artificial sequence

<220>

<223> Probe

<400> 44

acagagttga atgcaagcaa tccagaagaa gtgttacagc tggcagcgca gagaaggaaa	60
aaaaagtttc tccaagcaat ggcaaaactt tacttttaag cagttaaatt tttttaactt	120
ttatttttta aacaatgggc taaaaataaa cagtattaaa aggttaagtt tatataatac	180
atatgtacac aattagtggt gttttctttt cagacaaaat actgaaacaa atattagttt	240
aaaaacaaac tatacagaag acttcatacc gtaacaataa atgtatagtt tcttcaaagg	300
gagaagagat tcacatatct gataacaaaa taaactagca atctagtttt ctaatctact	360
ttatgaggct ggattttttt ttagaaaag ctaatttaaa atatttagaa atagctagcc	420
tatgtacagc aagttttcat gtcttttttt aataaataga tttctaggag tcagtatata	480
tttaatactc ttcttcctta agaaaataga agtttaggtc aagtgttaag ctttatcact	540
ttgacactgt ccttatctca caatggagga atttagaaag gaccttaaca gtttcacaaa	600
cataaataaa gccttagtca cactaaatta aaaaaaaaaa ttccttaggg atatcttaga	660
gtagtaaagt gacttcctca tataaatagt ttgaaagggt acttaagttt ttcacccaaa	720
ttgtgatata caaaaagggt attaccaagc aacctacatg tcaagaaagc cccagttagg	780
aaggagccac agc	793

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.